,source,target,value,type,source layer,target layer,normalized value
0,IGLC7,Initial triggering of complement,0.003674122808633495,0,0,1,0.004011238105711954
1,IGLC7,Initial triggering of complement,0.003944251939848179,1,0,1,0.004306152652946212
2,IGLC7,Regulation of Complement cascade,0.003674122808633495,0,0,1,0.004011238105711954
3,IGLC7,Regulation of Complement cascade,0.003944251939848179,1,0,1,0.004306152652946212
4,IGLC7,FCGR activation,0.003674122808633495,0,0,1,0.004011238105711954
5,IGLC7,FCGR activation,0.003944251939848179,1,0,1,0.004306152652946212
6,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.003674122808633495,0,0,1,0.004011238105711954
7,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.003944251939848179,1,0,1,0.004306152652946212
8,IGLC7,Role of phospholipids in phagocytosis,0.003674122808633495,0,0,1,0.004011238105711954
9,IGLC7,Role of phospholipids in phagocytosis,0.003944251939848179,1,0,1,0.004306152652946212
10,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.003674122808633495,0,0,1,0.004011238105711954
11,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.003944251939848179,1,0,1,0.004306152652946212
12,IGLC7,FCERI mediated MAPK activation,0.003674122808633495,0,0,1,0.004011238105711954
13,IGLC7,FCERI mediated MAPK activation,0.003944251939848179,1,0,1,0.004306152652946212
14,IGLC7,FCERI mediated Ca+2 mobilization,0.003674122808633495,0,0,1,0.004011238105711954
15,IGLC7,FCERI mediated Ca+2 mobilization,0.003944251939848179,1,0,1,0.004306152652946212
16,IGLC7,FCERI mediated NF-kB activation,0.003674122808633495,0,0,1,0.004011238105711954
17,IGLC7,FCERI mediated NF-kB activation,0.003944251939848179,1,0,1,0.004306152652946212
18,IGLC7,Parasite infection,0.003674122808633495,0,0,1,0.004011238105711954
19,IGLC7,Parasite infection,0.003944251939848179,1,0,1,0.004306152652946212
20,IGLC7,Leishmania parasite growth and survival,0.003674122808633495,0,0,1,0.004011238105711954
21,IGLC7,Leishmania parasite growth and survival,0.003944251939848179,1,0,1,0.004306152652946212
22,IGLC7,Potential therapeutics for SARS,0.003674122808633495,0,0,1,0.004011238105711954
23,IGLC7,Potential therapeutics for SARS,0.003944251939848179,1,0,1,0.004306152652946212
24,IGLC7,CD22 mediated BCR regulation,0.003674122808633495,0,0,1,0.004011238105711954
25,IGLC7,CD22 mediated BCR regulation,0.003944251939848179,1,0,1,0.004306152652946212
26,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003674122808633495,0,0,1,0.004011238105711954
27,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003944251939848179,1,0,1,0.004306152652946212
28,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003674122808633495,0,0,1,0.004011238105711954
29,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003944251939848179,1,0,1,0.004306152652946212
30,IGLC7,Scavenging of heme from plasma,0.003674122808633495,0,0,1,0.004011238105711954
31,IGLC7,Scavenging of heme from plasma,0.003944251939848179,1,0,1,0.004306152652946212
32,RB27B,Platelet degranulation ,1.5159943851580152e-05,0,0,1,1.655092865023989e-05
33,RB27B,Platelet degranulation ,0.0001503991923984848,1,0,1,0.000164198913057423
34,RB27B,RAB GEFs exchange GTP for GDP on RABs,1.5159943851580152e-05,0,0,1,1.655092865023989e-05
35,RB27B,RAB GEFs exchange GTP for GDP on RABs,0.0001503991923984848,1,0,1,0.000164198913057423
36,RB27B,RAB geranylgeranylation,1.5159943851580152e-05,0,0,1,1.655092865023989e-05
37,RB27B,RAB geranylgeranylation,0.0001503991923984848,1,0,1,0.000164198913057423
38,QSOX1,Platelet degranulation ,0.0023209629601984804,0,0,1,0.0025339204900874774
39,QSOX1,Platelet degranulation ,0.0018211304576454246,1,0,1,0.001988226378828339
40,QSOX1,Neutrophil degranulation,0.0023209629601984804,0,0,1,0.0025339204900874774
41,QSOX1,Neutrophil degranulation,0.0018211304576454246,1,0,1,0.001988226378828339
42,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0023209629601984804,0,0,1,0.0025339204900874774
43,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0018211304576454246,1,0,1,0.001988226378828339
44,QSOX1,Post-translational protein phosphorylation,0.0023209629601984804,0,0,1,0.0025339204900874774
45,QSOX1,Post-translational protein phosphorylation,0.0018211304576454246,1,0,1,0.001988226378828339
46,NRP1,Neurophilin interactions with VEGF and VEGFR,0.00018770795012813156,0,0,1,0.00020493089684693464
47,NRP1,Neurophilin interactions with VEGF and VEGFR,0.0008102067486891378,1,0,1,0.0008845464218588807
48,NRP1,Semaphorin interactions,0.00018770795012813156,0,0,1,0.00020493089684693464
49,NRP1,Semaphorin interactions,0.0008102067486891378,1,0,1,0.0008845464218588807
50,NRP1,L1CAM interactions,0.00018770795012813156,0,0,1,0.00020493089684693464
51,NRP1,L1CAM interactions,0.0008102067486891378,1,0,1,0.0008845464218588807
52,NRP1,Signaling by ROBO receptors,0.00018770795012813156,0,0,1,0.00020493089684693464
53,NRP1,Signaling by ROBO receptors,0.0008102067486891378,1,0,1,0.0008845464218588807
54,NRP1,SARS-CoV-2 Infection,0.00018770795012813156,0,0,1,0.00020493089684693464
55,NRP1,SARS-CoV-2 Infection,0.0008102067486891378,1,0,1,0.0008845464218588807
56,APOL1,Scavenging of heme from plasma,0.0024260956328925466,0,0,1,0.002648699501250315
57,APOL1,Scavenging of heme from plasma,0.0027977457152216635,1,0,1,0.0030544499483302263
58,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0024260956328925466,0,0,1,0.002648699501250315
59,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0027977457152216635,1,0,1,0.0030544499483302263
60,APOL1,Post-translational protein phosphorylation,0.0024260956328925466,0,0,1,0.002648699501250315
61,APOL1,Post-translational protein phosphorylation,0.0027977457152216635,1,0,1,0.0030544499483302263
62,ARPC3,RHO GTPase Effectors,0.0005255293699473658,0,0,1,0.0005737487678556121
63,ARPC3,RHO GTPase Effectors,0.0007462570400019815,1,0,1,0.0008147290745093767
64,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.0005255293699473658,0,0,1,0.0005737487678556121
65,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.0007462570400019815,1,0,1,0.0008147290745093767
66,ARPC3,EPH-Ephrin signaling,0.0005255293699473658,0,0,1,0.0005737487678556121
67,ARPC3,EPH-Ephrin signaling,0.0007462570400019815,1,0,1,0.0008147290745093767
68,ARPC3,Parasite infection,0.0005255293699473658,0,0,1,0.0005737487678556121
69,ARPC3,Parasite infection,0.0007462570400019815,1,0,1,0.0008147290745093767
70,ACTN4,Platelet degranulation ,0.00015330783823771854,0,0,1,0.0001673744386547
71,ACTN4,Platelet degranulation ,0.0007470322317540703,1,0,1,0.0008155753931702296
72,ACTN4,Nephrin family interactions,0.00015330783823771854,0,0,1,0.0001673744386547
73,ACTN4,Nephrin family interactions,0.0007470322317540703,1,0,1,0.0008155753931702296
74,FLNB,Antiviral mechanism by IFN-stimulated genes,0.0011631479685674634,0,0,1,0.001269871394373599
75,FLNB,Antiviral mechanism by IFN-stimulated genes,0.001595281142957726,1,0,1,0.0017416544963927679
76,PGRP1,Neutrophil degranulation,0.0011439336027103822,0,0,1,0.0012488940344655669
77,PGRP1,Neutrophil degranulation,0.0011584024774714322,1,0,1,0.001264690485703375
78,FCN3,Initial triggering of complement,2.3307324157594778e-05,0,0,1,2.544586331829688e-05
79,FCN3,Initial triggering of complement,2.257105595785115e-05,1,0,1,2.4642039599640616e-05
80,IDHC,NADPH regeneration,0.0002654766314280959,0,0,1,0.0002898351621938537
81,IDHC,NADPH regeneration,0.00034808340163453515,1,0,1,0.00038002143023672843
82,IDHC,KEAP1-NFE2L2 pathway,0.0002654766314280959,0,0,1,0.0002898351621938537
83,IDHC,KEAP1-NFE2L2 pathway,0.00034808340163453515,1,0,1,0.00038002143023672843
84,IDHC,Neutrophil degranulation,0.0002654766314280959,0,0,1,0.0002898351621938537
85,IDHC,Neutrophil degranulation,0.00034808340163453515,1,0,1,0.00038002143023672843
86,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0002654766314280959,0,0,1,0.0002898351621938537
87,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00034808340163453515,1,0,1,0.00038002143023672843
88,UTS2,Class A/1 (Rhodopsin-like receptors),0.003044666258971618,0,0,1,0.0033240264284210785
89,UTS2,Class A/1 (Rhodopsin-like receptors),0.004371097667567044,1,0,1,0.004772163164152577
90,UTS2,G alpha (q) signalling events,0.003044666258971618,0,0,1,0.0033240264284210785
91,UTS2,G alpha (q) signalling events,0.004371097667567044,1,0,1,0.004772163164152577
92,APOM,Retinoid metabolism and transport,0.0071682091969114715,0,0,1,0.007825920737543433
93,APOM,Retinoid metabolism and transport,0.006747400786406416,1,0,1,0.007366501491279926
94,VNN1,Vitamin B5 (pantothenate) metabolism,0.00028030323881069716,0,0,1,0.0003060221694359006
95,VNN1,Vitamin B5 (pantothenate) metabolism,0.0002730249891221301,1,0,1,0.0002980761115564351
96,VNN1,Neutrophil degranulation,0.00028030323881069716,0,0,1,0.0003060221694359006
97,VNN1,Neutrophil degranulation,0.0002730249891221301,1,0,1,0.0002980761115564351
98,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.00028030323881069716,0,0,1,0.0003060221694359006
99,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.0002730249891221301,1,0,1,0.0002980761115564351
100,FSTL3,Antagonism of Activin by Follistatin,0.0002459575017904721,0,0,1,0.00026852507522322016
101,FSTL3,Antagonism of Activin by Follistatin,9.29785396600416e-05,1,0,1,0.0001015096883591985
102,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002459575017904721,0,0,1,0.00026852507522322016
103,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),9.29785396600416e-05,1,0,1,0.0001015096883591985
104,FSTL3,Post-translational protein phosphorylation,0.0002459575017904721,0,0,1,0.00026852507522322016
105,FSTL3,Post-translational protein phosphorylation,9.29785396600416e-05,1,0,1,0.0001015096883591985
106,K2C75,Formation of the cornified envelope,0.002259708878047632,0,0,1,0.002467046103668892
107,K2C75,Formation of the cornified envelope,0.0028999677903862753,1,0,1,0.0031660513031302705
108,PAK4,RHO GTPase cycle,0.00114307339818939,0,0,1,0.001247954902778079
109,PAK4,RHO GTPase cycle,0.0012104659491263834,1,0,1,0.0013215309867686258
110,PAK4,Signaling by ROBO receptors,0.00114307339818939,0,0,1,0.001247954902778079
111,PAK4,Signaling by ROBO receptors,0.0012104659491263834,1,0,1,0.0013215309867686258
112,ADH1B,Ethanol oxidation,0.0013455891549447787,0,0,1,0.0014690522810680657
113,ADH1B,Ethanol oxidation,0.0012147236973824934,1,0,1,0.001326179400264578
114,LDHA,Pyruvate metabolism,0.001911213196019836,0,0,1,0.002086574564682451
115,LDHA,Pyruvate metabolism,0.000767350476427207,1,0,1,0.0008377579171409995
116,AL1A1,Ethanol oxidation,0.0015718349464888316,0,0,1,0.0017160570186794365
117,AL1A1,Ethanol oxidation,0.0013052439184145538,1,0,1,0.0014250052095402116
118,AL1A1,RA biosynthesis pathway,0.0015718349464888316,0,0,1,0.0017160570186794365
119,AL1A1,RA biosynthesis pathway,0.0013052439184145538,1,0,1,0.0014250052095402116
120,AL1A1,Fructose catabolism,0.0015718349464888316,0,0,1,0.0017160570186794365
121,AL1A1,Fructose catabolism,0.0013052439184145538,1,0,1,0.0014250052095402116
122,DHE3,Transcriptional activation of mitochondrial biogenesis,0.0021801837578151128,0,0,1,0.0023802242391714862
123,DHE3,Transcriptional activation of mitochondrial biogenesis,0.004005123351743151,1,0,1,0.004372609257599668
124,DHE3,Glutamate and glutamine metabolism,0.0021801837578151128,0,0,1,0.0023802242391714862
125,DHE3,Glutamate and glutamine metabolism,0.004005123351743151,1,0,1,0.004372609257599668
126,CERU,Metal ion SLC transporters,0.0057268380155319435,0,0,1,0.006252298050343439
127,CERU,Metal ion SLC transporters,0.006365155231584038,1,0,1,0.006949183395205506
128,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0057268380155319435,0,0,1,0.006252298050343439
129,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.006365155231584038,1,0,1,0.006949183395205506
130,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.0057268380155319435,0,0,1,0.006252298050343439
131,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.006365155231584038,1,0,1,0.006949183395205506
132,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0057268380155319435,0,0,1,0.006252298050343439
133,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006365155231584038,1,0,1,0.006949183395205506
134,CERU,Post-translational protein phosphorylation,0.0057268380155319435,0,0,1,0.006252298050343439
135,CERU,Post-translational protein phosphorylation,0.006365155231584038,1,0,1,0.006949183395205506
136,OTC,Urea cycle,0.0009391129984246179,0,0,1,0.0010252803297697306
137,OTC,Urea cycle,0.000419767056181105,1,0,1,0.0004582823435622786
138,OTC,Mitochondrial protein import,0.0009391129984246179,0,0,1,0.0010252803297697306
139,OTC,Mitochondrial protein import,0.000419767056181105,1,0,1,0.0004582823435622786
140,F13A,Interleukin-4 and Interleukin-13 signaling,0.0027732249627153236,0,0,1,0.003027679319813662
141,F13A,Interleukin-4 and Interleukin-13 signaling,0.003763640421514856,1,0,1,0.00410896931357423
142,F13A,Platelet degranulation ,0.0027732249627153236,0,0,1,0.003027679319813662
143,F13A,Platelet degranulation ,0.003763640421514856,1,0,1,0.00410896931357423
144,F13A,Common Pathway of Fibrin Clot Formation,0.0027732249627153236,0,0,1,0.003027679319813662
145,F13A,Common Pathway of Fibrin Clot Formation,0.003763640421514856,1,0,1,0.00410896931357423
146,PGK1,Glycolysis,0.0009724442040586731,0,0,1,0.001061669805329577
147,PGK1,Glycolysis,0.0010985110874280693,1,0,1,0.0011993038237819284
148,PGK1,Gluconeogenesis,0.0009724442040586731,0,0,1,0.001061669805329577
149,PGK1,Gluconeogenesis,0.0010985110874280693,1,0,1,0.0011993038237819284
150,PGK1,Response of Mtb to phagocytosis,0.0009724442040586731,0,0,1,0.001061669805329577
151,PGK1,Response of Mtb to phagocytosis,0.0010985110874280693,1,0,1,0.0011993038237819284
152,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02095509001627747,0,0,1,0.022877802392560466
153,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02155470784705104,1,0,1,0.023532437530507263
154,THRB,Regulation of Complement cascade,0.02095509001627747,0,0,1,0.022877802392560466
155,THRB,Regulation of Complement cascade,0.02155470784705104,1,0,1,0.023532437530507263
156,THRB,Class A/1 (Rhodopsin-like receptors),0.02095509001627747,0,0,1,0.022877802392560466
157,THRB,Class A/1 (Rhodopsin-like receptors),0.02155470784705104,1,0,1,0.023532437530507263
158,THRB,G alpha (q) signalling events,0.02095509001627747,0,0,1,0.022877802392560466
159,THRB,G alpha (q) signalling events,0.02155470784705104,1,0,1,0.023532437530507263
160,THRB,Defective factor XII causes hereditary angioedema,0.02095509001627747,0,0,1,0.022877802392560466
161,THRB,Defective factor XII causes hereditary angioedema,0.02155470784705104,1,0,1,0.023532437530507263
162,THRB,Defective factor VIII causes hemophilia A,0.02095509001627747,0,0,1,0.022877802392560466
163,THRB,Defective factor VIII causes hemophilia A,0.02155470784705104,1,0,1,0.023532437530507263
164,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.02095509001627747,0,0,1,0.022877802392560466
165,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.02155470784705104,1,0,1,0.023532437530507263
166,THRB,Common Pathway of Fibrin Clot Formation,0.02095509001627747,0,0,1,0.022877802392560466
167,THRB,Common Pathway of Fibrin Clot Formation,0.02155470784705104,1,0,1,0.023532437530507263
168,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02095509001627747,0,0,1,0.022877802392560466
169,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02155470784705104,1,0,1,0.023532437530507263
170,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.02095509001627747,0,0,1,0.022877802392560466
171,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.02155470784705104,1,0,1,0.023532437530507263
172,C1R,Initial triggering of complement,0.000625162212844803,0,0,1,0.0006825233180888021
173,C1R,Initial triggering of complement,0.000730418852611037,1,0,1,0.0007974376707929092
174,C1R,Regulation of Complement cascade,0.000625162212844803,0,0,1,0.0006825233180888021
175,C1R,Regulation of Complement cascade,0.000730418852611037,1,0,1,0.0007974376707929092
176,HPT,Neutrophil degranulation,0.0006871302530871525,0,0,1,0.0007501771710771439
177,HPT,Neutrophil degranulation,0.0011238383174501448,1,0,1,0.001226954927315527
178,HPT,Scavenging of heme from plasma,0.0006871302530871525,0,0,1,0.0007501771710771439
179,HPT,Scavenging of heme from plasma,0.0011238383174501448,1,0,1,0.001226954927315527
180,HPTR,Scavenging of heme from plasma,9.548920772360896e-05,0,0,1,0.00010425072014608128
181,HPTR,Scavenging of heme from plasma,0.00020609486155776354,1,0,1,0.00022500488011161534
182,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00754846973754658,0,0,1,0.008241071686529124
183,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.008445769005932557,1,0,1,0.009220701711176003
184,FA9,Defective factor VIII causes hemophilia A,0.00754846973754658,0,0,1,0.008241071686529124
185,FA9,Defective factor VIII causes hemophilia A,0.008445769005932557,1,0,1,0.009220701711176003
186,FA9,Defective factor IX causes hemophilia B,0.00754846973754658,0,0,1,0.008241071686529124
187,FA9,Defective factor IX causes hemophilia B,0.008445769005932557,1,0,1,0.009220701711176003
188,FA9,Defective factor IX causes thrombophilia,0.00754846973754658,0,0,1,0.008241071686529124
189,FA9,Defective factor IX causes thrombophilia,0.008445769005932557,1,0,1,0.009220701711176003
190,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.00754846973754658,0,0,1,0.008241071686529124
191,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.008445769005932557,1,0,1,0.009220701711176003
192,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.00754846973754658,0,0,1,0.008241071686529124
193,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.008445769005932557,1,0,1,0.009220701711176003
194,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.01931042821920089,0,0,1,0.02108223637175673
195,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02175696679046153,1,0,1,0.023753254531812387
196,FA10,Defective factor VIII causes hemophilia A,0.01931042821920089,0,0,1,0.02108223637175673
197,FA10,Defective factor VIII causes hemophilia A,0.02175696679046153,1,0,1,0.023753254531812387
198,FA10,Defective factor IX causes hemophilia B,0.01931042821920089,0,0,1,0.02108223637175673
199,FA10,Defective factor IX causes hemophilia B,0.02175696679046153,1,0,1,0.023753254531812387
200,FA10,Defective factor IX causes thrombophilia,0.01931042821920089,0,0,1,0.02108223637175673
201,FA10,Defective factor IX causes thrombophilia,0.02175696679046153,1,0,1,0.023753254531812387
202,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.01931042821920089,0,0,1,0.02108223637175673
203,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.02175696679046153,1,0,1,0.023753254531812387
204,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.01931042821920089,0,0,1,0.02108223637175673
205,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.02175696679046153,1,0,1,0.023753254531812387
206,FA10,Common Pathway of Fibrin Clot Formation,0.01931042821920089,0,0,1,0.02108223637175673
207,FA10,Common Pathway of Fibrin Clot Formation,0.02175696679046153,1,0,1,0.023753254531812387
208,CFAD,Initial triggering of complement,7.625177010415456e-05,0,0,1,8.324817155024043e-05
209,CFAD,Initial triggering of complement,7.269031198005083e-05,1,0,1,7.935993555939842e-05
210,CFAD,Platelet degranulation ,7.625177010415456e-05,0,0,1,8.324817155024043e-05
211,CFAD,Platelet degranulation ,7.269031198005083e-05,1,0,1,7.935993555939842e-05
212,CFAD,Neutrophil degranulation,7.625177010415456e-05,0,0,1,8.324817155024043e-05
213,CFAD,Neutrophil degranulation,7.269031198005083e-05,1,0,1,7.935993555939842e-05
214,PLMN,Platelet degranulation ,0.0029622063280507534,0,0,1,0.0032340004727489085
215,PLMN,Platelet degranulation ,0.0021444821087164842,1,0,1,0.0023412468225852295
216,PLMN,Dissolution of Fibrin Clot,0.0029622063280507534,0,0,1,0.0032340004727489085
217,PLMN,Dissolution of Fibrin Clot,0.0021444821087164842,1,0,1,0.0023412468225852295
218,PLMN,Activation of Matrix Metalloproteinases,0.0029622063280507534,0,0,1,0.0032340004727489085
219,PLMN,Activation of Matrix Metalloproteinases,0.0021444821087164842,1,0,1,0.0023412468225852295
220,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0029622063280507534,0,0,1,0.0032340004727489085
221,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0021444821087164842,1,0,1,0.0023412468225852295
222,PLMN,Signaling by PDGF,0.0029622063280507534,0,0,1,0.0032340004727489085
223,PLMN,Signaling by PDGF,0.0021444821087164842,1,0,1,0.0023412468225852295
224,FA12,Defective factor XII causes hereditary angioedema,0.0010467230022094078,0,0,1,0.0011427639769475174
225,FA12,Defective factor XII causes hereditary angioedema,0.001414255481239739,1,0,1,0.001544019014342841
226,FA12,Defective SERPING1 causes hereditary angioedema,0.0010467230022094078,0,0,1,0.0011427639769475174
227,FA12,Defective SERPING1 causes hereditary angioedema,0.001414255481239739,1,0,1,0.001544019014342841
228,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0010467230022094078,0,0,1,0.0011427639769475174
229,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.001414255481239739,1,0,1,0.001544019014342841
230,CFAB,Initial triggering of complement,0.0019371395076535373,0,0,1,0.002114879717934621
231,CFAB,Initial triggering of complement,0.0016293611378839922,1,0,1,0.0017788614656234865
232,CFAB,Activation of C3 and C5,0.0019371395076535373,0,0,1,0.002114879717934621
233,CFAB,Activation of C3 and C5,0.0016293611378839922,1,0,1,0.0017788614656234865
234,CFAB,Regulation of Complement cascade,0.0019371395076535373,0,0,1,0.002114879717934621
235,CFAB,Regulation of Complement cascade,0.0016293611378839922,1,0,1,0.0017788614656234865
236,CAH1,Interleukin-12 family signaling,0.0018611995005651202,0,0,1,0.002031971914889685
237,CAH1,Interleukin-12 family signaling,0.002710262957056523,1,0,1,0.002958940301151255
238,CAH1,Reversible hydration of carbon dioxide,0.0018611995005651202,0,0,1,0.002031971914889685
239,CAH1,Reversible hydration of carbon dioxide,0.002710262957056523,1,0,1,0.002958940301151255
240,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.0018611995005651202,0,0,1,0.002031971914889685
241,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.002710262957056523,1,0,1,0.002958940301151255
242,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.0018611995005651202,0,0,1,0.002031971914889685
243,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.002710262957056523,1,0,1,0.002958940301151255
244,CAH2,Reversible hydration of carbon dioxide,0.006334025091326176,0,0,1,0.006915196941474271
245,CAH2,Reversible hydration of carbon dioxide,0.006551807775838196,1,0,1,0.007152962048515907
246,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.006334025091326176,0,0,1,0.006915196941474271
247,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.006551807775838196,1,0,1,0.007152962048515907
248,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.006334025091326176,0,0,1,0.006915196941474271
249,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.006551807775838196,1,0,1,0.007152962048515907
250,ASSY,Urea cycle,0.0001454372443727083,0,0,1,0.0001587816866781666
251,ASSY,Urea cycle,2.040389042034397e-05,1,0,1,2.2276028053971108e-05
252,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.0057907104174926205,0,0,1,0.006322030997768599
253,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.007587045243735009,1,0,1,0.008283186647957894
254,ANT3,Common Pathway of Fibrin Clot Formation,0.0057907104174926205,0,0,1,0.006322030997768599
255,ANT3,Common Pathway of Fibrin Clot Formation,0.007587045243735009,1,0,1,0.008283186647957894
256,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0057907104174926205,0,0,1,0.006322030997768599
257,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007587045243735009,1,0,1,0.008283186647957894
258,ANT3,Post-translational protein phosphorylation,0.0057907104174926205,0,0,1,0.006322030997768599
259,ANT3,Post-translational protein phosphorylation,0.007587045243735009,1,0,1,0.008283186647957894
260,A1AT,COPII-mediated vesicle transport,0.001427222887099939,0,0,1,0.0015581762309705598
261,A1AT,COPII-mediated vesicle transport,0.001535712363464175,1,0,1,0.0016766200458148476
262,A1AT,Cargo concentration in the ER,0.001427222887099939,0,0,1,0.0015581762309705598
263,A1AT,Cargo concentration in the ER,0.001535712363464175,1,0,1,0.0016766200458148476
264,A1AT,Platelet degranulation ,0.001427222887099939,0,0,1,0.0015581762309705598
265,A1AT,Platelet degranulation ,0.001535712363464175,1,0,1,0.0016766200458148476
266,A1AT,Neutrophil degranulation,0.001427222887099939,0,0,1,0.0015581762309705598
267,A1AT,Neutrophil degranulation,0.001535712363464175,1,0,1,0.0016766200458148476
268,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001427222887099939,0,0,1,0.0015581762309705598
269,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001535712363464175,1,0,1,0.0016766200458148476
270,A1AT,Post-translational protein phosphorylation,0.001427222887099939,0,0,1,0.0015581762309705598
271,A1AT,Post-translational protein phosphorylation,0.001535712363464175,1,0,1,0.0016766200458148476
272,AACT,Platelet degranulation ,0.00037330679476048464,0,0,1,0.0004075591694283566
273,AACT,Platelet degranulation ,0.00037880900559202513,1,0,1,0.00041356622986228505
274,AACT,Neutrophil degranulation,0.00037330679476048464,0,0,1,0.0004075591694283566
275,AACT,Neutrophil degranulation,0.00037880900559202513,1,0,1,0.00041356622986228505
276,ANGT,Class A/1 (Rhodopsin-like receptors),0.0036018420738991833,0,0,1,0.003932325327730273
277,ANGT,Class A/1 (Rhodopsin-like receptors),0.003262942701472214,1,0,1,0.0035623305976993174
278,ANGT,G alpha (q) signalling events,0.0036018420738991833,0,0,1,0.003932325327730273
279,ANGT,G alpha (q) signalling events,0.003262942701472214,1,0,1,0.0035623305976993174
280,ANGT,G alpha (i) signalling events,0.0036018420738991833,0,0,1,0.003932325327730273
281,ANGT,G alpha (i) signalling events,0.003262942701472214,1,0,1,0.0035623305976993174
282,ANGT,PPARA activates gene expression,0.0036018420738991833,0,0,1,0.003932325327730273
283,ANGT,PPARA activates gene expression,0.003262942701472214,1,0,1,0.0035623305976993174
284,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.0036018420738991833,0,0,1,0.003932325327730273
285,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.003262942701472214,1,0,1,0.0035623305976993174
286,A2MG,Platelet degranulation ,0.004087320783305978,0,0,1,0.004462348628559642
287,A2MG,Platelet degranulation ,0.0060425127267080825,1,0,1,0.006596937164611451
288,A2MG,HDL assembly,0.004087320783305978,0,0,1,0.004462348628559642
289,A2MG,HDL assembly,0.0060425127267080825,1,0,1,0.006596937164611451
290,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.004087320783305978,0,0,1,0.004462348628559642
291,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.0060425127267080825,1,0,1,0.006596937164611451
292,CO3,Initial triggering of complement,0.0003987318330896651,0,0,1,0.00043531705556802187
293,CO3,Initial triggering of complement,0.0003169266716199753,1,0,1,0.00034600594703346985
294,CO3,Activation of C3 and C5,0.0003987318330896651,0,0,1,0.00043531705556802187
295,CO3,Activation of C3 and C5,0.0003169266716199753,1,0,1,0.00034600594703346985
296,CO3,Regulation of Complement cascade,0.0003987318330896651,0,0,1,0.00043531705556802187
297,CO3,Regulation of Complement cascade,0.0003169266716199753,1,0,1,0.00034600594703346985
298,CO3,Class A/1 (Rhodopsin-like receptors),0.0003987318330896651,0,0,1,0.00043531705556802187
299,CO3,Class A/1 (Rhodopsin-like receptors),0.0003169266716199753,1,0,1,0.00034600594703346985
300,CO3,G alpha (i) signalling events,0.0003987318330896651,0,0,1,0.00043531705556802187
301,CO3,G alpha (i) signalling events,0.0003169266716199753,1,0,1,0.00034600594703346985
302,CO3,Cell recruitment (pro-inflammatory response),0.0003987318330896651,0,0,1,0.00043531705556802187
303,CO3,Cell recruitment (pro-inflammatory response),0.0003169266716199753,1,0,1,0.00034600594703346985
304,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0003987318330896651,0,0,1,0.00043531705556802187
305,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0003169266716199753,1,0,1,0.00034600594703346985
306,CO3,Neutrophil degranulation,0.0003987318330896651,0,0,1,0.00043531705556802187
307,CO3,Neutrophil degranulation,0.0003169266716199753,1,0,1,0.00034600594703346985
308,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003987318330896651,0,0,1,0.00043531705556802187
309,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003169266716199753,1,0,1,0.00034600594703346985
310,CO3,Post-translational protein phosphorylation,0.0003987318330896651,0,0,1,0.00043531705556802187
311,CO3,Post-translational protein phosphorylation,0.0003169266716199753,1,0,1,0.00034600594703346985
312,CO5,Terminal pathway of complement,0.003010073067454712,0,0,1,0.0032862591747830827
313,CO5,Terminal pathway of complement,0.0037524790902772956,1,0,1,0.004096783886057933
314,CO5,Activation of C3 and C5,0.003010073067454712,0,0,1,0.0032862591747830827
315,CO5,Activation of C3 and C5,0.0037524790902772956,1,0,1,0.004096783886057933
316,CO5,Regulation of Complement cascade,0.003010073067454712,0,0,1,0.0032862591747830827
317,CO5,Regulation of Complement cascade,0.0037524790902772956,1,0,1,0.004096783886057933
318,CO5,Class A/1 (Rhodopsin-like receptors),0.003010073067454712,0,0,1,0.0032862591747830827
319,CO5,Class A/1 (Rhodopsin-like receptors),0.0037524790902772956,1,0,1,0.004096783886057933
320,CO5,G alpha (i) signalling events,0.003010073067454712,0,0,1,0.0032862591747830827
321,CO5,G alpha (i) signalling events,0.0037524790902772956,1,0,1,0.004096783886057933
322,TIMP1,Interleukin-10 signaling,0.0032250299201560264,0,0,1,0.003520939168770577
323,TIMP1,Interleukin-10 signaling,0.0026664156296642362,1,0,1,0.002911069808075662
324,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.0032250299201560264,0,0,1,0.003520939168770577
325,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.0026664156296642362,1,0,1,0.002911069808075662
326,TIMP1,Platelet degranulation ,0.0032250299201560264,0,0,1,0.003520939168770577
327,TIMP1,Platelet degranulation ,0.0026664156296642362,1,0,1,0.002911069808075662
328,TIMP1,Activation of Matrix Metalloproteinases,0.0032250299201560264,0,0,1,0.003520939168770577
329,TIMP1,Activation of Matrix Metalloproteinases,0.0026664156296642362,1,0,1,0.002911069808075662
330,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0032250299201560264,0,0,1,0.003520939168770577
331,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0026664156296642362,1,0,1,0.002911069808075662
332,TIMP1,Post-translational protein phosphorylation,0.0032250299201560264,0,0,1,0.003520939168770577
333,TIMP1,Post-translational protein phosphorylation,0.0026664156296642362,1,0,1,0.002911069808075662
334,CYTC,Neutrophil degranulation,0.0037658965413453734,0,0,1,0.004111432441321065
335,CYTC,Neutrophil degranulation,0.0030246726772223476,1,0,1,0.003302198356481325
336,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0037658965413453734,0,0,1,0.004111432441321065
337,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0030246726772223476,1,0,1,0.003302198356481325
338,CYTC,Amyloid fiber formation,0.0037658965413453734,0,0,1,0.004111432441321065
339,CYTC,Amyloid fiber formation,0.0030246726772223476,1,0,1,0.003302198356481325
340,CYTC,Post-translational protein phosphorylation,0.0037658965413453734,0,0,1,0.004111432441321065
341,CYTC,Post-translational protein phosphorylation,0.0030246726772223476,1,0,1,0.003302198356481325
342,KNG1,Class A/1 (Rhodopsin-like receptors),0.0045139400104250715,0,0,1,0.0049281118568405054
343,KNG1,Class A/1 (Rhodopsin-like receptors),0.005537208738294489,1,0,1,0.006045269537026978
344,KNG1,G alpha (q) signalling events,0.0045139400104250715,0,0,1,0.0049281118568405054
345,KNG1,G alpha (q) signalling events,0.005537208738294489,1,0,1,0.006045269537026978
346,KNG1,G alpha (i) signalling events,0.0045139400104250715,0,0,1,0.0049281118568405054
347,KNG1,G alpha (i) signalling events,0.005537208738294489,1,0,1,0.006045269537026978
348,KNG1,Platelet degranulation ,0.0045139400104250715,0,0,1,0.0049281118568405054
349,KNG1,Platelet degranulation ,0.005537208738294489,1,0,1,0.006045269537026978
350,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.0045139400104250715,0,0,1,0.0049281118568405054
351,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.005537208738294489,1,0,1,0.006045269537026978
352,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0045139400104250715,0,0,1,0.0049281118568405054
353,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005537208738294489,1,0,1,0.006045269537026978
354,KNG1,Post-translational protein phosphorylation,0.0045139400104250715,0,0,1,0.0049281118568405054
355,KNG1,Post-translational protein phosphorylation,0.005537208738294489,1,0,1,0.006045269537026978
356,IGF2,IGF1R signaling cascade,0.0007782899144197282,0,0,1,0.0008497010918295437
357,IGF2,IGF1R signaling cascade,0.000246326951559082,1,0,1,0.00026892842346909593
358,IGF2,Platelet degranulation ,0.0007782899144197282,0,0,1,0.0008497010918295437
359,IGF2,Platelet degranulation ,0.000246326951559082,1,0,1,0.00026892842346909593
360,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0007782899144197282,0,0,1,0.0008497010918295437
361,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.000246326951559082,1,0,1,0.00026892842346909593
362,IGJ,Scavenging of heme from plasma,0.0005143715710256415,0,0,1,0.0005615671967590983
363,IGJ,Scavenging of heme from plasma,0.0011173618398486395,1,0,1,0.0012198842072827334
364,KVD33,Initial triggering of complement,0.00024755836073284994,0,0,1,0.0002702728193041873
365,KVD33,Initial triggering of complement,0.0008282554169782457,1,0,1,0.0009042511268373055
366,KVD33,Regulation of Complement cascade,0.00024755836073284994,0,0,1,0.0002702728193041873
367,KVD33,Regulation of Complement cascade,0.0008282554169782457,1,0,1,0.0009042511268373055
368,KVD33,FCGR activation,0.00024755836073284994,0,0,1,0.0002702728193041873
369,KVD33,FCGR activation,0.0008282554169782457,1,0,1,0.0009042511268373055
370,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.00024755836073284994,0,0,1,0.0002702728193041873
371,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.0008282554169782457,1,0,1,0.0009042511268373055
372,KVD33,Role of phospholipids in phagocytosis,0.00024755836073284994,0,0,1,0.0002702728193041873
373,KVD33,Role of phospholipids in phagocytosis,0.0008282554169782457,1,0,1,0.0009042511268373055
374,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.00024755836073284994,0,0,1,0.0002702728193041873
375,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008282554169782457,1,0,1,0.0009042511268373055
376,KVD33,FCERI mediated MAPK activation,0.00024755836073284994,0,0,1,0.0002702728193041873
377,KVD33,FCERI mediated MAPK activation,0.0008282554169782457,1,0,1,0.0009042511268373055
378,KVD33,FCERI mediated Ca+2 mobilization,0.00024755836073284994,0,0,1,0.0002702728193041873
379,KVD33,FCERI mediated Ca+2 mobilization,0.0008282554169782457,1,0,1,0.0009042511268373055
380,KVD33,FCERI mediated NF-kB activation,0.00024755836073284994,0,0,1,0.0002702728193041873
381,KVD33,FCERI mediated NF-kB activation,0.0008282554169782457,1,0,1,0.0009042511268373055
382,KVD33,Parasite infection,0.00024755836073284994,0,0,1,0.0002702728193041873
383,KVD33,Parasite infection,0.0008282554169782457,1,0,1,0.0009042511268373055
384,KVD33,Leishmania parasite growth and survival,0.00024755836073284994,0,0,1,0.0002702728193041873
385,KVD33,Leishmania parasite growth and survival,0.0008282554169782457,1,0,1,0.0009042511268373055
386,KVD33,Potential therapeutics for SARS,0.00024755836073284994,0,0,1,0.0002702728193041873
387,KVD33,Potential therapeutics for SARS,0.0008282554169782457,1,0,1,0.0009042511268373055
388,KVD33,CD22 mediated BCR regulation,0.00024755836073284994,0,0,1,0.0002702728193041873
389,KVD33,CD22 mediated BCR regulation,0.0008282554169782457,1,0,1,0.0009042511268373055
390,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00024755836073284994,0,0,1,0.0002702728193041873
391,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008282554169782457,1,0,1,0.0009042511268373055
392,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00024755836073284994,0,0,1,0.0002702728193041873
393,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008282554169782457,1,0,1,0.0009042511268373055
394,KVD33,Scavenging of heme from plasma,0.00024755836073284994,0,0,1,0.0002702728193041873
395,KVD33,Scavenging of heme from plasma,0.0008282554169782457,1,0,1,0.0009042511268373055
396,KVD16,Initial triggering of complement,0.0002032799923715987,0,0,1,0.00022193173554616784
397,KVD16,Initial triggering of complement,0.0012230799648069262,1,0,1,0.001335302388270216
398,KVD16,Regulation of Complement cascade,0.0002032799923715987,0,0,1,0.00022193173554616784
399,KVD16,Regulation of Complement cascade,0.0012230799648069262,1,0,1,0.001335302388270216
400,KVD16,FCGR activation,0.0002032799923715987,0,0,1,0.00022193173554616784
401,KVD16,FCGR activation,0.0012230799648069262,1,0,1,0.001335302388270216
402,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.0002032799923715987,0,0,1,0.00022193173554616784
403,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.0012230799648069262,1,0,1,0.001335302388270216
404,KVD16,Role of phospholipids in phagocytosis,0.0002032799923715987,0,0,1,0.00022193173554616784
405,KVD16,Role of phospholipids in phagocytosis,0.0012230799648069262,1,0,1,0.001335302388270216
406,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.0002032799923715987,0,0,1,0.00022193173554616784
407,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.0012230799648069262,1,0,1,0.001335302388270216
408,KVD16,FCERI mediated MAPK activation,0.0002032799923715987,0,0,1,0.00022193173554616784
409,KVD16,FCERI mediated MAPK activation,0.0012230799648069262,1,0,1,0.001335302388270216
410,KVD16,FCERI mediated Ca+2 mobilization,0.0002032799923715987,0,0,1,0.00022193173554616784
411,KVD16,FCERI mediated Ca+2 mobilization,0.0012230799648069262,1,0,1,0.001335302388270216
412,KVD16,FCERI mediated NF-kB activation,0.0002032799923715987,0,0,1,0.00022193173554616784
413,KVD16,FCERI mediated NF-kB activation,0.0012230799648069262,1,0,1,0.001335302388270216
414,KVD16,Parasite infection,0.0002032799923715987,0,0,1,0.00022193173554616784
415,KVD16,Parasite infection,0.0012230799648069262,1,0,1,0.001335302388270216
416,KVD16,Leishmania parasite growth and survival,0.0002032799923715987,0,0,1,0.00022193173554616784
417,KVD16,Leishmania parasite growth and survival,0.0012230799648069262,1,0,1,0.001335302388270216
418,KVD16,Potential therapeutics for SARS,0.0002032799923715987,0,0,1,0.00022193173554616784
419,KVD16,Potential therapeutics for SARS,0.0012230799648069262,1,0,1,0.001335302388270216
420,KVD16,CD22 mediated BCR regulation,0.0002032799923715987,0,0,1,0.00022193173554616784
421,KVD16,CD22 mediated BCR regulation,0.0012230799648069262,1,0,1,0.001335302388270216
422,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0002032799923715987,0,0,1,0.00022193173554616784
423,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0012230799648069262,1,0,1,0.001335302388270216
424,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002032799923715987,0,0,1,0.00022193173554616784
425,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0012230799648069262,1,0,1,0.001335302388270216
426,KVD16,Scavenging of heme from plasma,0.0002032799923715987,0,0,1,0.00022193173554616784
427,KVD16,Scavenging of heme from plasma,0.0012230799648069262,1,0,1,0.001335302388270216
428,KV105,Initial triggering of complement,0.006302361644556726,0,0,1,0.00688062824825004
429,KV105,Initial triggering of complement,0.007193657037389712,1,0,1,0.007853703518019504
430,KV105,Regulation of Complement cascade,0.006302361644556726,0,0,1,0.00688062824825004
431,KV105,Regulation of Complement cascade,0.007193657037389712,1,0,1,0.007853703518019504
432,KV105,FCGR activation,0.006302361644556726,0,0,1,0.00688062824825004
433,KV105,FCGR activation,0.007193657037389712,1,0,1,0.007853703518019504
434,KV105,Regulation of actin dynamics for phagocytic cup formation,0.006302361644556726,0,0,1,0.00688062824825004
435,KV105,Regulation of actin dynamics for phagocytic cup formation,0.007193657037389712,1,0,1,0.007853703518019504
436,KV105,Role of phospholipids in phagocytosis,0.006302361644556726,0,0,1,0.00688062824825004
437,KV105,Role of phospholipids in phagocytosis,0.007193657037389712,1,0,1,0.007853703518019504
438,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.006302361644556726,0,0,1,0.00688062824825004
439,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.007193657037389712,1,0,1,0.007853703518019504
440,KV105,FCERI mediated MAPK activation,0.006302361644556726,0,0,1,0.00688062824825004
441,KV105,FCERI mediated MAPK activation,0.007193657037389712,1,0,1,0.007853703518019504
442,KV105,FCERI mediated Ca+2 mobilization,0.006302361644556726,0,0,1,0.00688062824825004
443,KV105,FCERI mediated Ca+2 mobilization,0.007193657037389712,1,0,1,0.007853703518019504
444,KV105,FCERI mediated NF-kB activation,0.006302361644556726,0,0,1,0.00688062824825004
445,KV105,FCERI mediated NF-kB activation,0.007193657037389712,1,0,1,0.007853703518019504
446,KV105,Parasite infection,0.006302361644556726,0,0,1,0.00688062824825004
447,KV105,Parasite infection,0.007193657037389712,1,0,1,0.007853703518019504
448,KV105,Leishmania parasite growth and survival,0.006302361644556726,0,0,1,0.00688062824825004
449,KV105,Leishmania parasite growth and survival,0.007193657037389712,1,0,1,0.007853703518019504
450,KV105,Potential therapeutics for SARS,0.006302361644556726,0,0,1,0.00688062824825004
451,KV105,Potential therapeutics for SARS,0.007193657037389712,1,0,1,0.007853703518019504
452,KV105,CD22 mediated BCR regulation,0.006302361644556726,0,0,1,0.00688062824825004
453,KV105,CD22 mediated BCR regulation,0.007193657037389712,1,0,1,0.007853703518019504
454,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006302361644556726,0,0,1,0.00688062824825004
455,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007193657037389712,1,0,1,0.007853703518019504
456,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006302361644556726,0,0,1,0.00688062824825004
457,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007193657037389712,1,0,1,0.007853703518019504
458,KV105,Scavenging of heme from plasma,0.006302361644556726,0,0,1,0.00688062824825004
459,KV105,Scavenging of heme from plasma,0.007193657037389712,1,0,1,0.007853703518019504
460,KVD12,Initial triggering of complement,0.0013440444602145427,0,0,1,0.0014673658544878069
461,KVD12,Initial triggering of complement,0.001988508483558745,1,0,1,0.0021709620005186934
462,KVD12,Regulation of Complement cascade,0.0013440444602145427,0,0,1,0.0014673658544878069
463,KVD12,Regulation of Complement cascade,0.001988508483558745,1,0,1,0.0021709620005186934
464,KVD12,FCGR activation,0.0013440444602145427,0,0,1,0.0014673658544878069
465,KVD12,FCGR activation,0.001988508483558745,1,0,1,0.0021709620005186934
466,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.0013440444602145427,0,0,1,0.0014673658544878069
467,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.001988508483558745,1,0,1,0.0021709620005186934
468,KVD12,Role of phospholipids in phagocytosis,0.0013440444602145427,0,0,1,0.0014673658544878069
469,KVD12,Role of phospholipids in phagocytosis,0.001988508483558745,1,0,1,0.0021709620005186934
470,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013440444602145427,0,0,1,0.0014673658544878069
471,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.001988508483558745,1,0,1,0.0021709620005186934
472,KVD12,FCERI mediated MAPK activation,0.0013440444602145427,0,0,1,0.0014673658544878069
473,KVD12,FCERI mediated MAPK activation,0.001988508483558745,1,0,1,0.0021709620005186934
474,KVD12,FCERI mediated Ca+2 mobilization,0.0013440444602145427,0,0,1,0.0014673658544878069
475,KVD12,FCERI mediated Ca+2 mobilization,0.001988508483558745,1,0,1,0.0021709620005186934
476,KVD12,FCERI mediated NF-kB activation,0.0013440444602145427,0,0,1,0.0014673658544878069
477,KVD12,FCERI mediated NF-kB activation,0.001988508483558745,1,0,1,0.0021709620005186934
478,KVD12,Parasite infection,0.0013440444602145427,0,0,1,0.0014673658544878069
479,KVD12,Parasite infection,0.001988508483558745,1,0,1,0.0021709620005186934
480,KVD12,Leishmania parasite growth and survival,0.0013440444602145427,0,0,1,0.0014673658544878069
481,KVD12,Leishmania parasite growth and survival,0.001988508483558745,1,0,1,0.0021709620005186934
482,KVD12,Potential therapeutics for SARS,0.0013440444602145427,0,0,1,0.0014673658544878069
483,KVD12,Potential therapeutics for SARS,0.001988508483558745,1,0,1,0.0021709620005186934
484,KVD12,CD22 mediated BCR regulation,0.0013440444602145427,0,0,1,0.0014673658544878069
485,KVD12,CD22 mediated BCR regulation,0.001988508483558745,1,0,1,0.0021709620005186934
486,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013440444602145427,0,0,1,0.0014673658544878069
487,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001988508483558745,1,0,1,0.0021709620005186934
488,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013440444602145427,0,0,1,0.0014673658544878069
489,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001988508483558745,1,0,1,0.0021709620005186934
490,KVD12,Scavenging of heme from plasma,0.0013440444602145427,0,0,1,0.0014673658544878069
491,KVD12,Scavenging of heme from plasma,0.001988508483558745,1,0,1,0.0021709620005186934
492,KVD40,Initial triggering of complement,0.005040991468603107,0,0,1,0.005503522370541077
493,KVD40,Initial triggering of complement,0.005674188883249325,1,0,1,0.006194818151971928
494,KVD40,Regulation of Complement cascade,0.005040991468603107,0,0,1,0.005503522370541077
495,KVD40,Regulation of Complement cascade,0.005674188883249325,1,0,1,0.006194818151971928
496,KVD40,FCGR activation,0.005040991468603107,0,0,1,0.005503522370541077
497,KVD40,FCGR activation,0.005674188883249325,1,0,1,0.006194818151971928
498,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.005040991468603107,0,0,1,0.005503522370541077
499,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.005674188883249325,1,0,1,0.006194818151971928
500,KVD40,Role of phospholipids in phagocytosis,0.005040991468603107,0,0,1,0.005503522370541077
501,KVD40,Role of phospholipids in phagocytosis,0.005674188883249325,1,0,1,0.006194818151971928
502,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.005040991468603107,0,0,1,0.005503522370541077
503,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.005674188883249325,1,0,1,0.006194818151971928
504,KVD40,FCERI mediated MAPK activation,0.005040991468603107,0,0,1,0.005503522370541077
505,KVD40,FCERI mediated MAPK activation,0.005674188883249325,1,0,1,0.006194818151971928
506,KVD40,FCERI mediated Ca+2 mobilization,0.005040991468603107,0,0,1,0.005503522370541077
507,KVD40,FCERI mediated Ca+2 mobilization,0.005674188883249325,1,0,1,0.006194818151971928
508,KVD40,FCERI mediated NF-kB activation,0.005040991468603107,0,0,1,0.005503522370541077
509,KVD40,FCERI mediated NF-kB activation,0.005674188883249325,1,0,1,0.006194818151971928
510,KVD40,Parasite infection,0.005040991468603107,0,0,1,0.005503522370541077
511,KVD40,Parasite infection,0.005674188883249325,1,0,1,0.006194818151971928
512,KVD40,Leishmania parasite growth and survival,0.005040991468603107,0,0,1,0.005503522370541077
513,KVD40,Leishmania parasite growth and survival,0.005674188883249325,1,0,1,0.006194818151971928
514,KVD40,Potential therapeutics for SARS,0.005040991468603107,0,0,1,0.005503522370541077
515,KVD40,Potential therapeutics for SARS,0.005674188883249325,1,0,1,0.006194818151971928
516,KVD40,CD22 mediated BCR regulation,0.005040991468603107,0,0,1,0.005503522370541077
517,KVD40,CD22 mediated BCR regulation,0.005674188883249325,1,0,1,0.006194818151971928
518,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005040991468603107,0,0,1,0.005503522370541077
519,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005674188883249325,1,0,1,0.006194818151971928
520,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005040991468603107,0,0,1,0.005503522370541077
521,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005674188883249325,1,0,1,0.006194818151971928
522,KVD40,Scavenging of heme from plasma,0.005040991468603107,0,0,1,0.005503522370541077
523,KVD40,Scavenging of heme from plasma,0.005674188883249325,1,0,1,0.006194818151971928
524,KV320,Initial triggering of complement,0.005802308107598633,0,0,1,0.006334692821805118
525,KV320,Initial triggering of complement,0.006196337000367605,1,0,1,0.006764875423680159
526,KV320,Regulation of Complement cascade,0.005802308107598633,0,0,1,0.006334692821805118
527,KV320,Regulation of Complement cascade,0.006196337000367605,1,0,1,0.006764875423680159
528,KV320,FCGR activation,0.005802308107598633,0,0,1,0.006334692821805118
529,KV320,FCGR activation,0.006196337000367605,1,0,1,0.006764875423680159
530,KV320,Regulation of actin dynamics for phagocytic cup formation,0.005802308107598633,0,0,1,0.006334692821805118
531,KV320,Regulation of actin dynamics for phagocytic cup formation,0.006196337000367605,1,0,1,0.006764875423680159
532,KV320,Role of phospholipids in phagocytosis,0.005802308107598633,0,0,1,0.006334692821805118
533,KV320,Role of phospholipids in phagocytosis,0.006196337000367605,1,0,1,0.006764875423680159
534,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.005802308107598633,0,0,1,0.006334692821805118
535,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.006196337000367605,1,0,1,0.006764875423680159
536,KV320,FCERI mediated MAPK activation,0.005802308107598633,0,0,1,0.006334692821805118
537,KV320,FCERI mediated MAPK activation,0.006196337000367605,1,0,1,0.006764875423680159
538,KV320,FCERI mediated Ca+2 mobilization,0.005802308107598633,0,0,1,0.006334692821805118
539,KV320,FCERI mediated Ca+2 mobilization,0.006196337000367605,1,0,1,0.006764875423680159
540,KV320,FCERI mediated NF-kB activation,0.005802308107598633,0,0,1,0.006334692821805118
541,KV320,FCERI mediated NF-kB activation,0.006196337000367605,1,0,1,0.006764875423680159
542,KV320,Parasite infection,0.005802308107598633,0,0,1,0.006334692821805118
543,KV320,Parasite infection,0.006196337000367605,1,0,1,0.006764875423680159
544,KV320,Leishmania parasite growth and survival,0.005802308107598633,0,0,1,0.006334692821805118
545,KV320,Leishmania parasite growth and survival,0.006196337000367605,1,0,1,0.006764875423680159
546,KV320,Potential therapeutics for SARS,0.005802308107598633,0,0,1,0.006334692821805118
547,KV320,Potential therapeutics for SARS,0.006196337000367605,1,0,1,0.006764875423680159
548,KV320,CD22 mediated BCR regulation,0.005802308107598633,0,0,1,0.006334692821805118
549,KV320,CD22 mediated BCR regulation,0.006196337000367605,1,0,1,0.006764875423680159
550,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005802308107598633,0,0,1,0.006334692821805118
551,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006196337000367605,1,0,1,0.006764875423680159
552,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005802308107598633,0,0,1,0.006334692821805118
553,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006196337000367605,1,0,1,0.006764875423680159
554,KV320,Scavenging of heme from plasma,0.005802308107598633,0,0,1,0.006334692821805118
555,KV320,Scavenging of heme from plasma,0.006196337000367605,1,0,1,0.006764875423680159
556,LV147,Initial triggering of complement,0.004264243391165844,0,0,1,0.004655504585334362
557,LV147,Initial triggering of complement,0.005190931991247052,1,0,1,0.005667220529080163
558,LV147,Regulation of Complement cascade,0.004264243391165844,0,0,1,0.004655504585334362
559,LV147,Regulation of Complement cascade,0.005190931991247052,1,0,1,0.005667220529080163
560,LV147,FCGR activation,0.004264243391165844,0,0,1,0.004655504585334362
561,LV147,FCGR activation,0.005190931991247052,1,0,1,0.005667220529080163
562,LV147,Regulation of actin dynamics for phagocytic cup formation,0.004264243391165844,0,0,1,0.004655504585334362
563,LV147,Regulation of actin dynamics for phagocytic cup formation,0.005190931991247052,1,0,1,0.005667220529080163
564,LV147,Role of phospholipids in phagocytosis,0.004264243391165844,0,0,1,0.004655504585334362
565,LV147,Role of phospholipids in phagocytosis,0.005190931991247052,1,0,1,0.005667220529080163
566,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.004264243391165844,0,0,1,0.004655504585334362
567,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.005190931991247052,1,0,1,0.005667220529080163
568,LV147,FCERI mediated MAPK activation,0.004264243391165844,0,0,1,0.004655504585334362
569,LV147,FCERI mediated MAPK activation,0.005190931991247052,1,0,1,0.005667220529080163
570,LV147,FCERI mediated Ca+2 mobilization,0.004264243391165844,0,0,1,0.004655504585334362
571,LV147,FCERI mediated Ca+2 mobilization,0.005190931991247052,1,0,1,0.005667220529080163
572,LV147,FCERI mediated NF-kB activation,0.004264243391165844,0,0,1,0.004655504585334362
573,LV147,FCERI mediated NF-kB activation,0.005190931991247052,1,0,1,0.005667220529080163
574,LV147,Parasite infection,0.004264243391165844,0,0,1,0.004655504585334362
575,LV147,Parasite infection,0.005190931991247052,1,0,1,0.005667220529080163
576,LV147,Leishmania parasite growth and survival,0.004264243391165844,0,0,1,0.004655504585334362
577,LV147,Leishmania parasite growth and survival,0.005190931991247052,1,0,1,0.005667220529080163
578,LV147,Potential therapeutics for SARS,0.004264243391165844,0,0,1,0.004655504585334362
579,LV147,Potential therapeutics for SARS,0.005190931991247052,1,0,1,0.005667220529080163
580,LV147,CD22 mediated BCR regulation,0.004264243391165844,0,0,1,0.004655504585334362
581,LV147,CD22 mediated BCR regulation,0.005190931991247052,1,0,1,0.005667220529080163
582,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004264243391165844,0,0,1,0.004655504585334362
583,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005190931991247052,1,0,1,0.005667220529080163
584,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004264243391165844,0,0,1,0.004655504585334362
585,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005190931991247052,1,0,1,0.005667220529080163
586,LV147,Scavenging of heme from plasma,0.004264243391165844,0,0,1,0.004655504585334362
587,LV147,Scavenging of heme from plasma,0.005190931991247052,1,0,1,0.005667220529080163
588,LV319,Initial triggering of complement,0.004969099748094901,0,0,1,0.005425034300379111
589,LV319,Initial triggering of complement,0.004967687284633154,1,0,1,0.0054234922378091355
590,LV319,Regulation of Complement cascade,0.004969099748094901,0,0,1,0.005425034300379111
591,LV319,Regulation of Complement cascade,0.004967687284633154,1,0,1,0.0054234922378091355
592,LV319,FCGR activation,0.004969099748094901,0,0,1,0.005425034300379111
593,LV319,FCGR activation,0.004967687284633154,1,0,1,0.0054234922378091355
594,LV319,Regulation of actin dynamics for phagocytic cup formation,0.004969099748094901,0,0,1,0.005425034300379111
595,LV319,Regulation of actin dynamics for phagocytic cup formation,0.004967687284633154,1,0,1,0.0054234922378091355
596,LV319,Role of phospholipids in phagocytosis,0.004969099748094901,0,0,1,0.005425034300379111
597,LV319,Role of phospholipids in phagocytosis,0.004967687284633154,1,0,1,0.0054234922378091355
598,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.004969099748094901,0,0,1,0.005425034300379111
599,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.004967687284633154,1,0,1,0.0054234922378091355
600,LV319,FCERI mediated MAPK activation,0.004969099748094901,0,0,1,0.005425034300379111
601,LV319,FCERI mediated MAPK activation,0.004967687284633154,1,0,1,0.0054234922378091355
602,LV319,FCERI mediated Ca+2 mobilization,0.004969099748094901,0,0,1,0.005425034300379111
603,LV319,FCERI mediated Ca+2 mobilization,0.004967687284633154,1,0,1,0.0054234922378091355
604,LV319,FCERI mediated NF-kB activation,0.004969099748094901,0,0,1,0.005425034300379111
605,LV319,FCERI mediated NF-kB activation,0.004967687284633154,1,0,1,0.0054234922378091355
606,LV319,Parasite infection,0.004969099748094901,0,0,1,0.005425034300379111
607,LV319,Parasite infection,0.004967687284633154,1,0,1,0.0054234922378091355
608,LV319,Leishmania parasite growth and survival,0.004969099748094901,0,0,1,0.005425034300379111
609,LV319,Leishmania parasite growth and survival,0.004967687284633154,1,0,1,0.0054234922378091355
610,LV319,Potential therapeutics for SARS,0.004969099748094901,0,0,1,0.005425034300379111
611,LV319,Potential therapeutics for SARS,0.004967687284633154,1,0,1,0.0054234922378091355
612,LV319,CD22 mediated BCR regulation,0.004969099748094901,0,0,1,0.005425034300379111
613,LV319,CD22 mediated BCR regulation,0.004967687284633154,1,0,1,0.0054234922378091355
614,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004969099748094901,0,0,1,0.005425034300379111
615,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004967687284633154,1,0,1,0.0054234922378091355
616,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004969099748094901,0,0,1,0.005425034300379111
617,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004967687284633154,1,0,1,0.0054234922378091355
618,LV319,Scavenging of heme from plasma,0.004969099748094901,0,0,1,0.005425034300379111
619,LV319,Scavenging of heme from plasma,0.004967687284633154,1,0,1,0.0054234922378091355
620,LV325,Initial triggering of complement,0.0026773527454351637,0,0,1,0.0029230104474695976
621,LV325,Initial triggering of complement,0.002805783989282331,1,0,1,0.003063225765823463
622,LV325,Regulation of Complement cascade,0.0026773527454351637,0,0,1,0.0029230104474695976
623,LV325,Regulation of Complement cascade,0.002805783989282331,1,0,1,0.003063225765823463
624,LV325,FCGR activation,0.0026773527454351637,0,0,1,0.0029230104474695976
625,LV325,FCGR activation,0.002805783989282331,1,0,1,0.003063225765823463
626,LV325,Regulation of actin dynamics for phagocytic cup formation,0.0026773527454351637,0,0,1,0.0029230104474695976
627,LV325,Regulation of actin dynamics for phagocytic cup formation,0.002805783989282331,1,0,1,0.003063225765823463
628,LV325,Role of phospholipids in phagocytosis,0.0026773527454351637,0,0,1,0.0029230104474695976
629,LV325,Role of phospholipids in phagocytosis,0.002805783989282331,1,0,1,0.003063225765823463
630,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.0026773527454351637,0,0,1,0.0029230104474695976
631,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.002805783989282331,1,0,1,0.003063225765823463
632,LV325,FCERI mediated MAPK activation,0.0026773527454351637,0,0,1,0.0029230104474695976
633,LV325,FCERI mediated MAPK activation,0.002805783989282331,1,0,1,0.003063225765823463
634,LV325,FCERI mediated Ca+2 mobilization,0.0026773527454351637,0,0,1,0.0029230104474695976
635,LV325,FCERI mediated Ca+2 mobilization,0.002805783989282331,1,0,1,0.003063225765823463
636,LV325,FCERI mediated NF-kB activation,0.0026773527454351637,0,0,1,0.0029230104474695976
637,LV325,FCERI mediated NF-kB activation,0.002805783989282331,1,0,1,0.003063225765823463
638,LV325,Parasite infection,0.0026773527454351637,0,0,1,0.0029230104474695976
639,LV325,Parasite infection,0.002805783989282331,1,0,1,0.003063225765823463
640,LV325,Leishmania parasite growth and survival,0.0026773527454351637,0,0,1,0.0029230104474695976
641,LV325,Leishmania parasite growth and survival,0.002805783989282331,1,0,1,0.003063225765823463
642,LV325,Potential therapeutics for SARS,0.0026773527454351637,0,0,1,0.0029230104474695976
643,LV325,Potential therapeutics for SARS,0.002805783989282331,1,0,1,0.003063225765823463
644,LV325,CD22 mediated BCR regulation,0.0026773527454351637,0,0,1,0.0029230104474695976
645,LV325,CD22 mediated BCR regulation,0.002805783989282331,1,0,1,0.003063225765823463
646,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0026773527454351637,0,0,1,0.0029230104474695976
647,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002805783989282331,1,0,1,0.003063225765823463
648,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0026773527454351637,0,0,1,0.0029230104474695976
649,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002805783989282331,1,0,1,0.003063225765823463
650,LV325,Scavenging of heme from plasma,0.0026773527454351637,0,0,1,0.0029230104474695976
651,LV325,Scavenging of heme from plasma,0.002805783989282331,1,0,1,0.003063225765823463
652,HV169,Initial triggering of complement,0.0026263602263811824,0,0,1,0.0028673391631415576
653,HV169,Initial triggering of complement,0.002633784762577025,1,0,1,0.002875444929893834
654,HV169,Regulation of Complement cascade,0.0026263602263811824,0,0,1,0.0028673391631415576
655,HV169,Regulation of Complement cascade,0.002633784762577025,1,0,1,0.002875444929893834
656,HV169,FCGR activation,0.0026263602263811824,0,0,1,0.0028673391631415576
657,HV169,FCGR activation,0.002633784762577025,1,0,1,0.002875444929893834
658,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0026263602263811824,0,0,1,0.0028673391631415576
659,HV169,Regulation of actin dynamics for phagocytic cup formation,0.002633784762577025,1,0,1,0.002875444929893834
660,HV169,Role of phospholipids in phagocytosis,0.0026263602263811824,0,0,1,0.0028673391631415576
661,HV169,Role of phospholipids in phagocytosis,0.002633784762577025,1,0,1,0.002875444929893834
662,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0026263602263811824,0,0,1,0.0028673391631415576
663,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.002633784762577025,1,0,1,0.002875444929893834
664,HV169,FCERI mediated MAPK activation,0.0026263602263811824,0,0,1,0.0028673391631415576
665,HV169,FCERI mediated MAPK activation,0.002633784762577025,1,0,1,0.002875444929893834
666,HV169,FCERI mediated Ca+2 mobilization,0.0026263602263811824,0,0,1,0.0028673391631415576
667,HV169,FCERI mediated Ca+2 mobilization,0.002633784762577025,1,0,1,0.002875444929893834
668,HV169,FCERI mediated NF-kB activation,0.0026263602263811824,0,0,1,0.0028673391631415576
669,HV169,FCERI mediated NF-kB activation,0.002633784762577025,1,0,1,0.002875444929893834
670,HV169,Parasite infection,0.0026263602263811824,0,0,1,0.0028673391631415576
671,HV169,Parasite infection,0.002633784762577025,1,0,1,0.002875444929893834
672,HV169,Leishmania parasite growth and survival,0.0026263602263811824,0,0,1,0.0028673391631415576
673,HV169,Leishmania parasite growth and survival,0.002633784762577025,1,0,1,0.002875444929893834
674,HV169,Potential therapeutics for SARS,0.0026263602263811824,0,0,1,0.0028673391631415576
675,HV169,Potential therapeutics for SARS,0.002633784762577025,1,0,1,0.002875444929893834
676,HV169,CD22 mediated BCR regulation,0.0026263602263811824,0,0,1,0.0028673391631415576
677,HV169,CD22 mediated BCR regulation,0.002633784762577025,1,0,1,0.002875444929893834
678,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0026263602263811824,0,0,1,0.0028673391631415576
679,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002633784762577025,1,0,1,0.002875444929893834
680,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0026263602263811824,0,0,1,0.0028673391631415576
681,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002633784762577025,1,0,1,0.002875444929893834
682,HV169,Scavenging of heme from plasma,0.0026263602263811824,0,0,1,0.0028673391631415576
683,HV169,Scavenging of heme from plasma,0.002633784762577025,1,0,1,0.002875444929893834
684,HV146,Initial triggering of complement,0.0023699021165729793,0,0,1,0.002587350007590132
685,HV146,Initial triggering of complement,0.0022098529639451906,1,0,1,0.002412615712291421
686,HV146,Regulation of Complement cascade,0.0023699021165729793,0,0,1,0.002587350007590132
687,HV146,Regulation of Complement cascade,0.0022098529639451906,1,0,1,0.002412615712291421
688,HV146,FCGR activation,0.0023699021165729793,0,0,1,0.002587350007590132
689,HV146,FCGR activation,0.0022098529639451906,1,0,1,0.002412615712291421
690,HV146,Regulation of actin dynamics for phagocytic cup formation,0.0023699021165729793,0,0,1,0.002587350007590132
691,HV146,Regulation of actin dynamics for phagocytic cup formation,0.0022098529639451906,1,0,1,0.002412615712291421
692,HV146,Role of phospholipids in phagocytosis,0.0023699021165729793,0,0,1,0.002587350007590132
693,HV146,Role of phospholipids in phagocytosis,0.0022098529639451906,1,0,1,0.002412615712291421
694,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.0023699021165729793,0,0,1,0.002587350007590132
695,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.0022098529639451906,1,0,1,0.002412615712291421
696,HV146,FCERI mediated MAPK activation,0.0023699021165729793,0,0,1,0.002587350007590132
697,HV146,FCERI mediated MAPK activation,0.0022098529639451906,1,0,1,0.002412615712291421
698,HV146,FCERI mediated Ca+2 mobilization,0.0023699021165729793,0,0,1,0.002587350007590132
699,HV146,FCERI mediated Ca+2 mobilization,0.0022098529639451906,1,0,1,0.002412615712291421
700,HV146,FCERI mediated NF-kB activation,0.0023699021165729793,0,0,1,0.002587350007590132
701,HV146,FCERI mediated NF-kB activation,0.0022098529639451906,1,0,1,0.002412615712291421
702,HV146,Parasite infection,0.0023699021165729793,0,0,1,0.002587350007590132
703,HV146,Parasite infection,0.0022098529639451906,1,0,1,0.002412615712291421
704,HV146,Leishmania parasite growth and survival,0.0023699021165729793,0,0,1,0.002587350007590132
705,HV146,Leishmania parasite growth and survival,0.0022098529639451906,1,0,1,0.002412615712291421
706,HV146,Potential therapeutics for SARS,0.0023699021165729793,0,0,1,0.002587350007590132
707,HV146,Potential therapeutics for SARS,0.0022098529639451906,1,0,1,0.002412615712291421
708,HV146,CD22 mediated BCR regulation,0.0023699021165729793,0,0,1,0.002587350007590132
709,HV146,CD22 mediated BCR regulation,0.0022098529639451906,1,0,1,0.002412615712291421
710,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0023699021165729793,0,0,1,0.002587350007590132
711,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0022098529639451906,1,0,1,0.002412615712291421
712,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0023699021165729793,0,0,1,0.002587350007590132
713,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0022098529639451906,1,0,1,0.002412615712291421
714,HV146,Scavenging of heme from plasma,0.0023699021165729793,0,0,1,0.002587350007590132
715,HV146,Scavenging of heme from plasma,0.0022098529639451906,1,0,1,0.002412615712291421
716,HV348,Initial triggering of complement,0.006592074200765231,0,0,1,0.007196923077164317
717,HV348,Initial triggering of complement,0.006629105695270103,1,0,1,0.007237352357731738
718,HV348,Regulation of Complement cascade,0.006592074200765231,0,0,1,0.007196923077164317
719,HV348,Regulation of Complement cascade,0.006629105695270103,1,0,1,0.007237352357731738
720,HV348,FCGR activation,0.006592074200765231,0,0,1,0.007196923077164317
721,HV348,FCGR activation,0.006629105695270103,1,0,1,0.007237352357731738
722,HV348,Regulation of actin dynamics for phagocytic cup formation,0.006592074200765231,0,0,1,0.007196923077164317
723,HV348,Regulation of actin dynamics for phagocytic cup formation,0.006629105695270103,1,0,1,0.007237352357731738
724,HV348,Role of phospholipids in phagocytosis,0.006592074200765231,0,0,1,0.007196923077164317
725,HV348,Role of phospholipids in phagocytosis,0.006629105695270103,1,0,1,0.007237352357731738
726,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.006592074200765231,0,0,1,0.007196923077164317
727,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.006629105695270103,1,0,1,0.007237352357731738
728,HV348,FCERI mediated MAPK activation,0.006592074200765231,0,0,1,0.007196923077164317
729,HV348,FCERI mediated MAPK activation,0.006629105695270103,1,0,1,0.007237352357731738
730,HV348,FCERI mediated Ca+2 mobilization,0.006592074200765231,0,0,1,0.007196923077164317
731,HV348,FCERI mediated Ca+2 mobilization,0.006629105695270103,1,0,1,0.007237352357731738
732,HV348,FCERI mediated NF-kB activation,0.006592074200765231,0,0,1,0.007196923077164317
733,HV348,FCERI mediated NF-kB activation,0.006629105695270103,1,0,1,0.007237352357731738
734,HV348,Parasite infection,0.006592074200765231,0,0,1,0.007196923077164317
735,HV348,Parasite infection,0.006629105695270103,1,0,1,0.007237352357731738
736,HV348,Leishmania parasite growth and survival,0.006592074200765231,0,0,1,0.007196923077164317
737,HV348,Leishmania parasite growth and survival,0.006629105695270103,1,0,1,0.007237352357731738
738,HV348,Potential therapeutics for SARS,0.006592074200765231,0,0,1,0.007196923077164317
739,HV348,Potential therapeutics for SARS,0.006629105695270103,1,0,1,0.007237352357731738
740,HV348,CD22 mediated BCR regulation,0.006592074200765231,0,0,1,0.007196923077164317
741,HV348,CD22 mediated BCR regulation,0.006629105695270103,1,0,1,0.007237352357731738
742,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006592074200765231,0,0,1,0.007196923077164317
743,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006629105695270103,1,0,1,0.007237352357731738
744,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006592074200765231,0,0,1,0.007196923077164317
745,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006629105695270103,1,0,1,0.007237352357731738
746,HV348,Scavenging of heme from plasma,0.006592074200765231,0,0,1,0.007196923077164317
747,HV348,Scavenging of heme from plasma,0.006629105695270103,1,0,1,0.007237352357731738
748,HV323,Initial triggering of complement,0.007346648595705516,0,0,1,0.008020732656818718
749,HV323,Initial triggering of complement,0.007519819226217805,1,0,1,0.00820979237748696
750,HV323,Regulation of Complement cascade,0.007346648595705516,0,0,1,0.008020732656818718
751,HV323,Regulation of Complement cascade,0.007519819226217805,1,0,1,0.00820979237748696
752,HV323,FCGR activation,0.007346648595705516,0,0,1,0.008020732656818718
753,HV323,FCGR activation,0.007519819226217805,1,0,1,0.00820979237748696
754,HV323,Regulation of actin dynamics for phagocytic cup formation,0.007346648595705516,0,0,1,0.008020732656818718
755,HV323,Regulation of actin dynamics for phagocytic cup formation,0.007519819226217805,1,0,1,0.00820979237748696
756,HV323,Role of phospholipids in phagocytosis,0.007346648595705516,0,0,1,0.008020732656818718
757,HV323,Role of phospholipids in phagocytosis,0.007519819226217805,1,0,1,0.00820979237748696
758,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.007346648595705516,0,0,1,0.008020732656818718
759,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.007519819226217805,1,0,1,0.00820979237748696
760,HV323,FCERI mediated MAPK activation,0.007346648595705516,0,0,1,0.008020732656818718
761,HV323,FCERI mediated MAPK activation,0.007519819226217805,1,0,1,0.00820979237748696
762,HV323,FCERI mediated Ca+2 mobilization,0.007346648595705516,0,0,1,0.008020732656818718
763,HV323,FCERI mediated Ca+2 mobilization,0.007519819226217805,1,0,1,0.00820979237748696
764,HV323,FCERI mediated NF-kB activation,0.007346648595705516,0,0,1,0.008020732656818718
765,HV323,FCERI mediated NF-kB activation,0.007519819226217805,1,0,1,0.00820979237748696
766,HV323,Parasite infection,0.007346648595705516,0,0,1,0.008020732656818718
767,HV323,Parasite infection,0.007519819226217805,1,0,1,0.00820979237748696
768,HV323,Leishmania parasite growth and survival,0.007346648595705516,0,0,1,0.008020732656818718
769,HV323,Leishmania parasite growth and survival,0.007519819226217805,1,0,1,0.00820979237748696
770,HV323,Potential therapeutics for SARS,0.007346648595705516,0,0,1,0.008020732656818718
771,HV323,Potential therapeutics for SARS,0.007519819226217805,1,0,1,0.00820979237748696
772,HV323,CD22 mediated BCR regulation,0.007346648595705516,0,0,1,0.008020732656818718
773,HV323,CD22 mediated BCR regulation,0.007519819226217805,1,0,1,0.00820979237748696
774,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007346648595705516,0,0,1,0.008020732656818718
775,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007519819226217805,1,0,1,0.00820979237748696
776,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007346648595705516,0,0,1,0.008020732656818718
777,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007519819226217805,1,0,1,0.00820979237748696
778,HV323,Scavenging of heme from plasma,0.007346648595705516,0,0,1,0.008020732656818718
779,HV323,Scavenging of heme from plasma,0.007519819226217805,1,0,1,0.00820979237748696
780,HV313,Initial triggering of complement,0.0013137384821352198,0,0,1,0.0014342791830741575
781,HV313,Initial triggering of complement,0.0008224226086784413,1,0,1,0.0008978831353100461
782,HV313,Regulation of Complement cascade,0.0013137384821352198,0,0,1,0.0014342791830741575
783,HV313,Regulation of Complement cascade,0.0008224226086784413,1,0,1,0.0008978831353100461
784,HV313,FCGR activation,0.0013137384821352198,0,0,1,0.0014342791830741575
785,HV313,FCGR activation,0.0008224226086784413,1,0,1,0.0008978831353100461
786,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0013137384821352198,0,0,1,0.0014342791830741575
787,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0008224226086784413,1,0,1,0.0008978831353100461
788,HV313,Role of phospholipids in phagocytosis,0.0013137384821352198,0,0,1,0.0014342791830741575
789,HV313,Role of phospholipids in phagocytosis,0.0008224226086784413,1,0,1,0.0008978831353100461
790,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013137384821352198,0,0,1,0.0014342791830741575
791,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008224226086784413,1,0,1,0.0008978831353100461
792,HV313,FCERI mediated MAPK activation,0.0013137384821352198,0,0,1,0.0014342791830741575
793,HV313,FCERI mediated MAPK activation,0.0008224226086784413,1,0,1,0.0008978831353100461
794,HV313,FCERI mediated Ca+2 mobilization,0.0013137384821352198,0,0,1,0.0014342791830741575
795,HV313,FCERI mediated Ca+2 mobilization,0.0008224226086784413,1,0,1,0.0008978831353100461
796,HV313,FCERI mediated NF-kB activation,0.0013137384821352198,0,0,1,0.0014342791830741575
797,HV313,FCERI mediated NF-kB activation,0.0008224226086784413,1,0,1,0.0008978831353100461
798,HV313,Parasite infection,0.0013137384821352198,0,0,1,0.0014342791830741575
799,HV313,Parasite infection,0.0008224226086784413,1,0,1,0.0008978831353100461
800,HV313,Leishmania parasite growth and survival,0.0013137384821352198,0,0,1,0.0014342791830741575
801,HV313,Leishmania parasite growth and survival,0.0008224226086784413,1,0,1,0.0008978831353100461
802,HV313,Potential therapeutics for SARS,0.0013137384821352198,0,0,1,0.0014342791830741575
803,HV313,Potential therapeutics for SARS,0.0008224226086784413,1,0,1,0.0008978831353100461
804,HV313,CD22 mediated BCR regulation,0.0013137384821352198,0,0,1,0.0014342791830741575
805,HV313,CD22 mediated BCR regulation,0.0008224226086784413,1,0,1,0.0008978831353100461
806,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013137384821352198,0,0,1,0.0014342791830741575
807,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008224226086784413,1,0,1,0.0008978831353100461
808,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013137384821352198,0,0,1,0.0014342791830741575
809,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008224226086784413,1,0,1,0.0008978831353100461
810,HV313,Scavenging of heme from plasma,0.0013137384821352198,0,0,1,0.0014342791830741575
811,HV313,Scavenging of heme from plasma,0.0008224226086784413,1,0,1,0.0008978831353100461
812,HV353,Initial triggering of complement,0.01171439830544712,0,0,1,0.012789240674775812
813,HV353,Initial triggering of complement,0.012892458308960884,1,0,1,0.014075392342271951
814,HV353,Regulation of Complement cascade,0.01171439830544712,0,0,1,0.012789240674775812
815,HV353,Regulation of Complement cascade,0.012892458308960884,1,0,1,0.014075392342271951
816,HV353,FCGR activation,0.01171439830544712,0,0,1,0.012789240674775812
817,HV353,FCGR activation,0.012892458308960884,1,0,1,0.014075392342271951
818,HV353,Regulation of actin dynamics for phagocytic cup formation,0.01171439830544712,0,0,1,0.012789240674775812
819,HV353,Regulation of actin dynamics for phagocytic cup formation,0.012892458308960884,1,0,1,0.014075392342271951
820,HV353,Role of phospholipids in phagocytosis,0.01171439830544712,0,0,1,0.012789240674775812
821,HV353,Role of phospholipids in phagocytosis,0.012892458308960884,1,0,1,0.014075392342271951
822,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.01171439830544712,0,0,1,0.012789240674775812
823,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.012892458308960884,1,0,1,0.014075392342271951
824,HV353,FCERI mediated MAPK activation,0.01171439830544712,0,0,1,0.012789240674775812
825,HV353,FCERI mediated MAPK activation,0.012892458308960884,1,0,1,0.014075392342271951
826,HV353,FCERI mediated Ca+2 mobilization,0.01171439830544712,0,0,1,0.012789240674775812
827,HV353,FCERI mediated Ca+2 mobilization,0.012892458308960884,1,0,1,0.014075392342271951
828,HV353,FCERI mediated NF-kB activation,0.01171439830544712,0,0,1,0.012789240674775812
829,HV353,FCERI mediated NF-kB activation,0.012892458308960884,1,0,1,0.014075392342271951
830,HV353,Parasite infection,0.01171439830544712,0,0,1,0.012789240674775812
831,HV353,Parasite infection,0.012892458308960884,1,0,1,0.014075392342271951
832,HV353,Leishmania parasite growth and survival,0.01171439830544712,0,0,1,0.012789240674775812
833,HV353,Leishmania parasite growth and survival,0.012892458308960884,1,0,1,0.014075392342271951
834,HV353,Potential therapeutics for SARS,0.01171439830544712,0,0,1,0.012789240674775812
835,HV353,Potential therapeutics for SARS,0.012892458308960884,1,0,1,0.014075392342271951
836,HV353,CD22 mediated BCR regulation,0.01171439830544712,0,0,1,0.012789240674775812
837,HV353,CD22 mediated BCR regulation,0.012892458308960884,1,0,1,0.014075392342271951
838,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01171439830544712,0,0,1,0.012789240674775812
839,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012892458308960884,1,0,1,0.014075392342271951
840,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01171439830544712,0,0,1,0.012789240674775812
841,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012892458308960884,1,0,1,0.014075392342271951
842,HV353,Scavenging of heme from plasma,0.01171439830544712,0,0,1,0.012789240674775812
843,HV353,Scavenging of heme from plasma,0.012892458308960884,1,0,1,0.014075392342271951
844,HV307,Initial triggering of complement,0.006734462378092753,0,0,1,0.00735237593283831
845,HV307,Initial triggering of complement,0.007820523677270878,1,0,1,0.008538087651065443
846,HV307,Regulation of Complement cascade,0.006734462378092753,0,0,1,0.00735237593283831
847,HV307,Regulation of Complement cascade,0.007820523677270878,1,0,1,0.008538087651065443
848,HV307,FCGR activation,0.006734462378092753,0,0,1,0.00735237593283831
849,HV307,FCGR activation,0.007820523677270878,1,0,1,0.008538087651065443
850,HV307,Regulation of actin dynamics for phagocytic cup formation,0.006734462378092753,0,0,1,0.00735237593283831
851,HV307,Regulation of actin dynamics for phagocytic cup formation,0.007820523677270878,1,0,1,0.008538087651065443
852,HV307,Role of phospholipids in phagocytosis,0.006734462378092753,0,0,1,0.00735237593283831
853,HV307,Role of phospholipids in phagocytosis,0.007820523677270878,1,0,1,0.008538087651065443
854,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.006734462378092753,0,0,1,0.00735237593283831
855,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.007820523677270878,1,0,1,0.008538087651065443
856,HV307,FCERI mediated MAPK activation,0.006734462378092753,0,0,1,0.00735237593283831
857,HV307,FCERI mediated MAPK activation,0.007820523677270878,1,0,1,0.008538087651065443
858,HV307,FCERI mediated Ca+2 mobilization,0.006734462378092753,0,0,1,0.00735237593283831
859,HV307,FCERI mediated Ca+2 mobilization,0.007820523677270878,1,0,1,0.008538087651065443
860,HV307,FCERI mediated NF-kB activation,0.006734462378092753,0,0,1,0.00735237593283831
861,HV307,FCERI mediated NF-kB activation,0.007820523677270878,1,0,1,0.008538087651065443
862,HV307,Parasite infection,0.006734462378092753,0,0,1,0.00735237593283831
863,HV307,Parasite infection,0.007820523677270878,1,0,1,0.008538087651065443
864,HV307,Leishmania parasite growth and survival,0.006734462378092753,0,0,1,0.00735237593283831
865,HV307,Leishmania parasite growth and survival,0.007820523677270878,1,0,1,0.008538087651065443
866,HV307,Potential therapeutics for SARS,0.006734462378092753,0,0,1,0.00735237593283831
867,HV307,Potential therapeutics for SARS,0.007820523677270878,1,0,1,0.008538087651065443
868,HV307,CD22 mediated BCR regulation,0.006734462378092753,0,0,1,0.00735237593283831
869,HV307,CD22 mediated BCR regulation,0.007820523677270878,1,0,1,0.008538087651065443
870,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006734462378092753,0,0,1,0.00735237593283831
871,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007820523677270878,1,0,1,0.008538087651065443
872,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006734462378092753,0,0,1,0.00735237593283831
873,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007820523677270878,1,0,1,0.008538087651065443
874,HV307,Scavenging of heme from plasma,0.006734462378092753,0,0,1,0.00735237593283831
875,HV307,Scavenging of heme from plasma,0.007820523677270878,1,0,1,0.008538087651065443
876,PIGR,Neutrophil degranulation,0.0007028887549970789,0,0,1,0.0007673815778545921
877,PIGR,Neutrophil degranulation,0.0007132939905149293,1,0,1,0.0007787415348789009
878,IGKC,Initial triggering of complement,0.0005282408192382727,0,0,1,0.000576709003341436
879,IGKC,Initial triggering of complement,0.0007744527024119334,1,0,1,0.000845511800445708
880,IGKC,Regulation of Complement cascade,0.0005282408192382727,0,0,1,0.000576709003341436
881,IGKC,Regulation of Complement cascade,0.0007744527024119334,1,0,1,0.000845511800445708
882,IGKC,FCGR activation,0.0005282408192382727,0,0,1,0.000576709003341436
883,IGKC,FCGR activation,0.0007744527024119334,1,0,1,0.000845511800445708
884,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0005282408192382727,0,0,1,0.000576709003341436
885,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0007744527024119334,1,0,1,0.000845511800445708
886,IGKC,Role of phospholipids in phagocytosis,0.0005282408192382727,0,0,1,0.000576709003341436
887,IGKC,Role of phospholipids in phagocytosis,0.0007744527024119334,1,0,1,0.000845511800445708
888,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0005282408192382727,0,0,1,0.000576709003341436
889,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007744527024119334,1,0,1,0.000845511800445708
890,IGKC,FCERI mediated MAPK activation,0.0005282408192382727,0,0,1,0.000576709003341436
891,IGKC,FCERI mediated MAPK activation,0.0007744527024119334,1,0,1,0.000845511800445708
892,IGKC,FCERI mediated Ca+2 mobilization,0.0005282408192382727,0,0,1,0.000576709003341436
893,IGKC,FCERI mediated Ca+2 mobilization,0.0007744527024119334,1,0,1,0.000845511800445708
894,IGKC,FCERI mediated NF-kB activation,0.0005282408192382727,0,0,1,0.000576709003341436
895,IGKC,FCERI mediated NF-kB activation,0.0007744527024119334,1,0,1,0.000845511800445708
896,IGKC,Parasite infection,0.0005282408192382727,0,0,1,0.000576709003341436
897,IGKC,Parasite infection,0.0007744527024119334,1,0,1,0.000845511800445708
898,IGKC,Leishmania parasite growth and survival,0.0005282408192382727,0,0,1,0.000576709003341436
899,IGKC,Leishmania parasite growth and survival,0.0007744527024119334,1,0,1,0.000845511800445708
900,IGKC,Potential therapeutics for SARS,0.0005282408192382727,0,0,1,0.000576709003341436
901,IGKC,Potential therapeutics for SARS,0.0007744527024119334,1,0,1,0.000845511800445708
902,IGKC,CD22 mediated BCR regulation,0.0005282408192382727,0,0,1,0.000576709003341436
903,IGKC,CD22 mediated BCR regulation,0.0007744527024119334,1,0,1,0.000845511800445708
904,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005282408192382727,0,0,1,0.000576709003341436
905,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007744527024119334,1,0,1,0.000845511800445708
906,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005282408192382727,0,0,1,0.000576709003341436
907,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007744527024119334,1,0,1,0.000845511800445708
908,IGKC,Scavenging of heme from plasma,0.0005282408192382727,0,0,1,0.000576709003341436
909,IGKC,Scavenging of heme from plasma,0.0007744527024119334,1,0,1,0.000845511800445708
910,IGHG1,Initial triggering of complement,0.004505549181808396,0,0,1,0.004918951136516563
911,IGHG1,Initial triggering of complement,0.004176086830142656,1,0,1,0.004559259311220552
912,IGHG1,Regulation of Complement cascade,0.004505549181808396,0,0,1,0.004918951136516563
913,IGHG1,Regulation of Complement cascade,0.004176086830142656,1,0,1,0.004559259311220552
914,IGHG1,FCGR activation,0.004505549181808396,0,0,1,0.004918951136516563
915,IGHG1,FCGR activation,0.004176086830142656,1,0,1,0.004559259311220552
916,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.004505549181808396,0,0,1,0.004918951136516563
917,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.004176086830142656,1,0,1,0.004559259311220552
918,IGHG1,Role of phospholipids in phagocytosis,0.004505549181808396,0,0,1,0.004918951136516563
919,IGHG1,Role of phospholipids in phagocytosis,0.004176086830142656,1,0,1,0.004559259311220552
920,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.004505549181808396,0,0,1,0.004918951136516563
921,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.004176086830142656,1,0,1,0.004559259311220552
922,IGHG1,Parasite infection,0.004505549181808396,0,0,1,0.004918951136516563
923,IGHG1,Parasite infection,0.004176086830142656,1,0,1,0.004559259311220552
924,IGHG1,Leishmania parasite growth and survival,0.004505549181808396,0,0,1,0.004918951136516563
925,IGHG1,Leishmania parasite growth and survival,0.004176086830142656,1,0,1,0.004559259311220552
926,IGHG2,Initial triggering of complement,0.0031930542812878583,0,0,1,0.003486029638588002
927,IGHG2,Initial triggering of complement,0.0030802945117185455,1,0,1,0.003362923714250118
928,IGHG2,Regulation of Complement cascade,0.0031930542812878583,0,0,1,0.003486029638588002
929,IGHG2,Regulation of Complement cascade,0.0030802945117185455,1,0,1,0.003362923714250118
930,IGHG2,FCGR activation,0.0031930542812878583,0,0,1,0.003486029638588002
931,IGHG2,FCGR activation,0.0030802945117185455,1,0,1,0.003362923714250118
932,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.0031930542812878583,0,0,1,0.003486029638588002
933,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.0030802945117185455,1,0,1,0.003362923714250118
934,IGHG2,Role of phospholipids in phagocytosis,0.0031930542812878583,0,0,1,0.003486029638588002
935,IGHG2,Role of phospholipids in phagocytosis,0.0030802945117185455,1,0,1,0.003362923714250118
936,IGHG2,Parasite infection,0.0031930542812878583,0,0,1,0.003486029638588002
937,IGHG2,Parasite infection,0.0030802945117185455,1,0,1,0.003362923714250118
938,IGHG2,Leishmania parasite growth and survival,0.0031930542812878583,0,0,1,0.003486029638588002
939,IGHG2,Leishmania parasite growth and survival,0.0030802945117185455,1,0,1,0.003362923714250118
940,IGHG3,Initial triggering of complement,0.0001740786377874156,0,0,1,0.00019005104120159124
941,IGHG3,Initial triggering of complement,0.00012453482988809215,1,0,1,0.00013596139300560376
942,IGHG3,Regulation of Complement cascade,0.0001740786377874156,0,0,1,0.00019005104120159124
943,IGHG3,Regulation of Complement cascade,0.00012453482988809215,1,0,1,0.00013596139300560376
944,IGHG3,FCGR activation,0.0001740786377874156,0,0,1,0.00019005104120159124
945,IGHG3,FCGR activation,0.00012453482988809215,1,0,1,0.00013596139300560376
946,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0001740786377874156,0,0,1,0.00019005104120159124
947,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.00012453482988809215,1,0,1,0.00013596139300560376
948,IGHG3,Role of phospholipids in phagocytosis,0.0001740786377874156,0,0,1,0.00019005104120159124
949,IGHG3,Role of phospholipids in phagocytosis,0.00012453482988809215,1,0,1,0.00013596139300560376
950,IGHG3,Parasite infection,0.0001740786377874156,0,0,1,0.00019005104120159124
951,IGHG3,Parasite infection,0.00012453482988809215,1,0,1,0.00013596139300560376
952,IGHG3,Leishmania parasite growth and survival,0.0001740786377874156,0,0,1,0.00019005104120159124
953,IGHG3,Leishmania parasite growth and survival,0.00012453482988809215,1,0,1,0.00013596139300560376
954,IGHG4,Initial triggering of complement,0.0027433110479592538,0,0,1,0.0029950206850835955
955,IGHG4,Initial triggering of complement,0.00269860516508452,1,0,1,0.0029462128606648676
956,IGHG4,Regulation of Complement cascade,0.0027433110479592538,0,0,1,0.0029950206850835955
957,IGHG4,Regulation of Complement cascade,0.00269860516508452,1,0,1,0.0029462128606648676
958,IGHG4,FCGR activation,0.0027433110479592538,0,0,1,0.0029950206850835955
959,IGHG4,FCGR activation,0.00269860516508452,1,0,1,0.0029462128606648676
960,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.0027433110479592538,0,0,1,0.0029950206850835955
961,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.00269860516508452,1,0,1,0.0029462128606648676
962,IGHG4,Role of phospholipids in phagocytosis,0.0027433110479592538,0,0,1,0.0029950206850835955
963,IGHG4,Role of phospholipids in phagocytosis,0.00269860516508452,1,0,1,0.0029462128606648676
964,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.0027433110479592538,0,0,1,0.0029950206850835955
965,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.00269860516508452,1,0,1,0.0029462128606648676
966,IGHG4,Parasite infection,0.0027433110479592538,0,0,1,0.0029950206850835955
967,IGHG4,Parasite infection,0.00269860516508452,1,0,1,0.0029462128606648676
968,IGHG4,Leishmania parasite growth and survival,0.0027433110479592538,0,0,1,0.0029950206850835955
969,IGHG4,Leishmania parasite growth and survival,0.00269860516508452,1,0,1,0.0029462128606648676
970,IGHM,Potential therapeutics for SARS,0.004312422353471304,0,0,1,0.004708104157955943
971,IGHM,Potential therapeutics for SARS,0.004988551300336583,1,0,1,0.005446270609460488
972,IGHM,CD22 mediated BCR regulation,0.004312422353471304,0,0,1,0.004708104157955943
973,IGHM,CD22 mediated BCR regulation,0.004988551300336583,1,0,1,0.005446270609460488
974,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004312422353471304,0,0,1,0.004708104157955943
975,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004988551300336583,1,0,1,0.005446270609460488
976,IGHA1,Scavenging of heme from plasma,0.00012661974933553903,0,0,1,0.00013823761205720625
977,IGHA1,Scavenging of heme from plasma,0.00027615664484140873,1,0,1,0.0003014951090721478
978,IGHA2,Scavenging of heme from plasma,4.77241460253328e-05,0,0,1,5.2103025149171786e-05
979,IGHA2,Scavenging of heme from plasma,0.0001040023707256229,1,0,1,0.00011354499951898992
980,IGHD,Potential therapeutics for SARS,0.006022095060487736,0,0,1,0.006574646096773351
981,IGHD,Potential therapeutics for SARS,0.006967492154983702,1,0,1,0.007606787113279548
982,IGHD,CD22 mediated BCR regulation,0.006022095060487736,0,0,1,0.006574646096773351
983,IGHD,CD22 mediated BCR regulation,0.006967492154983702,1,0,1,0.007606787113279548
984,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006022095060487736,0,0,1,0.006574646096773351
985,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006967492154983702,1,0,1,0.007606787113279548
986,P01891,Antigen processing-Cross presentation,0.000196608704196573,0,0,1,0.00021464833029935152
987,P01891,Antigen processing-Cross presentation,0.00011488824224779172,1,0,1,0.00012542969280169723
988,P01891,Interferon gamma signaling,0.000196608704196573,0,0,1,0.00021464833029935152
989,P01891,Interferon gamma signaling,0.00011488824224779172,1,0,1,0.00012542969280169723
990,P01891,Interferon alpha/beta signaling,0.000196608704196573,0,0,1,0.00021464833029935152
991,P01891,Interferon alpha/beta signaling,0.00011488824224779172,1,0,1,0.00012542969280169723
992,P01891,SARS-CoV-2 Infection,0.000196608704196573,0,0,1,0.00021464833029935152
993,P01891,SARS-CoV-2 Infection,0.00011488824224779172,1,0,1,0.00012542969280169723
994,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.000196608704196573,0,0,1,0.00021464833029935152
995,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00011488824224779172,1,0,1,0.00012542969280169723
996,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000196608704196573,0,0,1,0.00021464833029935152
997,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00011488824224779172,1,0,1,0.00012542969280169723
998,MYG,Intracellular oxygen transport,0.0015262058566130584,0,0,1,0.0016662412793664843
999,MYG,Intracellular oxygen transport,0.0009288938499178718,1,0,1,0.0010141235339756794
1000,CO1A1,Collagen chain trimerization,0.02101459967233666,0,0,1,0.022942772294895112
1001,CO1A1,Collagen chain trimerization,0.0209827424791703,1,0,1,0.022907992078275884
1002,CO1A1,Anchoring fibril formation,0.02101459967233666,0,0,1,0.022942772294895112
1003,CO1A1,Anchoring fibril formation,0.0209827424791703,1,0,1,0.022907992078275884
1004,CO1A1,Crosslinking of collagen fibrils,0.02101459967233666,0,0,1,0.022942772294895112
1005,CO1A1,Crosslinking of collagen fibrils,0.0209827424791703,1,0,1,0.022907992078275884
1006,CO1A1,Transcriptional regulation by RUNX2,0.02101459967233666,0,0,1,0.022942772294895112
1007,CO1A1,Transcriptional regulation by RUNX2,0.0209827424791703,1,0,1,0.022907992078275884
1008,CO1A1,MET promotes cell motility,0.02101459967233666,0,0,1,0.022942772294895112
1009,CO1A1,MET promotes cell motility,0.0209827424791703,1,0,1,0.022907992078275884
1010,CO1A1,Platelet Adhesion to exposed collagen,0.02101459967233666,0,0,1,0.022942772294895112
1011,CO1A1,Platelet Adhesion to exposed collagen,0.0209827424791703,1,0,1,0.022907992078275884
1012,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.02101459967233666,0,0,1,0.022942772294895112
1013,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0209827424791703,1,0,1,0.022907992078275884
1014,CO1A1,Collagen degradation,0.02101459967233666,0,0,1,0.022942772294895112
1015,CO1A1,Collagen degradation,0.0209827424791703,1,0,1,0.022907992078275884
1016,CO1A1,Integrin cell surface interactions,0.02101459967233666,0,0,1,0.022942772294895112
1017,CO1A1,Integrin cell surface interactions,0.0209827424791703,1,0,1,0.022907992078275884
1018,CO1A1,ECM proteoglycans,0.02101459967233666,0,0,1,0.022942772294895112
1019,CO1A1,ECM proteoglycans,0.0209827424791703,1,0,1,0.022907992078275884
1020,CO1A1,Scavenging by Class A Receptors,0.02101459967233666,0,0,1,0.022942772294895112
1021,CO1A1,Scavenging by Class A Receptors,0.0209827424791703,1,0,1,0.022907992078275884
1022,CO1A1,Syndecan interactions,0.02101459967233666,0,0,1,0.022942772294895112
1023,CO1A1,Syndecan interactions,0.0209827424791703,1,0,1,0.022907992078275884
1024,CO1A1,GPVI-mediated activation cascade,0.02101459967233666,0,0,1,0.022942772294895112
1025,CO1A1,GPVI-mediated activation cascade,0.0209827424791703,1,0,1,0.022907992078275884
1026,CO1A1,GP1b-IX-V activation signalling,0.02101459967233666,0,0,1,0.022942772294895112
1027,CO1A1,GP1b-IX-V activation signalling,0.0209827424791703,1,0,1,0.022907992078275884
1028,K1C14,Type I hemidesmosome assembly,0.0032812191361353406,0,0,1,0.0035822839675172836
1029,K1C14,Type I hemidesmosome assembly,0.0027821911277301457,1,0,1,0.003037468165925459
1030,K1C14,Formation of the cornified envelope,0.0032812191361353406,0,0,1,0.0035822839675172836
1031,K1C14,Formation of the cornified envelope,0.0027821911277301457,1,0,1,0.003037468165925459
1032,K2C6A,Formation of the cornified envelope,0.0013558898245363833,0,0,1,0.0014802980778288878
1033,K2C6A,Formation of the cornified envelope,0.00172054142910434,1,0,1,0.001878407909137443
1034,APOA1,PPARA activates gene expression,0.022264694217965786,0,0,1,0.024307567958607623
1035,APOA1,PPARA activates gene expression,0.026289094625874705,1,0,1,0.028701223018507745
1036,APOA1,Defective ABCA1 causes TGD,0.022264694217965786,0,0,1,0.024307567958607623
1037,APOA1,Defective ABCA1 causes TGD,0.026289094625874705,1,0,1,0.028701223018507745
1038,APOA1,Platelet degranulation ,0.022264694217965786,0,0,1,0.024307567958607623
1039,APOA1,Platelet degranulation ,0.026289094625874705,1,0,1,0.028701223018507745
1040,APOA1,Chylomicron assembly,0.022264694217965786,0,0,1,0.024307567958607623
1041,APOA1,Chylomicron assembly,0.026289094625874705,1,0,1,0.028701223018507745
1042,APOA1,HDL assembly,0.022264694217965786,0,0,1,0.024307567958607623
1043,APOA1,HDL assembly,0.026289094625874705,1,0,1,0.028701223018507745
1044,APOA1,Chylomicron remodeling,0.022264694217965786,0,0,1,0.024307567958607623
1045,APOA1,Chylomicron remodeling,0.026289094625874705,1,0,1,0.028701223018507745
1046,APOA1,HDL remodeling,0.022264694217965786,0,0,1,0.024307567958607623
1047,APOA1,HDL remodeling,0.026289094625874705,1,0,1,0.028701223018507745
1048,APOA1,HDL clearance,0.022264694217965786,0,0,1,0.024307567958607623
1049,APOA1,HDL clearance,0.026289094625874705,1,0,1,0.028701223018507745
1050,APOA1,Scavenging of heme from plasma,0.022264694217965786,0,0,1,0.024307567958607623
1051,APOA1,Scavenging of heme from plasma,0.026289094625874705,1,0,1,0.028701223018507745
1052,APOA1,Scavenging by Class B Receptors,0.022264694217965786,0,0,1,0.024307567958607623
1053,APOA1,Scavenging by Class B Receptors,0.026289094625874705,1,0,1,0.028701223018507745
1054,APOA1,Scavenging by Class A Receptors,0.022264694217965786,0,0,1,0.024307567958607623
1055,APOA1,Scavenging by Class A Receptors,0.026289094625874705,1,0,1,0.028701223018507745
1056,APOA1,Retinoid metabolism and transport,0.022264694217965786,0,0,1,0.024307567958607623
1057,APOA1,Retinoid metabolism and transport,0.026289094625874705,1,0,1,0.028701223018507745
1058,APOA1,Heme signaling,0.022264694217965786,0,0,1,0.024307567958607623
1059,APOA1,Heme signaling,0.026289094625874705,1,0,1,0.028701223018507745
1060,APOA1,ABC transporters in lipid homeostasis,0.022264694217965786,0,0,1,0.024307567958607623
1061,APOA1,ABC transporters in lipid homeostasis,0.026289094625874705,1,0,1,0.028701223018507745
1062,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.022264694217965786,0,0,1,0.024307567958607623
1063,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.026289094625874705,1,0,1,0.028701223018507745
1064,APOA1,Amyloid fiber formation,0.022264694217965786,0,0,1,0.024307567958607623
1065,APOA1,Amyloid fiber formation,0.026289094625874705,1,0,1,0.028701223018507745
1066,APOA1,Post-translational protein phosphorylation,0.022264694217965786,0,0,1,0.024307567958607623
1067,APOA1,Post-translational protein phosphorylation,0.026289094625874705,1,0,1,0.028701223018507745
1068,APOE,Nuclear signaling by ERBB4,0.009255207014751153,0,0,1,0.010104408858241223
1069,APOE,Nuclear signaling by ERBB4,0.007325747923312123,1,0,1,0.007997914265081138
1070,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.009255207014751153,0,0,1,0.010104408858241223
1071,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.007325747923312123,1,0,1,0.007997914265081138
1072,APOE,Chylomicron assembly,0.009255207014751153,0,0,1,0.010104408858241223
1073,APOE,Chylomicron assembly,0.007325747923312123,1,0,1,0.007997914265081138
1074,APOE,Chylomicron remodeling,0.009255207014751153,0,0,1,0.010104408858241223
1075,APOE,Chylomicron remodeling,0.007325747923312123,1,0,1,0.007997914265081138
1076,APOE,HDL remodeling,0.009255207014751153,0,0,1,0.010104408858241223
1077,APOE,HDL remodeling,0.007325747923312123,1,0,1,0.007997914265081138
1078,APOE,Chylomicron clearance,0.009255207014751153,0,0,1,0.010104408858241223
1079,APOE,Chylomicron clearance,0.007325747923312123,1,0,1,0.007997914265081138
1080,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.009255207014751153,0,0,1,0.010104408858241223
1081,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.007325747923312123,1,0,1,0.007997914265081138
1082,APOE,Scavenging by Class A Receptors,0.009255207014751153,0,0,1,0.010104408858241223
1083,APOE,Scavenging by Class A Receptors,0.007325747923312123,1,0,1,0.007997914265081138
1084,APOE,Retinoid metabolism and transport,0.009255207014751153,0,0,1,0.010104408858241223
1085,APOE,Retinoid metabolism and transport,0.007325747923312123,1,0,1,0.007997914265081138
1086,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009255207014751153,0,0,1,0.010104408858241223
1087,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007325747923312123,1,0,1,0.007997914265081138
1088,APOE,Amyloid fiber formation,0.009255207014751153,0,0,1,0.010104408858241223
1089,APOE,Amyloid fiber formation,0.007325747923312123,1,0,1,0.007997914265081138
1090,APOE,Post-translational protein phosphorylation,0.009255207014751153,0,0,1,0.010104408858241223
1091,APOE,Post-translational protein phosphorylation,0.007325747923312123,1,0,1,0.007997914265081138
1092,APOA2,PPARA activates gene expression,0.0058518563289938355,0,0,1,0.006388787288452684
1093,APOA2,PPARA activates gene expression,0.005172507958166322,1,0,1,0.005647106018106098
1094,APOA2,Chylomicron assembly,0.0058518563289938355,0,0,1,0.006388787288452684
1095,APOA2,Chylomicron assembly,0.005172507958166322,1,0,1,0.005647106018106098
1096,APOA2,Chylomicron remodeling,0.0058518563289938355,0,0,1,0.006388787288452684
1097,APOA2,Chylomicron remodeling,0.005172507958166322,1,0,1,0.005647106018106098
1098,APOA2,Retinoid metabolism and transport,0.0058518563289938355,0,0,1,0.006388787288452684
1099,APOA2,Retinoid metabolism and transport,0.005172507958166322,1,0,1,0.005647106018106098
1100,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0058518563289938355,0,0,1,0.006388787288452684
1101,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005172507958166322,1,0,1,0.005647106018106098
1102,APOA2,Post-translational protein phosphorylation,0.0058518563289938355,0,0,1,0.006388787288452684
1103,APOA2,Post-translational protein phosphorylation,0.005172507958166322,1,0,1,0.005647106018106098
1104,APOC1,VLDL assembly,0.0016618332911509108,0,0,1,0.0018143130673643735
1105,APOC1,VLDL assembly,0.003286117382305036,1,0,1,0.003587631647143253
1106,APOC1,VLDL clearance,0.0016618332911509108,0,0,1,0.0018143130673643735
1107,APOC1,VLDL clearance,0.003286117382305036,1,0,1,0.003587631647143253
1108,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0016618332911509108,0,0,1,0.0018143130673643735
1109,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.003286117382305036,1,0,1,0.003587631647143253
1110,APOC2,Chylomicron assembly,0.005460089262147809,0,0,1,0.005961074043973451
1111,APOC2,Chylomicron assembly,0.005121759695352436,1,0,1,0.005591701401494098
1112,APOC2,Assembly of active LPL and LIPC lipase complexes,0.005460089262147809,0,0,1,0.005961074043973451
1113,APOC2,Assembly of active LPL and LIPC lipase complexes,0.005121759695352436,1,0,1,0.005591701401494098
1114,APOC2,Chylomicron remodeling,0.005460089262147809,0,0,1,0.005961074043973451
1115,APOC2,Chylomicron remodeling,0.005121759695352436,1,0,1,0.005591701401494098
1116,APOC2,HDL remodeling,0.005460089262147809,0,0,1,0.005961074043973451
1117,APOC2,HDL remodeling,0.005121759695352436,1,0,1,0.005591701401494098
1118,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.005460089262147809,0,0,1,0.005961074043973451
1119,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.005121759695352436,1,0,1,0.005591701401494098
1120,APOC2,Retinoid metabolism and transport,0.005460089262147809,0,0,1,0.005961074043973451
1121,APOC2,Retinoid metabolism and transport,0.005121759695352436,1,0,1,0.005591701401494098
1122,APOC3,Chylomicron assembly,0.010069284477814215,0,0,1,0.010993181147824648
1123,APOC3,Chylomicron assembly,0.010799035518004697,1,0,1,0.01178988973176654
1124,APOC3,Chylomicron remodeling,0.010069284477814215,0,0,1,0.010993181147824648
1125,APOC3,Chylomicron remodeling,0.010799035518004697,1,0,1,0.01178988973176654
1126,APOC3,HDL remodeling,0.010069284477814215,0,0,1,0.010993181147824648
1127,APOC3,HDL remodeling,0.010799035518004697,1,0,1,0.01178988973176654
1128,APOC3,Retinoid metabolism and transport,0.010069284477814215,0,0,1,0.010993181147824648
1129,APOC3,Retinoid metabolism and transport,0.010799035518004697,1,0,1,0.01178988973176654
1130,FIBA,Antigen processing-Cross presentation,0.00864233016961273,0,0,1,0.009435298138928575
1131,FIBA,Antigen processing-Cross presentation,0.008251584637738755,1,0,1,0.00900870015929476
1132,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.00864233016961273,0,0,1,0.009435298138928575
1133,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.008251584637738755,1,0,1,0.00900870015929476
1134,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.00864233016961273,0,0,1,0.009435298138928575
1135,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.008251584637738755,1,0,1,0.00900870015929476
1136,FIBA,Regulation of TLR by endogenous ligand,0.00864233016961273,0,0,1,0.009435298138928575
1137,FIBA,Regulation of TLR by endogenous ligand,0.008251584637738755,1,0,1,0.00900870015929476
1138,FIBA,MyD88 deficiency (TLR2/4),0.00864233016961273,0,0,1,0.009435298138928575
1139,FIBA,MyD88 deficiency (TLR2/4),0.008251584637738755,1,0,1,0.00900870015929476
1140,FIBA,IRAK4 deficiency (TLR2/4),0.00864233016961273,0,0,1,0.009435298138928575
1141,FIBA,IRAK4 deficiency (TLR2/4),0.008251584637738755,1,0,1,0.00900870015929476
1142,FIBA,RAF/MAP kinase cascade,0.00864233016961273,0,0,1,0.009435298138928575
1143,FIBA,RAF/MAP kinase cascade,0.008251584637738755,1,0,1,0.00900870015929476
1144,FIBA,Signaling by RAS mutants,0.00864233016961273,0,0,1,0.009435298138928575
1145,FIBA,Signaling by RAS mutants,0.008251584637738755,1,0,1,0.00900870015929476
1146,FIBA,Signaling by moderate kinase activity BRAF mutants,0.00864233016961273,0,0,1,0.009435298138928575
1147,FIBA,Signaling by moderate kinase activity BRAF mutants,0.008251584637738755,1,0,1,0.00900870015929476
1148,FIBA,Signaling by high-kinase activity BRAF mutants,0.00864233016961273,0,0,1,0.009435298138928575
1149,FIBA,Signaling by high-kinase activity BRAF mutants,0.008251584637738755,1,0,1,0.00900870015929476
1150,FIBA,Signaling by BRAF and RAF1 fusions,0.00864233016961273,0,0,1,0.009435298138928575
1151,FIBA,Signaling by BRAF and RAF1 fusions,0.008251584637738755,1,0,1,0.00900870015929476
1152,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00864233016961273,0,0,1,0.009435298138928575
1153,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008251584637738755,1,0,1,0.00900870015929476
1154,FIBA,Signaling by RAF1 mutants,0.00864233016961273,0,0,1,0.009435298138928575
1155,FIBA,Signaling by RAF1 mutants,0.008251584637738755,1,0,1,0.00900870015929476
1156,FIBA,Platelet degranulation ,0.00864233016961273,0,0,1,0.009435298138928575
1157,FIBA,Platelet degranulation ,0.008251584637738755,1,0,1,0.00900870015929476
1158,FIBA,Common Pathway of Fibrin Clot Formation,0.00864233016961273,0,0,1,0.009435298138928575
1159,FIBA,Common Pathway of Fibrin Clot Formation,0.008251584637738755,1,0,1,0.00900870015929476
1160,FIBA,Integrin cell surface interactions,0.00864233016961273,0,0,1,0.009435298138928575
1161,FIBA,Integrin cell surface interactions,0.008251584637738755,1,0,1,0.00900870015929476
1162,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00864233016961273,0,0,1,0.009435298138928575
1163,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008251584637738755,1,0,1,0.00900870015929476
1164,FIBA,p130Cas linkage to MAPK signaling for integrins,0.00864233016961273,0,0,1,0.009435298138928575
1165,FIBA,p130Cas linkage to MAPK signaling for integrins,0.008251584637738755,1,0,1,0.00900870015929476
1166,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00864233016961273,0,0,1,0.009435298138928575
1167,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008251584637738755,1,0,1,0.00900870015929476
1168,FIBA,Amyloid fiber formation,0.00864233016961273,0,0,1,0.009435298138928575
1169,FIBA,Amyloid fiber formation,0.008251584637738755,1,0,1,0.00900870015929476
1170,FIBA,Post-translational protein phosphorylation,0.00864233016961273,0,0,1,0.009435298138928575
1171,FIBA,Post-translational protein phosphorylation,0.008251584637738755,1,0,1,0.00900870015929476
1172,FIBB,Antigen processing-Cross presentation,0.0040621735068843414,0,0,1,0.004434893990080952
1173,FIBB,Antigen processing-Cross presentation,0.005322065063516449,1,0,1,0.005810385579298428
1174,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0040621735068843414,0,0,1,0.004434893990080952
1175,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.005322065063516449,1,0,1,0.005810385579298428
1176,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0040621735068843414,0,0,1,0.004434893990080952
1177,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.005322065063516449,1,0,1,0.005810385579298428
1178,FIBB,Regulation of TLR by endogenous ligand,0.0040621735068843414,0,0,1,0.004434893990080952
1179,FIBB,Regulation of TLR by endogenous ligand,0.005322065063516449,1,0,1,0.005810385579298428
1180,FIBB,MyD88 deficiency (TLR2/4),0.0040621735068843414,0,0,1,0.004434893990080952
1181,FIBB,MyD88 deficiency (TLR2/4),0.005322065063516449,1,0,1,0.005810385579298428
1182,FIBB,IRAK4 deficiency (TLR2/4),0.0040621735068843414,0,0,1,0.004434893990080952
1183,FIBB,IRAK4 deficiency (TLR2/4),0.005322065063516449,1,0,1,0.005810385579298428
1184,FIBB,RAF/MAP kinase cascade,0.0040621735068843414,0,0,1,0.004434893990080952
1185,FIBB,RAF/MAP kinase cascade,0.005322065063516449,1,0,1,0.005810385579298428
1186,FIBB,Signaling by RAS mutants,0.0040621735068843414,0,0,1,0.004434893990080952
1187,FIBB,Signaling by RAS mutants,0.005322065063516449,1,0,1,0.005810385579298428
1188,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0040621735068843414,0,0,1,0.004434893990080952
1189,FIBB,Signaling by moderate kinase activity BRAF mutants,0.005322065063516449,1,0,1,0.005810385579298428
1190,FIBB,Signaling by high-kinase activity BRAF mutants,0.0040621735068843414,0,0,1,0.004434893990080952
1191,FIBB,Signaling by high-kinase activity BRAF mutants,0.005322065063516449,1,0,1,0.005810385579298428
1192,FIBB,Signaling by BRAF and RAF1 fusions,0.0040621735068843414,0,0,1,0.004434893990080952
1193,FIBB,Signaling by BRAF and RAF1 fusions,0.005322065063516449,1,0,1,0.005810385579298428
1194,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0040621735068843414,0,0,1,0.004434893990080952
1195,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005322065063516449,1,0,1,0.005810385579298428
1196,FIBB,Signaling by RAF1 mutants,0.0040621735068843414,0,0,1,0.004434893990080952
1197,FIBB,Signaling by RAF1 mutants,0.005322065063516449,1,0,1,0.005810385579298428
1198,FIBB,Platelet degranulation ,0.0040621735068843414,0,0,1,0.004434893990080952
1199,FIBB,Platelet degranulation ,0.005322065063516449,1,0,1,0.005810385579298428
1200,FIBB,Common Pathway of Fibrin Clot Formation,0.0040621735068843414,0,0,1,0.004434893990080952
1201,FIBB,Common Pathway of Fibrin Clot Formation,0.005322065063516449,1,0,1,0.005810385579298428
1202,FIBB,Integrin cell surface interactions,0.0040621735068843414,0,0,1,0.004434893990080952
1203,FIBB,Integrin cell surface interactions,0.005322065063516449,1,0,1,0.005810385579298428
1204,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0040621735068843414,0,0,1,0.004434893990080952
1205,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.005322065063516449,1,0,1,0.005810385579298428
1206,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0040621735068843414,0,0,1,0.004434893990080952
1207,FIBB,p130Cas linkage to MAPK signaling for integrins,0.005322065063516449,1,0,1,0.005810385579298428
1208,FIBG,Antigen processing-Cross presentation,0.0022585957819690632,0,0,1,0.0024658308766233555
1209,FIBG,Antigen processing-Cross presentation,0.0027585539857109833,1,0,1,0.0030116622226525245
1210,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0022585957819690632,0,0,1,0.0024658308766233555
1211,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0027585539857109833,1,0,1,0.0030116622226525245
1212,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0022585957819690632,0,0,1,0.0024658308766233555
1213,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0027585539857109833,1,0,1,0.0030116622226525245
1214,FIBG,Regulation of TLR by endogenous ligand,0.0022585957819690632,0,0,1,0.0024658308766233555
1215,FIBG,Regulation of TLR by endogenous ligand,0.0027585539857109833,1,0,1,0.0030116622226525245
1216,FIBG,MyD88 deficiency (TLR2/4),0.0022585957819690632,0,0,1,0.0024658308766233555
1217,FIBG,MyD88 deficiency (TLR2/4),0.0027585539857109833,1,0,1,0.0030116622226525245
1218,FIBG,IRAK4 deficiency (TLR2/4),0.0022585957819690632,0,0,1,0.0024658308766233555
1219,FIBG,IRAK4 deficiency (TLR2/4),0.0027585539857109833,1,0,1,0.0030116622226525245
1220,FIBG,RAF/MAP kinase cascade,0.0022585957819690632,0,0,1,0.0024658308766233555
1221,FIBG,RAF/MAP kinase cascade,0.0027585539857109833,1,0,1,0.0030116622226525245
1222,FIBG,Signaling by RAS mutants,0.0022585957819690632,0,0,1,0.0024658308766233555
1223,FIBG,Signaling by RAS mutants,0.0027585539857109833,1,0,1,0.0030116622226525245
1224,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0022585957819690632,0,0,1,0.0024658308766233555
1225,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0027585539857109833,1,0,1,0.0030116622226525245
1226,FIBG,Signaling by high-kinase activity BRAF mutants,0.0022585957819690632,0,0,1,0.0024658308766233555
1227,FIBG,Signaling by high-kinase activity BRAF mutants,0.0027585539857109833,1,0,1,0.0030116622226525245
1228,FIBG,Signaling by BRAF and RAF1 fusions,0.0022585957819690632,0,0,1,0.0024658308766233555
1229,FIBG,Signaling by BRAF and RAF1 fusions,0.0027585539857109833,1,0,1,0.0030116622226525245
1230,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0022585957819690632,0,0,1,0.0024658308766233555
1231,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0027585539857109833,1,0,1,0.0030116622226525245
1232,FIBG,Signaling by RAF1 mutants,0.0022585957819690632,0,0,1,0.0024658308766233555
1233,FIBG,Signaling by RAF1 mutants,0.0027585539857109833,1,0,1,0.0030116622226525245
1234,FIBG,Platelet degranulation ,0.0022585957819690632,0,0,1,0.0024658308766233555
1235,FIBG,Platelet degranulation ,0.0027585539857109833,1,0,1,0.0030116622226525245
1236,FIBG,Common Pathway of Fibrin Clot Formation,0.0022585957819690632,0,0,1,0.0024658308766233555
1237,FIBG,Common Pathway of Fibrin Clot Formation,0.0027585539857109833,1,0,1,0.0030116622226525245
1238,FIBG,Integrin cell surface interactions,0.0022585957819690632,0,0,1,0.0024658308766233555
1239,FIBG,Integrin cell surface interactions,0.0027585539857109833,1,0,1,0.0030116622226525245
1240,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0022585957819690632,0,0,1,0.0024658308766233555
1241,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0027585539857109833,1,0,1,0.0030116622226525245
1242,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0022585957819690632,0,0,1,0.0024658308766233555
1243,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0027585539857109833,1,0,1,0.0030116622226525245
1244,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0022585957819690632,0,0,1,0.0024658308766233555
1245,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0027585539857109833,1,0,1,0.0030116622226525245
1246,FIBG,Post-translational protein phosphorylation,0.0022585957819690632,0,0,1,0.0024658308766233555
1247,FIBG,Post-translational protein phosphorylation,0.0027585539857109833,1,0,1,0.0030116622226525245
1248,B3AT,Bicarbonate transporters,0.0022179251835152017,0,0,1,0.002421428589928721
1249,B3AT,Bicarbonate transporters,0.0030286762843305614,1,0,1,0.0033065693103740555
1250,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0022179251835152017,0,0,1,0.002421428589928721
1251,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0030286762843305614,1,0,1,0.0033065693103740555
1252,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0022179251835152017,0,0,1,0.002421428589928721
1253,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0030286762843305614,1,0,1,0.0033065693103740555
1254,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0022179251835152017,0,0,1,0.002421428589928721
1255,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0030286762843305614,1,0,1,0.0033065693103740555
1256,CRP,Initial triggering of complement,0.000178138282353151,0,0,1,0.0001944831742101721
1257,CRP,Initial triggering of complement,0.0001716130483774568,1,0,1,0.00018735922421305
1258,SAMP,Amyloid fiber formation,0.0009555939502245698,0,0,1,0.0010432734740715556
1259,SAMP,Amyloid fiber formation,0.0008462025163676625,1,0,1,0.0009238449435678365
1260,C1QA,Initial triggering of complement,0.0007857080902975185,0,0,1,0.0008577999146794343
1261,C1QA,Initial triggering of complement,0.0009192249670014938,1,0,1,0.0010035674928159481
1262,C1QA,Regulation of Complement cascade,0.0007857080902975185,0,0,1,0.0008577999146794343
1263,C1QA,Regulation of Complement cascade,0.0009192249670014938,1,0,1,0.0010035674928159481
1264,C1QB,Initial triggering of complement,0.0002458643725454232,0,0,1,0.0002684234010016567
1265,C1QB,Initial triggering of complement,0.00031967703121661884,1,0,1,0.0003490086629994531
1266,C1QB,Regulation of Complement cascade,0.0002458643725454232,0,0,1,0.0002684234010016567
1267,C1QB,Regulation of Complement cascade,0.00031967703121661884,1,0,1,0.0003490086629994531
1268,C1QC,Initial triggering of complement,0.0004740935018471738,0,0,1,0.0005175934554531395
1269,C1QC,Initial triggering of complement,0.0005642875528764801,1,0,1,0.000616063167338421
1270,C1QC,Regulation of Complement cascade,0.0004740935018471738,0,0,1,0.0005175934554531395
1271,C1QC,Regulation of Complement cascade,0.0005642875528764801,1,0,1,0.000616063167338421
1272,CO9,Terminal pathway of complement,0.0001140665921617154,0,0,1,0.000124532653070993
1273,CO9,Terminal pathway of complement,6.09556754904108e-05,1,0,1,6.654859976699773e-05
1274,CO9,Regulation of Complement cascade,0.0001140665921617154,0,0,1,0.000124532653070993
1275,CO9,Regulation of Complement cascade,6.09556754904108e-05,1,0,1,6.654859976699773e-05
1276,APOH,Platelet degranulation ,0.0006200556254886029,0,0,1,0.0006769481811485767
1277,APOH,Platelet degranulation ,0.0006598822170015751,1,0,1,0.000720429019927854
1278,A2GL,Neutrophil degranulation,0.0009152610075339021,0,0,1,0.0009992398243916542
1279,A2GL,Neutrophil degranulation,0.000931241713820239,1,0,1,0.00101668682367576
1280,FINC,G alpha (s) signalling events,0.0036626649132000784,0,0,1,0.003998728903062064
1281,FINC,G alpha (s) signalling events,0.0006507088956011892,1,0,1,0.0007104140100129142
1282,FINC,Interleukin-4 and Interleukin-13 signaling,0.0036626649132000784,0,0,1,0.003998728903062064
1283,FINC,Interleukin-4 and Interleukin-13 signaling,0.0006507088956011892,1,0,1,0.0007104140100129142
1284,FINC,RAF/MAP kinase cascade,0.0036626649132000784,0,0,1,0.003998728903062064
1285,FINC,RAF/MAP kinase cascade,0.0006507088956011892,1,0,1,0.0007104140100129142
1286,FINC,Signaling by RAS mutants,0.0036626649132000784,0,0,1,0.003998728903062064
1287,FINC,Signaling by RAS mutants,0.0006507088956011892,1,0,1,0.0007104140100129142
1288,FINC,Signaling by moderate kinase activity BRAF mutants,0.0036626649132000784,0,0,1,0.003998728903062064
1289,FINC,Signaling by moderate kinase activity BRAF mutants,0.0006507088956011892,1,0,1,0.0007104140100129142
1290,FINC,Signaling by high-kinase activity BRAF mutants,0.0036626649132000784,0,0,1,0.003998728903062064
1291,FINC,Signaling by high-kinase activity BRAF mutants,0.0006507088956011892,1,0,1,0.0007104140100129142
1292,FINC,Signaling by BRAF and RAF1 fusions,0.0036626649132000784,0,0,1,0.003998728903062064
1293,FINC,Signaling by BRAF and RAF1 fusions,0.0006507088956011892,1,0,1,0.0007104140100129142
1294,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0036626649132000784,0,0,1,0.003998728903062064
1295,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0006507088956011892,1,0,1,0.0007104140100129142
1296,FINC,Signaling by RAF1 mutants,0.0036626649132000784,0,0,1,0.003998728903062064
1297,FINC,Signaling by RAF1 mutants,0.0006507088956011892,1,0,1,0.0007104140100129142
1298,FINC,MET promotes cell motility,0.0036626649132000784,0,0,1,0.003998728903062064
1299,FINC,MET promotes cell motility,0.0006507088956011892,1,0,1,0.0007104140100129142
1300,FINC,Platelet degranulation ,0.0036626649132000784,0,0,1,0.003998728903062064
1301,FINC,Platelet degranulation ,0.0006507088956011892,1,0,1,0.0007104140100129142
1302,FINC,ALK mutants bind TKIs,0.0036626649132000784,0,0,1,0.003998728903062064
1303,FINC,ALK mutants bind TKIs,0.0006507088956011892,1,0,1,0.0007104140100129142
1304,FINC,Signaling by ALK fusions and activated point mutants,0.0036626649132000784,0,0,1,0.003998728903062064
1305,FINC,Signaling by ALK fusions and activated point mutants,0.0006507088956011892,1,0,1,0.0007104140100129142
1306,FINC,Fibronectin matrix formation,0.0036626649132000784,0,0,1,0.003998728903062064
1307,FINC,Fibronectin matrix formation,0.0006507088956011892,1,0,1,0.0007104140100129142
1308,FINC,Integrin cell surface interactions,0.0036626649132000784,0,0,1,0.003998728903062064
1309,FINC,Integrin cell surface interactions,0.0006507088956011892,1,0,1,0.0007104140100129142
1310,FINC,ECM proteoglycans,0.0036626649132000784,0,0,1,0.003998728903062064
1311,FINC,ECM proteoglycans,0.0006507088956011892,1,0,1,0.0007104140100129142
1312,FINC,Molecules associated with elastic fibres,0.0036626649132000784,0,0,1,0.003998728903062064
1313,FINC,Molecules associated with elastic fibres,0.0006507088956011892,1,0,1,0.0007104140100129142
1314,FINC,Syndecan interactions,0.0036626649132000784,0,0,1,0.003998728903062064
1315,FINC,Syndecan interactions,0.0006507088956011892,1,0,1,0.0007104140100129142
1316,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0036626649132000784,0,0,1,0.003998728903062064
1317,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0006507088956011892,1,0,1,0.0007104140100129142
1318,FINC,p130Cas linkage to MAPK signaling for integrins,0.0036626649132000784,0,0,1,0.003998728903062064
1319,FINC,p130Cas linkage to MAPK signaling for integrins,0.0006507088956011892,1,0,1,0.0007104140100129142
1320,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0036626649132000784,0,0,1,0.003998728903062064
1321,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006507088956011892,1,0,1,0.0007104140100129142
1322,FINC,Post-translational protein phosphorylation,0.0036626649132000784,0,0,1,0.003998728903062064
1323,FINC,Post-translational protein phosphorylation,0.0006507088956011892,1,0,1,0.0007104140100129142
1324,RET4,Retinoid cycle disease events,0.009291721364031315,0,0,1,0.010144273543464507
1325,RET4,Retinoid cycle disease events,0.007217695455830355,1,0,1,0.007879947556412444
1326,RET4,Retinoid metabolism disease events,0.009291721364031315,0,0,1,0.010144273543464507
1327,RET4,Retinoid metabolism disease events,0.007217695455830355,1,0,1,0.007879947556412444
1328,RET4,The canonical retinoid cycle in rods (twilight vision),0.009291721364031315,0,0,1,0.010144273543464507
1329,RET4,The canonical retinoid cycle in rods (twilight vision),0.007217695455830355,1,0,1,0.007879947556412444
1330,RET4,Retinoid metabolism and transport,0.009291721364031315,0,0,1,0.010144273543464507
1331,RET4,Retinoid metabolism and transport,0.007217695455830355,1,0,1,0.007879947556412444
1332,AMBP,Scavenging of heme from plasma,0.0006513590871903491,0,0,1,0.0007111238592515743
1333,AMBP,Scavenging of heme from plasma,0.0014190337489228188,1,0,1,0.001549235706981591
1334,A1AG1,Platelet degranulation ,0.00038099339683770635,0,0,1,0.0004159510476429729
1335,A1AG1,Platelet degranulation ,0.00039636108825102316,1,0,1,0.0004327287855152804
1336,A1AG1,Neutrophil degranulation,0.00038099339683770635,0,0,1,0.0004159510476429729
1337,A1AG1,Neutrophil degranulation,0.00039636108825102316,1,0,1,0.0004327287855152804
1338,FETUA,Platelet degranulation ,0.0014066800720287076,0,0,1,0.0015357485313796024
1339,FETUA,Platelet degranulation ,0.001526715696148449,1,0,1,0.0016667978986954172
1340,FETUA,Neutrophil degranulation,0.0014066800720287076,0,0,1,0.0015357485313796024
1341,FETUA,Neutrophil degranulation,0.001526715696148449,1,0,1,0.0016667978986954172
1342,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0014066800720287076,0,0,1,0.0015357485313796024
1343,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001526715696148449,1,0,1,0.0016667978986954172
1344,FETUA,Post-translational protein phosphorylation,0.0014066800720287076,0,0,1,0.0015357485313796024
1345,FETUA,Post-translational protein phosphorylation,0.001526715696148449,1,0,1,0.0016667978986954172
1346,TTHY,Retinoid cycle disease events,0.006852921403728503,0,0,1,0.007481704042524539
1347,TTHY,Retinoid cycle disease events,0.004847991894928385,1,0,1,0.00529281432276133
1348,TTHY,Neutrophil degranulation,0.006852921403728503,0,0,1,0.007481704042524539
1349,TTHY,Neutrophil degranulation,0.004847991894928385,1,0,1,0.00529281432276133
1350,TTHY,The canonical retinoid cycle in rods (twilight vision),0.006852921403728503,0,0,1,0.007481704042524539
1351,TTHY,The canonical retinoid cycle in rods (twilight vision),0.004847991894928385,1,0,1,0.00529281432276133
1352,TTHY,Retinoid metabolism and transport,0.006852921403728503,0,0,1,0.007481704042524539
1353,TTHY,Retinoid metabolism and transport,0.004847991894928385,1,0,1,0.00529281432276133
1354,TTHY,Amyloid fiber formation,0.006852921403728503,0,0,1,0.007481704042524539
1355,TTHY,Amyloid fiber formation,0.004847991894928385,1,0,1,0.00529281432276133
1356,ALBU,Bile acid and bile salt metabolism,0.002343746308810213,0,0,1,0.002558794301031508
1357,ALBU,Bile acid and bile salt metabolism,0.0004743097411745407,1,0,1,0.0005178295355939147
1358,ALBU,Platelet degranulation ,0.002343746308810213,0,0,1,0.002558794301031508
1359,ALBU,Platelet degranulation ,0.0004743097411745407,1,0,1,0.0005178295355939147
1360,ALBU,HDL remodeling,0.002343746308810213,0,0,1,0.002558794301031508
1361,ALBU,HDL remodeling,0.0004743097411745407,1,0,1,0.0005178295355939147
1362,ALBU,Cytoprotection by HMOX1,0.002343746308810213,0,0,1,0.002558794301031508
1363,ALBU,Cytoprotection by HMOX1,0.0004743097411745407,1,0,1,0.0005178295355939147
1364,ALBU,Heme biosynthesis,0.002343746308810213,0,0,1,0.002558794301031508
1365,ALBU,Heme biosynthesis,0.0004743097411745407,1,0,1,0.0005178295355939147
1366,ALBU,Heme degradation,0.002343746308810213,0,0,1,0.002558794301031508
1367,ALBU,Heme degradation,0.0004743097411745407,1,0,1,0.0005178295355939147
1368,ALBU,Scavenging of heme from plasma,0.002343746308810213,0,0,1,0.002558794301031508
1369,ALBU,Scavenging of heme from plasma,0.0004743097411745407,1,0,1,0.0005178295355939147
1370,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002343746308810213,0,0,1,0.002558794301031508
1371,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004743097411745407,1,0,1,0.0005178295355939147
1372,ALBU,Post-translational protein phosphorylation,0.002343746308810213,0,0,1,0.002558794301031508
1373,ALBU,Post-translational protein phosphorylation,0.0004743097411745407,1,0,1,0.0005178295355939147
1374,ALBU,Aspirin ADME,0.002343746308810213,0,0,1,0.002558794301031508
1375,ALBU,Aspirin ADME,0.0004743097411745407,1,0,1,0.0005178295355939147
1376,VTDB,Vitamin D (calciferol) metabolism,0.00030632963554445743,0,0,1,0.0003344365909918488
1377,VTDB,Vitamin D (calciferol) metabolism,0.0006719340248717316,1,0,1,0.0007335866288291937
1378,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0003839238945561723,0,0,1,0.0004191504301158153
1379,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0005067906769088691,1,0,1,0.0005532907256283265
1380,CXCL7,G alpha (i) signalling events,0.0003839238945561723,0,0,1,0.0004191504301158153
1381,CXCL7,G alpha (i) signalling events,0.0005067906769088691,1,0,1,0.0005532907256283265
1382,CXCL7,Platelet degranulation ,0.0003839238945561723,0,0,1,0.0004191504301158153
1383,CXCL7,Platelet degranulation ,0.0005067906769088691,1,0,1,0.0005532907256283265
1384,CXCL7,Neutrophil degranulation,0.0003839238945561723,0,0,1,0.0004191504301158153
1385,CXCL7,Neutrophil degranulation,0.0005067906769088691,1,0,1,0.0005532907256283265
1386,PLF4,Transcriptional regulation by RUNX1,0.0013214945539047347,0,0,1,0.001442746905100054
1387,PLF4,Transcriptional regulation by RUNX1,0.0015780619656735662,1,0,1,0.0017228553914992327
1388,PLF4,Class A/1 (Rhodopsin-like receptors),0.0013214945539047347,0,0,1,0.001442746905100054
1389,PLF4,Class A/1 (Rhodopsin-like receptors),0.0015780619656735662,1,0,1,0.0017228553914992327
1390,PLF4,G alpha (i) signalling events,0.0013214945539047347,0,0,1,0.001442746905100054
1391,PLF4,G alpha (i) signalling events,0.0015780619656735662,1,0,1,0.0017228553914992327
1392,PLF4,Platelet degranulation ,0.0013214945539047347,0,0,1,0.001442746905100054
1393,PLF4,Platelet degranulation ,0.0015780619656735662,1,0,1,0.0017228553914992327
1394,PLF4,Common Pathway of Fibrin Clot Formation,0.0013214945539047347,0,0,1,0.001442746905100054
1395,PLF4,Common Pathway of Fibrin Clot Formation,0.0015780619656735662,1,0,1,0.0017228553914992327
1396,TFR1,RHO GTPase cycle,0.0033804122206762665,0,0,1,0.0036905784098257193
1397,TFR1,RHO GTPase cycle,0.0040605484086905,1,0,1,0.004433119782701345
1398,TFR1,Golgi Associated Vesicle Biogenesis,0.0033804122206762665,0,0,1,0.0036905784098257193
1399,TFR1,Golgi Associated Vesicle Biogenesis,0.0040605484086905,1,0,1,0.004433119782701345
1400,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.0033804122206762665,0,0,1,0.0036905784098257193
1401,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.0040605484086905,1,0,1,0.004433119782701345
1402,TFR1,Transferrin endocytosis and recycling,0.0033804122206762665,0,0,1,0.0036905784098257193
1403,TFR1,Transferrin endocytosis and recycling,0.0040605484086905,1,0,1,0.004433119782701345
1404,TRFE,Platelet degranulation ,0.00038129200052666707,0,0,1,0.0004162770494012295
1405,TRFE,Platelet degranulation ,0.0013056388172629752,1,0,1,0.0014254363419196104
1406,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.00038129200052666707,0,0,1,0.0004162770494012295
1407,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0013056388172629752,1,0,1,0.0014254363419196104
1408,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00038129200052666707,0,0,1,0.0004162770494012295
1409,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0013056388172629752,1,0,1,0.0014254363419196104
1410,TRFE,Post-translational protein phosphorylation,0.00038129200052666707,0,0,1,0.0004162770494012295
1411,TRFE,Post-translational protein phosphorylation,0.0013056388172629752,1,0,1,0.0014254363419196104
1412,TRFE,Transferrin endocytosis and recycling,0.00038129200052666707,0,0,1,0.0004162770494012295
1413,TRFE,Transferrin endocytosis and recycling,0.0013056388172629752,1,0,1,0.0014254363419196104
1414,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.005478430694196052,0,0,1,0.005981098374943651
1415,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.004887238104099663,1,0,1,0.005335661526823929
1416,TRFL,Metal sequestration by antimicrobial proteins,0.005478430694196052,0,0,1,0.005981098374943651
1417,TRFL,Metal sequestration by antimicrobial proteins,0.004887238104099663,1,0,1,0.005335661526823929
1418,TRFL,Neutrophil degranulation,0.005478430694196052,0,0,1,0.005981098374943651
1419,TRFL,Neutrophil degranulation,0.004887238104099663,1,0,1,0.005335661526823929
1420,TRFL,Amyloid fiber formation,0.005478430694196052,0,0,1,0.005981098374943651
1421,TRFL,Amyloid fiber formation,0.004887238104099663,1,0,1,0.005335661526823929
1422,HEMO,Scavenging of heme from plasma,6.128560264355044e-05,0,0,1,6.690879904114093e-05
1423,HEMO,Scavenging of heme from plasma,0.00013250756214305798,1,0,1,0.0001446656549732793
1424,ANGI,Adherens junctions interactions,0.0031955687558605822,0,0,1,0.0034887748261463094
1425,ANGI,Adherens junctions interactions,0.002254301981536877,1,0,1,0.0024611431030216037
1426,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0031955687558605822,0,0,1,0.0034887748261463094
1427,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.002254301981536877,1,0,1,0.0024611431030216037
1428,FA11,Defective factor IX causes hemophilia B,0.002682021726244349,0,0,1,0.0029281078257315965
1429,FA11,Defective factor IX causes hemophilia B,0.0031472005067523707,1,0,1,0.003435968598909287
1430,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.002682021726244349,0,0,1,0.0029281078257315965
1431,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.0031472005067523707,1,0,1,0.003435968598909287
1432,KLKB1,Defective factor XII causes hereditary angioedema,0.0024540026701066696,0,0,1,0.0026791671194877267
1433,KLKB1,Defective factor XII causes hereditary angioedema,0.002784580027861556,1,0,1,0.003040076257090875
1434,KLKB1,Defective SERPING1 causes hereditary angioedema,0.0024540026701066696,0,0,1,0.0026791671194877267
1435,KLKB1,Defective SERPING1 causes hereditary angioedema,0.002784580027861556,1,0,1,0.003040076257090875
1436,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.0024540026701066696,0,0,1,0.0026791671194877267
1437,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.002784580027861556,1,0,1,0.003040076257090875
1438,KLKB1,Activation of Matrix Metalloproteinases,0.0024540026701066696,0,0,1,0.0026791671194877267
1439,KLKB1,Activation of Matrix Metalloproteinases,0.002784580027861556,1,0,1,0.003040076257090875
1440,C4BPA,Regulation of Complement cascade,0.0002313140809001382,0,0,1,0.0002525380625585204
1441,C4BPA,Regulation of Complement cascade,0.00027264069920883123,1,0,1,0.0002976565615239095
1442,VTNC,Regulation of Complement cascade,0.0058267844916524624,0,0,1,0.006361415010888198
1443,VTNC,Regulation of Complement cascade,0.00395949814448641,1,0,1,0.004322797757151399
1444,VTNC,Integrin cell surface interactions,0.0058267844916524624,0,0,1,0.006361415010888198
1445,VTNC,Integrin cell surface interactions,0.00395949814448641,1,0,1,0.004322797757151399
1446,VTNC,ECM proteoglycans,0.0058267844916524624,0,0,1,0.006361415010888198
1447,VTNC,ECM proteoglycans,0.00395949814448641,1,0,1,0.004322797757151399
1448,VTNC,Molecules associated with elastic fibres,0.0058267844916524624,0,0,1,0.006361415010888198
1449,VTNC,Molecules associated with elastic fibres,0.00395949814448641,1,0,1,0.004322797757151399
1450,VTNC,Syndecan interactions,0.0058267844916524624,0,0,1,0.006361415010888198
1451,VTNC,Syndecan interactions,0.00395949814448641,1,0,1,0.004322797757151399
1452,CATA,FOXO-mediated transcription,0.002194161309688092,0,0,1,0.0023954842867032976
1453,CATA,FOXO-mediated transcription,0.0019856167376291972,1,0,1,0.002167804925464647
1454,CATA,Detoxification of Reactive Oxygen Species,0.002194161309688092,0,0,1,0.0023954842867032976
1455,CATA,Detoxification of Reactive Oxygen Species,0.0019856167376291972,1,0,1,0.002167804925464647
1456,CATA,Neutrophil degranulation,0.002194161309688092,0,0,1,0.0023954842867032976
1457,CATA,Neutrophil degranulation,0.0019856167376291972,1,0,1,0.002167804925464647
1458,FUCO,Neutrophil degranulation,0.0008644920707027887,0,0,1,0.00094381263683959
1459,FUCO,Neutrophil degranulation,0.0008789819374510328,1,0,1,0.0009596320061624307
1460,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00276564687723332,0,0,1,0.0030194059150210058
1461,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.002902712026667442,1,0,1,0.003169047333942367
1462,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.00276564687723332,0,0,1,0.0030194059150210058
1463,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.002902712026667442,1,0,1,0.003169047333942367
1464,PROC,Common Pathway of Fibrin Clot Formation,0.00276564687723332,0,0,1,0.0030194059150210058
1465,PROC,Common Pathway of Fibrin Clot Formation,0.002902712026667442,1,0,1,0.003169047333942367
1466,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00276564687723332,0,0,1,0.0030194059150210058
1467,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002902712026667442,1,0,1,0.003169047333942367
1468,PROC,Post-translational protein phosphorylation,0.00276564687723332,0,0,1,0.0030194059150210058
1469,PROC,Post-translational protein phosphorylation,0.002902712026667442,1,0,1,0.003169047333942367
1470,ALDOA,Glycolysis,0.00035213535031132243,0,0,1,0.0003844451612281166
1471,ALDOA,Glycolysis,0.0004126832463083575,1,0,1,0.00045054856612064987
1472,ALDOA,Gluconeogenesis,0.00035213535031132243,0,0,1,0.0003844451612281166
1473,ALDOA,Gluconeogenesis,0.0004126832463083575,1,0,1,0.00045054856612064987
1474,ALDOA,Platelet degranulation ,0.00035213535031132243,0,0,1,0.0003844451612281166
1475,ALDOA,Platelet degranulation ,0.0004126832463083575,1,0,1,0.00045054856612064987
1476,ALDOA,Neutrophil degranulation,0.00035213535031132243,0,0,1,0.0003844451612281166
1477,ALDOA,Neutrophil degranulation,0.0004126832463083575,1,0,1,0.00045054856612064987
1478,APOB,Regulation of TLR by endogenous ligand,0.03542320512537726,0,0,1,0.03867342427734791
1479,APOB,Regulation of TLR by endogenous ligand,0.043710089551251226,1,0,1,0.04772066311993295
1480,APOB,Cargo recognition for clathrin-mediated endocytosis,0.03542320512537726,0,0,1,0.03867342427734791
1481,APOB,Cargo recognition for clathrin-mediated endocytosis,0.043710089551251226,1,0,1,0.04772066311993295
1482,APOB,VLDL assembly,0.03542320512537726,0,0,1,0.03867342427734791
1483,APOB,VLDL assembly,0.043710089551251226,1,0,1,0.04772066311993295
1484,APOB,Chylomicron assembly,0.03542320512537726,0,0,1,0.03867342427734791
1485,APOB,Chylomicron assembly,0.043710089551251226,1,0,1,0.04772066311993295
1486,APOB,Chylomicron remodeling,0.03542320512537726,0,0,1,0.03867342427734791
1487,APOB,Chylomicron remodeling,0.043710089551251226,1,0,1,0.04772066311993295
1488,APOB,LDL remodeling,0.03542320512537726,0,0,1,0.03867342427734791
1489,APOB,LDL remodeling,0.043710089551251226,1,0,1,0.04772066311993295
1490,APOB,Chylomicron clearance,0.03542320512537726,0,0,1,0.03867342427734791
1491,APOB,Chylomicron clearance,0.043710089551251226,1,0,1,0.04772066311993295
1492,APOB,LDL clearance,0.03542320512537726,0,0,1,0.03867342427734791
1493,APOB,LDL clearance,0.043710089551251226,1,0,1,0.04772066311993295
1494,APOB,VLDL clearance,0.03542320512537726,0,0,1,0.03867342427734791
1495,APOB,VLDL clearance,0.043710089551251226,1,0,1,0.04772066311993295
1496,APOB,Scavenging by Class B Receptors,0.03542320512537726,0,0,1,0.03867342427734791
1497,APOB,Scavenging by Class B Receptors,0.043710089551251226,1,0,1,0.04772066311993295
1498,APOB,Scavenging by Class A Receptors,0.03542320512537726,0,0,1,0.03867342427734791
1499,APOB,Scavenging by Class A Receptors,0.043710089551251226,1,0,1,0.04772066311993295
1500,APOB,Scavenging by Class F Receptors,0.03542320512537726,0,0,1,0.03867342427734791
1501,APOB,Scavenging by Class F Receptors,0.043710089551251226,1,0,1,0.04772066311993295
1502,APOB,Scavenging by Class H Receptors,0.03542320512537726,0,0,1,0.03867342427734791
1503,APOB,Scavenging by Class H Receptors,0.043710089551251226,1,0,1,0.04772066311993295
1504,APOB,Retinoid metabolism and transport,0.03542320512537726,0,0,1,0.03867342427734791
1505,APOB,Retinoid metabolism and transport,0.043710089551251226,1,0,1,0.04772066311993295
1506,APOB,Heme signaling,0.03542320512537726,0,0,1,0.03867342427734791
1507,APOB,Heme signaling,0.043710089551251226,1,0,1,0.04772066311993295
1508,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03542320512537726,0,0,1,0.03867342427734791
1509,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.043710089551251226,1,0,1,0.04772066311993295
1510,APOB,Platelet sensitization by LDL,0.03542320512537726,0,0,1,0.03867342427734791
1511,APOB,Platelet sensitization by LDL,0.043710089551251226,1,0,1,0.04772066311993295
1512,APOB,Post-translational protein phosphorylation,0.03542320512537726,0,0,1,0.03867342427734791
1513,APOB,Post-translational protein phosphorylation,0.043710089551251226,1,0,1,0.04772066311993295
1514,SODM,FOXO-mediated transcription,0.0009424068261355133,0,0,1,0.001028876379198603
1515,SODM,FOXO-mediated transcription,0.001071227331932984,1,0,1,0.001169516675826055
1516,SODM,Interleukin-12 family signaling,0.0009424068261355133,0,0,1,0.001028876379198603
1517,SODM,Interleukin-12 family signaling,0.001071227331932984,1,0,1,0.001169516675826055
1518,SODM,Neurodegenerative Diseases,0.0009424068261355133,0,0,1,0.001028876379198603
1519,SODM,Neurodegenerative Diseases,0.001071227331932984,1,0,1,0.001169516675826055
1520,SODM,Detoxification of Reactive Oxygen Species,0.0009424068261355133,0,0,1,0.001028876379198603
1521,SODM,Detoxification of Reactive Oxygen Species,0.001071227331932984,1,0,1,0.001169516675826055
1522,SODM,Transcriptional activation of mitochondrial biogenesis,0.0009424068261355133,0,0,1,0.001028876379198603
1523,SODM,Transcriptional activation of mitochondrial biogenesis,0.001071227331932984,1,0,1,0.001169516675826055
1524,LCAT,HDL remodeling,0.00017132188251831344,0,0,1,0.00018704134273490945
1525,LCAT,HDL remodeling,0.00023146104920411504,1,0,1,0.00025269851578557596
1526,HRG,Platelet degranulation ,0.0007218599114770915,0,0,1,0.0007880934129634338
1527,HRG,Platelet degranulation ,0.0014248281467221689,1,0,1,0.0015555617636930845
1528,HRG,Dissolution of Fibrin Clot,0.0007218599114770915,0,0,1,0.0007880934129634338
1529,HRG,Dissolution of Fibrin Clot,0.0014248281467221689,1,0,1,0.0015555617636930845
1530,LV743,Initial triggering of complement,0.00483848816849029,0,0,1,0.005282438591839878
1531,LV743,Initial triggering of complement,0.005410099600995465,1,0,1,0.005906497633725343
1532,LV743,Regulation of Complement cascade,0.00483848816849029,0,0,1,0.005282438591839878
1533,LV743,Regulation of Complement cascade,0.005410099600995465,1,0,1,0.005906497633725343
1534,LV743,FCGR activation,0.00483848816849029,0,0,1,0.005282438591839878
1535,LV743,FCGR activation,0.005410099600995465,1,0,1,0.005906497633725343
1536,LV743,Regulation of actin dynamics for phagocytic cup formation,0.00483848816849029,0,0,1,0.005282438591839878
1537,LV743,Regulation of actin dynamics for phagocytic cup formation,0.005410099600995465,1,0,1,0.005906497633725343
1538,LV743,Role of phospholipids in phagocytosis,0.00483848816849029,0,0,1,0.005282438591839878
1539,LV743,Role of phospholipids in phagocytosis,0.005410099600995465,1,0,1,0.005906497633725343
1540,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.00483848816849029,0,0,1,0.005282438591839878
1541,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.005410099600995465,1,0,1,0.005906497633725343
1542,LV743,FCERI mediated MAPK activation,0.00483848816849029,0,0,1,0.005282438591839878
1543,LV743,FCERI mediated MAPK activation,0.005410099600995465,1,0,1,0.005906497633725343
1544,LV743,FCERI mediated Ca+2 mobilization,0.00483848816849029,0,0,1,0.005282438591839878
1545,LV743,FCERI mediated Ca+2 mobilization,0.005410099600995465,1,0,1,0.005906497633725343
1546,LV743,FCERI mediated NF-kB activation,0.00483848816849029,0,0,1,0.005282438591839878
1547,LV743,FCERI mediated NF-kB activation,0.005410099600995465,1,0,1,0.005906497633725343
1548,LV743,Parasite infection,0.00483848816849029,0,0,1,0.005282438591839878
1549,LV743,Parasite infection,0.005410099600995465,1,0,1,0.005906497633725343
1550,LV743,Leishmania parasite growth and survival,0.00483848816849029,0,0,1,0.005282438591839878
1551,LV743,Leishmania parasite growth and survival,0.005410099600995465,1,0,1,0.005906497633725343
1552,LV743,Potential therapeutics for SARS,0.00483848816849029,0,0,1,0.005282438591839878
1553,LV743,Potential therapeutics for SARS,0.005410099600995465,1,0,1,0.005906497633725343
1554,LV743,CD22 mediated BCR regulation,0.00483848816849029,0,0,1,0.005282438591839878
1555,LV743,CD22 mediated BCR regulation,0.005410099600995465,1,0,1,0.005906497633725343
1556,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00483848816849029,0,0,1,0.005282438591839878
1557,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005410099600995465,1,0,1,0.005906497633725343
1558,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00483848816849029,0,0,1,0.005282438591839878
1559,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005410099600995465,1,0,1,0.005906497633725343
1560,LV743,Scavenging of heme from plasma,0.00483848816849029,0,0,1,0.005282438591839878
1561,LV743,Scavenging of heme from plasma,0.005410099600995465,1,0,1,0.005906497633725343
1562,A1BG,Platelet degranulation ,0.0020922505391354207,0,0,1,0.002284222799944399
1563,A1BG,Platelet degranulation ,0.0021294310919550154,1,0,1,0.0023248148155163724
1564,A1BG,Neutrophil degranulation,0.0020922505391354207,0,0,1,0.002284222799944399
1565,A1BG,Neutrophil degranulation,0.0021294310919550154,1,0,1,0.0023248148155163724
1566,K2C6B,Formation of the cornified envelope,0.001222759073063599,0,0,1,0.0013349520534404662
1567,K2C6B,Formation of the cornified envelope,0.001576669659698382,1,0,1,0.0017213353359449256
1568,K2C1,Neutrophil degranulation,0.002293117348816097,0,0,1,0.002503519933744777
1569,K2C1,Neutrophil degranulation,0.0027433563814606645,1,0,1,0.0029950701781130333
1570,K2C1,Formation of the cornified envelope,0.002293117348816097,0,0,1,0.002503519933744777
1571,K2C1,Formation of the cornified envelope,0.0027433563814606645,1,0,1,0.0029950701781130333
1572,VWF,RAF/MAP kinase cascade,0.004981106575574388,0,0,1,0.005438142801761061
1573,VWF,RAF/MAP kinase cascade,0.003321853334556795,1,0,1,0.0036266465143325924
1574,VWF,Signaling by RAS mutants,0.004981106575574388,0,0,1,0.005438142801761061
1575,VWF,Signaling by RAS mutants,0.003321853334556795,1,0,1,0.0036266465143325924
1576,VWF,Signaling by moderate kinase activity BRAF mutants,0.004981106575574388,0,0,1,0.005438142801761061
1577,VWF,Signaling by moderate kinase activity BRAF mutants,0.003321853334556795,1,0,1,0.0036266465143325924
1578,VWF,Signaling by high-kinase activity BRAF mutants,0.004981106575574388,0,0,1,0.005438142801761061
1579,VWF,Signaling by high-kinase activity BRAF mutants,0.003321853334556795,1,0,1,0.0036266465143325924
1580,VWF,Signaling by BRAF and RAF1 fusions,0.004981106575574388,0,0,1,0.005438142801761061
1581,VWF,Signaling by BRAF and RAF1 fusions,0.003321853334556795,1,0,1,0.0036266465143325924
1582,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.004981106575574388,0,0,1,0.005438142801761061
1583,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.003321853334556795,1,0,1,0.0036266465143325924
1584,VWF,Signaling by RAF1 mutants,0.004981106575574388,0,0,1,0.005438142801761061
1585,VWF,Signaling by RAF1 mutants,0.003321853334556795,1,0,1,0.0036266465143325924
1586,VWF,Platelet degranulation ,0.004981106575574388,0,0,1,0.005438142801761061
1587,VWF,Platelet degranulation ,0.003321853334556795,1,0,1,0.0036266465143325924
1588,VWF,Defective factor VIII causes hemophilia A,0.004981106575574388,0,0,1,0.005438142801761061
1589,VWF,Defective factor VIII causes hemophilia A,0.003321853334556795,1,0,1,0.0036266465143325924
1590,VWF,Platelet Adhesion to exposed collagen,0.004981106575574388,0,0,1,0.005438142801761061
1591,VWF,Platelet Adhesion to exposed collagen,0.003321853334556795,1,0,1,0.0036266465143325924
1592,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.004981106575574388,0,0,1,0.005438142801761061
1593,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.003321853334556795,1,0,1,0.0036266465143325924
1594,VWF,Integrin cell surface interactions,0.004981106575574388,0,0,1,0.005438142801761061
1595,VWF,Integrin cell surface interactions,0.003321853334556795,1,0,1,0.0036266465143325924
1596,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.004981106575574388,0,0,1,0.005438142801761061
1597,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.003321853334556795,1,0,1,0.0036266465143325924
1598,VWF,p130Cas linkage to MAPK signaling for integrins,0.004981106575574388,0,0,1,0.005438142801761061
1599,VWF,p130Cas linkage to MAPK signaling for integrins,0.003321853334556795,1,0,1,0.0036266465143325924
1600,VWF,GP1b-IX-V activation signalling,0.004981106575574388,0,0,1,0.005438142801761061
1601,VWF,GP1b-IX-V activation signalling,0.003321853334556795,1,0,1,0.0036266465143325924
1602,G3P,Glycolysis,0.000303234721665143,0,0,1,0.0003310577065252133
1603,G3P,Glycolysis,0.0004997326152429911,1,0,1,0.0005455850588933694
1604,G3P,Gluconeogenesis,0.000303234721665143,0,0,1,0.0003310577065252133
1605,G3P,Gluconeogenesis,0.0004997326152429911,1,0,1,0.0005455850588933694
1606,ARLY,Urea cycle,0.0009841416458076877,0,0,1,0.0010744405336168127
1607,ARLY,Urea cycle,0.00010231843471093053,1,0,1,0.00011170655571579352
1608,KV116,Initial triggering of complement,0.0029654345337210286,0,0,1,0.00323752487905543
1609,KV116,Initial triggering of complement,0.003651428825385314,1,0,1,0.0039864618597569785
1610,KV116,Regulation of Complement cascade,0.0029654345337210286,0,0,1,0.00323752487905543
1611,KV116,Regulation of Complement cascade,0.003651428825385314,1,0,1,0.0039864618597569785
1612,KV116,FCGR activation,0.0029654345337210286,0,0,1,0.00323752487905543
1613,KV116,FCGR activation,0.003651428825385314,1,0,1,0.0039864618597569785
1614,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0029654345337210286,0,0,1,0.00323752487905543
1615,KV116,Regulation of actin dynamics for phagocytic cup formation,0.003651428825385314,1,0,1,0.0039864618597569785
1616,KV116,Role of phospholipids in phagocytosis,0.0029654345337210286,0,0,1,0.00323752487905543
1617,KV116,Role of phospholipids in phagocytosis,0.003651428825385314,1,0,1,0.0039864618597569785
1618,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0029654345337210286,0,0,1,0.00323752487905543
1619,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.003651428825385314,1,0,1,0.0039864618597569785
1620,KV116,FCERI mediated MAPK activation,0.0029654345337210286,0,0,1,0.00323752487905543
1621,KV116,FCERI mediated MAPK activation,0.003651428825385314,1,0,1,0.0039864618597569785
1622,KV116,FCERI mediated Ca+2 mobilization,0.0029654345337210286,0,0,1,0.00323752487905543
1623,KV116,FCERI mediated Ca+2 mobilization,0.003651428825385314,1,0,1,0.0039864618597569785
1624,KV116,FCERI mediated NF-kB activation,0.0029654345337210286,0,0,1,0.00323752487905543
1625,KV116,FCERI mediated NF-kB activation,0.003651428825385314,1,0,1,0.0039864618597569785
1626,KV116,Parasite infection,0.0029654345337210286,0,0,1,0.00323752487905543
1627,KV116,Parasite infection,0.003651428825385314,1,0,1,0.0039864618597569785
1628,KV116,Leishmania parasite growth and survival,0.0029654345337210286,0,0,1,0.00323752487905543
1629,KV116,Leishmania parasite growth and survival,0.003651428825385314,1,0,1,0.0039864618597569785
1630,KV116,Potential therapeutics for SARS,0.0029654345337210286,0,0,1,0.00323752487905543
1631,KV116,Potential therapeutics for SARS,0.003651428825385314,1,0,1,0.0039864618597569785
1632,KV116,CD22 mediated BCR regulation,0.0029654345337210286,0,0,1,0.00323752487905543
1633,KV116,CD22 mediated BCR regulation,0.003651428825385314,1,0,1,0.0039864618597569785
1634,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0029654345337210286,0,0,1,0.00323752487905543
1635,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003651428825385314,1,0,1,0.0039864618597569785
1636,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0029654345337210286,0,0,1,0.00323752487905543
1637,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003651428825385314,1,0,1,0.0039864618597569785
1638,KV116,Scavenging of heme from plasma,0.0029654345337210286,0,0,1,0.00323752487905543
1639,KV116,Scavenging of heme from plasma,0.003651428825385314,1,0,1,0.0039864618597569785
1640,KV311,Initial triggering of complement,0.0037599768597390507,0,0,1,0.004104969605517872
1641,KV311,Initial triggering of complement,0.004785616318868097,1,0,1,0.005224715540932146
1642,KV311,Regulation of Complement cascade,0.0037599768597390507,0,0,1,0.004104969605517872
1643,KV311,Regulation of Complement cascade,0.004785616318868097,1,0,1,0.005224715540932146
1644,KV311,FCGR activation,0.0037599768597390507,0,0,1,0.004104969605517872
1645,KV311,FCGR activation,0.004785616318868097,1,0,1,0.005224715540932146
1646,KV311,Regulation of actin dynamics for phagocytic cup formation,0.0037599768597390507,0,0,1,0.004104969605517872
1647,KV311,Regulation of actin dynamics for phagocytic cup formation,0.004785616318868097,1,0,1,0.005224715540932146
1648,KV311,Role of phospholipids in phagocytosis,0.0037599768597390507,0,0,1,0.004104969605517872
1649,KV311,Role of phospholipids in phagocytosis,0.004785616318868097,1,0,1,0.005224715540932146
1650,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.0037599768597390507,0,0,1,0.004104969605517872
1651,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.004785616318868097,1,0,1,0.005224715540932146
1652,KV311,FCERI mediated MAPK activation,0.0037599768597390507,0,0,1,0.004104969605517872
1653,KV311,FCERI mediated MAPK activation,0.004785616318868097,1,0,1,0.005224715540932146
1654,KV311,FCERI mediated Ca+2 mobilization,0.0037599768597390507,0,0,1,0.004104969605517872
1655,KV311,FCERI mediated Ca+2 mobilization,0.004785616318868097,1,0,1,0.005224715540932146
1656,KV311,FCERI mediated NF-kB activation,0.0037599768597390507,0,0,1,0.004104969605517872
1657,KV311,FCERI mediated NF-kB activation,0.004785616318868097,1,0,1,0.005224715540932146
1658,KV311,Parasite infection,0.0037599768597390507,0,0,1,0.004104969605517872
1659,KV311,Parasite infection,0.004785616318868097,1,0,1,0.005224715540932146
1660,KV311,Leishmania parasite growth and survival,0.0037599768597390507,0,0,1,0.004104969605517872
1661,KV311,Leishmania parasite growth and survival,0.004785616318868097,1,0,1,0.005224715540932146
1662,KV311,Potential therapeutics for SARS,0.0037599768597390507,0,0,1,0.004104969605517872
1663,KV311,Potential therapeutics for SARS,0.004785616318868097,1,0,1,0.005224715540932146
1664,KV311,CD22 mediated BCR regulation,0.0037599768597390507,0,0,1,0.004104969605517872
1665,KV311,CD22 mediated BCR regulation,0.004785616318868097,1,0,1,0.005224715540932146
1666,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0037599768597390507,0,0,1,0.004104969605517872
1667,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004785616318868097,1,0,1,0.005224715540932146
1668,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0037599768597390507,0,0,1,0.004104969605517872
1669,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004785616318868097,1,0,1,0.005224715540932146
1670,KV311,Scavenging of heme from plasma,0.0037599768597390507,0,0,1,0.004104969605517872
1671,KV311,Scavenging of heme from plasma,0.004785616318868097,1,0,1,0.005224715540932146
1672,MT1A,Metallothioneins bind metals,0.0014571379778580505,0,0,1,0.0015908361496055057
1673,MT1A,Metallothioneins bind metals,0.0009324908532647813,1,0,1,0.001018050576604084
1674,MT1E,Metallothioneins bind metals,0.006017809312998643,0,0,1,0.006569967115004066
1675,MT1E,Metallothioneins bind metals,0.003883501965089271,1,0,1,0.00423982862776628
1676,H2A1B,Packaging Of Telomere Ends,0.05740436837833545,0,0,1,0.06267144618368006
1677,H2A1B,Packaging Of Telomere Ends,0.04390595085578521,1,0,1,0.04793449547369506
1678,H2A1B,Inhibition of DNA recombination at telomere,0.05740436837833545,0,0,1,0.06267144618368006
1679,H2A1B,Inhibition of DNA recombination at telomere,0.04390595085578521,1,0,1,0.04793449547369506
1680,H2A1B,Pre-NOTCH Transcription and Translation,0.05740436837833545,0,0,1,0.06267144618368006
1681,H2A1B,Pre-NOTCH Transcription and Translation,0.04390595085578521,1,0,1,0.04793449547369506
1682,H2A1B,RHO GTPase Effectors,0.05740436837833545,0,0,1,0.06267144618368006
1683,H2A1B,RHO GTPase Effectors,0.04390595085578521,1,0,1,0.04793449547369506
1684,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.05740436837833545,0,0,1,0.06267144618368006
1685,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.04390595085578521,1,0,1,0.04793449547369506
1686,H2A1B,Transcriptional regulation by RUNX1,0.05740436837833545,0,0,1,0.06267144618368006
1687,H2A1B,Transcriptional regulation by RUNX1,0.04390595085578521,1,0,1,0.04793449547369506
1688,H2A1B,Oxidative Stress Induced Senescence,0.05740436837833545,0,0,1,0.06267144618368006
1689,H2A1B,Oxidative Stress Induced Senescence,0.04390595085578521,1,0,1,0.04793449547369506
1690,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.05740436837833545,0,0,1,0.06267144618368006
1691,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.04390595085578521,1,0,1,0.04793449547369506
1692,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.05740436837833545,0,0,1,0.06267144618368006
1693,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.04390595085578521,1,0,1,0.04793449547369506
1694,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.05740436837833545,0,0,1,0.06267144618368006
1695,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.04390595085578521,1,0,1,0.04793449547369506
1696,H2A1B,B-WICH complex positively regulates rRNA expression,0.05740436837833545,0,0,1,0.06267144618368006
1697,H2A1B,B-WICH complex positively regulates rRNA expression,0.04390595085578521,1,0,1,0.04793449547369506
1698,H2A1B,SIRT1 negatively regulates rRNA expression,0.05740436837833545,0,0,1,0.06267144618368006
1699,H2A1B,SIRT1 negatively regulates rRNA expression,0.04390595085578521,1,0,1,0.04793449547369506
1700,H2A1B,NoRC negatively regulates rRNA expression,0.05740436837833545,0,0,1,0.06267144618368006
1701,H2A1B,NoRC negatively regulates rRNA expression,0.04390595085578521,1,0,1,0.04793449547369506
1702,H2A1B,UCH proteinases,0.05740436837833545,0,0,1,0.06267144618368006
1703,H2A1B,UCH proteinases,0.04390595085578521,1,0,1,0.04793449547369506
1704,H2A1B,Ub-specific processing proteases,0.05740436837833545,0,0,1,0.06267144618368006
1705,H2A1B,Ub-specific processing proteases,0.04390595085578521,1,0,1,0.04793449547369506
1706,H2A1B,Metalloprotease DUBs,0.05740436837833545,0,0,1,0.06267144618368006
1707,H2A1B,Metalloprotease DUBs,0.04390595085578521,1,0,1,0.04793449547369506
1708,H2A1B,Assembly of the ORC complex at the origin of replication,0.05740436837833545,0,0,1,0.06267144618368006
1709,H2A1B,Assembly of the ORC complex at the origin of replication,0.04390595085578521,1,0,1,0.04793449547369506
1710,H2A1B,Mitotic Prophase,0.05740436837833545,0,0,1,0.06267144618368006
1711,H2A1B,Mitotic Prophase,0.04390595085578521,1,0,1,0.04793449547369506
1712,H2A1B,RNA Polymerase I Promoter Opening,0.05740436837833545,0,0,1,0.06267144618368006
1713,H2A1B,RNA Polymerase I Promoter Opening,0.04390595085578521,1,0,1,0.04793449547369506
1714,H2A1B,RNA Polymerase I Promoter Escape,0.05740436837833545,0,0,1,0.06267144618368006
1715,H2A1B,RNA Polymerase I Promoter Escape,0.04390595085578521,1,0,1,0.04793449547369506
1716,H2A1B,Depurination,0.05740436837833545,0,0,1,0.06267144618368006
1717,H2A1B,Depurination,0.04390595085578521,1,0,1,0.04793449547369506
1718,H2A1B,Depyrimidination,0.05740436837833545,0,0,1,0.06267144618368006
1719,H2A1B,Depyrimidination,0.04390595085578521,1,0,1,0.04793449547369506
1720,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.05740436837833545,0,0,1,0.06267144618368006
1721,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.04390595085578521,1,0,1,0.04793449547369506
1722,H2A1B,Estrogen-dependent gene expression,0.05740436837833545,0,0,1,0.06267144618368006
1723,H2A1B,Estrogen-dependent gene expression,0.04390595085578521,1,0,1,0.04793449547369506
1724,H2A1B,HCMV Early Events,0.05740436837833545,0,0,1,0.06267144618368006
1725,H2A1B,HCMV Early Events,0.04390595085578521,1,0,1,0.04793449547369506
1726,H2A1B,HCMV Late Events,0.05740436837833545,0,0,1,0.06267144618368006
1727,H2A1B,HCMV Late Events,0.04390595085578521,1,0,1,0.04793449547369506
1728,H2A1B,Transcriptional regulation of granulopoiesis,0.05740436837833545,0,0,1,0.06267144618368006
1729,H2A1B,Transcriptional regulation of granulopoiesis,0.04390595085578521,1,0,1,0.04793449547369506
1730,H2A1B,Meiotic synapsis,0.05740436837833545,0,0,1,0.06267144618368006
1731,H2A1B,Meiotic synapsis,0.04390595085578521,1,0,1,0.04793449547369506
1732,H2A1B,Meiotic recombination,0.05740436837833545,0,0,1,0.06267144618368006
1733,H2A1B,Meiotic recombination,0.04390595085578521,1,0,1,0.04793449547369506
1734,H2A1B,Transcriptional regulation by small RNAs,0.05740436837833545,0,0,1,0.06267144618368006
1735,H2A1B,Transcriptional regulation by small RNAs,0.04390595085578521,1,0,1,0.04793449547369506
1736,H2A1B,PRC2 methylates histones and DNA,0.05740436837833545,0,0,1,0.06267144618368006
1737,H2A1B,PRC2 methylates histones and DNA,0.04390595085578521,1,0,1,0.04793449547369506
1738,H2A1B,DNA methylation,0.05740436837833545,0,0,1,0.06267144618368006
1739,H2A1B,DNA methylation,0.04390595085578521,1,0,1,0.04793449547369506
1740,H2A1B,HDACs deacetylate histones,0.05740436837833545,0,0,1,0.06267144618368006
1741,H2A1B,HDACs deacetylate histones,0.04390595085578521,1,0,1,0.04793449547369506
1742,H2A1B,HATs acetylate histones,0.05740436837833545,0,0,1,0.06267144618368006
1743,H2A1B,HATs acetylate histones,0.04390595085578521,1,0,1,0.04793449547369506
1744,H2A1B,RMTs methylate histone arginines,0.05740436837833545,0,0,1,0.06267144618368006
1745,H2A1B,RMTs methylate histone arginines,0.04390595085578521,1,0,1,0.04793449547369506
1746,H2A1B,Amyloid fiber formation,0.05740436837833545,0,0,1,0.06267144618368006
1747,H2A1B,Amyloid fiber formation,0.04390595085578521,1,0,1,0.04793449547369506
1748,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.05740436837833545,0,0,1,0.06267144618368006
1749,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.04390595085578521,1,0,1,0.04793449547369506
1750,H2A1B,Defective pyroptosis,0.05740436837833545,0,0,1,0.06267144618368006
1751,H2A1B,Defective pyroptosis,0.04390595085578521,1,0,1,0.04793449547369506
1752,IGF1,IGF1R signaling cascade,0.0005921291478618749,0,0,1,0.0006464593387638263
1753,IGF1,IGF1R signaling cascade,0.0018130310835921901,1,0,1,0.001979383855176596
1754,IGF1,Platelet degranulation ,0.0005921291478618749,0,0,1,0.0006464593387638263
1755,IGF1,Platelet degranulation ,0.0018130310835921901,1,0,1,0.001979383855176596
1756,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0005921291478618749,0,0,1,0.0006464593387638263
1757,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0018130310835921901,1,0,1,0.001979383855176596
1758,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005921291478618749,0,0,1,0.0006464593387638263
1759,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0018130310835921901,1,0,1,0.001979383855176596
1760,ALDOB,Fructose catabolism,0.006815227018313206,0,0,1,0.007440551048184247
1761,ALDOB,Fructose catabolism,0.006178343672559671,1,0,1,0.0067452311368909005
1762,ALDOB,Hereditary fructose intolerance,0.006815227018313206,0,0,1,0.007440551048184247
1763,ALDOB,Hereditary fructose intolerance,0.006178343672559671,1,0,1,0.0067452311368909005
1764,ALDOB,Glycolysis,0.006815227018313206,0,0,1,0.007440551048184247
1765,ALDOB,Glycolysis,0.006178343672559671,1,0,1,0.0067452311368909005
1766,ALDOB,Gluconeogenesis,0.006815227018313206,0,0,1,0.007440551048184247
1767,ALDOB,Gluconeogenesis,0.006178343672559671,1,0,1,0.0067452311368909005
1768,APOD,Transport of fatty acids,0.001660751543161768,0,0,1,0.0018131320647194345
1769,APOD,Transport of fatty acids,0.000590325566843737,1,0,1,0.0006444902720549798
1770,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.001660751543161768,0,0,1,0.0018131320647194345
1771,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.000590325566843737,1,0,1,0.0006444902720549798
1772,ALDH2,Serotonin clearance from the synaptic cleft,0.0007442360692025224,0,0,1,0.0008125226716471009
1773,ALDH2,Serotonin clearance from the synaptic cleft,0.0005801093208306318,1,0,1,0.0006333366450698391
1774,ALDH2,Ethanol oxidation,0.0007442360692025224,0,0,1,0.0008125226716471009
1775,ALDH2,Ethanol oxidation,0.0005801093208306318,1,0,1,0.0006333366450698391
1776,ALDH2,Smooth Muscle Contraction,0.0007442360692025224,0,0,1,0.0008125226716471009
1777,ALDH2,Smooth Muscle Contraction,0.0005801093208306318,1,0,1,0.0006333366450698391
1778,ITB3,TGF-beta receptor signaling activates SMADs,0.013252908328481888,0,0,1,0.01446891507649025
1779,ITB3,TGF-beta receptor signaling activates SMADs,0.009686009058974645,1,0,1,0.010574738693636843
1780,ITB3,VEGFA-VEGFR2 Pathway,0.013252908328481888,0,0,1,0.01446891507649025
1781,ITB3,VEGFA-VEGFR2 Pathway,0.009686009058974645,1,0,1,0.010574738693636843
1782,ITB3,L1CAM interactions,0.013252908328481888,0,0,1,0.01446891507649025
1783,ITB3,L1CAM interactions,0.009686009058974645,1,0,1,0.010574738693636843
1784,ITB3,RAF/MAP kinase cascade,0.013252908328481888,0,0,1,0.01446891507649025
1785,ITB3,RAF/MAP kinase cascade,0.009686009058974645,1,0,1,0.010574738693636843
1786,ITB3,Signaling by RAS mutants,0.013252908328481888,0,0,1,0.01446891507649025
1787,ITB3,Signaling by RAS mutants,0.009686009058974645,1,0,1,0.010574738693636843
1788,ITB3,Signaling by moderate kinase activity BRAF mutants,0.013252908328481888,0,0,1,0.01446891507649025
1789,ITB3,Signaling by moderate kinase activity BRAF mutants,0.009686009058974645,1,0,1,0.010574738693636843
1790,ITB3,Signaling by high-kinase activity BRAF mutants,0.013252908328481888,0,0,1,0.01446891507649025
1791,ITB3,Signaling by high-kinase activity BRAF mutants,0.009686009058974645,1,0,1,0.010574738693636843
1792,ITB3,Signaling by BRAF and RAF1 fusions,0.013252908328481888,0,0,1,0.01446891507649025
1793,ITB3,Signaling by BRAF and RAF1 fusions,0.009686009058974645,1,0,1,0.010574738693636843
1794,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.013252908328481888,0,0,1,0.01446891507649025
1795,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.009686009058974645,1,0,1,0.010574738693636843
1796,ITB3,Signaling by RAF1 mutants,0.013252908328481888,0,0,1,0.01446891507649025
1797,ITB3,Signaling by RAF1 mutants,0.009686009058974645,1,0,1,0.010574738693636843
1798,ITB3,Platelet degranulation ,0.013252908328481888,0,0,1,0.01446891507649025
1799,ITB3,Platelet degranulation ,0.009686009058974645,1,0,1,0.010574738693636843
1800,ITB3,Integrin cell surface interactions,0.013252908328481888,0,0,1,0.01446891507649025
1801,ITB3,Integrin cell surface interactions,0.009686009058974645,1,0,1,0.010574738693636843
1802,ITB3,ECM proteoglycans,0.013252908328481888,0,0,1,0.01446891507649025
1803,ITB3,ECM proteoglycans,0.009686009058974645,1,0,1,0.010574738693636843
1804,ITB3,Molecules associated with elastic fibres,0.013252908328481888,0,0,1,0.01446891507649025
1805,ITB3,Molecules associated with elastic fibres,0.009686009058974645,1,0,1,0.010574738693636843
1806,ITB3,PECAM1 interactions,0.013252908328481888,0,0,1,0.01446891507649025
1807,ITB3,PECAM1 interactions,0.009686009058974645,1,0,1,0.010574738693636843
1808,ITB3,Syndecan interactions,0.013252908328481888,0,0,1,0.01446891507649025
1809,ITB3,Syndecan interactions,0.009686009058974645,1,0,1,0.010574738693636843
1810,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.013252908328481888,0,0,1,0.01446891507649025
1811,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.009686009058974645,1,0,1,0.010574738693636843
1812,ITB3,p130Cas linkage to MAPK signaling for integrins,0.013252908328481888,0,0,1,0.01446891507649025
1813,ITB3,p130Cas linkage to MAPK signaling for integrins,0.009686009058974645,1,0,1,0.010574738693636843
1814,S10A8,Antigen processing-Cross presentation,0.009458975343528289,0,0,1,0.010326873736989272
1815,S10A8,Antigen processing-Cross presentation,0.010852920516193307,1,0,1,0.011848718891628172
1816,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.009458975343528289,0,0,1,0.010326873736989272
1817,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.010852920516193307,1,0,1,0.011848718891628172
1818,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.009458975343528289,0,0,1,0.010326873736989272
1819,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.010852920516193307,1,0,1,0.011848718891628172
1820,S10A8,Regulation of TLR by endogenous ligand,0.009458975343528289,0,0,1,0.010326873736989272
1821,S10A8,Regulation of TLR by endogenous ligand,0.010852920516193307,1,0,1,0.011848718891628172
1822,S10A8,RHO GTPase Effectors,0.009458975343528289,0,0,1,0.010326873736989272
1823,S10A8,RHO GTPase Effectors,0.010852920516193307,1,0,1,0.011848718891628172
1824,S10A8,MyD88 deficiency (TLR2/4),0.009458975343528289,0,0,1,0.010326873736989272
1825,S10A8,MyD88 deficiency (TLR2/4),0.010852920516193307,1,0,1,0.011848718891628172
1826,S10A8,IRAK4 deficiency (TLR2/4),0.009458975343528289,0,0,1,0.010326873736989272
1827,S10A8,IRAK4 deficiency (TLR2/4),0.010852920516193307,1,0,1,0.011848718891628172
1828,S10A8,Metal sequestration by antimicrobial proteins,0.009458975343528289,0,0,1,0.010326873736989272
1829,S10A8,Metal sequestration by antimicrobial proteins,0.010852920516193307,1,0,1,0.011848718891628172
1830,S10A8,Neutrophil degranulation,0.009458975343528289,0,0,1,0.010326873736989272
1831,S10A8,Neutrophil degranulation,0.010852920516193307,1,0,1,0.011848718891628172
1832,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0062116075538779575,0,0,1,0.006781547110862771
1833,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.004524510968972924,1,0,1,0.004939652742638174
1834,PAI1,Platelet degranulation ,0.0062116075538779575,0,0,1,0.006781547110862771
1835,PAI1,Platelet degranulation ,0.004524510968972924,1,0,1,0.004939652742638174
1836,PAI1,Dissolution of Fibrin Clot,0.0062116075538779575,0,0,1,0.006781547110862771
1837,PAI1,Dissolution of Fibrin Clot,0.004524510968972924,1,0,1,0.004939652742638174
1838,PAI1,ECM proteoglycans,0.0062116075538779575,0,0,1,0.006781547110862771
1839,PAI1,ECM proteoglycans,0.004524510968972924,1,0,1,0.004939652742638174
1840,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0062116075538779575,0,0,1,0.006781547110862771
1841,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.004524510968972924,1,0,1,0.004939652742638174
1842,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.00039949324127519503,0,0,1,0.0004361483259655769
1843,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0006310487150017829,1,0,1,0.000688949930096966
1844,IPSP,Common Pathway of Fibrin Clot Formation,0.00039949324127519503,0,0,1,0.0004361483259655769
1845,IPSP,Common Pathway of Fibrin Clot Formation,0.0006310487150017829,1,0,1,0.000688949930096966
1846,IC1,Regulation of Complement cascade,0.0009330631619804574,0,0,1,0.0010186753969076286
1847,IC1,Regulation of Complement cascade,0.0009550487457552312,1,0,1,0.001042678244936134
1848,IC1,Platelet degranulation ,0.0009330631619804574,0,0,1,0.0010186753969076286
1849,IC1,Platelet degranulation ,0.0009550487457552312,1,0,1,0.001042678244936134
1850,IC1,Defective SERPING1 causes hereditary angioedema,0.0009330631619804574,0,0,1,0.0010186753969076286
1851,IC1,Defective SERPING1 causes hereditary angioedema,0.0009550487457552312,1,0,1,0.001042678244936134
1852,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.0009330631619804574,0,0,1,0.0010186753969076286
1853,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.0009550487457552312,1,0,1,0.001042678244936134
1854,CFAI,Regulation of Complement cascade,1.1525016087620059e-05,0,0,1,1.2582481889547648e-05
1855,CFAI,Regulation of Complement cascade,1.3642181618068699e-05,1,0,1,1.4893905729785046e-05
1856,F13B,Common Pathway of Fibrin Clot Formation,0.0002048677117669784,0,0,1,0.00022366513447473924
1857,F13B,Common Pathway of Fibrin Clot Formation,0.00032051201093091195,1,0,1,0.0003499202554044753
1858,PERM,Events associated with phagocytolytic activity of PMN cells,0.002322343584069708,0,0,1,0.0025354277916585927
1859,PERM,Events associated with phagocytolytic activity of PMN cells,0.003248647287922916,1,0,1,0.003546723523425395
1860,PERM,Neutrophil degranulation,0.002322343584069708,0,0,1,0.0025354277916585927
1861,PERM,Neutrophil degranulation,0.003248647287922916,1,0,1,0.003546723523425395
1862,ICAM1,Interleukin-10 signaling,0.006883813545926221,0,0,1,0.0075154306609324425
1863,ICAM1,Interleukin-10 signaling,0.007319742382707477,1,0,1,0.007991357692376997
1864,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.006883813545926221,0,0,1,0.0075154306609324425
1865,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.007319742382707477,1,0,1,0.007991357692376997
1866,ICAM1,Interferon gamma signaling,0.006883813545926221,0,0,1,0.0075154306609324425
1867,ICAM1,Interferon gamma signaling,0.007319742382707477,1,0,1,0.007991357692376997
1868,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006883813545926221,0,0,1,0.0075154306609324425
1869,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007319742382707477,1,0,1,0.007991357692376997
1870,ICAM1,Integrin cell surface interactions,0.006883813545926221,0,0,1,0.0075154306609324425
1871,ICAM1,Integrin cell surface interactions,0.007319742382707477,1,0,1,0.007991357692376997
1872,TETN,Platelet degranulation ,0.0002248633015143486,0,0,1,0.00024549539865435864
1873,TETN,Platelet degranulation ,0.0002398699587959107,1,0,1,0.00026187897608560677
1874,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.003824110849467071,0,0,1,0.004174988142422482
1875,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.005480327576366145,1,0,1,0.005983169303554106
1876,HEP2,Common Pathway of Fibrin Clot Formation,0.003824110849467071,0,0,1,0.004174988142422482
1877,HEP2,Common Pathway of Fibrin Clot Formation,0.005480327576366145,1,0,1,0.005983169303554106
1878,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003824110849467071,0,0,1,0.004174988142422482
1879,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005480327576366145,1,0,1,0.005983169303554106
1880,HEP2,Post-translational protein phosphorylation,0.003824110849467071,0,0,1,0.004174988142422482
1881,HEP2,Post-translational protein phosphorylation,0.005480327576366145,1,0,1,0.005983169303554106
1882,K2C8,Formation of the cornified envelope,0.00030501117565427427,0,0,1,0.0003329971571928674
1883,K2C8,Formation of the cornified envelope,0.0003840196737369551,1,0,1,0.0004192549974151955
1884,CHLE,Glycerophospholipid biosynthesis,0.0007013055067581572,0,0,1,0.000765653060328765
1885,CHLE,Glycerophospholipid biosynthesis,0.001168590869300378,1,0,1,0.0012758137027728098
1886,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.0007013055067581572,0,0,1,0.000765653060328765
1887,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.001168590869300378,1,0,1,0.0012758137027728098
1888,CHLE,Aspirin ADME,0.0007013055067581572,0,0,1,0.000765653060328765
1889,CHLE,Aspirin ADME,0.001168590869300378,1,0,1,0.0012758137027728098
1890,KV230,Initial triggering of complement,0.005001668424137542,0,0,1,0.005460591281242093
1891,KV230,Initial triggering of complement,0.00493577066548925,1,0,1,0.00538864714264392
1892,KV230,Regulation of Complement cascade,0.005001668424137542,0,0,1,0.005460591281242093
1893,KV230,Regulation of Complement cascade,0.00493577066548925,1,0,1,0.00538864714264392
1894,KV230,FCGR activation,0.005001668424137542,0,0,1,0.005460591281242093
1895,KV230,FCGR activation,0.00493577066548925,1,0,1,0.00538864714264392
1896,KV230,Regulation of actin dynamics for phagocytic cup formation,0.005001668424137542,0,0,1,0.005460591281242093
1897,KV230,Regulation of actin dynamics for phagocytic cup formation,0.00493577066548925,1,0,1,0.00538864714264392
1898,KV230,Role of phospholipids in phagocytosis,0.005001668424137542,0,0,1,0.005460591281242093
1899,KV230,Role of phospholipids in phagocytosis,0.00493577066548925,1,0,1,0.00538864714264392
1900,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.005001668424137542,0,0,1,0.005460591281242093
1901,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.00493577066548925,1,0,1,0.00538864714264392
1902,KV230,FCERI mediated MAPK activation,0.005001668424137542,0,0,1,0.005460591281242093
1903,KV230,FCERI mediated MAPK activation,0.00493577066548925,1,0,1,0.00538864714264392
1904,KV230,FCERI mediated Ca+2 mobilization,0.005001668424137542,0,0,1,0.005460591281242093
1905,KV230,FCERI mediated Ca+2 mobilization,0.00493577066548925,1,0,1,0.00538864714264392
1906,KV230,FCERI mediated NF-kB activation,0.005001668424137542,0,0,1,0.005460591281242093
1907,KV230,FCERI mediated NF-kB activation,0.00493577066548925,1,0,1,0.00538864714264392
1908,KV230,Parasite infection,0.005001668424137542,0,0,1,0.005460591281242093
1909,KV230,Parasite infection,0.00493577066548925,1,0,1,0.00538864714264392
1910,KV230,Leishmania parasite growth and survival,0.005001668424137542,0,0,1,0.005460591281242093
1911,KV230,Leishmania parasite growth and survival,0.00493577066548925,1,0,1,0.00538864714264392
1912,KV230,Potential therapeutics for SARS,0.005001668424137542,0,0,1,0.005460591281242093
1913,KV230,Potential therapeutics for SARS,0.00493577066548925,1,0,1,0.00538864714264392
1914,KV230,CD22 mediated BCR regulation,0.005001668424137542,0,0,1,0.005460591281242093
1915,KV230,CD22 mediated BCR regulation,0.00493577066548925,1,0,1,0.00538864714264392
1916,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005001668424137542,0,0,1,0.005460591281242093
1917,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00493577066548925,1,0,1,0.00538864714264392
1918,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005001668424137542,0,0,1,0.005460591281242093
1919,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00493577066548925,1,0,1,0.00538864714264392
1920,KV230,Scavenging of heme from plasma,0.005001668424137542,0,0,1,0.005460591281242093
1921,KV230,Scavenging of heme from plasma,0.00493577066548925,1,0,1,0.00538864714264392
1922,KV401,Initial triggering of complement,0.004582282182032885,0,0,1,0.005002724692953713
1923,KV401,Initial triggering of complement,0.005936748896698736,1,0,1,0.006481469084953732
1924,KV401,Regulation of Complement cascade,0.004582282182032885,0,0,1,0.005002724692953713
1925,KV401,Regulation of Complement cascade,0.005936748896698736,1,0,1,0.006481469084953732
1926,KV401,FCGR activation,0.004582282182032885,0,0,1,0.005002724692953713
1927,KV401,FCGR activation,0.005936748896698736,1,0,1,0.006481469084953732
1928,KV401,Regulation of actin dynamics for phagocytic cup formation,0.004582282182032885,0,0,1,0.005002724692953713
1929,KV401,Regulation of actin dynamics for phagocytic cup formation,0.005936748896698736,1,0,1,0.006481469084953732
1930,KV401,Role of phospholipids in phagocytosis,0.004582282182032885,0,0,1,0.005002724692953713
1931,KV401,Role of phospholipids in phagocytosis,0.005936748896698736,1,0,1,0.006481469084953732
1932,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.004582282182032885,0,0,1,0.005002724692953713
1933,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.005936748896698736,1,0,1,0.006481469084953732
1934,KV401,FCERI mediated MAPK activation,0.004582282182032885,0,0,1,0.005002724692953713
1935,KV401,FCERI mediated MAPK activation,0.005936748896698736,1,0,1,0.006481469084953732
1936,KV401,FCERI mediated Ca+2 mobilization,0.004582282182032885,0,0,1,0.005002724692953713
1937,KV401,FCERI mediated Ca+2 mobilization,0.005936748896698736,1,0,1,0.006481469084953732
1938,KV401,FCERI mediated NF-kB activation,0.004582282182032885,0,0,1,0.005002724692953713
1939,KV401,FCERI mediated NF-kB activation,0.005936748896698736,1,0,1,0.006481469084953732
1940,KV401,Parasite infection,0.004582282182032885,0,0,1,0.005002724692953713
1941,KV401,Parasite infection,0.005936748896698736,1,0,1,0.006481469084953732
1942,KV401,Leishmania parasite growth and survival,0.004582282182032885,0,0,1,0.005002724692953713
1943,KV401,Leishmania parasite growth and survival,0.005936748896698736,1,0,1,0.006481469084953732
1944,KV401,Potential therapeutics for SARS,0.004582282182032885,0,0,1,0.005002724692953713
1945,KV401,Potential therapeutics for SARS,0.005936748896698736,1,0,1,0.006481469084953732
1946,KV401,CD22 mediated BCR regulation,0.004582282182032885,0,0,1,0.005002724692953713
1947,KV401,CD22 mediated BCR regulation,0.005936748896698736,1,0,1,0.006481469084953732
1948,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004582282182032885,0,0,1,0.005002724692953713
1949,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005936748896698736,1,0,1,0.006481469084953732
1950,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004582282182032885,0,0,1,0.005002724692953713
1951,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005936748896698736,1,0,1,0.006481469084953732
1952,KV401,Scavenging of heme from plasma,0.004582282182032885,0,0,1,0.005002724692953713
1953,KV401,Scavenging of heme from plasma,0.005936748896698736,1,0,1,0.006481469084953732
1954,HV434,Initial triggering of complement,0.0010741518962736406,0,0,1,0.0011727095805102105
1955,HV434,Initial triggering of complement,0.0010224683933048083,1,0,1,0.0011162839117606232
1956,HV434,Regulation of Complement cascade,0.0010741518962736406,0,0,1,0.0011727095805102105
1957,HV434,Regulation of Complement cascade,0.0010224683933048083,1,0,1,0.0011162839117606232
1958,HV434,FCGR activation,0.0010741518962736406,0,0,1,0.0011727095805102105
1959,HV434,FCGR activation,0.0010224683933048083,1,0,1,0.0011162839117606232
1960,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0010741518962736406,0,0,1,0.0011727095805102105
1961,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0010224683933048083,1,0,1,0.0011162839117606232
1962,HV434,Role of phospholipids in phagocytosis,0.0010741518962736406,0,0,1,0.0011727095805102105
1963,HV434,Role of phospholipids in phagocytosis,0.0010224683933048083,1,0,1,0.0011162839117606232
1964,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0010741518962736406,0,0,1,0.0011727095805102105
1965,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0010224683933048083,1,0,1,0.0011162839117606232
1966,HV434,FCERI mediated MAPK activation,0.0010741518962736406,0,0,1,0.0011727095805102105
1967,HV434,FCERI mediated MAPK activation,0.0010224683933048083,1,0,1,0.0011162839117606232
1968,HV434,FCERI mediated Ca+2 mobilization,0.0010741518962736406,0,0,1,0.0011727095805102105
1969,HV434,FCERI mediated Ca+2 mobilization,0.0010224683933048083,1,0,1,0.0011162839117606232
1970,HV434,FCERI mediated NF-kB activation,0.0010741518962736406,0,0,1,0.0011727095805102105
1971,HV434,FCERI mediated NF-kB activation,0.0010224683933048083,1,0,1,0.0011162839117606232
1972,HV434,Parasite infection,0.0010741518962736406,0,0,1,0.0011727095805102105
1973,HV434,Parasite infection,0.0010224683933048083,1,0,1,0.0011162839117606232
1974,HV434,Leishmania parasite growth and survival,0.0010741518962736406,0,0,1,0.0011727095805102105
1975,HV434,Leishmania parasite growth and survival,0.0010224683933048083,1,0,1,0.0011162839117606232
1976,HV434,Potential therapeutics for SARS,0.0010741518962736406,0,0,1,0.0011727095805102105
1977,HV434,Potential therapeutics for SARS,0.0010224683933048083,1,0,1,0.0011162839117606232
1978,HV434,CD22 mediated BCR regulation,0.0010741518962736406,0,0,1,0.0011727095805102105
1979,HV434,CD22 mediated BCR regulation,0.0010224683933048083,1,0,1,0.0011162839117606232
1980,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0010741518962736406,0,0,1,0.0011727095805102105
1981,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0010224683933048083,1,0,1,0.0011162839117606232
1982,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0010741518962736406,0,0,1,0.0011727095805102105
1983,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0010224683933048083,1,0,1,0.0011162839117606232
1984,HV434,Scavenging of heme from plasma,0.0010741518962736406,0,0,1,0.0011727095805102105
1985,HV434,Scavenging of heme from plasma,0.0010224683933048083,1,0,1,0.0011162839117606232
1986,GELS,Apoptotic cleavage of cellular proteins,0.0003497888925159695,0,0,1,0.0003818834066509295
1987,GELS,Apoptotic cleavage of cellular proteins,0.001168209650173308,1,0,1,0.001275397505283293
1988,GELS,Neutrophil degranulation,0.0003497888925159695,0,0,1,0.0003818834066509295
1989,GELS,Neutrophil degranulation,0.001168209650173308,1,0,1,0.001275397505283293
1990,GELS,Amyloid fiber formation,0.0003497888925159695,0,0,1,0.0003818834066509295
1991,GELS,Amyloid fiber formation,0.001168209650173308,1,0,1,0.001275397505283293
1992,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.0003497888925159695,0,0,1,0.0003818834066509295
1993,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.001168209650173308,1,0,1,0.001275397505283293
1994,CO2,Initial triggering of complement,0.00030386337623451883,0,0,1,0.0003317440426373555
1995,CO2,Initial triggering of complement,0.00046942157705831826,1,0,1,0.0005124928630896938
1996,CO2,Activation of C3 and C5,0.00030386337623451883,0,0,1,0.0003317440426373555
1997,CO2,Activation of C3 and C5,0.00046942157705831826,1,0,1,0.0005124928630896938
1998,CO2,Regulation of Complement cascade,0.00030386337623451883,0,0,1,0.0003317440426373555
1999,CO2,Regulation of Complement cascade,0.00046942157705831826,1,0,1,0.0005124928630896938
2000,S10A9,Antigen processing-Cross presentation,0.002899962988808257,0,0,1,0.0031660460609884812
2001,S10A9,Antigen processing-Cross presentation,0.0032089071393442614,1,0,1,0.003503337059061499
2002,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.002899962988808257,0,0,1,0.0031660460609884812
2003,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.0032089071393442614,1,0,1,0.003503337059061499
2004,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.002899962988808257,0,0,1,0.0031660460609884812
2005,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.0032089071393442614,1,0,1,0.003503337059061499
2006,S10A9,Regulation of TLR by endogenous ligand,0.002899962988808257,0,0,1,0.0031660460609884812
2007,S10A9,Regulation of TLR by endogenous ligand,0.0032089071393442614,1,0,1,0.003503337059061499
2008,S10A9,RHO GTPase Effectors,0.002899962988808257,0,0,1,0.0031660460609884812
2009,S10A9,RHO GTPase Effectors,0.0032089071393442614,1,0,1,0.003503337059061499
2010,S10A9,MyD88 deficiency (TLR2/4),0.002899962988808257,0,0,1,0.0031660460609884812
2011,S10A9,MyD88 deficiency (TLR2/4),0.0032089071393442614,1,0,1,0.003503337059061499
2012,S10A9,IRAK4 deficiency (TLR2/4),0.002899962988808257,0,0,1,0.0031660460609884812
2013,S10A9,IRAK4 deficiency (TLR2/4),0.0032089071393442614,1,0,1,0.003503337059061499
2014,S10A9,Metal sequestration by antimicrobial proteins,0.002899962988808257,0,0,1,0.0031660460609884812
2015,S10A9,Metal sequestration by antimicrobial proteins,0.0032089071393442614,1,0,1,0.003503337059061499
2016,S10A9,Neutrophil degranulation,0.002899962988808257,0,0,1,0.0031660460609884812
2017,S10A9,Neutrophil degranulation,0.0032089071393442614,1,0,1,0.003503337059061499
2018,APOA4,Chylomicron assembly,0.020001995775869013,0,0,1,0.021837257986565797
2019,APOA4,Chylomicron assembly,0.021029890091067222,1,0,1,0.022959465670010448
2020,APOA4,Assembly of active LPL and LIPC lipase complexes,0.020001995775869013,0,0,1,0.021837257986565797
2021,APOA4,Assembly of active LPL and LIPC lipase complexes,0.021029890091067222,1,0,1,0.022959465670010448
2022,APOA4,Chylomicron remodeling,0.020001995775869013,0,0,1,0.021837257986565797
2023,APOA4,Chylomicron remodeling,0.021029890091067222,1,0,1,0.022959465670010448
2024,APOA4,Retinoid metabolism and transport,0.020001995775869013,0,0,1,0.021837257986565797
2025,APOA4,Retinoid metabolism and transport,0.021029890091067222,1,0,1,0.022959465670010448
2026,APOA4,Amyloid fiber formation,0.020001995775869013,0,0,1,0.021837257986565797
2027,APOA4,Amyloid fiber formation,0.021029890091067222,1,0,1,0.022959465670010448
2028,ENOA,Glycolysis,0.0008599609544330518,0,0,1,0.000938865772733722
2029,ENOA,Glycolysis,0.00024514559409737725,1,0,1,0.0002676386717885799
2030,ENOA,Gluconeogenesis,0.0008599609544330518,0,0,1,0.000938865772733722
2031,ENOA,Gluconeogenesis,0.00024514559409737725,1,0,1,0.0002676386717885799
2032,ENOA,Response of Mtb to phagocytosis,0.0008599609544330518,0,0,1,0.000938865772733722
2033,ENOA,Response of Mtb to phagocytosis,0.00024514559409737725,1,0,1,0.0002676386717885799
2034,PYGL,Glycogen breakdown (glycogenolysis),0.0005792664925891051,0,0,1,0.0006324164840041725
2035,PYGL,Glycogen breakdown (glycogenolysis),0.0007767664616676945,1,0,1,0.000848037856262989
2036,PYGL,Neutrophil degranulation,0.0005792664925891051,0,0,1,0.0006324164840041725
2037,PYGL,Neutrophil degranulation,0.0007767664616676945,1,0,1,0.000848037856262989
2038,G6PI,Transcriptional Regulation by TP53,0.0005377558296588297,0,0,1,0.000587097053595363
2039,G6PI,Transcriptional Regulation by TP53,0.0004754247960323104,1,0,1,0.0005190469011443897
2040,G6PI,Glycolysis,0.0005377558296588297,0,0,1,0.000587097053595363
2041,G6PI,Glycolysis,0.0004754247960323104,1,0,1,0.0005190469011443897
2042,G6PI,Gluconeogenesis,0.0005377558296588297,0,0,1,0.000587097053595363
2043,G6PI,Gluconeogenesis,0.0004754247960323104,1,0,1,0.0005190469011443897
2044,G6PI,Neutrophil degranulation,0.0005377558296588297,0,0,1,0.000587097053595363
2045,G6PI,Neutrophil degranulation,0.0004754247960323104,1,0,1,0.0005190469011443897
2046,TPM3,RHO GTPase cycle,0.0008229173382843618,0,0,1,0.0008984232583137273
2047,TPM3,RHO GTPase cycle,0.0025143952012596283,1,0,1,0.0027451009041973462
2048,TPM3,Signaling by ALK fusions and activated point mutants,0.0008229173382843618,0,0,1,0.0008984232583137273
2049,TPM3,Signaling by ALK fusions and activated point mutants,0.0025143952012596283,1,0,1,0.0027451009041973462
2050,TPM3,Striated Muscle Contraction,0.0008229173382843618,0,0,1,0.0008984232583137273
2051,TPM3,Striated Muscle Contraction,0.0025143952012596283,1,0,1,0.0027451009041973462
2052,TPM3,Smooth Muscle Contraction,0.0008229173382843618,0,0,1,0.0008984232583137273
2053,TPM3,Smooth Muscle Contraction,0.0025143952012596283,1,0,1,0.0027451009041973462
2054,FABPL,PPARA activates gene expression,0.008908952693904036,0,0,1,0.009726384334187294
2055,FABPL,PPARA activates gene expression,0.006382456916824058,1,0,1,0.00696807257848613
2056,FABPL,Triglyceride catabolism,0.008908952693904036,0,0,1,0.009726384334187294
2057,FABPL,Triglyceride catabolism,0.006382456916824058,1,0,1,0.00696807257848613
2058,FABPL,Cytoprotection by HMOX1,0.008908952693904036,0,0,1,0.009726384334187294
2059,FABPL,Cytoprotection by HMOX1,0.006382456916824058,1,0,1,0.00696807257848613
2060,FABPL,Heme degradation,0.008908952693904036,0,0,1,0.009726384334187294
2061,FABPL,Heme degradation,0.006382456916824058,1,0,1,0.00696807257848613
2062,LDHB,Pyruvate metabolism,0.0012163164740667328,0,0,1,0.001327918320508261
2063,LDHB,Pyruvate metabolism,0.0006103000357193958,1,0,1,0.0006662974774393855
2064,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.004042183134035514,0,0,1,0.004413069421470947
2065,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.004302316320676541,1,0,1,0.004697070856687768
2066,PROS,Regulation of Complement cascade,0.004042183134035514,0,0,1,0.004413069421470947
2067,PROS,Regulation of Complement cascade,0.004302316320676541,1,0,1,0.004697070856687768
2068,PROS,Platelet degranulation ,0.004042183134035514,0,0,1,0.004413069421470947
2069,PROS,Platelet degranulation ,0.004302316320676541,1,0,1,0.004697070856687768
2070,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.004042183134035514,0,0,1,0.004413069421470947
2071,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.004302316320676541,1,0,1,0.004697070856687768
2072,PROS,Common Pathway of Fibrin Clot Formation,0.004042183134035514,0,0,1,0.004413069421470947
2073,PROS,Common Pathway of Fibrin Clot Formation,0.004302316320676541,1,0,1,0.004697070856687768
2074,PDIA1,Interleukin-12 family signaling,0.0017565608350796444,0,0,1,0.001917732238050386
2075,PDIA1,Interleukin-12 family signaling,0.0017423558511019586,1,0,1,0.0019022238906188768
2076,PDIA1,VLDL assembly,0.0017565608350796444,0,0,1,0.001917732238050386
2077,PDIA1,VLDL assembly,0.0017423558511019586,1,0,1,0.0019022238906188768
2078,PDIA1,Chylomicron assembly,0.0017565608350796444,0,0,1,0.001917732238050386
2079,PDIA1,Chylomicron assembly,0.0017423558511019586,1,0,1,0.0019022238906188768
2080,PDIA1,LDL remodeling,0.0017565608350796444,0,0,1,0.001917732238050386
2081,PDIA1,LDL remodeling,0.0017423558511019586,1,0,1,0.0019022238906188768
2082,PDIA1,Detoxification of Reactive Oxygen Species,0.0017565608350796444,0,0,1,0.001917732238050386
2083,PDIA1,Detoxification of Reactive Oxygen Species,0.0017423558511019586,1,0,1,0.0019022238906188768
2084,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017565608350796444,0,0,1,0.001917732238050386
2085,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017423558511019586,1,0,1,0.0019022238906188768
2086,PDIA1,Hedgehog ligand biogenesis,0.0017565608350796444,0,0,1,0.001917732238050386
2087,PDIA1,Hedgehog ligand biogenesis,0.0017423558511019586,1,0,1,0.0019022238906188768
2088,PDIA1,Post-translational protein phosphorylation,0.0017565608350796444,0,0,1,0.001917732238050386
2089,PDIA1,Post-translational protein phosphorylation,0.0017423558511019586,1,0,1,0.0019022238906188768
2090,ADH1A,Ethanol oxidation,0.007031900383919704,0,0,1,0.0076771050519239565
2091,ADH1A,Ethanol oxidation,0.007730463509055488,1,0,1,0.008439764106271697
2092,ADH1A,RA biosynthesis pathway,0.007031900383919704,0,0,1,0.0076771050519239565
2093,ADH1A,RA biosynthesis pathway,0.007730463509055488,1,0,1,0.008439764106271697
2094,ADH1A,Abacavir metabolism,0.007031900383919704,0,0,1,0.0076771050519239565
2095,ADH1A,Abacavir metabolism,0.007730463509055488,1,0,1,0.008439764106271697
2096,CSF1R,Transcriptional Regulation by VENTX,0.005501098069835095,0,0,1,0.006005845571936131
2097,CSF1R,Transcriptional Regulation by VENTX,0.004431368669655722,1,0,1,0.00483796426902568
2098,CSF1R,Other interleukin signaling,0.005501098069835095,0,0,1,0.006005845571936131
2099,CSF1R,Other interleukin signaling,0.004431368669655722,1,0,1,0.00483796426902568
2100,CATD,Estrogen-dependent gene expression,0.00252961787021557,0,0,1,0.0027617203132283205
2101,CATD,Estrogen-dependent gene expression,0.0023360795920997204,1,0,1,0.0025504241327446555
2102,CATD,MHC class II antigen presentation,0.00252961787021557,0,0,1,0.0027617203132283205
2103,CATD,MHC class II antigen presentation,0.0023360795920997204,1,0,1,0.0025504241327446555
2104,CATD,Collagen degradation,0.00252961787021557,0,0,1,0.0027617203132283205
2105,CATD,Collagen degradation,0.0023360795920997204,1,0,1,0.0025504241327446555
2106,CATD,Neutrophil degranulation,0.00252961787021557,0,0,1,0.0027617203132283205
2107,CATD,Neutrophil degranulation,0.0023360795920997204,1,0,1,0.0025504241327446555
2108,CATD,Metabolism of Angiotensinogen to Angiotensins,0.00252961787021557,0,0,1,0.0027617203132283205
2109,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0023360795920997204,1,0,1,0.0025504241327446555
2110,CO8A,Terminal pathway of complement,0.0008699411439188617,0,0,1,0.0009497616840716982
2111,CO8A,Terminal pathway of complement,0.0008866745537651059,1,0,1,0.0009680304504439128
2112,CO8A,Regulation of Complement cascade,0.0008699411439188617,0,0,1,0.0009497616840716982
2113,CO8A,Regulation of Complement cascade,0.0008866745537651059,1,0,1,0.0009680304504439128
2114,CO8B,Terminal pathway of complement,0.0005772387663353879,0,0,1,0.000630202705847996
2115,CO8B,Terminal pathway of complement,0.0004109629694663837,1,0,1,0.0004486704470755585
2116,CO8B,Regulation of Complement cascade,0.0005772387663353879,0,0,1,0.000630202705847996
2117,CO8B,Regulation of Complement cascade,0.0004109629694663837,1,0,1,0.0004486704470755585
2118,GP1BA,Transcriptional regulation by RUNX1,0.000709904260934378,0,0,1,0.0007750407842045859
2119,GP1BA,Transcriptional regulation by RUNX1,0.000722773699822559,1,0,1,0.0007890910450031907
2120,GP1BA,Defective factor IX causes hemophilia B,0.000709904260934378,0,0,1,0.0007750407842045859
2121,GP1BA,Defective factor IX causes hemophilia B,0.000722773699822559,1,0,1,0.0007890910450031907
2122,GP1BA,Platelet Adhesion to exposed collagen,0.000709904260934378,0,0,1,0.0007750407842045859
2123,GP1BA,Platelet Adhesion to exposed collagen,0.000722773699822559,1,0,1,0.0007890910450031907
2124,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.000709904260934378,0,0,1,0.0007750407842045859
2125,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.000722773699822559,1,0,1,0.0007890910450031907
2126,GP1BA,GP1b-IX-V activation signalling,0.000709904260934378,0,0,1,0.0007750407842045859
2127,GP1BA,GP1b-IX-V activation signalling,0.000722773699822559,1,0,1,0.0007890910450031907
2128,CO8G,Terminal pathway of complement,8.80779139019124e-05,0,0,1,9.61594108081461e-05
2129,CO8G,Terminal pathway of complement,0.00014181782848751896,1,0,1,0.00015483017507246434
2130,CO8G,Regulation of Complement cascade,8.80779139019124e-05,0,0,1,9.61594108081461e-05
2131,CO8G,Regulation of Complement cascade,0.00014181782848751896,1,0,1,0.00015483017507246434
2132,TBB5,G2/M Transition,0.0006455069329964262,0,0,1,0.0007047347467679073
2133,TBB5,G2/M Transition,0.0006838368818040956,1,0,1,0.0007465816199551692
2134,TBB5,Mitotic Prometaphase,0.0006455069329964262,0,0,1,0.0007047347467679073
2135,TBB5,Mitotic Prometaphase,0.0006838368818040956,1,0,1,0.0007465816199551692
2136,TBB5,Potential therapeutics for SARS,0.0006455069329964262,0,0,1,0.0007047347467679073
2137,TBB5,Potential therapeutics for SARS,0.0006838368818040956,1,0,1,0.0007465816199551692
2138,TBB5,Neutrophil degranulation,0.0006455069329964262,0,0,1,0.0007047347467679073
2139,TBB5,Neutrophil degranulation,0.0006838368818040956,1,0,1,0.0007465816199551692
2140,TBB5,Anchoring of the basal body to the plasma membrane,0.0006455069329964262,0,0,1,0.0007047347467679073
2141,TBB5,Anchoring of the basal body to the plasma membrane,0.0006838368818040956,1,0,1,0.0007465816199551692
2142,CAH3,Reversible hydration of carbon dioxide,0.0032143167620122923,0,0,1,0.0035092430360017745
2143,CAH3,Reversible hydration of carbon dioxide,0.0020237837676998927,1,0,1,0.0022094739314765526
2144,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.00015096637753058206,0,0,1,0.00016481813966833422
2145,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.00020630314259339919,1,0,1,0.00022523227175592176
2146,TRY1,Activation of Matrix Metalloproteinases,0.00015096637753058206,0,0,1,0.00016481813966833422
2147,TRY1,Activation of Matrix Metalloproteinases,0.00020630314259339919,1,0,1,0.00022523227175592176
2148,TRY2,Defensins,0.005573095056478899,0,0,1,0.006084448566817914
2149,TRY2,Defensins,0.004699497743684628,1,0,1,0.005130695245918101
2150,TRY2,Collagen degradation,0.005573095056478899,0,0,1,0.006084448566817914
2151,TRY2,Collagen degradation,0.004699497743684628,1,0,1,0.005130695245918101
2152,TRY2,Activation of Matrix Metalloproteinases,0.005573095056478899,0,0,1,0.006084448566817914
2153,TRY2,Activation of Matrix Metalloproteinases,0.004699497743684628,1,0,1,0.005130695245918101
2154,TRY2,Neutrophil degranulation,0.005573095056478899,0,0,1,0.006084448566817914
2155,TRY2,Neutrophil degranulation,0.004699497743684628,1,0,1,0.005130695245918101
2156,SAP,Class A/1 (Rhodopsin-like receptors),0.0012319100182148898,0,0,1,0.001344942633996969
2157,SAP,Class A/1 (Rhodopsin-like receptors),0.0016077915141548072,1,0,1,0.0017553127436196745
2158,SAP,G alpha (i) signalling events,0.0012319100182148898,0,0,1,0.001344942633996969
2159,SAP,G alpha (i) signalling events,0.0016077915141548072,1,0,1,0.0017553127436196745
2160,SAP,Glycosphingolipid metabolism,0.0012319100182148898,0,0,1,0.001344942633996969
2161,SAP,Glycosphingolipid metabolism,0.0016077915141548072,1,0,1,0.0017553127436196745
2162,SAP,Platelet degranulation ,0.0012319100182148898,0,0,1,0.001344942633996969
2163,SAP,Platelet degranulation ,0.0016077915141548072,1,0,1,0.0017553127436196745
2164,SAP,Neutrophil degranulation,0.0012319100182148898,0,0,1,0.001344942633996969
2165,SAP,Neutrophil degranulation,0.0016077915141548072,1,0,1,0.0017553127436196745
2166,PROF1,RHO GTPase Effectors,0.00026116786921193125,0,0,1,0.00028513105400527637
2167,PROF1,RHO GTPase Effectors,0.00012382962577341025,1,0,1,0.00013519148362465714
2168,PROF1,Signaling by ROBO receptors,0.00026116786921193125,0,0,1,0.00028513105400527637
2169,PROF1,Signaling by ROBO receptors,0.00012382962577341025,1,0,1,0.00013519148362465714
2170,PROF1,PCP/CE pathway,0.00026116786921193125,0,0,1,0.00028513105400527637
2171,PROF1,PCP/CE pathway,0.00012382962577341025,1,0,1,0.00013519148362465714
2172,PROF1,Platelet degranulation ,0.00026116786921193125,0,0,1,0.00028513105400527637
2173,PROF1,Platelet degranulation ,0.00012382962577341025,1,0,1,0.00013519148362465714
2174,CATB,Trafficking and processing of endosomal TLR,0.00458030117974678,0,0,1,0.0050005619258739475
2175,CATB,Trafficking and processing of endosomal TLR,0.0038611401176212477,1,0,1,0.004215414992362728
2176,CATB,MHC class II antigen presentation,0.00458030117974678,0,0,1,0.0050005619258739475
2177,CATB,MHC class II antigen presentation,0.0038611401176212477,1,0,1,0.004215414992362728
2178,CATB,Collagen degradation,0.00458030117974678,0,0,1,0.0050005619258739475
2179,CATB,Collagen degradation,0.0038611401176212477,1,0,1,0.004215414992362728
2180,CATB,Neutrophil degranulation,0.00458030117974678,0,0,1,0.0050005619258739475
2181,CATB,Neutrophil degranulation,0.0038611401176212477,1,0,1,0.004215414992362728
2182,HS90A,Downregulation of ERBB2 signaling,0.01716411472794595,0,0,1,0.018738990130042908
2183,HS90A,Downregulation of ERBB2 signaling,0.01852818519151226,1,0,1,0.020228219452883202
2184,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.01716411472794595,0,0,1,0.018738990130042908
2185,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.01852818519151226,1,0,1,0.020228219452883202
2186,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.01716411472794595,0,0,1,0.018738990130042908
2187,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.01852818519151226,1,0,1,0.020228219452883202
2188,HS90A,Signaling by ERBB2 KD Mutants,0.01716411472794595,0,0,1,0.018738990130042908
2189,HS90A,Signaling by ERBB2 KD Mutants,0.01852818519151226,1,0,1,0.020228219452883202
2190,HS90A,Drug resistance in ERBB2 KD mutants,0.01716411472794595,0,0,1,0.018738990130042908
2191,HS90A,Drug resistance in ERBB2 KD mutants,0.01852818519151226,1,0,1,0.020228219452883202
2192,HS90A,Signaling by ERBB2 ECD mutants,0.01716411472794595,0,0,1,0.018738990130042908
2193,HS90A,Signaling by ERBB2 ECD mutants,0.01852818519151226,1,0,1,0.020228219452883202
2194,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.01716411472794595,0,0,1,0.018738990130042908
2195,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.01852818519151226,1,0,1,0.020228219452883202
2196,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.01716411472794595,0,0,1,0.018738990130042908
2197,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.01852818519151226,1,0,1,0.020228219452883202
2198,HS90A,Signaling by EGFRvIII in Cancer,0.01716411472794595,0,0,1,0.018738990130042908
2199,HS90A,Signaling by EGFRvIII in Cancer,0.01852818519151226,1,0,1,0.020228219452883202
2200,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.01716411472794595,0,0,1,0.018738990130042908
2201,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.01852818519151226,1,0,1,0.020228219452883202
2202,HS90A,Influenza Viral RNA Transcription and Replication,0.01716411472794595,0,0,1,0.018738990130042908
2203,HS90A,Influenza Viral RNA Transcription and Replication,0.01852818519151226,1,0,1,0.020228219452883202
2204,HS90A,VEGFA-VEGFR2 Pathway,0.01716411472794595,0,0,1,0.018738990130042908
2205,HS90A,VEGFA-VEGFR2 Pathway,0.01852818519151226,1,0,1,0.020228219452883202
2206,HS90A,RHO GTPase cycle,0.01716411472794595,0,0,1,0.018738990130042908
2207,HS90A,RHO GTPase cycle,0.01852818519151226,1,0,1,0.020228219452883202
2208,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.01716411472794595,0,0,1,0.018738990130042908
2209,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.01852818519151226,1,0,1,0.020228219452883202
2210,HS90A,HSF1 activation,0.01716411472794595,0,0,1,0.018738990130042908
2211,HS90A,HSF1 activation,0.01852818519151226,1,0,1,0.020228219452883202
2212,HS90A,HSF1-dependent transactivation,0.01716411472794595,0,0,1,0.018738990130042908
2213,HS90A,HSF1-dependent transactivation,0.01852818519151226,1,0,1,0.020228219452883202
2214,HS90A,Semaphorin interactions,0.01716411472794595,0,0,1,0.018738990130042908
2215,HS90A,Semaphorin interactions,0.01852818519151226,1,0,1,0.020228219452883202
2216,HS90A,Interleukin-4 and Interleukin-13 signaling,0.01716411472794595,0,0,1,0.018738990130042908
2217,HS90A,Interleukin-4 and Interleukin-13 signaling,0.01852818519151226,1,0,1,0.020228219452883202
2218,HS90A,G2/M Transition,0.01716411472794595,0,0,1,0.018738990130042908
2219,HS90A,G2/M Transition,0.01852818519151226,1,0,1,0.020228219452883202
2220,HS90A,Regulation of necroptotic cell death,0.01716411472794595,0,0,1,0.018738990130042908
2221,HS90A,Regulation of necroptotic cell death,0.01852818519151226,1,0,1,0.020228219452883202
2222,HS90A,Uptake and function of diphtheria toxin,0.01716411472794595,0,0,1,0.018738990130042908
2223,HS90A,Uptake and function of diphtheria toxin,0.01852818519151226,1,0,1,0.020228219452883202
2224,HS90A,Mitotic Prometaphase,0.01716411472794595,0,0,1,0.018738990130042908
2225,HS90A,Mitotic Prometaphase,0.01852818519151226,1,0,1,0.020228219452883202
2226,HS90A,Extra-nuclear estrogen signaling,0.01716411472794595,0,0,1,0.018738990130042908
2227,HS90A,Extra-nuclear estrogen signaling,0.01852818519151226,1,0,1,0.020228219452883202
2228,HS90A,Estrogen-dependent gene expression,0.01716411472794595,0,0,1,0.018738990130042908
2229,HS90A,Estrogen-dependent gene expression,0.01852818519151226,1,0,1,0.020228219452883202
2230,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.01716411472794595,0,0,1,0.018738990130042908
2231,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.01852818519151226,1,0,1,0.020228219452883202
2232,HS90A,Aggrephagy,0.01716411472794595,0,0,1,0.018738990130042908
2233,HS90A,Aggrephagy,0.01852818519151226,1,0,1,0.020228219452883202
2234,HS90A,Potential therapeutics for SARS,0.01716411472794595,0,0,1,0.018738990130042908
2235,HS90A,Potential therapeutics for SARS,0.01852818519151226,1,0,1,0.020228219452883202
2236,HS90A,SARS-CoV-2 Infection,0.01716411472794595,0,0,1,0.018738990130042908
2237,HS90A,SARS-CoV-2 Infection,0.01852818519151226,1,0,1,0.020228219452883202
2238,HS90A,Neutrophil degranulation,0.01716411472794595,0,0,1,0.018738990130042908
2239,HS90A,Neutrophil degranulation,0.01852818519151226,1,0,1,0.020228219452883202
2240,HS90A,eNOS activation,0.01716411472794595,0,0,1,0.018738990130042908
2241,HS90A,eNOS activation,0.01852818519151226,1,0,1,0.020228219452883202
2242,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.01716411472794595,0,0,1,0.018738990130042908
2243,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.01852818519151226,1,0,1,0.020228219452883202
2244,HS90A,Scavenging by Class F Receptors,0.01716411472794595,0,0,1,0.018738990130042908
2245,HS90A,Scavenging by Class F Receptors,0.01852818519151226,1,0,1,0.020228219452883202
2246,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.01716411472794595,0,0,1,0.018738990130042908
2247,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.01852818519151226,1,0,1,0.020228219452883202
2248,HS90A,Anchoring of the basal body to the plasma membrane,0.01716411472794595,0,0,1,0.018738990130042908
2249,HS90A,Anchoring of the basal body to the plasma membrane,0.01852818519151226,1,0,1,0.020228219452883202
2250,HS90A,Chaperone Mediated Autophagy,0.01716411472794595,0,0,1,0.018738990130042908
2251,HS90A,Chaperone Mediated Autophagy,0.01852818519151226,1,0,1,0.020228219452883202
2252,FUMH,Citric acid cycle (TCA cycle),0.0007555492300313287,0,0,1,0.0008248738597200531
2253,FUMH,Citric acid cycle (TCA cycle),2.949435859448058e-05,1,0,1,3.220058263150862e-05
2254,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.004015957870459193,0,0,1,0.00438443788625321
2255,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.005692886553827654,1,0,1,0.006215231407766101
2256,PSPB,Defective CSF2RB causes SMDP5,0.004015957870459193,0,0,1,0.00438443788625321
2257,PSPB,Defective CSF2RB causes SMDP5,0.005692886553827654,1,0,1,0.006215231407766101
2258,PSPB,Defective CSF2RA causes SMDP4,0.004015957870459193,0,0,1,0.00438443788625321
2259,PSPB,Defective CSF2RA causes SMDP4,0.005692886553827654,1,0,1,0.006215231407766101
2260,PSPB,Surfactant metabolism,0.004015957870459193,0,0,1,0.00438443788625321
2261,PSPB,Surfactant metabolism,0.005692886553827654,1,0,1,0.006215231407766101
2262,TSP1,Transcriptional regulation by RUNX1,0.003956469098743652,0,0,1,0.004319490784483324
2263,TSP1,Transcriptional regulation by RUNX1,0.0038805748226831602,1,0,1,0.00423663290846897
2264,TSP1,Diseases associated with O-glycosylation of proteins,0.003956469098743652,0,0,1,0.004319490784483324
2265,TSP1,Diseases associated with O-glycosylation of proteins,0.0038805748226831602,1,0,1,0.00423663290846897
2266,TSP1,O-glycosylation of TSR domain-containing proteins,0.003956469098743652,0,0,1,0.004319490784483324
2267,TSP1,O-glycosylation of TSR domain-containing proteins,0.0038805748226831602,1,0,1,0.00423663290846897
2268,TSP1,Platelet degranulation ,0.003956469098743652,0,0,1,0.004319490784483324
2269,TSP1,Platelet degranulation ,0.0038805748226831602,1,0,1,0.00423663290846897
2270,TSP1,Integrin cell surface interactions,0.003956469098743652,0,0,1,0.004319490784483324
2271,TSP1,Integrin cell surface interactions,0.0038805748226831602,1,0,1,0.00423663290846897
2272,TSP1,Syndecan interactions,0.003956469098743652,0,0,1,0.004319490784483324
2273,TSP1,Syndecan interactions,0.0038805748226831602,1,0,1,0.00423663290846897
2274,TSP1,Signaling by PDGF,0.003956469098743652,0,0,1,0.004319490784483324
2275,TSP1,Signaling by PDGF,0.0038805748226831602,1,0,1,0.00423663290846897
2276,RNAS1,Chaperone Mediated Autophagy,0.019530912820162227,0,0,1,0.021322951306766685
2277,RNAS1,Chaperone Mediated Autophagy,0.008882041324301874,1,0,1,0.009697003740002626
2278,RNAS1,Late endosomal microautophagy,0.019530912820162227,0,0,1,0.021322951306766685
2279,RNAS1,Late endosomal microautophagy,0.008882041324301874,1,0,1,0.009697003740002626
2280,CO1A2,Collagen chain trimerization,0.0020296206794735896,0,0,1,0.002215846402987661
2281,CO1A2,Collagen chain trimerization,0.0032860275924082864,1,0,1,0.0035875336186684008
2282,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0020296206794735896,0,0,1,0.002215846402987661
2283,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0032860275924082864,1,0,1,0.0035875336186684008
2284,CO1A2,Anchoring fibril formation,0.0020296206794735896,0,0,1,0.002215846402987661
2285,CO1A2,Anchoring fibril formation,0.0032860275924082864,1,0,1,0.0035875336186684008
2286,CO1A2,Crosslinking of collagen fibrils,0.0020296206794735896,0,0,1,0.002215846402987661
2287,CO1A2,Crosslinking of collagen fibrils,0.0032860275924082864,1,0,1,0.0035875336186684008
2288,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.0020296206794735896,0,0,1,0.002215846402987661
2289,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.0032860275924082864,1,0,1,0.0035875336186684008
2290,CO1A2,MET promotes cell motility,0.0020296206794735896,0,0,1,0.002215846402987661
2291,CO1A2,MET promotes cell motility,0.0032860275924082864,1,0,1,0.0035875336186684008
2292,CO1A2,Platelet Adhesion to exposed collagen,0.0020296206794735896,0,0,1,0.002215846402987661
2293,CO1A2,Platelet Adhesion to exposed collagen,0.0032860275924082864,1,0,1,0.0035875336186684008
2294,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0020296206794735896,0,0,1,0.002215846402987661
2295,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0032860275924082864,1,0,1,0.0035875336186684008
2296,CO1A2,Collagen degradation,0.0020296206794735896,0,0,1,0.002215846402987661
2297,CO1A2,Collagen degradation,0.0032860275924082864,1,0,1,0.0035875336186684008
2298,CO1A2,Integrin cell surface interactions,0.0020296206794735896,0,0,1,0.002215846402987661
2299,CO1A2,Integrin cell surface interactions,0.0032860275924082864,1,0,1,0.0035875336186684008
2300,CO1A2,ECM proteoglycans,0.0020296206794735896,0,0,1,0.002215846402987661
2301,CO1A2,ECM proteoglycans,0.0032860275924082864,1,0,1,0.0035875336186684008
2302,CO1A2,Scavenging by Class A Receptors,0.0020296206794735896,0,0,1,0.002215846402987661
2303,CO1A2,Scavenging by Class A Receptors,0.0032860275924082864,1,0,1,0.0035875336186684008
2304,CO1A2,Syndecan interactions,0.0020296206794735896,0,0,1,0.002215846402987661
2305,CO1A2,Syndecan interactions,0.0032860275924082864,1,0,1,0.0035875336186684008
2306,CO1A2,GPVI-mediated activation cascade,0.0020296206794735896,0,0,1,0.002215846402987661
2307,CO1A2,GPVI-mediated activation cascade,0.0032860275924082864,1,0,1,0.0035875336186684008
2308,CO1A2,GP1b-IX-V activation signalling,0.0020296206794735896,0,0,1,0.002215846402987661
2309,CO1A2,GP1b-IX-V activation signalling,0.0032860275924082864,1,0,1,0.0035875336186684008
2310,CBG,Metabolism of steroid hormones,0.0019662993970391675,0,0,1,0.0021467151424847024
2311,CBG,Metabolism of steroid hormones,0.0012829726633961788,1,0,1,0.0014006904788018122
2312,4F2,Amino acid transport across the plasma membrane,0.0018894088562095754,0,0,1,0.002062769590468935
2313,4F2,Amino acid transport across the plasma membrane,0.0015207913200144046,1,0,1,0.0016603299376230195
2314,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0018894088562095754,0,0,1,0.002062769590468935
2315,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0015207913200144046,1,0,1,0.0016603299376230195
2316,4F2,Basigin interactions,0.0018894088562095754,0,0,1,0.002062769590468935
2317,4F2,Basigin interactions,0.0015207913200144046,1,0,1,0.0016603299376230195
2318,4F2,Tryptophan catabolism,0.0018894088562095754,0,0,1,0.002062769590468935
2319,4F2,Tryptophan catabolism,0.0015207913200144046,1,0,1,0.0016603299376230195
2320,HS90B,Inflammasomes,0.011909713748804658,0,0,1,0.013002477082439923
2321,HS90B,Inflammasomes,0.011193761956608537,1,0,1,0.012220833882065256
2322,HS90B,RHO GTPase cycle,0.011909713748804658,0,0,1,0.013002477082439923
2323,HS90B,RHO GTPase cycle,0.011193761956608537,1,0,1,0.012220833882065256
2324,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.011909713748804658,0,0,1,0.013002477082439923
2325,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.011193761956608537,1,0,1,0.012220833882065256
2326,HS90B,Aryl hydrocarbon receptor signalling,0.011909713748804658,0,0,1,0.013002477082439923
2327,HS90B,Aryl hydrocarbon receptor signalling,0.011193761956608537,1,0,1,0.012220833882065256
2328,HS90B,HSF1 activation,0.011909713748804658,0,0,1,0.013002477082439923
2329,HS90B,HSF1 activation,0.011193761956608537,1,0,1,0.012220833882065256
2330,HS90B,HSF1-dependent transactivation,0.011909713748804658,0,0,1,0.013002477082439923
2331,HS90B,HSF1-dependent transactivation,0.011193761956608537,1,0,1,0.012220833882065256
2332,HS90B,Semaphorin interactions,0.011909713748804658,0,0,1,0.013002477082439923
2333,HS90B,Semaphorin interactions,0.011193761956608537,1,0,1,0.012220833882065256
2334,HS90B,G2/M Transition,0.011909713748804658,0,0,1,0.013002477082439923
2335,HS90B,G2/M Transition,0.011193761956608537,1,0,1,0.012220833882065256
2336,HS90B,Uptake and function of diphtheria toxin,0.011909713748804658,0,0,1,0.013002477082439923
2337,HS90B,Uptake and function of diphtheria toxin,0.011193761956608537,1,0,1,0.012220833882065256
2338,HS90B,Estrogen-dependent gene expression,0.011909713748804658,0,0,1,0.013002477082439923
2339,HS90B,Estrogen-dependent gene expression,0.011193761956608537,1,0,1,0.012220833882065256
2340,HS90B,Cell recruitment (pro-inflammatory response),0.011909713748804658,0,0,1,0.013002477082439923
2341,HS90B,Cell recruitment (pro-inflammatory response),0.011193761956608537,1,0,1,0.012220833882065256
2342,HS90B,Potential therapeutics for SARS,0.011909713748804658,0,0,1,0.013002477082439923
2343,HS90B,Potential therapeutics for SARS,0.011193761956608537,1,0,1,0.012220833882065256
2344,HS90B,SARS-CoV-2 Infection,0.011909713748804658,0,0,1,0.013002477082439923
2345,HS90B,SARS-CoV-2 Infection,0.011193761956608537,1,0,1,0.012220833882065256
2346,HS90B,Neutrophil degranulation,0.011909713748804658,0,0,1,0.013002477082439923
2347,HS90B,Neutrophil degranulation,0.011193761956608537,1,0,1,0.012220833882065256
2348,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.011909713748804658,0,0,1,0.013002477082439923
2349,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.011193761956608537,1,0,1,0.012220833882065256
2350,HS90B,Chaperone Mediated Autophagy,0.011909713748804658,0,0,1,0.013002477082439923
2351,HS90B,Chaperone Mediated Autophagy,0.011193761956608537,1,0,1,0.012220833882065256
2352,SODE,Detoxification of Reactive Oxygen Species,2.650925949436057e-05,0,0,1,2.8941588884323215e-05
2353,SODE,Detoxification of Reactive Oxygen Species,2.0005200066507393e-05,1,0,1,2.1840756283541676e-05
2354,ITA2B,Transcriptional regulation by RUNX1,0.0018088111209536566,0,0,1,0.001974776694278057
2355,ITA2B,Transcriptional regulation by RUNX1,0.0012947911208112568,1,0,1,0.0014135933264210314
2356,ITA2B,L1CAM interactions,0.0018088111209536566,0,0,1,0.001974776694278057
2357,ITA2B,L1CAM interactions,0.0012947911208112568,1,0,1,0.0014135933264210314
2358,ITA2B,RAF/MAP kinase cascade,0.0018088111209536566,0,0,1,0.001974776694278057
2359,ITA2B,RAF/MAP kinase cascade,0.0012947911208112568,1,0,1,0.0014135933264210314
2360,ITA2B,Signaling by RAS mutants,0.0018088111209536566,0,0,1,0.001974776694278057
2361,ITA2B,Signaling by RAS mutants,0.0012947911208112568,1,0,1,0.0014135933264210314
2362,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0018088111209536566,0,0,1,0.001974776694278057
2363,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0012947911208112568,1,0,1,0.0014135933264210314
2364,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0018088111209536566,0,0,1,0.001974776694278057
2365,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0012947911208112568,1,0,1,0.0014135933264210314
2366,ITA2B,Signaling by BRAF and RAF1 fusions,0.0018088111209536566,0,0,1,0.001974776694278057
2367,ITA2B,Signaling by BRAF and RAF1 fusions,0.0012947911208112568,1,0,1,0.0014135933264210314
2368,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0018088111209536566,0,0,1,0.001974776694278057
2369,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0012947911208112568,1,0,1,0.0014135933264210314
2370,ITA2B,Signaling by RAF1 mutants,0.0018088111209536566,0,0,1,0.001974776694278057
2371,ITA2B,Signaling by RAF1 mutants,0.0012947911208112568,1,0,1,0.0014135933264210314
2372,ITA2B,Platelet degranulation ,0.0018088111209536566,0,0,1,0.001974776694278057
2373,ITA2B,Platelet degranulation ,0.0012947911208112568,1,0,1,0.0014135933264210314
2374,ITA2B,Integrin cell surface interactions,0.0018088111209536566,0,0,1,0.001974776694278057
2375,ITA2B,Integrin cell surface interactions,0.0012947911208112568,1,0,1,0.0014135933264210314
2376,ITA2B,ECM proteoglycans,0.0018088111209536566,0,0,1,0.001974776694278057
2377,ITA2B,ECM proteoglycans,0.0012947911208112568,1,0,1,0.0014135933264210314
2378,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0018088111209536566,0,0,1,0.001974776694278057
2379,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0012947911208112568,1,0,1,0.0014135933264210314
2380,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0018088111209536566,0,0,1,0.001974776694278057
2381,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0012947911208112568,1,0,1,0.0014135933264210314
2382,APOA,LDL remodeling,0.0009588070426104589,0,0,1,0.001046781380390083
2383,APOA,LDL remodeling,0.0009923515370680578,1,0,1,0.001083403714866488
2384,PLEK,Platelet degranulation ,0.0002421631720723693,0,0,1,0.00026438260074873463
2385,PLEK,Platelet degranulation ,0.0002588455433863319,1,0,1,0.00028259564560149806
2386,CD14,Antigen processing-Cross presentation,0.02873922610879024,0,0,1,0.03137616375407087
2387,CD14,Antigen processing-Cross presentation,0.03408808521904982,1,0,1,0.037215801839858655
2388,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.02873922610879024,0,0,1,0.03137616375407087
2389,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.03408808521904982,1,0,1,0.037215801839858655
2390,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.02873922610879024,0,0,1,0.03137616375407087
2391,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.03408808521904982,1,0,1,0.037215801839858655
2392,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.02873922610879024,0,0,1,0.03137616375407087
2393,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.03408808521904982,1,0,1,0.037215801839858655
2394,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.02873922610879024,0,0,1,0.03137616375407087
2395,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.03408808521904982,1,0,1,0.037215801839858655
2396,CD14,Regulation of TLR by endogenous ligand,0.02873922610879024,0,0,1,0.03137616375407087
2397,CD14,Regulation of TLR by endogenous ligand,0.03408808521904982,1,0,1,0.037215801839858655
2398,CD14,Caspase activation via Death Receptors in the presence of ligand,0.02873922610879024,0,0,1,0.03137616375407087
2399,CD14,Caspase activation via Death Receptors in the presence of ligand,0.03408808521904982,1,0,1,0.037215801839858655
2400,CD14,MyD88 deficiency (TLR2/4),0.02873922610879024,0,0,1,0.03137616375407087
2401,CD14,MyD88 deficiency (TLR2/4),0.03408808521904982,1,0,1,0.037215801839858655
2402,CD14,IRAK4 deficiency (TLR2/4),0.02873922610879024,0,0,1,0.03137616375407087
2403,CD14,IRAK4 deficiency (TLR2/4),0.03408808521904982,1,0,1,0.037215801839858655
2404,CD14,Neutrophil degranulation,0.02873922610879024,0,0,1,0.03137616375407087
2405,CD14,Neutrophil degranulation,0.03408808521904982,1,0,1,0.037215801839858655
2406,CFAH,Regulation of Complement cascade,0.0006893822143115401,0,0,1,0.0007526357586492912
2407,CFAH,Regulation of Complement cascade,0.0008108321690803497,1,0,1,0.0008852292270442228
2408,FCG3A,FCGR activation,0.0006359388568026926,0,0,1,0.000694288761746265
2409,FCG3A,FCGR activation,0.0004946890752610204,1,0,1,0.0005400787541732809
2410,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0006359388568026926,0,0,1,0.000694288761746265
2411,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0004946890752610204,1,0,1,0.0005400787541732809
2412,FCG3A,Role of phospholipids in phagocytosis,0.0006359388568026926,0,0,1,0.000694288761746265
2413,FCG3A,Role of phospholipids in phagocytosis,0.0004946890752610204,1,0,1,0.0005400787541732809
2414,FCG3A,Parasite infection,0.0006359388568026926,0,0,1,0.000694288761746265
2415,FCG3A,Parasite infection,0.0004946890752610204,1,0,1,0.0005400787541732809
2416,FCG3A,Leishmania parasite growth and survival,0.0006359388568026926,0,0,1,0.000694288761746265
2417,FCG3A,Leishmania parasite growth and survival,0.0004946890752610204,1,0,1,0.0005400787541732809
2418,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006359388568026926,0,0,1,0.000694288761746265
2419,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004946890752610204,1,0,1,0.0005400787541732809
2420,A2AP,Platelet degranulation ,0.002990409566226092,0,0,1,0.003264791469557059
2421,A2AP,Platelet degranulation ,0.005359044403384669,1,0,1,0.005850757919835037
2422,A2AP,Dissolution of Fibrin Clot,0.002990409566226092,0,0,1,0.003264791469557059
2423,A2AP,Dissolution of Fibrin Clot,0.005359044403384669,1,0,1,0.005850757919835037
2424,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0006117019203907783,0,0,1,0.000667827990573146
2425,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0032073500203346917,1,0,1,0.0035016370682251453
2426,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.0006117019203907783,0,0,1,0.000667827990573146
2427,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.0032073500203346917,1,0,1,0.0035016370682251453
2428,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0006117019203907783,0,0,1,0.000667827990573146
2429,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0032073500203346917,1,0,1,0.0035016370682251453
2430,K1C16,Formation of the cornified envelope,0.0012966700494797608,0,0,1,0.0014156446542251285
2431,K1C16,Formation of the cornified envelope,0.0016625179715045648,1,0,1,0.0018150605698480564
2432,ENOG,Glycolysis,0.000560549853016802,0,0,1,0.0006119825187358146
2433,ENOG,Glycolysis,0.0006069394598506996,1,0,1,0.0006626285554452773
2434,ENOG,Gluconeogenesis,0.000560549853016802,0,0,1,0.0006119825187358146
2435,ENOG,Gluconeogenesis,0.0006069394598506996,1,0,1,0.0006626285554452773
2436,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.00047639600396614883,0,0,1,0.0005201072212468175
2437,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.0001554561840418263,1,0,1,0.0001697199036820077
2438,THIK,Peroxisomal lipid metabolism,0.00047639600396614883,0,0,1,0.0005201072212468175
2439,THIK,Peroxisomal lipid metabolism,0.0001554561840418263,1,0,1,0.0001697199036820077
2440,THIK,Neutrophil degranulation,0.00047639600396614883,0,0,1,0.0005201072212468175
2441,THIK,Neutrophil degranulation,0.0001554561840418263,1,0,1,0.0001697199036820077
2442,THIK,TYSND1 cleaves peroxisomal proteins,0.00047639600396614883,0,0,1,0.0005201072212468175
2443,THIK,TYSND1 cleaves peroxisomal proteins,0.0001554561840418263,1,0,1,0.0001697199036820077
2444,DOPO,Catecholamine biosynthesis,0.0005461828041560818,0,0,1,0.0005962972363273638
2445,DOPO,Catecholamine biosynthesis,0.0004192334864573642,1,0,1,0.0004576998167063733
2446,F16P1,Gluconeogenesis,8.167909571260089e-05,0,0,1,8.917347574572083e-05
2447,F16P1,Gluconeogenesis,0.0001888897143355169,1,0,1,0.00020622109259365592
2448,C1S,Initial triggering of complement,0.00039115158797173495,0,0,1,0.00042704129298430264
2449,C1S,Initial triggering of complement,0.0004917012708833011,1,0,1,0.0005368168069285785
2450,C1S,Regulation of Complement cascade,0.00039115158797173495,0,0,1,0.00042704129298430264
2451,C1S,Regulation of Complement cascade,0.0004917012708833011,1,0,1,0.0005368168069285785
2452,LKHA4,Arachidonic acid metabolism,0.002909815489068665,0,0,1,0.0031768025671096755
2453,LKHA4,Arachidonic acid metabolism,0.0017440207208019828,1,0,1,0.001904041518697636
2454,LKHA4,Biosynthesis of DHA-derived SPMs,0.002909815489068665,0,0,1,0.0031768025671096755
2455,LKHA4,Biosynthesis of DHA-derived SPMs,0.0017440207208019828,1,0,1,0.001904041518697636
2456,LKHA4,Biosynthesis of EPA-derived SPMs,0.002909815489068665,0,0,1,0.0031768025671096755
2457,LKHA4,Biosynthesis of EPA-derived SPMs,0.0017440207208019828,1,0,1,0.001904041518697636
2458,LKHA4,Neutrophil degranulation,0.002909815489068665,0,0,1,0.0031768025671096755
2459,LKHA4,Neutrophil degranulation,0.0017440207208019828,1,0,1,0.001904041518697636
2460,CO4A,Initial triggering of complement,0.002065771290687324,0,0,1,0.0022553139757385135
2461,CO4A,Initial triggering of complement,0.0017856014920897938,1,0,1,0.0019494374901830298
2462,CO4A,Activation of C3 and C5,0.002065771290687324,0,0,1,0.0022553139757385135
2463,CO4A,Activation of C3 and C5,0.0017856014920897938,1,0,1,0.0019494374901830298
2464,CO4A,Regulation of Complement cascade,0.002065771290687324,0,0,1,0.0022553139757385135
2465,CO4A,Regulation of Complement cascade,0.0017856014920897938,1,0,1,0.0019494374901830298
2466,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002065771290687324,0,0,1,0.0022553139757385135
2467,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017856014920897938,1,0,1,0.0019494374901830298
2468,CO4A,Post-translational protein phosphorylation,0.002065771290687324,0,0,1,0.0022553139757385135
2469,CO4A,Post-translational protein phosphorylation,0.0017856014920897938,1,0,1,0.0019494374901830298
2470,CO4B,Initial triggering of complement,0.0001490574717710645,0,0,1,0.00016273408425657794
2471,CO4B,Initial triggering of complement,0.00013070204853928203,1,0,1,0.00014269447835642008
2472,CO4B,Activation of C3 and C5,0.0001490574717710645,0,0,1,0.00016273408425657794
2473,CO4B,Activation of C3 and C5,0.00013070204853928203,1,0,1,0.00014269447835642008
2474,CO4B,Regulation of Complement cascade,0.0001490574717710645,0,0,1,0.00016273408425657794
2475,CO4B,Regulation of Complement cascade,0.00013070204853928203,1,0,1,0.00014269447835642008
2476,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0025104399543230786,0,0,1,0.0027407827477132713
2477,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0018613718805354069,1,0,1,0.002032160111403925
2478,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0025104399543230786,0,0,1,0.0027407827477132713
2479,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0018613718805354069,1,0,1,0.002032160111403925
2480,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0025104399543230786,0,0,1,0.0027407827477132713
2481,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0018613718805354069,1,0,1,0.002032160111403925
2482,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0025104399543230786,0,0,1,0.0027407827477132713
2483,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0018613718805354069,1,0,1,0.002032160111403925
2484,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0025104399543230786,0,0,1,0.0027407827477132713
2485,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0018613718805354069,1,0,1,0.002032160111403925
2486,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0025104399543230786,0,0,1,0.0027407827477132713
2487,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0018613718805354069,1,0,1,0.002032160111403925
2488,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0025104399543230786,0,0,1,0.0027407827477132713
2489,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0018613718805354069,1,0,1,0.002032160111403925
2490,SAA1,TRAF6 mediated NF-kB activation,0.0025104399543230786,0,0,1,0.0027407827477132713
2491,SAA1,TRAF6 mediated NF-kB activation,0.0018613718805354069,1,0,1,0.002032160111403925
2492,SAA1,Class A/1 (Rhodopsin-like receptors),0.0025104399543230786,0,0,1,0.0027407827477132713
2493,SAA1,Class A/1 (Rhodopsin-like receptors),0.0018613718805354069,1,0,1,0.002032160111403925
2494,SAA1,G alpha (q) signalling events,0.0025104399543230786,0,0,1,0.0027407827477132713
2495,SAA1,G alpha (q) signalling events,0.0018613718805354069,1,0,1,0.002032160111403925
2496,SAA1,G alpha (i) signalling events,0.0025104399543230786,0,0,1,0.0027407827477132713
2497,SAA1,G alpha (i) signalling events,0.0018613718805354069,1,0,1,0.002032160111403925
2498,SAA1,Interleukin-1 family signaling,0.0025104399543230786,0,0,1,0.0027407827477132713
2499,SAA1,Interleukin-1 family signaling,0.0018613718805354069,1,0,1,0.002032160111403925
2500,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0025104399543230786,0,0,1,0.0027407827477132713
2501,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0018613718805354069,1,0,1,0.002032160111403925
2502,SAA1,Advanced glycosylation endproduct receptor signaling,0.0025104399543230786,0,0,1,0.0027407827477132713
2503,SAA1,Advanced glycosylation endproduct receptor signaling,0.0018613718805354069,1,0,1,0.002032160111403925
2504,SAA1,Scavenging by Class B Receptors,0.0025104399543230786,0,0,1,0.0027407827477132713
2505,SAA1,Scavenging by Class B Receptors,0.0018613718805354069,1,0,1,0.002032160111403925
2506,SAA1,Amyloid fiber formation,0.0025104399543230786,0,0,1,0.0027407827477132713
2507,SAA1,Amyloid fiber formation,0.0018613718805354069,1,0,1,0.002032160111403925
2508,OSTP,Transcriptional regulation by RUNX3,0.006732314358805756,0,0,1,0.007350030824287348
2509,OSTP,Transcriptional regulation by RUNX3,0.005672795323981209,1,0,1,0.006193296728130106
2510,OSTP,Integrin cell surface interactions,0.006732314358805756,0,0,1,0.007350030824287348
2511,OSTP,Integrin cell surface interactions,0.005672795323981209,1,0,1,0.006193296728130106
2512,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006732314358805756,0,0,1,0.007350030824287348
2513,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005672795323981209,1,0,1,0.006193296728130106
2514,OSTP,Post-translational protein phosphorylation,0.006732314358805756,0,0,1,0.007350030824287348
2515,OSTP,Post-translational protein phosphorylation,0.005672795323981209,1,0,1,0.006193296728130106
2516,OSTP,Signaling by PDGF,0.006732314358805756,0,0,1,0.007350030824287348
2517,OSTP,Signaling by PDGF,0.005672795323981209,1,0,1,0.006193296728130106
2518,CO7,Terminal pathway of complement,0.001580487052797772,0,0,1,0.0017255029899571359
2519,CO7,Terminal pathway of complement,0.0014604513524440806,1,0,1,0.0015944535394126047
2520,CO7,Regulation of Complement cascade,0.001580487052797772,0,0,1,0.0017255029899571359
2521,CO7,Regulation of Complement cascade,0.0014604513524440806,1,0,1,0.0015944535394126047
2522,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0007808879291139978,0,0,1,0.0008525374846459094
2523,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.00013126946354728331,1,0,1,0.0001433139559352586
2524,CH60,Mitochondrial protein import,0.0007808879291139978,0,0,1,0.0008525374846459094
2525,CH60,Mitochondrial protein import,0.00013126946354728331,1,0,1,0.0001433139559352586
2526,CLUS,Terminal pathway of complement,0.001561359732754289,0,0,1,0.0017046206626603238
2527,CLUS,Terminal pathway of complement,0.0014931931573485642,1,0,1,0.0016301995343951455
2528,CLUS,Regulation of Complement cascade,0.001561359732754289,0,0,1,0.0017046206626603238
2529,CLUS,Regulation of Complement cascade,0.0014931931573485642,1,0,1,0.0016301995343951455
2530,CLUS,Platelet degranulation ,0.001561359732754289,0,0,1,0.0017046206626603238
2531,CLUS,Platelet degranulation ,0.0014931931573485642,1,0,1,0.0016301995343951455
2532,BIP,Regulation of HSF1-mediated heat shock response,0.0031644534557492845,0,0,1,0.0034548045742037723
2533,BIP,Regulation of HSF1-mediated heat shock response,0.0021555015408168936,1,0,1,0.0023532773311573984
2534,BIP,ATF6 (ATF6-alpha) activates chaperones,0.0031644534557492845,0,0,1,0.0034548045742037723
2535,BIP,ATF6 (ATF6-alpha) activates chaperones,0.0021555015408168936,1,0,1,0.0023532773311573984
2536,BIP,IRE1alpha activates chaperones,0.0031644534557492845,0,0,1,0.0034548045742037723
2537,BIP,IRE1alpha activates chaperones,0.0021555015408168936,1,0,1,0.0023532773311573984
2538,BIP,PERK regulates gene expression,0.0031644534557492845,0,0,1,0.0034548045742037723
2539,BIP,PERK regulates gene expression,0.0021555015408168936,1,0,1,0.0023532773311573984
2540,BIP,Platelet degranulation ,0.0031644534557492845,0,0,1,0.0034548045742037723
2541,BIP,Platelet degranulation ,0.0021555015408168936,1,0,1,0.0023532773311573984
2542,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0031644534557492845,0,0,1,0.0034548045742037723
2543,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0021555015408168936,1,0,1,0.0023532773311573984
2544,LAMC1,L1CAM interactions,0.0014807187832731204,0,0,1,0.0016165805871681377
2545,LAMC1,L1CAM interactions,0.0023904107186026153,1,0,1,0.0026097403549576316
2546,LAMC1,MET promotes cell motility,0.0014807187832731204,0,0,1,0.0016165805871681377
2547,LAMC1,MET promotes cell motility,0.0023904107186026153,1,0,1,0.0026097403549576316
2548,LAMC1,Laminin interactions,0.0014807187832731204,0,0,1,0.0016165805871681377
2549,LAMC1,Laminin interactions,0.0023904107186026153,1,0,1,0.0026097403549576316
2550,LAMC1,ECM proteoglycans,0.0014807187832731204,0,0,1,0.0016165805871681377
2551,LAMC1,ECM proteoglycans,0.0023904107186026153,1,0,1,0.0026097403549576316
2552,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0014807187832731204,0,0,1,0.0016165805871681377
2553,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0023904107186026153,1,0,1,0.0026097403549576316
2554,LAMC1,Post-translational protein phosphorylation,0.0014807187832731204,0,0,1,0.0016165805871681377
2555,LAMC1,Post-translational protein phosphorylation,0.0023904107186026153,1,0,1,0.0026097403549576316
2556,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0014807187832731204,0,0,1,0.0016165805871681377
2557,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0023904107186026153,1,0,1,0.0026097403549576316
2558,HSP7C,"GABA synthesis, release, reuptake and degradation",0.012532646673244571,0,0,1,0.013682566566096925
2559,HSP7C,"GABA synthesis, release, reuptake and degradation",0.00839222749803915,1,0,1,0.009162247558202498
2560,HSP7C,Lysosome Vesicle Biogenesis,0.012532646673244571,0,0,1,0.013682566566096925
2561,HSP7C,Lysosome Vesicle Biogenesis,0.00839222749803915,1,0,1,0.009162247558202498
2562,HSP7C,Golgi Associated Vesicle Biogenesis,0.012532646673244571,0,0,1,0.013682566566096925
2563,HSP7C,Golgi Associated Vesicle Biogenesis,0.00839222749803915,1,0,1,0.009162247558202498
2564,HSP7C,Regulation of HSF1-mediated heat shock response,0.012532646673244571,0,0,1,0.013682566566096925
2565,HSP7C,Regulation of HSF1-mediated heat shock response,0.00839222749803915,1,0,1,0.009162247558202498
2566,HSP7C,HSF1-dependent transactivation,0.012532646673244571,0,0,1,0.013682566566096925
2567,HSP7C,HSF1-dependent transactivation,0.00839222749803915,1,0,1,0.009162247558202498
2568,HSP7C,L1CAM interactions,0.012532646673244571,0,0,1,0.013682566566096925
2569,HSP7C,L1CAM interactions,0.00839222749803915,1,0,1,0.009162247558202498
2570,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.012532646673244571,0,0,1,0.013682566566096925
2571,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.00839222749803915,1,0,1,0.009162247558202498
2572,HSP7C,mRNA Splicing - Major Pathway,0.012532646673244571,0,0,1,0.013682566566096925
2573,HSP7C,mRNA Splicing - Major Pathway,0.00839222749803915,1,0,1,0.009162247558202498
2574,HSP7C,Lipophagy,0.012532646673244571,0,0,1,0.013682566566096925
2575,HSP7C,Lipophagy,0.00839222749803915,1,0,1,0.009162247558202498
2576,HSP7C,Neutrophil degranulation,0.012532646673244571,0,0,1,0.013682566566096925
2577,HSP7C,Neutrophil degranulation,0.00839222749803915,1,0,1,0.009162247558202498
2578,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.012532646673244571,0,0,1,0.013682566566096925
2579,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00839222749803915,1,0,1,0.009162247558202498
2580,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.012532646673244571,0,0,1,0.013682566566096925
2581,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00839222749803915,1,0,1,0.009162247558202498
2582,HSP7C,Protein methylation,0.012532646673244571,0,0,1,0.013682566566096925
2583,HSP7C,Protein methylation,0.00839222749803915,1,0,1,0.009162247558202498
2584,HSP7C,Chaperone Mediated Autophagy,0.012532646673244571,0,0,1,0.013682566566096925
2585,HSP7C,Chaperone Mediated Autophagy,0.00839222749803915,1,0,1,0.009162247558202498
2586,HSP7C,Late endosomal microautophagy,0.012532646673244571,0,0,1,0.013682566566096925
2587,HSP7C,Late endosomal microautophagy,0.00839222749803915,1,0,1,0.009162247558202498
2588,PYGB,Glycogen breakdown (glycogenolysis),0.0002838538307076093,0,0,1,0.00030989854218023557
2589,PYGB,Glycogen breakdown (glycogenolysis),0.000149111508731293,1,0,1,0.00016279307932159755
2590,PYGB,Neutrophil degranulation,0.0002838538307076093,0,0,1,0.00030989854218023557
2591,PYGB,Neutrophil degranulation,0.000149111508731293,1,0,1,0.00016279307932159755
2592,C1TC,Metabolism of folate and pterines,1.9711213345922236e-05,0,0,1,2.1519795118766928e-05
2593,C1TC,Metabolism of folate and pterines,0.00026051873198047347,1,0,1,0.0002844223558658072
2594,CO6A1,Collagen chain trimerization,0.006222627605819781,0,0,1,0.006793578296149255
2595,CO6A1,Collagen chain trimerization,0.005933878815237688,1,0,1,0.006478335662168843
2596,CO6A1,NCAM signaling for neurite out-growth,0.006222627605819781,0,0,1,0.006793578296149255
2597,CO6A1,NCAM signaling for neurite out-growth,0.005933878815237688,1,0,1,0.006478335662168843
2598,CO6A1,Collagen degradation,0.006222627605819781,0,0,1,0.006793578296149255
2599,CO6A1,Collagen degradation,0.005933878815237688,1,0,1,0.006478335662168843
2600,CO6A1,Integrin cell surface interactions,0.006222627605819781,0,0,1,0.006793578296149255
2601,CO6A1,Integrin cell surface interactions,0.005933878815237688,1,0,1,0.006478335662168843
2602,CO6A1,ECM proteoglycans,0.006222627605819781,0,0,1,0.006793578296149255
2603,CO6A1,ECM proteoglycans,0.005933878815237688,1,0,1,0.006478335662168843
2604,CO6A1,Signaling by PDGF,0.006222627605819781,0,0,1,0.006793578296149255
2605,CO6A1,Signaling by PDGF,0.005933878815237688,1,0,1,0.006478335662168843
2606,CO6A3,Collagen chain trimerization,0.004560695297195845,0,0,1,0.004979157126067141
2607,CO6A3,Collagen chain trimerization,0.00405438365071993,1,0,1,0.0044263893838083265
2608,CO6A3,NCAM signaling for neurite out-growth,0.004560695297195845,0,0,1,0.004979157126067141
2609,CO6A3,NCAM signaling for neurite out-growth,0.00405438365071993,1,0,1,0.0044263893838083265
2610,CO6A3,Collagen degradation,0.004560695297195845,0,0,1,0.004979157126067141
2611,CO6A3,Collagen degradation,0.00405438365071993,1,0,1,0.0044263893838083265
2612,CO6A3,Integrin cell surface interactions,0.004560695297195845,0,0,1,0.004979157126067141
2613,CO6A3,Integrin cell surface interactions,0.00405438365071993,1,0,1,0.0044263893838083265
2614,CO6A3,ECM proteoglycans,0.004560695297195845,0,0,1,0.004979157126067141
2615,CO6A3,ECM proteoglycans,0.00405438365071993,1,0,1,0.0044263893838083265
2616,CO6A3,Signaling by PDGF,0.004560695297195845,0,0,1,0.004979157126067141
2617,CO6A3,Signaling by PDGF,0.00405438365071993,1,0,1,0.0044263893838083265
2618,FA5,COPII-mediated vesicle transport,0.00030758401232145355,0,0,1,0.0003358060617985904
2619,FA5,COPII-mediated vesicle transport,0.0006000310724981124,1,0,1,0.000655086296233745
2620,FA5,Cargo concentration in the ER,0.00030758401232145355,0,0,1,0.0003358060617985904
2621,FA5,Cargo concentration in the ER,0.0006000310724981124,1,0,1,0.000655086296233745
2622,FA5,Platelet degranulation ,0.00030758401232145355,0,0,1,0.0003358060617985904
2623,FA5,Platelet degranulation ,0.0006000310724981124,1,0,1,0.000655086296233745
2624,FA5,Common Pathway of Fibrin Clot Formation,0.00030758401232145355,0,0,1,0.0003358060617985904
2625,FA5,Common Pathway of Fibrin Clot Formation,0.0006000310724981124,1,0,1,0.000655086296233745
2626,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00030758401232145355,0,0,1,0.0003358060617985904
2627,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006000310724981124,1,0,1,0.000655086296233745
2628,FA5,Post-translational protein phosphorylation,0.00030758401232145355,0,0,1,0.0003358060617985904
2629,FA5,Post-translational protein phosphorylation,0.0006000310724981124,1,0,1,0.000655086296233745
2630,ACTN1,RHO GTPase cycle,0.0025531739702088956,0,0,1,0.0027874377785490653
2631,ACTN1,RHO GTPase cycle,0.0018698517451781382,1,0,1,0.0020414180371614078
2632,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.0025531739702088956,0,0,1,0.0027874377785490653
2633,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.0018698517451781382,1,0,1,0.0020414180371614078
2634,ACTN1,Platelet degranulation ,0.0025531739702088956,0,0,1,0.0027874377785490653
2635,ACTN1,Platelet degranulation ,0.0018698517451781382,1,0,1,0.0020414180371614078
2636,ACTN1,Nephrin family interactions,0.0025531739702088956,0,0,1,0.0027874377785490653
2637,ACTN1,Nephrin family interactions,0.0018698517451781382,1,0,1,0.0020414180371614078
2638,ACTN1,Syndecan interactions,0.0025531739702088956,0,0,1,0.0027874377785490653
2639,ACTN1,Syndecan interactions,0.0018698517451781382,1,0,1,0.0020414180371614078
2640,ICAM2,CD209 (DC-SIGN) signaling,0.0007699747675637417,0,0,1,0.000840622997367119
2641,ICAM2,CD209 (DC-SIGN) signaling,0.0015032469728715756,1,0,1,0.001641175827250392
2642,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007699747675637417,0,0,1,0.000840622997367119
2643,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015032469728715756,1,0,1,0.001641175827250392
2644,ICAM2,Integrin cell surface interactions,0.0007699747675637417,0,0,1,0.000840622997367119
2645,ICAM2,Integrin cell surface interactions,0.0015032469728715756,1,0,1,0.001641175827250392
2646,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.009843082740420693,0,0,1,0.010746224506506334
2647,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.009038366965339684,1,0,1,0.009867672876798282
2648,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.009843082740420693,0,0,1,0.010746224506506334
2649,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.009038366965339684,1,0,1,0.009867672876798282
2650,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.009843082740420693,0,0,1,0.010746224506506334
2651,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.009038366965339684,1,0,1,0.009867672876798282
2652,CSPG2,ECM proteoglycans,0.009843082740420693,0,0,1,0.010746224506506334
2653,CSPG2,ECM proteoglycans,0.009038366965339684,1,0,1,0.009867672876798282
2654,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009843082740420693,0,0,1,0.010746224506506334
2655,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009038366965339684,1,0,1,0.009867672876798282
2656,CSPG2,Post-translational protein phosphorylation,0.009843082740420693,0,0,1,0.010746224506506334
2657,CSPG2,Post-translational protein phosphorylation,0.009038366965339684,1,0,1,0.009867672876798282
2658,K1C10,Formation of the cornified envelope,0.001178676595094805,0,0,1,0.0012868248337930639
2659,K1C10,Formation of the cornified envelope,0.001539033458414862,1,0,1,0.0016802458643605913
2660,K2C5,Type I hemidesmosome assembly,0.00013865488139988994,0,0,1,0.00015137701508161284
2661,K2C5,Type I hemidesmosome assembly,0.0001224535409116486,1,0,1,0.0001336891375350759
2662,K2C5,Formation of the cornified envelope,0.00013865488139988994,0,0,1,0.00015137701508161284
2663,K2C5,Formation of the cornified envelope,0.0001224535409116486,1,0,1,0.0001336891375350759
2664,CO6,Terminal pathway of complement,0.001001838700428061,0,0,1,0.0010937613629819337
2665,CO6,Terminal pathway of complement,0.0008624732294978697,1,0,1,0.000941608558970575
2666,CO6,Regulation of Complement cascade,0.001001838700428061,0,0,1,0.0010937613629819337
2667,CO6,Regulation of Complement cascade,0.0008624732294978697,1,0,1,0.000941608558970575
2668,PRG2,Neutrophil degranulation,0.0007219145156922963,0,0,1,0.000788153027331317
2669,PRG2,Neutrophil degranulation,0.0007338412633451732,1,0,1,0.0008011741012458886
2670,PLSL,Interleukin-12 family signaling,0.000553601089043968,0,0,1,0.0006043961781894579
2671,PLSL,Interleukin-12 family signaling,0.000581474991115452,1,0,1,0.0006348276210038599
2672,CD59,Regulation of Complement cascade,0.002540610826223469,0,0,1,0.0027737219164217916
2673,CD59,Regulation of Complement cascade,0.002335451934051455,1,0,1,0.0025497388845883767
2674,CD59,COPII-mediated vesicle transport,0.002540610826223469,0,0,1,0.0027737219164217916
2675,CD59,COPII-mediated vesicle transport,0.002335451934051455,1,0,1,0.0025497388845883767
2676,CD59,Cargo concentration in the ER,0.002540610826223469,0,0,1,0.0027737219164217916
2677,CD59,Cargo concentration in the ER,0.002335451934051455,1,0,1,0.0025497388845883767
2678,CD59,COPI-mediated anterograde transport,0.002540610826223469,0,0,1,0.0027737219164217916
2679,CD59,COPI-mediated anterograde transport,0.002335451934051455,1,0,1,0.0025497388845883767
2680,CD59,Neutrophil degranulation,0.002540610826223469,0,0,1,0.0027737219164217916
2681,CD59,Neutrophil degranulation,0.002335451934051455,1,0,1,0.0025497388845883767
2682,GFAP,Nuclear signaling by ERBB4,0.002633908495240783,0,0,1,0.002875580015518795
2683,GFAP,Nuclear signaling by ERBB4,0.001247783051744614,1,0,1,0.0013622720811232488
2684,GFAP,Chaperone Mediated Autophagy,0.002633908495240783,0,0,1,0.002875580015518795
2685,GFAP,Chaperone Mediated Autophagy,0.001247783051744614,1,0,1,0.0013622720811232488
2686,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0020359009040429774,0,0,1,0.0022227028629965536
2687,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001905410754335406,1,0,1,0.0020802397260276115
2688,LYAM1,Neutrophil degranulation,0.0020359009040429774,0,0,1,0.0022227028629965536
2689,LYAM1,Neutrophil degranulation,0.001905410754335406,1,0,1,0.0020802397260276115
2690,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.004919338637494912,0,0,1,0.005370707411100344
2691,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0037765841113242705,1,0,1,0.004123100638109718
2692,GLU2B,SARS-CoV-1 Infection,0.004919338637494912,0,0,1,0.005370707411100344
2693,GLU2B,SARS-CoV-1 Infection,0.0037765841113242705,1,0,1,0.004123100638109718
2694,GLU2B,SARS-CoV-2 Infection,0.004919338637494912,0,0,1,0.005370707411100344
2695,GLU2B,SARS-CoV-2 Infection,0.0037765841113242705,1,0,1,0.004123100638109718
2696,GLU2B,Advanced glycosylation endproduct receptor signaling,0.004919338637494912,0,0,1,0.005370707411100344
2697,GLU2B,Advanced glycosylation endproduct receptor signaling,0.0037765841113242705,1,0,1,0.004123100638109718
2698,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004919338637494912,0,0,1,0.005370707411100344
2699,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0037765841113242705,1,0,1,0.004123100638109718
2700,GLU2B,Post-translational protein phosphorylation,0.004919338637494912,0,0,1,0.005370707411100344
2701,GLU2B,Post-translational protein phosphorylation,0.0037765841113242705,1,0,1,0.004123100638109718
2702,NID1,Laminin interactions,0.00010000994457579029,0,0,1,0.0001091862524817874
2703,NID1,Laminin interactions,0.0002522944036320438,1,0,1,0.0002754434128681511
2704,PA2GA,Glycerophospholipid biosynthesis,0.0016287446605883122,0,0,1,0.0017781884240980574
2705,PA2GA,Glycerophospholipid biosynthesis,0.0011607144288848707,1,0,1,0.0012672145678016512
2706,KPYM,Neutrophil degranulation,0.0013828292414593288,0,0,1,0.001509709292786934
2707,KPYM,Neutrophil degranulation,0.001402154819257463,1,0,1,0.0015308080687714005
2708,ENPL,Trafficking and processing of endosomal TLR,0.00026399148617124604,0,0,1,0.00028821374898665357
2709,ENPL,Trafficking and processing of endosomal TLR,0.00032110099447595644,1,0,1,0.0003505632805189239
2710,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.00026399148617124604,0,0,1,0.00028821374898665357
2711,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.00032110099447595644,1,0,1,0.0003505632805189239
2712,ENPL,Interleukin-4 and Interleukin-13 signaling,0.00026399148617124604,0,0,1,0.00028821374898665357
2713,ENPL,Interleukin-4 and Interleukin-13 signaling,0.00032110099447595644,1,0,1,0.0003505632805189239
2714,ENPL,Scavenging by Class A Receptors,0.00026399148617124604,0,0,1,0.00028821374898665357
2715,ENPL,Scavenging by Class A Receptors,0.00032110099447595644,1,0,1,0.0003505632805189239
2716,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00026399148617124604,0,0,1,0.00028821374898665357
2717,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00032110099447595644,1,0,1,0.0003505632805189239
2718,ENPL,Post-translational protein phosphorylation,0.00026399148617124604,0,0,1,0.00028821374898665357
2719,ENPL,Post-translational protein phosphorylation,0.00032110099447595644,1,0,1,0.0003505632805189239
2720,GPIX,Defective factor IX causes hemophilia B,0.0002872035828137446,0,0,1,0.0003135556472887652
2721,GPIX,Defective factor IX causes hemophilia B,0.0005242276430333289,1,0,1,0.0005723276023495093
2722,GPIX,Platelet Adhesion to exposed collagen,0.0002872035828137446,0,0,1,0.0003135556472887652
2723,GPIX,Platelet Adhesion to exposed collagen,0.0005242276430333289,1,0,1,0.0005723276023495093
2724,GPIX,Intrinsic Pathway of Fibrin Clot Formation,0.0002872035828137446,0,0,1,0.0003135556472887652
2725,GPIX,Intrinsic Pathway of Fibrin Clot Formation,0.0005242276430333289,1,0,1,0.0005723276023495093
2726,GPIX,GP1b-IX-V activation signalling,0.0002872035828137446,0,0,1,0.0003135556472887652
2727,GPIX,GP1b-IX-V activation signalling,0.0005242276430333289,1,0,1,0.0005723276023495093
2728,MMP9,EPH-Ephrin signaling,0.0065041280110475375,0,0,1,0.007100907476755198
2729,MMP9,EPH-Ephrin signaling,0.007240601234979512,1,0,1,0.007904955031379864
2730,MMP9,Interleukin-4 and Interleukin-13 signaling,0.0065041280110475375,0,0,1,0.007100907476755198
2731,MMP9,Interleukin-4 and Interleukin-13 signaling,0.007240601234979512,1,0,1,0.007904955031379864
2732,MMP9,Extra-nuclear estrogen signaling,0.0065041280110475375,0,0,1,0.007100907476755198
2733,MMP9,Extra-nuclear estrogen signaling,0.007240601234979512,1,0,1,0.007904955031379864
2734,MMP9,Collagen degradation,0.0065041280110475375,0,0,1,0.007100907476755198
2735,MMP9,Collagen degradation,0.007240601234979512,1,0,1,0.007904955031379864
2736,MMP9,Activation of Matrix Metalloproteinases,0.0065041280110475375,0,0,1,0.007100907476755198
2737,MMP9,Activation of Matrix Metalloproteinases,0.007240601234979512,1,0,1,0.007904955031379864
2738,MMP9,Neutrophil degranulation,0.0065041280110475375,0,0,1,0.007100907476755198
2739,MMP9,Neutrophil degranulation,0.007240601234979512,1,0,1,0.007904955031379864
2740,MMP9,Signaling by SCF-KIT,0.0065041280110475375,0,0,1,0.007100907476755198
2741,MMP9,Signaling by SCF-KIT,0.007240601234979512,1,0,1,0.007904955031379864
2742,AMPN,Neutrophil degranulation,0.0005858540323896507,0,0,1,0.0006396084566319657
2743,AMPN,Neutrophil degranulation,0.0005143468131902253,1,0,1,0.0005615401672943773
2744,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.0005858540323896507,0,0,1,0.0006396084566319657
2745,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.0005143468131902253,1,0,1,0.0005615401672943773
2746,PVR,Adherens junctions interactions,0.0007310113929901869,0,0,1,0.0007980845790950578
2747,PVR,Adherens junctions interactions,0.0006482081580589476,1,0,1,0.0007076838199119593
2748,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007310113929901869,0,0,1,0.0007980845790950578
2749,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006482081580589476,1,0,1,0.0007076838199119593
2750,CBPN,Regulation of Complement cascade,0.0008691131891055769,0,0,1,0.000948857761130132
2751,CBPN,Regulation of Complement cascade,0.001020616983529125,1,0,1,0.0011142626278165867
2752,B4GT1,Keratan sulfate/keratin metabolism,0.004624190131359826,0,0,1,0.005048477862357158
2753,B4GT1,Keratan sulfate/keratin metabolism,0.0048008038972216244,1,0,1,0.005241296639659168
2754,B4GT1,Pre-NOTCH Processing in Golgi,0.004624190131359826,0,0,1,0.005048477862357158
2755,B4GT1,Pre-NOTCH Processing in Golgi,0.0048008038972216244,1,0,1,0.005241296639659168
2756,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.004624190131359826,0,0,1,0.005048477862357158
2757,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.0048008038972216244,1,0,1,0.005241296639659168
2758,B4GT1,Diseases associated with N-glycosylation of proteins,0.004624190131359826,0,0,1,0.005048477862357158
2759,B4GT1,Diseases associated with N-glycosylation of proteins,0.0048008038972216244,1,0,1,0.005241296639659168
2760,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.004624190131359826,0,0,1,0.005048477862357158
2761,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.0048008038972216244,1,0,1,0.005241296639659168
2762,B4GT1,Neutrophil degranulation,0.004624190131359826,0,0,1,0.005048477862357158
2763,B4GT1,Neutrophil degranulation,0.0048008038972216244,1,0,1,0.005241296639659168
2764,B4GT1,Lactose synthesis,0.004624190131359826,0,0,1,0.005048477862357158
2765,B4GT1,Lactose synthesis,0.0048008038972216244,1,0,1,0.005241296639659168
2766,EZRI,L1CAM interactions,0.0003297001041601522,0,0,1,0.00035995139252198227
2767,EZRI,L1CAM interactions,0.00020912257811138204,1,0,1,0.00022831040163218925
2768,EZRI,Netrin-1 signaling,0.0003297001041601522,0,0,1,0.00035995139252198227
2769,EZRI,Netrin-1 signaling,0.00020912257811138204,1,0,1,0.00022831040163218925
2770,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.0003297001041601522,0,0,1,0.00035995139252198227
2771,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.00020912257811138204,1,0,1,0.00022831040163218925
2772,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.0003297001041601522,0,0,1,0.00035995139252198227
2773,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.00020912257811138204,1,0,1,0.00022831040163218925
2774,TIMP2,Activation of Matrix Metalloproteinases,0.0016887585719962258,0,0,1,0.0018437088492037651
2775,TIMP2,Activation of Matrix Metalloproteinases,0.0014487269822316632,1,0,1,0.00158165341186896
2776,TIMP2,Neutrophil degranulation,0.0016887585719962258,0,0,1,0.0018437088492037651
2777,TIMP2,Neutrophil degranulation,0.0014487269822316632,1,0,1,0.00158165341186896
2778,CD44,Hyaluronan metabolism,0.006999064565294654,0,0,1,0.007641256417090209
2779,CD44,Hyaluronan metabolism,0.005855287084875092,1,0,1,0.006392532829753034
2780,CD44,Interferon gamma signaling,0.006999064565294654,0,0,1,0.007641256417090209
2781,CD44,Interferon gamma signaling,0.005855287084875092,1,0,1,0.006392532829753034
2782,CD44,Integrin cell surface interactions,0.006999064565294654,0,0,1,0.007641256417090209
2783,CD44,Integrin cell surface interactions,0.005855287084875092,1,0,1,0.006392532829753034
2784,CD44,Neutrophil degranulation,0.006999064565294654,0,0,1,0.007641256417090209
2785,CD44,Neutrophil degranulation,0.005855287084875092,1,0,1,0.006392532829753034
2786,CD36,Antigen processing-Cross presentation,0.0004068450645699791,0,0,1,0.000444174708120578
2787,CD36,Antigen processing-Cross presentation,0.00030439011037382497,1,0,1,0.0003323191067169228
2788,CD36,Toll Like Receptor 4 (TLR4) Cascade,0.0004068450645699791,0,0,1,0.000444174708120578
2789,CD36,Toll Like Receptor 4 (TLR4) Cascade,0.00030439011037382497,1,0,1,0.0003323191067169228
2790,CD36,Toll Like Receptor 2 (TLR2) Cascade,0.0004068450645699791,0,0,1,0.000444174708120578
2791,CD36,Toll Like Receptor 2 (TLR2) Cascade,0.00030439011037382497,1,0,1,0.0003323191067169228
2792,CD36,Regulation of TLR by endogenous ligand,0.0004068450645699791,0,0,1,0.000444174708120578
2793,CD36,Regulation of TLR by endogenous ligand,0.00030439011037382497,1,0,1,0.0003323191067169228
2794,CD36,PPARA activates gene expression,0.0004068450645699791,0,0,1,0.000444174708120578
2795,CD36,PPARA activates gene expression,0.00030439011037382497,1,0,1,0.0003323191067169228
2796,CD36,Free fatty acids regulate insulin secretion,0.0004068450645699791,0,0,1,0.000444174708120578
2797,CD36,Free fatty acids regulate insulin secretion,0.00030439011037382497,1,0,1,0.0003323191067169228
2798,CD36,Interleukin-4 and Interleukin-13 signaling,0.0004068450645699791,0,0,1,0.000444174708120578
2799,CD36,Interleukin-4 and Interleukin-13 signaling,0.00030439011037382497,1,0,1,0.0003323191067169228
2800,CD36,MyD88 deficiency (TLR2/4),0.0004068450645699791,0,0,1,0.000444174708120578
2801,CD36,MyD88 deficiency (TLR2/4),0.00030439011037382497,1,0,1,0.0003323191067169228
2802,CD36,IRAK4 deficiency (TLR2/4),0.0004068450645699791,0,0,1,0.000444174708120578
2803,CD36,IRAK4 deficiency (TLR2/4),0.00030439011037382497,1,0,1,0.0003323191067169228
2804,CD36,Platelet degranulation ,0.0004068450645699791,0,0,1,0.000444174708120578
2805,CD36,Platelet degranulation ,0.00030439011037382497,1,0,1,0.0003323191067169228
2806,CD36,Transcriptional regulation of white adipocyte differentiation,0.0004068450645699791,0,0,1,0.000444174708120578
2807,CD36,Transcriptional regulation of white adipocyte differentiation,0.00030439011037382497,1,0,1,0.0003323191067169228
2808,CD36,Neutrophil degranulation,0.0004068450645699791,0,0,1,0.000444174708120578
2809,CD36,Neutrophil degranulation,0.00030439011037382497,1,0,1,0.0003323191067169228
2810,CD36,Scavenging by Class B Receptors,0.0004068450645699791,0,0,1,0.000444174708120578
2811,CD36,Scavenging by Class B Receptors,0.00030439011037382497,1,0,1,0.0003323191067169228
2812,FAAA,Tyrosine catabolism,0.0009579330610068808,0,0,1,0.0010458272075182004
2813,FAAA,Tyrosine catabolism,0.0003810994390446721,1,0,1,0.00041606681964177365
2814,HSP76,Regulation of HSF1-mediated heat shock response,0.00018111635489128787,0,0,1,0.00019773449668052573
2815,HSP76,Regulation of HSF1-mediated heat shock response,0.00018175228360477086,1,0,1,0.0001984287743682626
2816,HSP76,Neutrophil degranulation,0.00018111635489128787,0,0,1,0.00019773449668052573
2817,HSP76,Neutrophil degranulation,0.00018175228360477086,1,0,1,0.0001984287743682626
2818,AATC,Methionine salvage pathway,0.0011117005139248928,0,0,1,0.0012137034323176656
2819,AATC,Methionine salvage pathway,0.0015501871447700553,1,0,1,0.0016924229455463316
2820,AATC,Gluconeogenesis,0.0011117005139248928,0,0,1,0.0012137034323176656
2821,AATC,Gluconeogenesis,0.0015501871447700553,1,0,1,0.0016924229455463316
2822,AATC,Aspartate and asparagine metabolism,0.0011117005139248928,0,0,1,0.0012137034323176656
2823,AATC,Aspartate and asparagine metabolism,0.0015501871447700553,1,0,1,0.0016924229455463316
2824,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0006219204289922585,0,0,1,0.0006789840877480926
2825,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0006189497156266056,1,0,1,0.0006757407996834004
2826,CTRB1,Activation of Matrix Metalloproteinases,0.0006219204289922585,0,0,1,0.0006789840877480926
2827,CTRB1,Activation of Matrix Metalloproteinases,0.0006189497156266056,1,0,1,0.0006757407996834004
2828,IBP3,Transcriptional Regulation by TP53,0.0007358719252492685,0,0,1,0.0008033910844099745
2829,IBP3,Transcriptional Regulation by TP53,0.0006476337635499037,1,0,1,0.0007070567224352571
2830,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0007358719252492685,0,0,1,0.0008033910844099745
2831,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006476337635499037,1,0,1,0.0007070567224352571
2832,IBP3,Post-translational protein phosphorylation,0.0007358719252492685,0,0,1,0.0008033910844099745
2833,IBP3,Post-translational protein phosphorylation,0.0006476337635499037,1,0,1,0.0007070567224352571
2834,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1.9148534515205497e-05,0,0,1,2.0905488280208123e-05
2835,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),8.399076811484297e-06,1,0,1,9.169725323241972e-06
2836,VINC,RAF/MAP kinase cascade,0.005873698501866594,0,0,1,0.006412633567061794
2837,VINC,RAF/MAP kinase cascade,0.005805618476552823,1,0,1,0.006338306930201769
2838,VINC,Signaling by RAS mutants,0.005873698501866594,0,0,1,0.006412633567061794
2839,VINC,Signaling by RAS mutants,0.005805618476552823,1,0,1,0.006338306930201769
2840,VINC,Signaling by moderate kinase activity BRAF mutants,0.005873698501866594,0,0,1,0.006412633567061794
2841,VINC,Signaling by moderate kinase activity BRAF mutants,0.005805618476552823,1,0,1,0.006338306930201769
2842,VINC,Signaling by high-kinase activity BRAF mutants,0.005873698501866594,0,0,1,0.006412633567061794
2843,VINC,Signaling by high-kinase activity BRAF mutants,0.005805618476552823,1,0,1,0.006338306930201769
2844,VINC,Signaling by BRAF and RAF1 fusions,0.005873698501866594,0,0,1,0.006412633567061794
2845,VINC,Signaling by BRAF and RAF1 fusions,0.005805618476552823,1,0,1,0.006338306930201769
2846,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005873698501866594,0,0,1,0.006412633567061794
2847,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005805618476552823,1,0,1,0.006338306930201769
2848,VINC,Signaling by RAF1 mutants,0.005873698501866594,0,0,1,0.006412633567061794
2849,VINC,Signaling by RAF1 mutants,0.005805618476552823,1,0,1,0.006338306930201769
2850,VINC,Platelet degranulation ,0.005873698501866594,0,0,1,0.006412633567061794
2851,VINC,Platelet degranulation ,0.005805618476552823,1,0,1,0.006338306930201769
2852,VINC,Signaling by ALK fusions and activated point mutants,0.005873698501866594,0,0,1,0.006412633567061794
2853,VINC,Signaling by ALK fusions and activated point mutants,0.005805618476552823,1,0,1,0.006338306930201769
2854,VINC,Neutrophil degranulation,0.005873698501866594,0,0,1,0.006412633567061794
2855,VINC,Neutrophil degranulation,0.005805618476552823,1,0,1,0.006338306930201769
2856,VINC,Smooth Muscle Contraction,0.005873698501866594,0,0,1,0.006412633567061794
2857,VINC,Smooth Muscle Contraction,0.005805618476552823,1,0,1,0.006338306930201769
2858,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0022204959818298235,0,0,1,0.002424235269154979
2859,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.002814965572572407,1,0,1,0.0030732497956891436
2860,LBP,Regulation of TLR by endogenous ligand,0.0022204959818298235,0,0,1,0.002424235269154979
2861,LBP,Regulation of TLR by endogenous ligand,0.002814965572572407,1,0,1,0.0030732497956891436
2862,LBP,Interleukin-4 and Interleukin-13 signaling,0.0022204959818298235,0,0,1,0.002424235269154979
2863,LBP,Interleukin-4 and Interleukin-13 signaling,0.002814965572572407,1,0,1,0.0030732497956891436
2864,ML12A,EPH-Ephrin signaling,0.0008979310730837408,0,0,1,0.0009803197999241457
2865,ML12A,EPH-Ephrin signaling,0.00140749689189807,1,0,1,0.001536640297702108
2866,ML12A,Smooth Muscle Contraction,0.0008979310730837408,0,0,1,0.0009803197999241457
2867,ML12A,Smooth Muscle Contraction,0.00140749689189807,1,0,1,0.001536640297702108
2868,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.0016517082537995456,0,0,1,0.0018032590177963737
2869,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.0015230295681309136,1,0,1,0.0016627735538554116
2870,VCAM1,Interferon gamma signaling,0.0016517082537995456,0,0,1,0.0018032590177963737
2871,VCAM1,Interferon gamma signaling,0.0015230295681309136,1,0,1,0.0016627735538554116
2872,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0016517082537995456,0,0,1,0.0018032590177963737
2873,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015230295681309136,1,0,1,0.0016627735538554116
2874,VCAM1,Integrin cell surface interactions,0.0016517082537995456,0,0,1,0.0018032590177963737
2875,VCAM1,Integrin cell surface interactions,0.0015230295681309136,1,0,1,0.0016627735538554116
2876,A1AG2,Platelet degranulation ,0.0009429471757276162,0,0,1,0.0010294663080026038
2877,A1AG2,Platelet degranulation ,0.0009674157168802677,1,0,1,0.0010561799345673078
2878,A1AG2,Neutrophil degranulation,0.0009429471757276162,0,0,1,0.0010294663080026038
2879,A1AG2,Neutrophil degranulation,0.0009674157168802677,1,0,1,0.0010561799345673078
2880,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003930223639204987,0,0,1,0.004290837200243833
2881,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003344864044607343,1,0,1,0.0036517685480265552
2882,ITIH2,Post-translational protein phosphorylation,0.003930223639204987,0,0,1,0.004290837200243833
2883,ITIH2,Post-translational protein phosphorylation,0.003344864044607343,1,0,1,0.0036517685480265552
2884,TYPH,Pyrimidine catabolism,0.00019809233073395119,0,0,1,0.00021626808543856265
2885,TYPH,Pyrimidine catabolism,0.00023412123183394205,1,0,1,0.00025560278069143084
2886,TYPH,Pyrimidine salvage,0.00019809233073395119,0,0,1,0.00021626808543856265
2887,TYPH,Pyrimidine salvage,0.00023412123183394205,1,0,1,0.00025560278069143084
2888,C4BPB,Regulation of Complement cascade,0.0005608059106831615,0,0,1,0.0006122620707056474
2889,C4BPB,Regulation of Complement cascade,0.0006600289266062475,1,0,1,0.0007205891907189209
2890,FLNA,Antiviral mechanism by IFN-stimulated genes,0.00019460054181186462,0,0,1,0.00021245591107453102
2891,FLNA,Antiviral mechanism by IFN-stimulated genes,0.00046169298962775034,1,0,1,0.0005040551471995299
2892,FLNA,RHO GTPase Effectors,0.00019460054181186462,0,0,1,0.00021245591107453102
2893,FLNA,RHO GTPase Effectors,0.00046169298962775034,1,0,1,0.0005040551471995299
2894,FLNA,Platelet degranulation ,0.00019460054181186462,0,0,1,0.00021245591107453102
2895,FLNA,Platelet degranulation ,0.00046169298962775034,1,0,1,0.0005040551471995299
2896,FLNA,GP1b-IX-V activation signalling,0.00019460054181186462,0,0,1,0.00021245591107453102
2897,FLNA,GP1b-IX-V activation signalling,0.00046169298962775034,1,0,1,0.0005040551471995299
2898,TENX,ECM proteoglycans,0.002076484681920238,0,0,1,0.0022670103629833507
2899,TENX,ECM proteoglycans,0.001318198374766847,1,0,1,0.001439148288491464
2900,GPX3,Detoxification of Reactive Oxygen Species,0.00253861181190956,0,0,1,0.0027715394846394422
2901,GPX3,Detoxification of Reactive Oxygen Species,0.0019263113675054592,1,0,1,0.002103058053107877
2902,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00010148817135014034,0,0,1,0.00011080011240835908
2903,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5.62822000255683e-05,1,0,1,6.14463144469111e-05
2904,IBP4,Post-translational protein phosphorylation,0.00010148817135014034,0,0,1,0.00011080011240835908
2905,IBP4,Post-translational protein phosphorylation,5.62822000255683e-05,1,0,1,6.14463144469111e-05
2906,CPN2,Regulation of Complement cascade,0.00010584462378121806,0,0,1,0.00011555628657765958
2907,CPN2,Regulation of Complement cascade,0.0001247808853802291,1,0,1,0.00013623002506217525
2908,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0014574958062587426,0,0,1,0.0015912268101770002
2909,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0011446543409717753,1,0,1,0.0012496809033126154
2910,MMP8,Collagen degradation,0.0007515119002815242,0,0,1,0.0008204660890000091
2911,MMP8,Collagen degradation,0.0007095094731781953,1,0,1,0.000774609773110578
2912,MMP8,Activation of Matrix Metalloproteinases,0.0007515119002815242,0,0,1,0.0008204660890000091
2913,MMP8,Activation of Matrix Metalloproteinases,0.0007095094731781953,1,0,1,0.000774609773110578
2914,MMP8,Neutrophil degranulation,0.0007515119002815242,0,0,1,0.0008204660890000091
2915,MMP8,Neutrophil degranulation,0.0007095094731781953,1,0,1,0.000774609773110578
2916,MRC1,Antigen processing-Cross presentation,0.0044274755120088305,0,0,1,0.004833713898769122
2917,MRC1,Antigen processing-Cross presentation,0.0055334978898854805,1,0,1,0.006041218203601825
2918,MRC1,Modulation by Mtb of host immune system,0.0044274755120088305,0,0,1,0.004833713898769122
2919,MRC1,Modulation by Mtb of host immune system,0.0055334978898854805,1,0,1,0.006041218203601825
2920,HV102,Initial triggering of complement,0.0008386424017813338,0,0,1,0.0009155911585715997
2921,HV102,Initial triggering of complement,0.0009155465387418656,1,0,1,0.000999551554217087
2922,HV102,Regulation of Complement cascade,0.0008386424017813338,0,0,1,0.0009155911585715997
2923,HV102,Regulation of Complement cascade,0.0009155465387418656,1,0,1,0.000999551554217087
2924,HV102,FCGR activation,0.0008386424017813338,0,0,1,0.0009155911585715997
2925,HV102,FCGR activation,0.0009155465387418656,1,0,1,0.000999551554217087
2926,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0008386424017813338,0,0,1,0.0009155911585715997
2927,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0009155465387418656,1,0,1,0.000999551554217087
2928,HV102,Role of phospholipids in phagocytosis,0.0008386424017813338,0,0,1,0.0009155911585715997
2929,HV102,Role of phospholipids in phagocytosis,0.0009155465387418656,1,0,1,0.000999551554217087
2930,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008386424017813338,0,0,1,0.0009155911585715997
2931,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009155465387418656,1,0,1,0.000999551554217087
2932,HV102,FCERI mediated MAPK activation,0.0008386424017813338,0,0,1,0.0009155911585715997
2933,HV102,FCERI mediated MAPK activation,0.0009155465387418656,1,0,1,0.000999551554217087
2934,HV102,FCERI mediated Ca+2 mobilization,0.0008386424017813338,0,0,1,0.0009155911585715997
2935,HV102,FCERI mediated Ca+2 mobilization,0.0009155465387418656,1,0,1,0.000999551554217087
2936,HV102,FCERI mediated NF-kB activation,0.0008386424017813338,0,0,1,0.0009155911585715997
2937,HV102,FCERI mediated NF-kB activation,0.0009155465387418656,1,0,1,0.000999551554217087
2938,HV102,Parasite infection,0.0008386424017813338,0,0,1,0.0009155911585715997
2939,HV102,Parasite infection,0.0009155465387418656,1,0,1,0.000999551554217087
2940,HV102,Leishmania parasite growth and survival,0.0008386424017813338,0,0,1,0.0009155911585715997
2941,HV102,Leishmania parasite growth and survival,0.0009155465387418656,1,0,1,0.000999551554217087
2942,HV102,Potential therapeutics for SARS,0.0008386424017813338,0,0,1,0.0009155911585715997
2943,HV102,Potential therapeutics for SARS,0.0009155465387418656,1,0,1,0.000999551554217087
2944,HV102,CD22 mediated BCR regulation,0.0008386424017813338,0,0,1,0.0009155911585715997
2945,HV102,CD22 mediated BCR regulation,0.0009155465387418656,1,0,1,0.000999551554217087
2946,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008386424017813338,0,0,1,0.0009155911585715997
2947,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009155465387418656,1,0,1,0.000999551554217087
2948,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008386424017813338,0,0,1,0.0009155911585715997
2949,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009155465387418656,1,0,1,0.000999551554217087
2950,HV102,Scavenging of heme from plasma,0.0008386424017813338,0,0,1,0.0009155911585715997
2951,HV102,Scavenging of heme from plasma,0.0009155465387418656,1,0,1,0.000999551554217087
2952,EST1,Metabolism of Angiotensinogen to Angiotensins,0.006605778001768864,0,0,1,0.007211884256101967
2953,EST1,Metabolism of Angiotensinogen to Angiotensins,0.008032137455967099,1,0,1,0.00876911783078763
2954,EST1,Physiological factors,0.006605778001768864,0,0,1,0.007211884256101967
2955,EST1,Physiological factors,0.008032137455967099,1,0,1,0.00876911783078763
2956,EST1,Aspirin ADME,0.006605778001768864,0,0,1,0.007211884256101967
2957,EST1,Aspirin ADME,0.008032137455967099,1,0,1,0.00876911783078763
2958,FBLN1,Molecules associated with elastic fibres,0.00022785693769176974,0,0,1,0.0002487637127894476
2959,FBLN1,Molecules associated with elastic fibres,8.425120083058785e-05,1,0,1,9.198158167972018e-05
2960,SAHH,Methylation,0.0027455007412168315,0,0,1,0.0029974112913567384
2961,SAHH,Methylation,0.003104031523855091,1,0,1,0.0033888386911186436
2962,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0027455007412168315,0,0,1,0.0029974112913567384
2963,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.003104031523855091,1,0,1,0.0033888386911186436
2964,SAHH,Defective AHCY causes HMAHCHD,0.0027455007412168315,0,0,1,0.0029974112913567384
2965,SAHH,Defective AHCY causes HMAHCHD,0.003104031523855091,1,0,1,0.0033888386911186436
2966,PRTN3,Other interleukin signaling,0.0028913445082072967,0,0,1,0.0031566368007104424
2967,PRTN3,Other interleukin signaling,0.0031327660919468776,1,0,1,0.0034202097694642306
2968,PRTN3,Common Pathway of Fibrin Clot Formation,0.0028913445082072967,0,0,1,0.0031566368007104424
2969,PRTN3,Common Pathway of Fibrin Clot Formation,0.0031327660919468776,1,0,1,0.0034202097694642306
2970,PRTN3,Neutrophil degranulation,0.0028913445082072967,0,0,1,0.0031566368007104424
2971,PRTN3,Neutrophil degranulation,0.0031327660919468776,1,0,1,0.0034202097694642306
2972,ALAT1,Alanine metabolism,0.0002722837839959317,0,0,1,0.00029726689792879867
2973,ALAT1,Alanine metabolism,1.8004191355116583e-05,1,0,1,1.965614710985494e-05
2974,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00022685862736556935,0,0,1,0.0002476738035429818
2975,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00010066057949341041,1,0,1,0.00010989658572604694
2976,THIL,Utilization of Ketone Bodies,8.098962705170272e-05,0,0,1,8.842074560866873e-05
2977,THIL,Utilization of Ketone Bodies,0.0002785357318302678,1,0,1,0.0003040924867003779
2978,THIL,Synthesis of Ketone Bodies,8.098962705170272e-05,0,0,1,8.842074560866873e-05
2979,THIL,Synthesis of Ketone Bodies,0.0002785357318302678,1,0,1,0.0003040924867003779
2980,THIL,Branched-chain amino acid catabolism,8.098962705170272e-05,0,0,1,8.842074560866873e-05
2981,THIL,Branched-chain amino acid catabolism,0.0002785357318302678,1,0,1,0.0003040924867003779
2982,TENA,Integrin cell surface interactions,0.0006470368983676326,0,0,1,0.0007064050925121981
2983,TENA,Integrin cell surface interactions,0.0008828007903595356,1,0,1,0.0009638012539270127
2984,TENA,ECM proteoglycans,0.0006470368983676326,0,0,1,0.0007064050925121981
2985,TENA,ECM proteoglycans,0.0008828007903595356,1,0,1,0.0009638012539270127
2986,TENA,Syndecan interactions,0.0006470368983676326,0,0,1,0.0007064050925121981
2987,TENA,Syndecan interactions,0.0008828007903595356,1,0,1,0.0009638012539270127
2988,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006470368983676326,0,0,1,0.0007064050925121981
2989,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0008828007903595356,1,0,1,0.0009638012539270127
2990,TENA,Post-translational protein phosphorylation,0.0006470368983676326,0,0,1,0.0007064050925121981
2991,TENA,Post-translational protein phosphorylation,0.0008828007903595356,1,0,1,0.0009638012539270127
2992,ZA2G,Miscellaneous transport and binding events,0.0016867159368667685,0,0,1,0.001841478794223542
2993,ZA2G,Miscellaneous transport and binding events,0.00018170978335565728,1,0,1,0.00019838237455322485
2994,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.006761684667479795,0,0,1,0.007382095974927657
2995,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.008674930293008988,1,0,1,0.009470889452564229
2996,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.006761684667479795,0,0,1,0.007382095974927657
2997,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.008674930293008988,1,0,1,0.009470889452564229
2998,PSA1,Antigen processing-Cross presentation,0.006761684667479795,0,0,1,0.007382095974927657
2999,PSA1,Antigen processing-Cross presentation,0.008674930293008988,1,0,1,0.009470889452564229
3000,PSA1,PTEN Regulation,0.006761684667479795,0,0,1,0.007382095974927657
3001,PSA1,PTEN Regulation,0.008674930293008988,1,0,1,0.009470889452564229
3002,PSA1,Host Interactions of HIV factors,0.006761684667479795,0,0,1,0.007382095974927657
3003,PSA1,Host Interactions of HIV factors,0.008674930293008988,1,0,1,0.009470889452564229
3004,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.006761684667479795,0,0,1,0.007382095974927657
3005,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.008674930293008988,1,0,1,0.009470889452564229
3006,PSA1,APC/C-mediated degradation of cell cycle proteins,0.006761684667479795,0,0,1,0.007382095974927657
3007,PSA1,APC/C-mediated degradation of cell cycle proteins,0.008674930293008988,1,0,1,0.009470889452564229
3008,PSA1,Degradation of AXIN,0.006761684667479795,0,0,1,0.007382095974927657
3009,PSA1,Degradation of AXIN,0.008674930293008988,1,0,1,0.009470889452564229
3010,PSA1,Degradation of DVL,0.006761684667479795,0,0,1,0.007382095974927657
3011,PSA1,Degradation of DVL,0.008674930293008988,1,0,1,0.009470889452564229
3012,PSA1,Downstream TCR signaling,0.006761684667479795,0,0,1,0.007382095974927657
3013,PSA1,Downstream TCR signaling,0.008674930293008988,1,0,1,0.009470889452564229
3014,PSA1,Transcriptional regulation by RUNX3,0.006761684667479795,0,0,1,0.007382095974927657
3015,PSA1,Transcriptional regulation by RUNX3,0.008674930293008988,1,0,1,0.009470889452564229
3016,PSA1,Transcriptional regulation by RUNX2,0.006761684667479795,0,0,1,0.007382095974927657
3017,PSA1,Transcriptional regulation by RUNX2,0.008674930293008988,1,0,1,0.009470889452564229
3018,PSA1,Transcriptional regulation by RUNX1,0.006761684667479795,0,0,1,0.007382095974927657
3019,PSA1,Transcriptional regulation by RUNX1,0.008674930293008988,1,0,1,0.009470889452564229
3020,PSA1,FCERI mediated NF-kB activation,0.006761684667479795,0,0,1,0.007382095974927657
3021,PSA1,FCERI mediated NF-kB activation,0.008674930293008988,1,0,1,0.009470889452564229
3022,PSA1,Mitotic Metaphase and Anaphase,0.006761684667479795,0,0,1,0.007382095974927657
3023,PSA1,Mitotic Metaphase and Anaphase,0.008674930293008988,1,0,1,0.009470889452564229
3024,PSA1,Regulation of ornithine decarboxylase (ODC),0.006761684667479795,0,0,1,0.007382095974927657
3025,PSA1,Regulation of ornithine decarboxylase (ODC),0.008674930293008988,1,0,1,0.009470889452564229
3026,PSA1,Signaling by ROBO receptors,0.006761684667479795,0,0,1,0.007382095974927657
3027,PSA1,Signaling by ROBO receptors,0.008674930293008988,1,0,1,0.009470889452564229
3028,PSA1,PCP/CE pathway,0.006761684667479795,0,0,1,0.007382095974927657
3029,PSA1,PCP/CE pathway,0.008674930293008988,1,0,1,0.009470889452564229
3030,PSA1,Interleukin-1 family signaling,0.006761684667479795,0,0,1,0.007382095974927657
3031,PSA1,Interleukin-1 family signaling,0.008674930293008988,1,0,1,0.009470889452564229
3032,PSA1,G2/M Transition,0.006761684667479795,0,0,1,0.007382095974927657
3033,PSA1,G2/M Transition,0.008674930293008988,1,0,1,0.009470889452564229
3034,PSA1,G1/S Transition,0.006761684667479795,0,0,1,0.007382095974927657
3035,PSA1,G1/S Transition,0.008674930293008988,1,0,1,0.009470889452564229
3036,PSA1,Hh mutants are degraded by ERAD,0.006761684667479795,0,0,1,0.007382095974927657
3037,PSA1,Hh mutants are degraded by ERAD,0.008674930293008988,1,0,1,0.009470889452564229
3038,PSA1,CLEC7A (Dectin-1) signaling,0.006761684667479795,0,0,1,0.007382095974927657
3039,PSA1,CLEC7A (Dectin-1) signaling,0.008674930293008988,1,0,1,0.009470889452564229
3040,PSA1,Degradation of GLI1 by the proteasome,0.006761684667479795,0,0,1,0.007382095974927657
3041,PSA1,Degradation of GLI1 by the proteasome,0.008674930293008988,1,0,1,0.009470889452564229
3042,PSA1,Degradation of GLI2 by the proteasome,0.006761684667479795,0,0,1,0.007382095974927657
3043,PSA1,Degradation of GLI2 by the proteasome,0.008674930293008988,1,0,1,0.009470889452564229
3044,PSA1,GLI3 is processed to GLI3R by the proteasome,0.006761684667479795,0,0,1,0.007382095974927657
3045,PSA1,GLI3 is processed to GLI3R by the proteasome,0.008674930293008988,1,0,1,0.009470889452564229
3046,PSA1,Defective CFTR causes cystic fibrosis,0.006761684667479795,0,0,1,0.007382095974927657
3047,PSA1,Defective CFTR causes cystic fibrosis,0.008674930293008988,1,0,1,0.009470889452564229
3048,PSA1,NIK-->noncanonical NF-kB signaling,0.006761684667479795,0,0,1,0.007382095974927657
3049,PSA1,NIK-->noncanonical NF-kB signaling,0.008674930293008988,1,0,1,0.009470889452564229
3050,PSA1,RAF/MAP kinase cascade,0.006761684667479795,0,0,1,0.007382095974927657
3051,PSA1,RAF/MAP kinase cascade,0.008674930293008988,1,0,1,0.009470889452564229
3052,PSA1,UCH proteinases,0.006761684667479795,0,0,1,0.007382095974927657
3053,PSA1,UCH proteinases,0.008674930293008988,1,0,1,0.009470889452564229
3054,PSA1,Ub-specific processing proteases,0.006761684667479795,0,0,1,0.007382095974927657
3055,PSA1,Ub-specific processing proteases,0.008674930293008988,1,0,1,0.009470889452564229
3056,PSA1,Orc1 removal from chromatin,0.006761684667479795,0,0,1,0.007382095974927657
3057,PSA1,Orc1 removal from chromatin,0.008674930293008988,1,0,1,0.009470889452564229
3058,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.006761684667479795,0,0,1,0.007382095974927657
3059,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.008674930293008988,1,0,1,0.009470889452564229
3060,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.006761684667479795,0,0,1,0.007382095974927657
3061,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.008674930293008988,1,0,1,0.009470889452564229
3062,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.006761684667479795,0,0,1,0.007382095974927657
3063,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.008674930293008988,1,0,1,0.009470889452564229
3064,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.006761684667479795,0,0,1,0.007382095974927657
3065,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.008674930293008988,1,0,1,0.009470889452564229
3066,PSA1,p53-Independent G1/S DNA damage checkpoint,0.006761684667479795,0,0,1,0.007382095974927657
3067,PSA1,p53-Independent G1/S DNA damage checkpoint,0.008674930293008988,1,0,1,0.009470889452564229
3068,PSA1,Negative regulation of NOTCH4 signaling,0.006761684667479795,0,0,1,0.007382095974927657
3069,PSA1,Negative regulation of NOTCH4 signaling,0.008674930293008988,1,0,1,0.009470889452564229
3070,PSA1,KEAP1-NFE2L2 pathway,0.006761684667479795,0,0,1,0.007382095974927657
3071,PSA1,KEAP1-NFE2L2 pathway,0.008674930293008988,1,0,1,0.009470889452564229
3072,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.006761684667479795,0,0,1,0.007382095974927657
3073,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.008674930293008988,1,0,1,0.009470889452564229
3074,PSA1,Degradation of beta-catenin by the destruction complex,0.006761684667479795,0,0,1,0.007382095974927657
3075,PSA1,Degradation of beta-catenin by the destruction complex,0.008674930293008988,1,0,1,0.009470889452564229
3076,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.006761684667479795,0,0,1,0.007382095974927657
3077,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.008674930293008988,1,0,1,0.009470889452564229
3078,PSA1,Hedgehog ligand biogenesis,0.006761684667479795,0,0,1,0.007382095974927657
3079,PSA1,Hedgehog ligand biogenesis,0.008674930293008988,1,0,1,0.009470889452564229
3080,PSA1,Hedgehog 'on' state,0.006761684667479795,0,0,1,0.007382095974927657
3081,PSA1,Hedgehog 'on' state,0.008674930293008988,1,0,1,0.009470889452564229
3082,PSA1,MAPK6/MAPK4 signaling,0.006761684667479795,0,0,1,0.007382095974927657
3083,PSA1,MAPK6/MAPK4 signaling,0.008674930293008988,1,0,1,0.009470889452564229
3084,PSA1,Neddylation,0.006761684667479795,0,0,1,0.007382095974927657
3085,PSA1,Neddylation,0.008674930293008988,1,0,1,0.009470889452564229
3086,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.00547790546253853,0,0,1,0.005980524951204514
3087,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.004729766414032748,1,0,1,0.005163741186468676
3088,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00547790546253853,0,0,1,0.005980524951204514
3089,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.004729766414032748,1,0,1,0.005163741186468676
3090,PSA3,Antigen processing-Cross presentation,0.00547790546253853,0,0,1,0.005980524951204514
3091,PSA3,Antigen processing-Cross presentation,0.004729766414032748,1,0,1,0.005163741186468676
3092,PSA3,PTEN Regulation,0.00547790546253853,0,0,1,0.005980524951204514
3093,PSA3,PTEN Regulation,0.004729766414032748,1,0,1,0.005163741186468676
3094,PSA3,Host Interactions of HIV factors,0.00547790546253853,0,0,1,0.005980524951204514
3095,PSA3,Host Interactions of HIV factors,0.004729766414032748,1,0,1,0.005163741186468676
3096,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00547790546253853,0,0,1,0.005980524951204514
3097,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.004729766414032748,1,0,1,0.005163741186468676
3098,PSA3,APC/C-mediated degradation of cell cycle proteins,0.00547790546253853,0,0,1,0.005980524951204514
3099,PSA3,APC/C-mediated degradation of cell cycle proteins,0.004729766414032748,1,0,1,0.005163741186468676
3100,PSA3,Degradation of AXIN,0.00547790546253853,0,0,1,0.005980524951204514
3101,PSA3,Degradation of AXIN,0.004729766414032748,1,0,1,0.005163741186468676
3102,PSA3,Degradation of DVL,0.00547790546253853,0,0,1,0.005980524951204514
3103,PSA3,Degradation of DVL,0.004729766414032748,1,0,1,0.005163741186468676
3104,PSA3,Downstream TCR signaling,0.00547790546253853,0,0,1,0.005980524951204514
3105,PSA3,Downstream TCR signaling,0.004729766414032748,1,0,1,0.005163741186468676
3106,PSA3,Transcriptional regulation by RUNX3,0.00547790546253853,0,0,1,0.005980524951204514
3107,PSA3,Transcriptional regulation by RUNX3,0.004729766414032748,1,0,1,0.005163741186468676
3108,PSA3,Transcriptional regulation by RUNX2,0.00547790546253853,0,0,1,0.005980524951204514
3109,PSA3,Transcriptional regulation by RUNX2,0.004729766414032748,1,0,1,0.005163741186468676
3110,PSA3,Transcriptional regulation by RUNX1,0.00547790546253853,0,0,1,0.005980524951204514
3111,PSA3,Transcriptional regulation by RUNX1,0.004729766414032748,1,0,1,0.005163741186468676
3112,PSA3,FCERI mediated NF-kB activation,0.00547790546253853,0,0,1,0.005980524951204514
3113,PSA3,FCERI mediated NF-kB activation,0.004729766414032748,1,0,1,0.005163741186468676
3114,PSA3,Mitotic Metaphase and Anaphase,0.00547790546253853,0,0,1,0.005980524951204514
3115,PSA3,Mitotic Metaphase and Anaphase,0.004729766414032748,1,0,1,0.005163741186468676
3116,PSA3,Regulation of ornithine decarboxylase (ODC),0.00547790546253853,0,0,1,0.005980524951204514
3117,PSA3,Regulation of ornithine decarboxylase (ODC),0.004729766414032748,1,0,1,0.005163741186468676
3118,PSA3,Signaling by ROBO receptors,0.00547790546253853,0,0,1,0.005980524951204514
3119,PSA3,Signaling by ROBO receptors,0.004729766414032748,1,0,1,0.005163741186468676
3120,PSA3,PCP/CE pathway,0.00547790546253853,0,0,1,0.005980524951204514
3121,PSA3,PCP/CE pathway,0.004729766414032748,1,0,1,0.005163741186468676
3122,PSA3,Interleukin-1 family signaling,0.00547790546253853,0,0,1,0.005980524951204514
3123,PSA3,Interleukin-1 family signaling,0.004729766414032748,1,0,1,0.005163741186468676
3124,PSA3,G2/M Transition,0.00547790546253853,0,0,1,0.005980524951204514
3125,PSA3,G2/M Transition,0.004729766414032748,1,0,1,0.005163741186468676
3126,PSA3,G1/S Transition,0.00547790546253853,0,0,1,0.005980524951204514
3127,PSA3,G1/S Transition,0.004729766414032748,1,0,1,0.005163741186468676
3128,PSA3,Hh mutants are degraded by ERAD,0.00547790546253853,0,0,1,0.005980524951204514
3129,PSA3,Hh mutants are degraded by ERAD,0.004729766414032748,1,0,1,0.005163741186468676
3130,PSA3,CLEC7A (Dectin-1) signaling,0.00547790546253853,0,0,1,0.005980524951204514
3131,PSA3,CLEC7A (Dectin-1) signaling,0.004729766414032748,1,0,1,0.005163741186468676
3132,PSA3,Degradation of GLI1 by the proteasome,0.00547790546253853,0,0,1,0.005980524951204514
3133,PSA3,Degradation of GLI1 by the proteasome,0.004729766414032748,1,0,1,0.005163741186468676
3134,PSA3,Degradation of GLI2 by the proteasome,0.00547790546253853,0,0,1,0.005980524951204514
3135,PSA3,Degradation of GLI2 by the proteasome,0.004729766414032748,1,0,1,0.005163741186468676
3136,PSA3,GLI3 is processed to GLI3R by the proteasome,0.00547790546253853,0,0,1,0.005980524951204514
3137,PSA3,GLI3 is processed to GLI3R by the proteasome,0.004729766414032748,1,0,1,0.005163741186468676
3138,PSA3,Defective CFTR causes cystic fibrosis,0.00547790546253853,0,0,1,0.005980524951204514
3139,PSA3,Defective CFTR causes cystic fibrosis,0.004729766414032748,1,0,1,0.005163741186468676
3140,PSA3,NIK-->noncanonical NF-kB signaling,0.00547790546253853,0,0,1,0.005980524951204514
3141,PSA3,NIK-->noncanonical NF-kB signaling,0.004729766414032748,1,0,1,0.005163741186468676
3142,PSA3,RAF/MAP kinase cascade,0.00547790546253853,0,0,1,0.005980524951204514
3143,PSA3,RAF/MAP kinase cascade,0.004729766414032748,1,0,1,0.005163741186468676
3144,PSA3,UCH proteinases,0.00547790546253853,0,0,1,0.005980524951204514
3145,PSA3,UCH proteinases,0.004729766414032748,1,0,1,0.005163741186468676
3146,PSA3,Ub-specific processing proteases,0.00547790546253853,0,0,1,0.005980524951204514
3147,PSA3,Ub-specific processing proteases,0.004729766414032748,1,0,1,0.005163741186468676
3148,PSA3,Orc1 removal from chromatin,0.00547790546253853,0,0,1,0.005980524951204514
3149,PSA3,Orc1 removal from chromatin,0.004729766414032748,1,0,1,0.005163741186468676
3150,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.00547790546253853,0,0,1,0.005980524951204514
3151,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.004729766414032748,1,0,1,0.005163741186468676
3152,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.00547790546253853,0,0,1,0.005980524951204514
3153,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.004729766414032748,1,0,1,0.005163741186468676
3154,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.00547790546253853,0,0,1,0.005980524951204514
3155,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.004729766414032748,1,0,1,0.005163741186468676
3156,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.00547790546253853,0,0,1,0.005980524951204514
3157,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.004729766414032748,1,0,1,0.005163741186468676
3158,PSA3,p53-Independent G1/S DNA damage checkpoint,0.00547790546253853,0,0,1,0.005980524951204514
3159,PSA3,p53-Independent G1/S DNA damage checkpoint,0.004729766414032748,1,0,1,0.005163741186468676
3160,PSA3,Negative regulation of NOTCH4 signaling,0.00547790546253853,0,0,1,0.005980524951204514
3161,PSA3,Negative regulation of NOTCH4 signaling,0.004729766414032748,1,0,1,0.005163741186468676
3162,PSA3,KEAP1-NFE2L2 pathway,0.00547790546253853,0,0,1,0.005980524951204514
3163,PSA3,KEAP1-NFE2L2 pathway,0.004729766414032748,1,0,1,0.005163741186468676
3164,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.00547790546253853,0,0,1,0.005980524951204514
3165,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.004729766414032748,1,0,1,0.005163741186468676
3166,PSA3,Degradation of beta-catenin by the destruction complex,0.00547790546253853,0,0,1,0.005980524951204514
3167,PSA3,Degradation of beta-catenin by the destruction complex,0.004729766414032748,1,0,1,0.005163741186468676
3168,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00547790546253853,0,0,1,0.005980524951204514
3169,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.004729766414032748,1,0,1,0.005163741186468676
3170,PSA3,Hedgehog ligand biogenesis,0.00547790546253853,0,0,1,0.005980524951204514
3171,PSA3,Hedgehog ligand biogenesis,0.004729766414032748,1,0,1,0.005163741186468676
3172,PSA3,Hedgehog 'on' state,0.00547790546253853,0,0,1,0.005980524951204514
3173,PSA3,Hedgehog 'on' state,0.004729766414032748,1,0,1,0.005163741186468676
3174,PSA3,MAPK6/MAPK4 signaling,0.00547790546253853,0,0,1,0.005980524951204514
3175,PSA3,MAPK6/MAPK4 signaling,0.004729766414032748,1,0,1,0.005163741186468676
3176,PSA3,Neddylation,0.00547790546253853,0,0,1,0.005980524951204514
3177,PSA3,Neddylation,0.004729766414032748,1,0,1,0.005163741186468676
3178,PTX3,Neutrophil degranulation,0.00038563925957574324,0,0,1,0.0004210231866593745
3179,PTX3,Neutrophil degranulation,0.000391305182504392,1,0,1,0.0004272089804227234
3180,HGFL,Signaling by MST1,0.0006792124820099231,0,0,1,0.0007415329131926071
3181,HGFL,Signaling by MST1,0.00037158627008715585,1,0,1,0.00040568077981240335
3182,STOM,RHO GTPase cycle,0.0006925458316620307,0,0,1,0.0007560896504022724
3183,STOM,RHO GTPase cycle,0.0010657135134522666,1,0,1,0.0011634969426952352
3184,STOM,Neutrophil degranulation,0.0006925458316620307,0,0,1,0.0007560896504022724
3185,STOM,Neutrophil degranulation,0.0010657135134522666,1,0,1,0.0011634969426952352
3186,STOM,Stimuli-sensing channels,0.0006925458316620307,0,0,1,0.0007560896504022724
3187,STOM,Stimuli-sensing channels,0.0010657135134522666,1,0,1,0.0011634969426952352
3188,PON1,Arachidonic acid metabolism,0.008757774763334688,0,0,1,0.009561335230652297
3189,PON1,Arachidonic acid metabolism,0.01530955119255273,1,0,1,0.016714263056371692
3190,PON1,Atorvastatin ADME,0.008757774763334688,0,0,1,0.009561335230652297
3191,PON1,Atorvastatin ADME,0.01530955119255273,1,0,1,0.016714263056371692
3192,1433T,Activation of BH3-only proteins,0.00012116968561878052,0,0,1,0.00013228748344205776
3193,1433T,Activation of BH3-only proteins,0.0002567446324193495,1,0,1,0.00028030196774520385
3194,1433T,RHO GTPase Effectors,0.00012116968561878052,0,0,1,0.00013228748344205776
3195,1433T,RHO GTPase Effectors,0.0002567446324193495,1,0,1,0.00028030196774520385
3196,1433T,Transcriptional Regulation by TP53,0.00012116968561878052,0,0,1,0.00013228748344205776
3197,1433T,Transcriptional Regulation by TP53,0.0002567446324193495,1,0,1,0.00028030196774520385
3198,1433T,FOXO-mediated transcription,0.00012116968561878052,0,0,1,0.00013228748344205776
3199,1433T,FOXO-mediated transcription,0.0002567446324193495,1,0,1,0.00028030196774520385
3200,1433T,G2/M DNA damage checkpoint,0.00012116968561878052,0,0,1,0.00013228748344205776
3201,1433T,G2/M DNA damage checkpoint,0.0002567446324193495,1,0,1,0.00028030196774520385
3202,1433T,SARS-CoV-2 Infection,0.00012116968561878052,0,0,1,0.00013228748344205776
3203,1433T,SARS-CoV-2 Infection,0.0002567446324193495,1,0,1,0.00028030196774520385
3204,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00012116968561878052,0,0,1,0.00013228748344205776
3205,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0002567446324193495,1,0,1,0.00028030196774520385
3206,CALR,Antigen processing-Cross presentation,0.035930789529634306,0,0,1,0.039227581557947415
3207,CALR,Antigen processing-Cross presentation,0.03616380171736863,1,0,1,0.03948197353535736
3208,CALR,Virus Assembly and Release,0.035930789529634306,0,0,1,0.039227581557947415
3209,CALR,Virus Assembly and Release,0.03616380171736863,1,0,1,0.03948197353535736
3210,CALR,ATF6 (ATF6-alpha) activates chaperones,0.035930789529634306,0,0,1,0.039227581557947415
3211,CALR,ATF6 (ATF6-alpha) activates chaperones,0.03616380171736863,1,0,1,0.03948197353535736
3212,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.035930789529634306,0,0,1,0.039227581557947415
3213,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.03616380171736863,1,0,1,0.03948197353535736
3214,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.035930789529634306,0,0,1,0.039227581557947415
3215,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.03616380171736863,1,0,1,0.03948197353535736
3216,CALR,Scavenging by Class A Receptors,0.035930789529634306,0,0,1,0.039227581557947415
3217,CALR,Scavenging by Class A Receptors,0.03616380171736863,1,0,1,0.03948197353535736
3218,CALR,Scavenging by Class F Receptors,0.035930789529634306,0,0,1,0.039227581557947415
3219,CALR,Scavenging by Class F Receptors,0.03616380171736863,1,0,1,0.03948197353535736
3220,PROP,Initial triggering of complement,0.0034190316706408895,0,0,1,0.003732741347045923
3221,PROP,Initial triggering of complement,0.003859238954743522,1,0,1,0.004213339390272788
3222,PROP,Activation of C3 and C5,0.0034190316706408895,0,0,1,0.003732741347045923
3223,PROP,Activation of C3 and C5,0.003859238954743522,1,0,1,0.004213339390272788
3224,PROP,Regulation of Complement cascade,0.0034190316706408895,0,0,1,0.003732741347045923
3225,PROP,Regulation of Complement cascade,0.003859238954743522,1,0,1,0.004213339390272788
3226,PROP,Diseases associated with O-glycosylation of proteins,0.0034190316706408895,0,0,1,0.003732741347045923
3227,PROP,Diseases associated with O-glycosylation of proteins,0.003859238954743522,1,0,1,0.004213339390272788
3228,PROP,O-glycosylation of TSR domain-containing proteins,0.0034190316706408895,0,0,1,0.003732741347045923
3229,PROP,O-glycosylation of TSR domain-containing proteins,0.003859238954743522,1,0,1,0.004213339390272788
3230,PROP,Neutrophil degranulation,0.0034190316706408895,0,0,1,0.003732741347045923
3231,PROP,Neutrophil degranulation,0.003859238954743522,1,0,1,0.004213339390272788
3232,IL1R2,Interleukin-1 family signaling,0.00010648677159833581,0,0,1,0.00011625735399638325
3233,IL1R2,Interleukin-1 family signaling,4.4470414105792306e-05,1,0,1,4.8550750459070633e-05
3234,IL1R2,Interleukin-10 signaling,0.00010648677159833581,0,0,1,0.00011625735399638325
3235,IL1R2,Interleukin-10 signaling,4.4470414105792306e-05,1,0,1,4.8550750459070633e-05
3236,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.0008542250746239024,0,0,1,0.0009326036032694409
3237,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.0019102408537383518,1,0,1,0.002085513006151495
3238,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0008542250746239024,0,0,1,0.0009326036032694409
3239,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0019102408537383518,1,0,1,0.002085513006151495
3240,PSA5,Antigen processing-Cross presentation,0.0008542250746239024,0,0,1,0.0009326036032694409
3241,PSA5,Antigen processing-Cross presentation,0.0019102408537383518,1,0,1,0.002085513006151495
3242,PSA5,PTEN Regulation,0.0008542250746239024,0,0,1,0.0009326036032694409
3243,PSA5,PTEN Regulation,0.0019102408537383518,1,0,1,0.002085513006151495
3244,PSA5,Host Interactions of HIV factors,0.0008542250746239024,0,0,1,0.0009326036032694409
3245,PSA5,Host Interactions of HIV factors,0.0019102408537383518,1,0,1,0.002085513006151495
3246,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0008542250746239024,0,0,1,0.0009326036032694409
3247,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0019102408537383518,1,0,1,0.002085513006151495
3248,PSA5,APC/C-mediated degradation of cell cycle proteins,0.0008542250746239024,0,0,1,0.0009326036032694409
3249,PSA5,APC/C-mediated degradation of cell cycle proteins,0.0019102408537383518,1,0,1,0.002085513006151495
3250,PSA5,Degradation of AXIN,0.0008542250746239024,0,0,1,0.0009326036032694409
3251,PSA5,Degradation of AXIN,0.0019102408537383518,1,0,1,0.002085513006151495
3252,PSA5,Degradation of DVL,0.0008542250746239024,0,0,1,0.0009326036032694409
3253,PSA5,Degradation of DVL,0.0019102408537383518,1,0,1,0.002085513006151495
3254,PSA5,Downstream TCR signaling,0.0008542250746239024,0,0,1,0.0009326036032694409
3255,PSA5,Downstream TCR signaling,0.0019102408537383518,1,0,1,0.002085513006151495
3256,PSA5,Transcriptional regulation by RUNX3,0.0008542250746239024,0,0,1,0.0009326036032694409
3257,PSA5,Transcriptional regulation by RUNX3,0.0019102408537383518,1,0,1,0.002085513006151495
3258,PSA5,Transcriptional regulation by RUNX2,0.0008542250746239024,0,0,1,0.0009326036032694409
3259,PSA5,Transcriptional regulation by RUNX2,0.0019102408537383518,1,0,1,0.002085513006151495
3260,PSA5,Transcriptional regulation by RUNX1,0.0008542250746239024,0,0,1,0.0009326036032694409
3261,PSA5,Transcriptional regulation by RUNX1,0.0019102408537383518,1,0,1,0.002085513006151495
3262,PSA5,FCERI mediated NF-kB activation,0.0008542250746239024,0,0,1,0.0009326036032694409
3263,PSA5,FCERI mediated NF-kB activation,0.0019102408537383518,1,0,1,0.002085513006151495
3264,PSA5,Mitotic Metaphase and Anaphase,0.0008542250746239024,0,0,1,0.0009326036032694409
3265,PSA5,Mitotic Metaphase and Anaphase,0.0019102408537383518,1,0,1,0.002085513006151495
3266,PSA5,Regulation of ornithine decarboxylase (ODC),0.0008542250746239024,0,0,1,0.0009326036032694409
3267,PSA5,Regulation of ornithine decarboxylase (ODC),0.0019102408537383518,1,0,1,0.002085513006151495
3268,PSA5,Signaling by ROBO receptors,0.0008542250746239024,0,0,1,0.0009326036032694409
3269,PSA5,Signaling by ROBO receptors,0.0019102408537383518,1,0,1,0.002085513006151495
3270,PSA5,PCP/CE pathway,0.0008542250746239024,0,0,1,0.0009326036032694409
3271,PSA5,PCP/CE pathway,0.0019102408537383518,1,0,1,0.002085513006151495
3272,PSA5,Interleukin-1 family signaling,0.0008542250746239024,0,0,1,0.0009326036032694409
3273,PSA5,Interleukin-1 family signaling,0.0019102408537383518,1,0,1,0.002085513006151495
3274,PSA5,G2/M Transition,0.0008542250746239024,0,0,1,0.0009326036032694409
3275,PSA5,G2/M Transition,0.0019102408537383518,1,0,1,0.002085513006151495
3276,PSA5,G1/S Transition,0.0008542250746239024,0,0,1,0.0009326036032694409
3277,PSA5,G1/S Transition,0.0019102408537383518,1,0,1,0.002085513006151495
3278,PSA5,Hh mutants are degraded by ERAD,0.0008542250746239024,0,0,1,0.0009326036032694409
3279,PSA5,Hh mutants are degraded by ERAD,0.0019102408537383518,1,0,1,0.002085513006151495
3280,PSA5,CLEC7A (Dectin-1) signaling,0.0008542250746239024,0,0,1,0.0009326036032694409
3281,PSA5,CLEC7A (Dectin-1) signaling,0.0019102408537383518,1,0,1,0.002085513006151495
3282,PSA5,Degradation of GLI1 by the proteasome,0.0008542250746239024,0,0,1,0.0009326036032694409
3283,PSA5,Degradation of GLI1 by the proteasome,0.0019102408537383518,1,0,1,0.002085513006151495
3284,PSA5,Degradation of GLI2 by the proteasome,0.0008542250746239024,0,0,1,0.0009326036032694409
3285,PSA5,Degradation of GLI2 by the proteasome,0.0019102408537383518,1,0,1,0.002085513006151495
3286,PSA5,GLI3 is processed to GLI3R by the proteasome,0.0008542250746239024,0,0,1,0.0009326036032694409
3287,PSA5,GLI3 is processed to GLI3R by the proteasome,0.0019102408537383518,1,0,1,0.002085513006151495
3288,PSA5,Defective CFTR causes cystic fibrosis,0.0008542250746239024,0,0,1,0.0009326036032694409
3289,PSA5,Defective CFTR causes cystic fibrosis,0.0019102408537383518,1,0,1,0.002085513006151495
3290,PSA5,NIK-->noncanonical NF-kB signaling,0.0008542250746239024,0,0,1,0.0009326036032694409
3291,PSA5,NIK-->noncanonical NF-kB signaling,0.0019102408537383518,1,0,1,0.002085513006151495
3292,PSA5,RAF/MAP kinase cascade,0.0008542250746239024,0,0,1,0.0009326036032694409
3293,PSA5,RAF/MAP kinase cascade,0.0019102408537383518,1,0,1,0.002085513006151495
3294,PSA5,UCH proteinases,0.0008542250746239024,0,0,1,0.0009326036032694409
3295,PSA5,UCH proteinases,0.0019102408537383518,1,0,1,0.002085513006151495
3296,PSA5,Ub-specific processing proteases,0.0008542250746239024,0,0,1,0.0009326036032694409
3297,PSA5,Ub-specific processing proteases,0.0019102408537383518,1,0,1,0.002085513006151495
3298,PSA5,Orc1 removal from chromatin,0.0008542250746239024,0,0,1,0.0009326036032694409
3299,PSA5,Orc1 removal from chromatin,0.0019102408537383518,1,0,1,0.002085513006151495
3300,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.0008542250746239024,0,0,1,0.0009326036032694409
3301,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.0019102408537383518,1,0,1,0.002085513006151495
3302,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.0008542250746239024,0,0,1,0.0009326036032694409
3303,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.0019102408537383518,1,0,1,0.002085513006151495
3304,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.0008542250746239024,0,0,1,0.0009326036032694409
3305,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.0019102408537383518,1,0,1,0.002085513006151495
3306,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.0008542250746239024,0,0,1,0.0009326036032694409
3307,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.0019102408537383518,1,0,1,0.002085513006151495
3308,PSA5,p53-Independent G1/S DNA damage checkpoint,0.0008542250746239024,0,0,1,0.0009326036032694409
3309,PSA5,p53-Independent G1/S DNA damage checkpoint,0.0019102408537383518,1,0,1,0.002085513006151495
3310,PSA5,Negative regulation of NOTCH4 signaling,0.0008542250746239024,0,0,1,0.0009326036032694409
3311,PSA5,Negative regulation of NOTCH4 signaling,0.0019102408537383518,1,0,1,0.002085513006151495
3312,PSA5,KEAP1-NFE2L2 pathway,0.0008542250746239024,0,0,1,0.0009326036032694409
3313,PSA5,KEAP1-NFE2L2 pathway,0.0019102408537383518,1,0,1,0.002085513006151495
3314,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.0008542250746239024,0,0,1,0.0009326036032694409
3315,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.0019102408537383518,1,0,1,0.002085513006151495
3316,PSA5,Neutrophil degranulation,0.0008542250746239024,0,0,1,0.0009326036032694409
3317,PSA5,Neutrophil degranulation,0.0019102408537383518,1,0,1,0.002085513006151495
3318,PSA5,Degradation of beta-catenin by the destruction complex,0.0008542250746239024,0,0,1,0.0009326036032694409
3319,PSA5,Degradation of beta-catenin by the destruction complex,0.0019102408537383518,1,0,1,0.002085513006151495
3320,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0008542250746239024,0,0,1,0.0009326036032694409
3321,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0019102408537383518,1,0,1,0.002085513006151495
3322,PSA5,Hedgehog ligand biogenesis,0.0008542250746239024,0,0,1,0.0009326036032694409
3323,PSA5,Hedgehog ligand biogenesis,0.0019102408537383518,1,0,1,0.002085513006151495
3324,PSA5,Hedgehog 'on' state,0.0008542250746239024,0,0,1,0.0009326036032694409
3325,PSA5,Hedgehog 'on' state,0.0019102408537383518,1,0,1,0.002085513006151495
3326,PSA5,MAPK6/MAPK4 signaling,0.0008542250746239024,0,0,1,0.0009326036032694409
3327,PSA5,MAPK6/MAPK4 signaling,0.0019102408537383518,1,0,1,0.002085513006151495
3328,PSA5,Neddylation,0.0008542250746239024,0,0,1,0.0009326036032694409
3329,PSA5,Neddylation,0.0019102408537383518,1,0,1,0.002085513006151495
3330,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.00440060656557928,0,0,1,0.004804379620250917
3331,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.0073014902350431315,1,0,1,0.007971430837985993
3332,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00440060656557928,0,0,1,0.004804379620250917
3333,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0073014902350431315,1,0,1,0.007971430837985993
3334,PSB6,Antigen processing-Cross presentation,0.00440060656557928,0,0,1,0.004804379620250917
3335,PSB6,Antigen processing-Cross presentation,0.0073014902350431315,1,0,1,0.007971430837985993
3336,PSB6,PTEN Regulation,0.00440060656557928,0,0,1,0.004804379620250917
3337,PSB6,PTEN Regulation,0.0073014902350431315,1,0,1,0.007971430837985993
3338,PSB6,Host Interactions of HIV factors,0.00440060656557928,0,0,1,0.004804379620250917
3339,PSB6,Host Interactions of HIV factors,0.0073014902350431315,1,0,1,0.007971430837985993
3340,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00440060656557928,0,0,1,0.004804379620250917
3341,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0073014902350431315,1,0,1,0.007971430837985993
3342,PSB6,APC/C-mediated degradation of cell cycle proteins,0.00440060656557928,0,0,1,0.004804379620250917
3343,PSB6,APC/C-mediated degradation of cell cycle proteins,0.0073014902350431315,1,0,1,0.007971430837985993
3344,PSB6,Degradation of AXIN,0.00440060656557928,0,0,1,0.004804379620250917
3345,PSB6,Degradation of AXIN,0.0073014902350431315,1,0,1,0.007971430837985993
3346,PSB6,Degradation of DVL,0.00440060656557928,0,0,1,0.004804379620250917
3347,PSB6,Degradation of DVL,0.0073014902350431315,1,0,1,0.007971430837985993
3348,PSB6,Downstream TCR signaling,0.00440060656557928,0,0,1,0.004804379620250917
3349,PSB6,Downstream TCR signaling,0.0073014902350431315,1,0,1,0.007971430837985993
3350,PSB6,Transcriptional regulation by RUNX3,0.00440060656557928,0,0,1,0.004804379620250917
3351,PSB6,Transcriptional regulation by RUNX3,0.0073014902350431315,1,0,1,0.007971430837985993
3352,PSB6,Transcriptional regulation by RUNX2,0.00440060656557928,0,0,1,0.004804379620250917
3353,PSB6,Transcriptional regulation by RUNX2,0.0073014902350431315,1,0,1,0.007971430837985993
3354,PSB6,Transcriptional regulation by RUNX1,0.00440060656557928,0,0,1,0.004804379620250917
3355,PSB6,Transcriptional regulation by RUNX1,0.0073014902350431315,1,0,1,0.007971430837985993
3356,PSB6,FCERI mediated NF-kB activation,0.00440060656557928,0,0,1,0.004804379620250917
3357,PSB6,FCERI mediated NF-kB activation,0.0073014902350431315,1,0,1,0.007971430837985993
3358,PSB6,Mitotic Metaphase and Anaphase,0.00440060656557928,0,0,1,0.004804379620250917
3359,PSB6,Mitotic Metaphase and Anaphase,0.0073014902350431315,1,0,1,0.007971430837985993
3360,PSB6,Regulation of ornithine decarboxylase (ODC),0.00440060656557928,0,0,1,0.004804379620250917
3361,PSB6,Regulation of ornithine decarboxylase (ODC),0.0073014902350431315,1,0,1,0.007971430837985993
3362,PSB6,Signaling by ROBO receptors,0.00440060656557928,0,0,1,0.004804379620250917
3363,PSB6,Signaling by ROBO receptors,0.0073014902350431315,1,0,1,0.007971430837985993
3364,PSB6,PCP/CE pathway,0.00440060656557928,0,0,1,0.004804379620250917
3365,PSB6,PCP/CE pathway,0.0073014902350431315,1,0,1,0.007971430837985993
3366,PSB6,Interleukin-1 family signaling,0.00440060656557928,0,0,1,0.004804379620250917
3367,PSB6,Interleukin-1 family signaling,0.0073014902350431315,1,0,1,0.007971430837985993
3368,PSB6,G2/M Transition,0.00440060656557928,0,0,1,0.004804379620250917
3369,PSB6,G2/M Transition,0.0073014902350431315,1,0,1,0.007971430837985993
3370,PSB6,G1/S Transition,0.00440060656557928,0,0,1,0.004804379620250917
3371,PSB6,G1/S Transition,0.0073014902350431315,1,0,1,0.007971430837985993
3372,PSB6,Hh mutants are degraded by ERAD,0.00440060656557928,0,0,1,0.004804379620250917
3373,PSB6,Hh mutants are degraded by ERAD,0.0073014902350431315,1,0,1,0.007971430837985993
3374,PSB6,CLEC7A (Dectin-1) signaling,0.00440060656557928,0,0,1,0.004804379620250917
3375,PSB6,CLEC7A (Dectin-1) signaling,0.0073014902350431315,1,0,1,0.007971430837985993
3376,PSB6,Degradation of GLI1 by the proteasome,0.00440060656557928,0,0,1,0.004804379620250917
3377,PSB6,Degradation of GLI1 by the proteasome,0.0073014902350431315,1,0,1,0.007971430837985993
3378,PSB6,Degradation of GLI2 by the proteasome,0.00440060656557928,0,0,1,0.004804379620250917
3379,PSB6,Degradation of GLI2 by the proteasome,0.0073014902350431315,1,0,1,0.007971430837985993
3380,PSB6,GLI3 is processed to GLI3R by the proteasome,0.00440060656557928,0,0,1,0.004804379620250917
3381,PSB6,GLI3 is processed to GLI3R by the proteasome,0.0073014902350431315,1,0,1,0.007971430837985993
3382,PSB6,Defective CFTR causes cystic fibrosis,0.00440060656557928,0,0,1,0.004804379620250917
3383,PSB6,Defective CFTR causes cystic fibrosis,0.0073014902350431315,1,0,1,0.007971430837985993
3384,PSB6,NIK-->noncanonical NF-kB signaling,0.00440060656557928,0,0,1,0.004804379620250917
3385,PSB6,NIK-->noncanonical NF-kB signaling,0.0073014902350431315,1,0,1,0.007971430837985993
3386,PSB6,RAF/MAP kinase cascade,0.00440060656557928,0,0,1,0.004804379620250917
3387,PSB6,RAF/MAP kinase cascade,0.0073014902350431315,1,0,1,0.007971430837985993
3388,PSB6,UCH proteinases,0.00440060656557928,0,0,1,0.004804379620250917
3389,PSB6,UCH proteinases,0.0073014902350431315,1,0,1,0.007971430837985993
3390,PSB6,Ub-specific processing proteases,0.00440060656557928,0,0,1,0.004804379620250917
3391,PSB6,Ub-specific processing proteases,0.0073014902350431315,1,0,1,0.007971430837985993
3392,PSB6,Orc1 removal from chromatin,0.00440060656557928,0,0,1,0.004804379620250917
3393,PSB6,Orc1 removal from chromatin,0.0073014902350431315,1,0,1,0.007971430837985993
3394,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.00440060656557928,0,0,1,0.004804379620250917
3395,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.0073014902350431315,1,0,1,0.007971430837985993
3396,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.00440060656557928,0,0,1,0.004804379620250917
3397,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.0073014902350431315,1,0,1,0.007971430837985993
3398,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.00440060656557928,0,0,1,0.004804379620250917
3399,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.0073014902350431315,1,0,1,0.007971430837985993
3400,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.00440060656557928,0,0,1,0.004804379620250917
3401,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.0073014902350431315,1,0,1,0.007971430837985993
3402,PSB6,p53-Independent G1/S DNA damage checkpoint,0.00440060656557928,0,0,1,0.004804379620250917
3403,PSB6,p53-Independent G1/S DNA damage checkpoint,0.0073014902350431315,1,0,1,0.007971430837985993
3404,PSB6,Negative regulation of NOTCH4 signaling,0.00440060656557928,0,0,1,0.004804379620250917
3405,PSB6,Negative regulation of NOTCH4 signaling,0.0073014902350431315,1,0,1,0.007971430837985993
3406,PSB6,KEAP1-NFE2L2 pathway,0.00440060656557928,0,0,1,0.004804379620250917
3407,PSB6,KEAP1-NFE2L2 pathway,0.0073014902350431315,1,0,1,0.007971430837985993
3408,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.00440060656557928,0,0,1,0.004804379620250917
3409,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.0073014902350431315,1,0,1,0.007971430837985993
3410,PSB6,Degradation of beta-catenin by the destruction complex,0.00440060656557928,0,0,1,0.004804379620250917
3411,PSB6,Degradation of beta-catenin by the destruction complex,0.0073014902350431315,1,0,1,0.007971430837985993
3412,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00440060656557928,0,0,1,0.004804379620250917
3413,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0073014902350431315,1,0,1,0.007971430837985993
3414,PSB6,Hedgehog ligand biogenesis,0.00440060656557928,0,0,1,0.004804379620250917
3415,PSB6,Hedgehog ligand biogenesis,0.0073014902350431315,1,0,1,0.007971430837985993
3416,PSB6,Hedgehog 'on' state,0.00440060656557928,0,0,1,0.004804379620250917
3417,PSB6,Hedgehog 'on' state,0.0073014902350431315,1,0,1,0.007971430837985993
3418,PSB6,MAPK6/MAPK4 signaling,0.00440060656557928,0,0,1,0.004804379620250917
3419,PSB6,MAPK6/MAPK4 signaling,0.0073014902350431315,1,0,1,0.007971430837985993
3420,PSB6,Neddylation,0.00440060656557928,0,0,1,0.004804379620250917
3421,PSB6,Neddylation,0.0073014902350431315,1,0,1,0.007971430837985993
3422,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.008848487239964495,0,0,1,0.009660370935737048
3423,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.012036798014849198,1,0,1,0.013141221832451122
3424,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.008848487239964495,0,0,1,0.009660370935737048
3425,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.012036798014849198,1,0,1,0.013141221832451122
3426,PSB5,Antigen processing-Cross presentation,0.008848487239964495,0,0,1,0.009660370935737048
3427,PSB5,Antigen processing-Cross presentation,0.012036798014849198,1,0,1,0.013141221832451122
3428,PSB5,PTEN Regulation,0.008848487239964495,0,0,1,0.009660370935737048
3429,PSB5,PTEN Regulation,0.012036798014849198,1,0,1,0.013141221832451122
3430,PSB5,Host Interactions of HIV factors,0.008848487239964495,0,0,1,0.009660370935737048
3431,PSB5,Host Interactions of HIV factors,0.012036798014849198,1,0,1,0.013141221832451122
3432,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.008848487239964495,0,0,1,0.009660370935737048
3433,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.012036798014849198,1,0,1,0.013141221832451122
3434,PSB5,APC/C-mediated degradation of cell cycle proteins,0.008848487239964495,0,0,1,0.009660370935737048
3435,PSB5,APC/C-mediated degradation of cell cycle proteins,0.012036798014849198,1,0,1,0.013141221832451122
3436,PSB5,Degradation of AXIN,0.008848487239964495,0,0,1,0.009660370935737048
3437,PSB5,Degradation of AXIN,0.012036798014849198,1,0,1,0.013141221832451122
3438,PSB5,Degradation of DVL,0.008848487239964495,0,0,1,0.009660370935737048
3439,PSB5,Degradation of DVL,0.012036798014849198,1,0,1,0.013141221832451122
3440,PSB5,Downstream TCR signaling,0.008848487239964495,0,0,1,0.009660370935737048
3441,PSB5,Downstream TCR signaling,0.012036798014849198,1,0,1,0.013141221832451122
3442,PSB5,Transcriptional regulation by RUNX3,0.008848487239964495,0,0,1,0.009660370935737048
3443,PSB5,Transcriptional regulation by RUNX3,0.012036798014849198,1,0,1,0.013141221832451122
3444,PSB5,Transcriptional regulation by RUNX2,0.008848487239964495,0,0,1,0.009660370935737048
3445,PSB5,Transcriptional regulation by RUNX2,0.012036798014849198,1,0,1,0.013141221832451122
3446,PSB5,Transcriptional regulation by RUNX1,0.008848487239964495,0,0,1,0.009660370935737048
3447,PSB5,Transcriptional regulation by RUNX1,0.012036798014849198,1,0,1,0.013141221832451122
3448,PSB5,FCERI mediated NF-kB activation,0.008848487239964495,0,0,1,0.009660370935737048
3449,PSB5,FCERI mediated NF-kB activation,0.012036798014849198,1,0,1,0.013141221832451122
3450,PSB5,Mitotic Metaphase and Anaphase,0.008848487239964495,0,0,1,0.009660370935737048
3451,PSB5,Mitotic Metaphase and Anaphase,0.012036798014849198,1,0,1,0.013141221832451122
3452,PSB5,Regulation of ornithine decarboxylase (ODC),0.008848487239964495,0,0,1,0.009660370935737048
3453,PSB5,Regulation of ornithine decarboxylase (ODC),0.012036798014849198,1,0,1,0.013141221832451122
3454,PSB5,Signaling by ROBO receptors,0.008848487239964495,0,0,1,0.009660370935737048
3455,PSB5,Signaling by ROBO receptors,0.012036798014849198,1,0,1,0.013141221832451122
3456,PSB5,PCP/CE pathway,0.008848487239964495,0,0,1,0.009660370935737048
3457,PSB5,PCP/CE pathway,0.012036798014849198,1,0,1,0.013141221832451122
3458,PSB5,Interleukin-1 family signaling,0.008848487239964495,0,0,1,0.009660370935737048
3459,PSB5,Interleukin-1 family signaling,0.012036798014849198,1,0,1,0.013141221832451122
3460,PSB5,G2/M Transition,0.008848487239964495,0,0,1,0.009660370935737048
3461,PSB5,G2/M Transition,0.012036798014849198,1,0,1,0.013141221832451122
3462,PSB5,G1/S Transition,0.008848487239964495,0,0,1,0.009660370935737048
3463,PSB5,G1/S Transition,0.012036798014849198,1,0,1,0.013141221832451122
3464,PSB5,Hh mutants are degraded by ERAD,0.008848487239964495,0,0,1,0.009660370935737048
3465,PSB5,Hh mutants are degraded by ERAD,0.012036798014849198,1,0,1,0.013141221832451122
3466,PSB5,CLEC7A (Dectin-1) signaling,0.008848487239964495,0,0,1,0.009660370935737048
3467,PSB5,CLEC7A (Dectin-1) signaling,0.012036798014849198,1,0,1,0.013141221832451122
3468,PSB5,Degradation of GLI1 by the proteasome,0.008848487239964495,0,0,1,0.009660370935737048
3469,PSB5,Degradation of GLI1 by the proteasome,0.012036798014849198,1,0,1,0.013141221832451122
3470,PSB5,Degradation of GLI2 by the proteasome,0.008848487239964495,0,0,1,0.009660370935737048
3471,PSB5,Degradation of GLI2 by the proteasome,0.012036798014849198,1,0,1,0.013141221832451122
3472,PSB5,GLI3 is processed to GLI3R by the proteasome,0.008848487239964495,0,0,1,0.009660370935737048
3473,PSB5,GLI3 is processed to GLI3R by the proteasome,0.012036798014849198,1,0,1,0.013141221832451122
3474,PSB5,Defective CFTR causes cystic fibrosis,0.008848487239964495,0,0,1,0.009660370935737048
3475,PSB5,Defective CFTR causes cystic fibrosis,0.012036798014849198,1,0,1,0.013141221832451122
3476,PSB5,NIK-->noncanonical NF-kB signaling,0.008848487239964495,0,0,1,0.009660370935737048
3477,PSB5,NIK-->noncanonical NF-kB signaling,0.012036798014849198,1,0,1,0.013141221832451122
3478,PSB5,RAF/MAP kinase cascade,0.008848487239964495,0,0,1,0.009660370935737048
3479,PSB5,RAF/MAP kinase cascade,0.012036798014849198,1,0,1,0.013141221832451122
3480,PSB5,UCH proteinases,0.008848487239964495,0,0,1,0.009660370935737048
3481,PSB5,UCH proteinases,0.012036798014849198,1,0,1,0.013141221832451122
3482,PSB5,Ub-specific processing proteases,0.008848487239964495,0,0,1,0.009660370935737048
3483,PSB5,Ub-specific processing proteases,0.012036798014849198,1,0,1,0.013141221832451122
3484,PSB5,Orc1 removal from chromatin,0.008848487239964495,0,0,1,0.009660370935737048
3485,PSB5,Orc1 removal from chromatin,0.012036798014849198,1,0,1,0.013141221832451122
3486,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.008848487239964495,0,0,1,0.009660370935737048
3487,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.012036798014849198,1,0,1,0.013141221832451122
3488,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.008848487239964495,0,0,1,0.009660370935737048
3489,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.012036798014849198,1,0,1,0.013141221832451122
3490,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.008848487239964495,0,0,1,0.009660370935737048
3491,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.012036798014849198,1,0,1,0.013141221832451122
3492,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.008848487239964495,0,0,1,0.009660370935737048
3493,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.012036798014849198,1,0,1,0.013141221832451122
3494,PSB5,p53-Independent G1/S DNA damage checkpoint,0.008848487239964495,0,0,1,0.009660370935737048
3495,PSB5,p53-Independent G1/S DNA damage checkpoint,0.012036798014849198,1,0,1,0.013141221832451122
3496,PSB5,Negative regulation of NOTCH4 signaling,0.008848487239964495,0,0,1,0.009660370935737048
3497,PSB5,Negative regulation of NOTCH4 signaling,0.012036798014849198,1,0,1,0.013141221832451122
3498,PSB5,KEAP1-NFE2L2 pathway,0.008848487239964495,0,0,1,0.009660370935737048
3499,PSB5,KEAP1-NFE2L2 pathway,0.012036798014849198,1,0,1,0.013141221832451122
3500,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.008848487239964495,0,0,1,0.009660370935737048
3501,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.012036798014849198,1,0,1,0.013141221832451122
3502,PSB5,Degradation of beta-catenin by the destruction complex,0.008848487239964495,0,0,1,0.009660370935737048
3503,PSB5,Degradation of beta-catenin by the destruction complex,0.012036798014849198,1,0,1,0.013141221832451122
3504,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.008848487239964495,0,0,1,0.009660370935737048
3505,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.012036798014849198,1,0,1,0.013141221832451122
3506,PSB5,Hedgehog ligand biogenesis,0.008848487239964495,0,0,1,0.009660370935737048
3507,PSB5,Hedgehog ligand biogenesis,0.012036798014849198,1,0,1,0.013141221832451122
3508,PSB5,Hedgehog 'on' state,0.008848487239964495,0,0,1,0.009660370935737048
3509,PSB5,Hedgehog 'on' state,0.012036798014849198,1,0,1,0.013141221832451122
3510,PSB5,MAPK6/MAPK4 signaling,0.008848487239964495,0,0,1,0.009660370935737048
3511,PSB5,MAPK6/MAPK4 signaling,0.012036798014849198,1,0,1,0.013141221832451122
3512,PSB5,Neddylation,0.008848487239964495,0,0,1,0.009660370935737048
3513,PSB5,Neddylation,0.012036798014849198,1,0,1,0.013141221832451122
3514,GRN,Neutrophil degranulation,0.000140885184258979,0,0,1,0.00015381195704779706
3515,GRN,Neutrophil degranulation,0.0001405553989963184,1,0,1,0.00015345191268314545
3516,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0018087139454797893,0,0,1,0.0019746706025701804
3517,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0011042822014982457,1,0,1,0.0012056044603900203
3518,CCN2,Transcriptional regulation by RUNX3,0.0018087139454797893,0,0,1,0.0019746706025701804
3519,CCN2,Transcriptional regulation by RUNX3,0.0011042822014982457,1,0,1,0.0012056044603900203
3520,TKT,KEAP1-NFE2L2 pathway,0.0017843579540743025,0,0,1,0.0019480798526370232
3521,TKT,KEAP1-NFE2L2 pathway,0.0011745046292074724,1,0,1,0.0012822700735374525
3522,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0017843579540743025,0,0,1,0.0019480798526370232
3523,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0011745046292074724,1,0,1,0.0012822700735374525
3524,TKT,Pentose phosphate pathway,0.0017843579540743025,0,0,1,0.0019480798526370232
3525,TKT,Pentose phosphate pathway,0.0011745046292074724,1,0,1,0.0012822700735374525
3526,KAIN,Platelet degranulation ,4.633680237035026e-05,0,0,1,5.058838722756855e-05
3527,KAIN,Platelet degranulation ,4.8730080555767856e-05,1,0,1,5.3201258150760894e-05
3528,PRDX6,Detoxification of Reactive Oxygen Species,0.0007498479248964119,0,0,1,0.0008186494372930915
3529,PRDX6,Detoxification of Reactive Oxygen Species,0.0006334437252386346,1,0,1,0.000691564691994161
3530,PRDX6,Neutrophil degranulation,0.0007498479248964119,0,0,1,0.0008186494372930915
3531,PRDX6,Neutrophil degranulation,0.0006334437252386346,1,0,1,0.000691564691994161
3532,BLVRB,Cytoprotection by HMOX1,0.006043324602748915,0,0,1,0.0065978235334896084
3533,BLVRB,Cytoprotection by HMOX1,0.004014779541754935,1,0,1,0.004383151441230615
3534,BLVRB,Heme degradation,0.006043324602748915,0,0,1,0.0065978235334896084
3535,BLVRB,Heme degradation,0.004014779541754935,1,0,1,0.004383151441230615
3536,PEBP1,RAF/MAP kinase cascade,0.0005355769513735694,0,0,1,0.0005847182546110158
3537,PEBP1,RAF/MAP kinase cascade,0.00084430713088046,1,0,1,0.0009217756489668463
3538,PEBP1,Signaling by RAS mutants,0.0005355769513735694,0,0,1,0.0005847182546110158
3539,PEBP1,Signaling by RAS mutants,0.00084430713088046,1,0,1,0.0009217756489668463
3540,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.0005355769513735694,0,0,1,0.0005847182546110158
3541,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.00084430713088046,1,0,1,0.0009217756489668463
3542,PEBP1,Signaling by high-kinase activity BRAF mutants,0.0005355769513735694,0,0,1,0.0005847182546110158
3543,PEBP1,Signaling by high-kinase activity BRAF mutants,0.00084430713088046,1,0,1,0.0009217756489668463
3544,PEBP1,Signaling by BRAF and RAF1 fusions,0.0005355769513735694,0,0,1,0.0005847182546110158
3545,PEBP1,Signaling by BRAF and RAF1 fusions,0.00084430713088046,1,0,1,0.0009217756489668463
3546,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0005355769513735694,0,0,1,0.0005847182546110158
3547,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00084430713088046,1,0,1,0.0009217756489668463
3548,PDIA3,Antigen processing-Cross presentation,0.002346296954266538,0,0,1,0.0025615789782950254
3549,PDIA3,Antigen processing-Cross presentation,0.001866345335481225,1,0,1,0.002037589900508641
3550,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.002346296954266538,0,0,1,0.0025615789782950254
3551,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.001866345335481225,1,0,1,0.002037589900508641
3552,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.002346296954266538,0,0,1,0.0025615789782950254
3553,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.001866345335481225,1,0,1,0.002037589900508641
3554,P30443,Antigen processing-Cross presentation,0.004625942672692655,0,0,1,0.005050391206287731
3555,P30443,Antigen processing-Cross presentation,0.00466943081695265,1,0,1,0.005097869559758248
3556,P30443,Interferon gamma signaling,0.004625942672692655,0,0,1,0.005050391206287731
3557,P30443,Interferon gamma signaling,0.00466943081695265,1,0,1,0.005097869559758248
3558,P30443,Interferon alpha/beta signaling,0.004625942672692655,0,0,1,0.005050391206287731
3559,P30443,Interferon alpha/beta signaling,0.00466943081695265,1,0,1,0.005097869559758248
3560,P30443,SARS-CoV-2 Infection,0.004625942672692655,0,0,1,0.005050391206287731
3561,P30443,SARS-CoV-2 Infection,0.00466943081695265,1,0,1,0.005097869559758248
3562,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.004625942672692655,0,0,1,0.005050391206287731
3563,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00466943081695265,1,0,1,0.005097869559758248
3564,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004625942672692655,0,0,1,0.005050391206287731
3565,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00466943081695265,1,0,1,0.005097869559758248
3566,ILEU,Neutrophil degranulation,0.00046216617111585854,0,0,1,0.000504571744960377
3567,ILEU,Neutrophil degranulation,0.0004743297354183467,1,0,1,0.0005178513643886575
3568,CPSM,Urea cycle,0.0008100746391544374,0,0,1,0.000884402190751942
3569,CPSM,Urea cycle,0.00010557434531993901,1,0,1,0.00011526120899873702
3570,1433B,Activation of BH3-only proteins,0.0011734968177036992,0,0,1,0.001281169791342799
3571,1433B,Activation of BH3-only proteins,0.0005846546197349233,1,0,1,0.0006382989931230676
3572,1433B,Signaling by NTRK1 (TRKA),0.0011734968177036992,0,0,1,0.001281169791342799
3573,1433B,Signaling by NTRK1 (TRKA),0.0005846546197349233,1,0,1,0.0006382989931230676
3574,1433B,RHO GTPase Effectors,0.0011734968177036992,0,0,1,0.001281169791342799
3575,1433B,RHO GTPase Effectors,0.0005846546197349233,1,0,1,0.0006382989931230676
3576,1433B,Transcriptional Regulation by TP53,0.0011734968177036992,0,0,1,0.001281169791342799
3577,1433B,Transcriptional Regulation by TP53,0.0005846546197349233,1,0,1,0.0006382989931230676
3578,1433B,FOXO-mediated transcription,0.0011734968177036992,0,0,1,0.001281169791342799
3579,1433B,FOXO-mediated transcription,0.0005846546197349233,1,0,1,0.0006382989931230676
3580,1433B,RAF/MAP kinase cascade,0.0011734968177036992,0,0,1,0.001281169791342799
3581,1433B,RAF/MAP kinase cascade,0.0005846546197349233,1,0,1,0.0006382989931230676
3582,1433B,Signaling by RAS mutants,0.0011734968177036992,0,0,1,0.001281169791342799
3583,1433B,Signaling by RAS mutants,0.0005846546197349233,1,0,1,0.0006382989931230676
3584,1433B,Signaling by moderate kinase activity BRAF mutants,0.0011734968177036992,0,0,1,0.001281169791342799
3585,1433B,Signaling by moderate kinase activity BRAF mutants,0.0005846546197349233,1,0,1,0.0006382989931230676
3586,1433B,Signaling by high-kinase activity BRAF mutants,0.0011734968177036992,0,0,1,0.001281169791342799
3587,1433B,Signaling by high-kinase activity BRAF mutants,0.0005846546197349233,1,0,1,0.0006382989931230676
3588,1433B,Signaling by BRAF and RAF1 fusions,0.0011734968177036992,0,0,1,0.001281169791342799
3589,1433B,Signaling by BRAF and RAF1 fusions,0.0005846546197349233,1,0,1,0.0006382989931230676
3590,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0011734968177036992,0,0,1,0.001281169791342799
3591,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0005846546197349233,1,0,1,0.0006382989931230676
3592,1433B,Signaling by RAF1 mutants,0.0011734968177036992,0,0,1,0.001281169791342799
3593,1433B,Signaling by RAF1 mutants,0.0005846546197349233,1,0,1,0.0006382989931230676
3594,1433B,Signaling by MRAS-complex mutants,0.0011734968177036992,0,0,1,0.001281169791342799
3595,1433B,Signaling by MRAS-complex mutants,0.0005846546197349233,1,0,1,0.0006382989931230676
3596,1433B,G2/M DNA damage checkpoint,0.0011734968177036992,0,0,1,0.001281169791342799
3597,1433B,G2/M DNA damage checkpoint,0.0005846546197349233,1,0,1,0.0006382989931230676
3598,1433B,SARS-CoV-2 Infection,0.0011734968177036992,0,0,1,0.001281169791342799
3599,1433B,SARS-CoV-2 Infection,0.0005846546197349233,1,0,1,0.0006382989931230676
3600,1433B,Rap1 signalling,0.0011734968177036992,0,0,1,0.001281169791342799
3601,1433B,Rap1 signalling,0.0005846546197349233,1,0,1,0.0006382989931230676
3602,1433B,Signaling by Hippo,0.0011734968177036992,0,0,1,0.001281169791342799
3603,1433B,Signaling by Hippo,0.0005846546197349233,1,0,1,0.0006382989931230676
3604,1433B,mTORC1-mediated signalling,0.0011734968177036992,0,0,1,0.001281169791342799
3605,1433B,mTORC1-mediated signalling,0.0005846546197349233,1,0,1,0.0006382989931230676
3606,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0011734968177036992,0,0,1,0.001281169791342799
3607,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0005846546197349233,1,0,1,0.0006382989931230676
3608,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0011734968177036992,0,0,1,0.001281169791342799
3609,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0005846546197349233,1,0,1,0.0006382989931230676
3610,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0011734968177036992,0,0,1,0.001281169791342799
3611,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0005846546197349233,1,0,1,0.0006382989931230676
3612,PRDX2,Transcriptional Regulation by TP53,0.0005332157190127988,0,0,1,0.0005821403698436077
3613,PRDX2,Transcriptional Regulation by TP53,0.00046411637901706707,1,0,1,0.0005067008921486544
3614,PRDX2,Neurodegenerative Diseases,0.0005332157190127988,0,0,1,0.0005821403698436077
3615,PRDX2,Neurodegenerative Diseases,0.00046411637901706707,1,0,1,0.0005067008921486544
3616,PRDX2,Detoxification of Reactive Oxygen Species,0.0005332157190127988,0,0,1,0.0005821403698436077
3617,PRDX2,Detoxification of Reactive Oxygen Species,0.00046411637901706707,1,0,1,0.0005067008921486544
3618,HPPD,Tyrosine catabolism,0.001291821365212776,0,0,1,0.0014103510840024365
3619,HPPD,Tyrosine catabolism,0.0005068255783865928,1,0,1,0.0005533288294546499
3620,CADH5,VEGFA-VEGFR2 Pathway,0.0004035707456277756,0,0,1,0.0004405999574670727
3621,CADH5,VEGFA-VEGFR2 Pathway,0.00018816263347505967,1,0,1,0.00020542729918899706
3622,CADH5,Adherens junctions interactions,0.0004035707456277756,0,0,1,0.0004405999574670727
3623,CADH5,Adherens junctions interactions,0.00018816263347505967,1,0,1,0.00020542729918899706
3624,MA1A1,Intra-Golgi traffic,0.0002153645893854284,0,0,1,0.00023512514212477797
3625,MA1A1,Intra-Golgi traffic,0.0019637797746410225,1,0,1,0.0021439643347676346
3626,HS71L,Regulation of HSF1-mediated heat shock response,0.0008582323969833477,0,0,1,0.0009369786133023953
3627,HS71L,Regulation of HSF1-mediated heat shock response,0.00048526278448759145,1,0,1,0.0005297875639449495
3628,HS71L,HSF1-dependent transactivation,0.0008582323969833477,0,0,1,0.0009369786133023953
3629,HS71L,HSF1-dependent transactivation,0.00048526278448759145,1,0,1,0.0005297875639449495
3630,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0008582323969833477,0,0,1,0.0009369786133023953
3631,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00048526278448759145,1,0,1,0.0005297875639449495
3632,TRY3,Defensins,0.0001687852789307052,0,0,1,0.00018427199573709256
3633,TRY3,Defensins,0.0003373155864972035,1,0,1,0.00036826562547902323
3634,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0001687852789307052,0,0,1,0.00018427199573709256
3635,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0003373155864972035,1,0,1,0.00036826562547902323
3636,TRY3,Neutrophil degranulation,0.0001687852789307052,0,0,1,0.00018427199573709256
3637,TRY3,Neutrophil degranulation,0.0003373155864972035,1,0,1,0.00036826562547902323
3638,CBS,Cysteine formation from homocysteine,0.00019670024996258195,0,0,1,0.00021474827575141122
3639,CBS,Cysteine formation from homocysteine,0.00016889486959819247,1,0,1,0.00018439164178170008
3640,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.00019670024996258195,0,0,1,0.00021474827575141122
3641,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.00016889486959819247,1,0,1,0.00018439164178170008
3642,K1C9,Formation of the cornified envelope,0.00032846241973450834,0,0,1,0.00035860014565583975
3643,K1C9,Formation of the cornified envelope,0.00042384427048278286,1,0,1,0.0004627336583995545
3644,FBN1,TGF-beta receptor signaling activates SMADs,0.002492889357425821,0,0,1,0.0027216218141465315
3645,FBN1,TGF-beta receptor signaling activates SMADs,0.0009278531727288864,1,0,1,0.0010129873705392275
3646,FBN1,Integrin cell surface interactions,0.002492889357425821,0,0,1,0.0027216218141465315
3647,FBN1,Integrin cell surface interactions,0.0009278531727288864,1,0,1,0.0010129873705392275
3648,FBN1,Molecules associated with elastic fibres,0.002492889357425821,0,0,1,0.0027216218141465315
3649,FBN1,Molecules associated with elastic fibres,0.0009278531727288864,1,0,1,0.0010129873705392275
3650,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002492889357425821,0,0,1,0.0027216218141465315
3651,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0009278531727288864,1,0,1,0.0010129873705392275
3652,FBN1,Post-translational protein phosphorylation,0.002492889357425821,0,0,1,0.0027216218141465315
3653,FBN1,Post-translational protein phosphorylation,0.0009278531727288864,1,0,1,0.0010129873705392275
3654,MYH9,RHO GTPase Effectors,0.007094290717339455,0,0,1,0.007745219945158693
3655,MYH9,RHO GTPase Effectors,0.006612582633337999,1,0,1,0.00721931323952661
3656,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.007094290717339455,0,0,1,0.007745219945158693
3657,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.006612582633337999,1,0,1,0.00721931323952661
3658,MYH9,EPH-Ephrin signaling,0.007094290717339455,0,0,1,0.007745219945158693
3659,MYH9,EPH-Ephrin signaling,0.006612582633337999,1,0,1,0.00721931323952661
3660,MYH9,Semaphorin interactions,0.007094290717339455,0,0,1,0.007745219945158693
3661,MYH9,Semaphorin interactions,0.006612582633337999,1,0,1,0.00721931323952661
3662,MYH9,Parasite infection,0.007094290717339455,0,0,1,0.007745219945158693
3663,MYH9,Parasite infection,0.006612582633337999,1,0,1,0.00721931323952661
3664,MYH9,Leishmania parasite growth and survival,0.007094290717339455,0,0,1,0.007745219945158693
3665,MYH9,Leishmania parasite growth and survival,0.006612582633337999,1,0,1,0.00721931323952661
3666,MYH9,Signaling by ALK fusions and activated point mutants,0.007094290717339455,0,0,1,0.007745219945158693
3667,MYH9,Signaling by ALK fusions and activated point mutants,0.006612582633337999,1,0,1,0.00721931323952661
3668,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.007094290717339455,0,0,1,0.007745219945158693
3669,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.006612582633337999,1,0,1,0.00721931323952661
3670,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.007094290717339455,0,0,1,0.007745219945158693
3671,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.006612582633337999,1,0,1,0.00721931323952661
3672,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.007094290717339455,0,0,1,0.007745219945158693
3673,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.006612582633337999,1,0,1,0.00721931323952661
3674,MYH10,RHO GTPase Effectors,4.6171134632403745e-05,0,0,1,5.0407518819529324e-05
3675,MYH10,RHO GTPase Effectors,8.475026539498072e-05,1,0,1,9.25264373914561e-05
3676,MYH10,EPH-Ephrin signaling,4.6171134632403745e-05,0,0,1,5.0407518819529324e-05
3677,MYH10,EPH-Ephrin signaling,8.475026539498072e-05,1,0,1,9.25264373914561e-05
3678,MYH10,Semaphorin interactions,4.6171134632403745e-05,0,0,1,5.0407518819529324e-05
3679,MYH10,Semaphorin interactions,8.475026539498072e-05,1,0,1,9.25264373914561e-05
3680,MYH11,RHO GTPase Effectors,0.0002859846349680905,0,0,1,0.0003122248561579206
3681,MYH11,RHO GTPase Effectors,0.0003331977685899852,1,0,1,0.0003637699814948309
3682,MYH11,EPH-Ephrin signaling,0.0002859846349680905,0,0,1,0.0003122248561579206
3683,MYH11,EPH-Ephrin signaling,0.0003331977685899852,1,0,1,0.0003637699814948309
3684,MYH11,Semaphorin interactions,0.0002859846349680905,0,0,1,0.0003122248561579206
3685,MYH11,Semaphorin interactions,0.0003331977685899852,1,0,1,0.0003637699814948309
3686,MYH11,Smooth Muscle Contraction,0.0002859846349680905,0,0,1,0.0003122248561579206
3687,MYH11,Smooth Muscle Contraction,0.0003331977685899852,1,0,1,0.0003637699814948309
3688,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00017832683879400122,0,0,1,0.00019468903145012024
3689,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),8.053432619740283e-05,1,0,1,8.79236691004912e-05
3690,K1C20,Formation of the cornified envelope,0.0022311687233401603,0,0,1,0.0024358872769044424
3691,K1C20,Formation of the cornified envelope,0.002863479652891153,1,0,1,0.0031262152347269587
3692,K22E,Formation of the cornified envelope,0.005102650691438372,0,0,1,0.005570839070904011
3693,K22E,Formation of the cornified envelope,0.006624846424916901,1,0,1,0.007232702282480266
3694,CH3L1,Neutrophil degranulation,0.0013313544410349432,0,0,1,0.0014535114758655644
3695,CH3L1,Neutrophil degranulation,0.0013556774861656772,1,0,1,0.0014800662565729733
3696,PGM1,Diseases associated with glycosylation precursor biosynthesis,8.389180448988426e-05,0,0,1,9.158920930351756e-05
3697,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.00034591411180566136,1,0,1,0.00037765309948755885
3698,PGM1,Glycogen synthesis,8.389180448988426e-05,0,0,1,9.158920930351756e-05
3699,PGM1,Glycogen synthesis,0.00034591411180566136,1,0,1,0.00037765309948755885
3700,PGM1,Glycogen breakdown (glycogenolysis),8.389180448988426e-05,0,0,1,9.158920930351756e-05
3701,PGM1,Glycogen breakdown (glycogenolysis),0.00034591411180566136,1,0,1,0.00037765309948755885
3702,PGM1,Neutrophil degranulation,8.389180448988426e-05,0,0,1,9.158920930351756e-05
3703,PGM1,Neutrophil degranulation,0.00034591411180566136,1,0,1,0.00037765309948755885
3704,PGM1,Galactose catabolism,8.389180448988426e-05,0,0,1,9.158920930351756e-05
3705,PGM1,Galactose catabolism,0.00034591411180566136,1,0,1,0.00037765309948755885
3706,FHR2,Regulation of Complement cascade,0.00011979741804211491,0,0,1,0.00013078930488857567
3707,FHR2,Regulation of Complement cascade,0.00014058605371578063,1,0,1,0.000153485380094343
3708,TAGL2,Platelet degranulation ,0.00045193391772303825,0,0,1,0.0004934006418551307
3709,TAGL2,Platelet degranulation ,0.00048295813902200855,1,0,1,0.0005272714581441364
3710,TALDO,Interleukin-12 family signaling,0.0028073145463698673,0,0,1,0.0030648967575763967
3711,TALDO,Interleukin-12 family signaling,0.003367951072440459,1,0,1,0.0036769739019614366
3712,TALDO,Pentose phosphate pathway disease,0.0028073145463698673,0,0,1,0.0030648967575763967
3713,TALDO,Pentose phosphate pathway disease,0.003367951072440459,1,0,1,0.0036769739019614366
3714,TALDO,KEAP1-NFE2L2 pathway,0.0028073145463698673,0,0,1,0.0030648967575763967
3715,TALDO,KEAP1-NFE2L2 pathway,0.003367951072440459,1,0,1,0.0036769739019614366
3716,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0028073145463698673,0,0,1,0.0030648967575763967
3717,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.003367951072440459,1,0,1,0.0036769739019614366
3718,TALDO,Pentose phosphate pathway,0.0028073145463698673,0,0,1,0.0030648967575763967
3719,TALDO,Pentose phosphate pathway,0.003367951072440459,1,0,1,0.0036769739019614366
3720,GRP75,Regulation of HSF1-mediated heat shock response,0.0019104715196184134,0,0,1,0.0020857648365382245
3721,GRP75,Regulation of HSF1-mediated heat shock response,0.0002289006725040536,1,0,1,0.00024990321439822703
3722,GRP75,Interleukin-12 family signaling,0.0019104715196184134,0,0,1,0.0020857648365382245
3723,GRP75,Interleukin-12 family signaling,0.0002289006725040536,1,0,1,0.00024990321439822703
3724,GRP75,Cristae formation,0.0019104715196184134,0,0,1,0.0020857648365382245
3725,GRP75,Cristae formation,0.0002289006725040536,1,0,1,0.00024990321439822703
3726,GRP75,Mitochondrial protein import,0.0019104715196184134,0,0,1,0.0020857648365382245
3727,GRP75,Mitochondrial protein import,0.0002289006725040536,1,0,1,0.00024990321439822703
3728,COIA1,Collagen chain trimerization,0.004416381165226874,0,0,1,0.004821601601797123
3729,COIA1,Collagen chain trimerization,0.004558631902097294,1,0,1,0.004976904406308563
3730,COIA1,Collagen degradation,0.004416381165226874,0,0,1,0.004821601601797123
3731,COIA1,Collagen degradation,0.004558631902097294,1,0,1,0.004976904406308563
3732,COIA1,Activation of Matrix Metalloproteinases,0.004416381165226874,0,0,1,0.004821601601797123
3733,COIA1,Activation of Matrix Metalloproteinases,0.004558631902097294,1,0,1,0.004976904406308563
3734,COIA1,Integrin cell surface interactions,0.004416381165226874,0,0,1,0.004821601601797123
3735,COIA1,Integrin cell surface interactions,0.004558631902097294,1,0,1,0.004976904406308563
3736,COIA1,Laminin interactions,0.004416381165226874,0,0,1,0.004821601601797123
3737,COIA1,Laminin interactions,0.004558631902097294,1,0,1,0.004976904406308563
3738,MDHC,Gluconeogenesis,1.6552790308418165e-05,0,0,1,1.8071574277529766e-05
3739,MDHC,Gluconeogenesis,3.975235998544394e-05,1,0,1,4.339979621554836e-05
3740,MDHM,Gluconeogenesis,5.992129567880857e-05,0,0,1,6.541931151720697e-05
3741,MDHM,Gluconeogenesis,0.00023864190036408499,1,0,1,0.0002605382384362814
3742,MDHM,Citric acid cycle (TCA cycle),5.992129567880857e-05,0,0,1,6.541931151720697e-05
3743,MDHM,Citric acid cycle (TCA cycle),0.00023864190036408499,1,0,1,0.0002605382384362814
3744,PTGDS,Arachidonic acid metabolism,0.0040982033525384385,0,0,1,0.0044742297165545
3745,PTGDS,Arachidonic acid metabolism,0.0059163234262382385,1,0,1,0.006459169496805585
3746,PTGDS,Transcriptional regulation of testis differentiation,0.0040982033525384385,0,0,1,0.0044742297165545
3747,PTGDS,Transcriptional regulation of testis differentiation,0.0059163234262382385,1,0,1,0.006459169496805585
3748,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.0013184708955007497,0,0,1,0.0014394458140803905
3749,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.000964620519372715,1,0,1,0.001053128266634777
3750,MUC18,RHO GTPase cycle,0.0009995906716886304,0,0,1,0.0010913070687157893
3751,MUC18,RHO GTPase cycle,0.0011482624020037445,1,0,1,0.0012536200182124116
3752,BTD,Biotin transport and metabolism,0.0024905518369180797,0,0,1,0.0027190698168884373
3753,BTD,Biotin transport and metabolism,0.002995451760236697,1,0,1,0.0032702963048075865
3754,BTD,Defects in biotin (Btn) metabolism,0.0024905518369180797,0,0,1,0.0027190698168884373
3755,BTD,Defects in biotin (Btn) metabolism,0.002995451760236697,1,0,1,0.0032702963048075865
3756,GSHB,Glutathione conjugation,0.00015469965525562426,0,0,1,0.00016889396038796461
3757,GSHB,Glutathione conjugation,0.00024130712703536951,1,0,1,0.00026344801019434423
3758,GSHB,Defective GSS causes GSS deficiency,0.00015469965525562426,0,0,1,0.00016889396038796461
3759,GSHB,Defective GSS causes GSS deficiency,0.00024130712703536951,1,0,1,0.00026344801019434423
3760,MASP1,Initial triggering of complement,8.616606025271966e-05,0,0,1,9.407213702617943e-05
3761,MASP1,Initial triggering of complement,7.16430623492439e-05,1,0,1,7.821659663359699e-05
3762,MASP1,SARS-CoV-2 Infection,8.616606025271966e-05,0,0,1,9.407213702617943e-05
3763,MASP1,SARS-CoV-2 Infection,7.16430623492439e-05,1,0,1,7.821659663359699e-05
3764,MASP1,Scavenging by Class A Receptors,8.616606025271966e-05,0,0,1,9.407213702617943e-05
3765,MASP1,Scavenging by Class A Receptors,7.16430623492439e-05,1,0,1,7.821659663359699e-05
3766,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.005619315649760972,0,0,1,0.0061349100823138054
3767,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.005078566290182889,1,0,1,0.005544544830591128
3768,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.005619315649760972,0,0,1,0.0061349100823138054
3769,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.005078566290182889,1,0,1,0.005544544830591128
3770,PSB2,Antigen processing-Cross presentation,0.005619315649760972,0,0,1,0.0061349100823138054
3771,PSB2,Antigen processing-Cross presentation,0.005078566290182889,1,0,1,0.005544544830591128
3772,PSB2,PTEN Regulation,0.005619315649760972,0,0,1,0.0061349100823138054
3773,PSB2,PTEN Regulation,0.005078566290182889,1,0,1,0.005544544830591128
3774,PSB2,Host Interactions of HIV factors,0.005619315649760972,0,0,1,0.0061349100823138054
3775,PSB2,Host Interactions of HIV factors,0.005078566290182889,1,0,1,0.005544544830591128
3776,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.005619315649760972,0,0,1,0.0061349100823138054
3777,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.005078566290182889,1,0,1,0.005544544830591128
3778,PSB2,APC/C-mediated degradation of cell cycle proteins,0.005619315649760972,0,0,1,0.0061349100823138054
3779,PSB2,APC/C-mediated degradation of cell cycle proteins,0.005078566290182889,1,0,1,0.005544544830591128
3780,PSB2,Degradation of AXIN,0.005619315649760972,0,0,1,0.0061349100823138054
3781,PSB2,Degradation of AXIN,0.005078566290182889,1,0,1,0.005544544830591128
3782,PSB2,Degradation of DVL,0.005619315649760972,0,0,1,0.0061349100823138054
3783,PSB2,Degradation of DVL,0.005078566290182889,1,0,1,0.005544544830591128
3784,PSB2,Downstream TCR signaling,0.005619315649760972,0,0,1,0.0061349100823138054
3785,PSB2,Downstream TCR signaling,0.005078566290182889,1,0,1,0.005544544830591128
3786,PSB2,Transcriptional regulation by RUNX3,0.005619315649760972,0,0,1,0.0061349100823138054
3787,PSB2,Transcriptional regulation by RUNX3,0.005078566290182889,1,0,1,0.005544544830591128
3788,PSB2,Transcriptional regulation by RUNX2,0.005619315649760972,0,0,1,0.0061349100823138054
3789,PSB2,Transcriptional regulation by RUNX2,0.005078566290182889,1,0,1,0.005544544830591128
3790,PSB2,Transcriptional regulation by RUNX1,0.005619315649760972,0,0,1,0.0061349100823138054
3791,PSB2,Transcriptional regulation by RUNX1,0.005078566290182889,1,0,1,0.005544544830591128
3792,PSB2,FCERI mediated NF-kB activation,0.005619315649760972,0,0,1,0.0061349100823138054
3793,PSB2,FCERI mediated NF-kB activation,0.005078566290182889,1,0,1,0.005544544830591128
3794,PSB2,Mitotic Metaphase and Anaphase,0.005619315649760972,0,0,1,0.0061349100823138054
3795,PSB2,Mitotic Metaphase and Anaphase,0.005078566290182889,1,0,1,0.005544544830591128
3796,PSB2,Regulation of ornithine decarboxylase (ODC),0.005619315649760972,0,0,1,0.0061349100823138054
3797,PSB2,Regulation of ornithine decarboxylase (ODC),0.005078566290182889,1,0,1,0.005544544830591128
3798,PSB2,Signaling by ROBO receptors,0.005619315649760972,0,0,1,0.0061349100823138054
3799,PSB2,Signaling by ROBO receptors,0.005078566290182889,1,0,1,0.005544544830591128
3800,PSB2,PCP/CE pathway,0.005619315649760972,0,0,1,0.0061349100823138054
3801,PSB2,PCP/CE pathway,0.005078566290182889,1,0,1,0.005544544830591128
3802,PSB2,Interleukin-1 family signaling,0.005619315649760972,0,0,1,0.0061349100823138054
3803,PSB2,Interleukin-1 family signaling,0.005078566290182889,1,0,1,0.005544544830591128
3804,PSB2,G2/M Transition,0.005619315649760972,0,0,1,0.0061349100823138054
3805,PSB2,G2/M Transition,0.005078566290182889,1,0,1,0.005544544830591128
3806,PSB2,G1/S Transition,0.005619315649760972,0,0,1,0.0061349100823138054
3807,PSB2,G1/S Transition,0.005078566290182889,1,0,1,0.005544544830591128
3808,PSB2,Hh mutants are degraded by ERAD,0.005619315649760972,0,0,1,0.0061349100823138054
3809,PSB2,Hh mutants are degraded by ERAD,0.005078566290182889,1,0,1,0.005544544830591128
3810,PSB2,CLEC7A (Dectin-1) signaling,0.005619315649760972,0,0,1,0.0061349100823138054
3811,PSB2,CLEC7A (Dectin-1) signaling,0.005078566290182889,1,0,1,0.005544544830591128
3812,PSB2,Degradation of GLI1 by the proteasome,0.005619315649760972,0,0,1,0.0061349100823138054
3813,PSB2,Degradation of GLI1 by the proteasome,0.005078566290182889,1,0,1,0.005544544830591128
3814,PSB2,Degradation of GLI2 by the proteasome,0.005619315649760972,0,0,1,0.0061349100823138054
3815,PSB2,Degradation of GLI2 by the proteasome,0.005078566290182889,1,0,1,0.005544544830591128
3816,PSB2,GLI3 is processed to GLI3R by the proteasome,0.005619315649760972,0,0,1,0.0061349100823138054
3817,PSB2,GLI3 is processed to GLI3R by the proteasome,0.005078566290182889,1,0,1,0.005544544830591128
3818,PSB2,Defective CFTR causes cystic fibrosis,0.005619315649760972,0,0,1,0.0061349100823138054
3819,PSB2,Defective CFTR causes cystic fibrosis,0.005078566290182889,1,0,1,0.005544544830591128
3820,PSB2,NIK-->noncanonical NF-kB signaling,0.005619315649760972,0,0,1,0.0061349100823138054
3821,PSB2,NIK-->noncanonical NF-kB signaling,0.005078566290182889,1,0,1,0.005544544830591128
3822,PSB2,RAF/MAP kinase cascade,0.005619315649760972,0,0,1,0.0061349100823138054
3823,PSB2,RAF/MAP kinase cascade,0.005078566290182889,1,0,1,0.005544544830591128
3824,PSB2,UCH proteinases,0.005619315649760972,0,0,1,0.0061349100823138054
3825,PSB2,UCH proteinases,0.005078566290182889,1,0,1,0.005544544830591128
3826,PSB2,Ub-specific processing proteases,0.005619315649760972,0,0,1,0.0061349100823138054
3827,PSB2,Ub-specific processing proteases,0.005078566290182889,1,0,1,0.005544544830591128
3828,PSB2,Orc1 removal from chromatin,0.005619315649760972,0,0,1,0.0061349100823138054
3829,PSB2,Orc1 removal from chromatin,0.005078566290182889,1,0,1,0.005544544830591128
3830,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.005619315649760972,0,0,1,0.0061349100823138054
3831,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.005078566290182889,1,0,1,0.005544544830591128
3832,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.005619315649760972,0,0,1,0.0061349100823138054
3833,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.005078566290182889,1,0,1,0.005544544830591128
3834,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.005619315649760972,0,0,1,0.0061349100823138054
3835,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.005078566290182889,1,0,1,0.005544544830591128
3836,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.005619315649760972,0,0,1,0.0061349100823138054
3837,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.005078566290182889,1,0,1,0.005544544830591128
3838,PSB2,p53-Independent G1/S DNA damage checkpoint,0.005619315649760972,0,0,1,0.0061349100823138054
3839,PSB2,p53-Independent G1/S DNA damage checkpoint,0.005078566290182889,1,0,1,0.005544544830591128
3840,PSB2,Negative regulation of NOTCH4 signaling,0.005619315649760972,0,0,1,0.0061349100823138054
3841,PSB2,Negative regulation of NOTCH4 signaling,0.005078566290182889,1,0,1,0.005544544830591128
3842,PSB2,KEAP1-NFE2L2 pathway,0.005619315649760972,0,0,1,0.0061349100823138054
3843,PSB2,KEAP1-NFE2L2 pathway,0.005078566290182889,1,0,1,0.005544544830591128
3844,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.005619315649760972,0,0,1,0.0061349100823138054
3845,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.005078566290182889,1,0,1,0.005544544830591128
3846,PSB2,Degradation of beta-catenin by the destruction complex,0.005619315649760972,0,0,1,0.0061349100823138054
3847,PSB2,Degradation of beta-catenin by the destruction complex,0.005078566290182889,1,0,1,0.005544544830591128
3848,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.005619315649760972,0,0,1,0.0061349100823138054
3849,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.005078566290182889,1,0,1,0.005544544830591128
3850,PSB2,Hedgehog ligand biogenesis,0.005619315649760972,0,0,1,0.0061349100823138054
3851,PSB2,Hedgehog ligand biogenesis,0.005078566290182889,1,0,1,0.005544544830591128
3852,PSB2,Hedgehog 'on' state,0.005619315649760972,0,0,1,0.0061349100823138054
3853,PSB2,Hedgehog 'on' state,0.005078566290182889,1,0,1,0.005544544830591128
3854,PSB2,MAPK6/MAPK4 signaling,0.005619315649760972,0,0,1,0.0061349100823138054
3855,PSB2,MAPK6/MAPK4 signaling,0.005078566290182889,1,0,1,0.005544544830591128
3856,PSB2,Neddylation,0.005619315649760972,0,0,1,0.0061349100823138054
3857,PSB2,Neddylation,0.005078566290182889,1,0,1,0.005544544830591128
3858,COMP,Integrin cell surface interactions,0.0014909182140455336,0,0,1,0.0016277158560477566
3859,COMP,Integrin cell surface interactions,0.001179920748617761,1,0,1,0.0012881831433217792
3860,COMP,ECM proteoglycans,0.0014909182140455336,0,0,1,0.0016277158560477566
3861,COMP,ECM proteoglycans,0.001179920748617761,1,0,1,0.0012881831433217792
3862,SEPP1,Platelet degranulation ,0.0001587440828766514,0,0,1,0.0001733094802369845
3863,SEPP1,Platelet degranulation ,0.0001652027982173055,1,0,1,0.00018036080825125243
3864,CAMP,Neutrophil degranulation,0.0023340784080638573,0,0,1,0.0025482393321597826
3865,CAMP,Neutrophil degranulation,0.0023690135939741686,1,0,1,0.002586379959529201
3866,MMP14,Collagen degradation,0.00034288438256840095,0,0,1,0.00037434538061165975
3867,MMP14,Collagen degradation,0.00021655843562282752,1,0,1,0.00023642852847554537
3868,MMP14,Activation of Matrix Metalloproteinases,0.00034288438256840095,0,0,1,0.00037434538061165975
3869,MMP14,Activation of Matrix Metalloproteinases,0.00021655843562282752,1,0,1,0.00023642852847554537
3870,LUM,Keratan sulfate/keratin metabolism,0.0038500418064396046,0,0,1,0.004203298367241693
3871,LUM,Keratan sulfate/keratin metabolism,0.003408412348343412,1,0,1,0.0037211476599333464
3872,LUM,Diseases associated with glycosaminoglycan metabolism,0.0038500418064396046,0,0,1,0.004203298367241693
3873,LUM,Diseases associated with glycosaminoglycan metabolism,0.003408412348343412,1,0,1,0.0037211476599333464
3874,LUM,Integrin cell surface interactions,0.0038500418064396046,0,0,1,0.004203298367241693
3875,LUM,Integrin cell surface interactions,0.003408412348343412,1,0,1,0.0037211476599333464
3876,LUM,ECM proteoglycans,0.0038500418064396046,0,0,1,0.004203298367241693
3877,LUM,ECM proteoglycans,0.003408412348343412,1,0,1,0.0037211476599333464
3878,RIDA,Threonine catabolism,0.00031255832828225587,0,0,1,0.00034123679091982044
3879,RIDA,Threonine catabolism,3.7276721007304696e-05,1,0,1,4.0697007571204894e-05
3880,CRIS3,Neutrophil degranulation,0.00023931225783734115,0,0,1,0.0002612701038586498
3881,CRIS3,Neutrophil degranulation,0.00024350249426047666,1,0,1,0.0002658448110439751
3882,HSP72,Regulation of HSF1-mediated heat shock response,0.0028655948705361392,0,0,1,0.0031285245319555397
3883,HSP72,Regulation of HSF1-mediated heat shock response,0.0025950403730999583,1,0,1,0.0028331455894668447
3884,HSP72,HSF1-dependent transactivation,0.0028655948705361392,0,0,1,0.0031285245319555397
3885,HSP72,HSF1-dependent transactivation,0.0025950403730999583,1,0,1,0.0028331455894668447
3886,HSP72,Meiotic synapsis,0.0028655948705361392,0,0,1,0.0031285245319555397
3887,HSP72,Meiotic synapsis,0.0025950403730999583,1,0,1,0.0028331455894668447
3888,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0028655948705361392,0,0,1,0.0031285245319555397
3889,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0025950403730999583,1,0,1,0.0028331455894668447
3890,MFAP4,Molecules associated with elastic fibres,0.00010752808631721029,0,0,1,0.0001173942134586127
3891,MFAP4,Molecules associated with elastic fibres,3.909124642387691e-05,1,0,1,4.2678022870321793e-05
3892,CAD13,Adherens junctions interactions,0.00014455024955417785,0,0,1,0.00015781330657739867
3893,CAD13,Adherens junctions interactions,0.00012263588629545395,1,0,1,0.0001338882138289336
3894,DEF1,Defensins,0.0025643639215780834,0,0,1,0.002799654452207245
3895,DEF1,Defensins,0.002999940648588946,1,0,1,0.003275197066417546
3896,DEF1,Neutrophil degranulation,0.0025643639215780834,0,0,1,0.002799654452207245
3897,DEF1,Neutrophil degranulation,0.002999940648588946,1,0,1,0.003275197066417546
3898,TPIS,Glycolysis,0.0001579455587821469,0,0,1,0.000172437688399031
3899,TPIS,Glycolysis,0.00024194682869326848,1,0,1,0.00026414640700906744
3900,TPIS,Gluconeogenesis,0.0001579455587821469,0,0,1,0.000172437688399031
3901,TPIS,Gluconeogenesis,0.00024194682869326848,1,0,1,0.00026414640700906744
3902,MYL6,RHO GTPase Effectors,0.00012908555431218922,0,0,1,0.0001409296643915353
3903,MYL6,RHO GTPase Effectors,0.00026469887259475004,1,0,1,0.0002889860409118867
3904,MYL6,EPH-Ephrin signaling,0.00012908555431218922,0,0,1,0.0001409296643915353
3905,MYL6,EPH-Ephrin signaling,0.00026469887259475004,1,0,1,0.0002889860409118867
3906,MYL6,Semaphorin interactions,0.00012908555431218922,0,0,1,0.0001409296643915353
3907,MYL6,Semaphorin interactions,0.00026469887259475004,1,0,1,0.0002889860409118867
3908,MYL6,Smooth Muscle Contraction,0.00012908555431218922,0,0,1,0.0001409296643915353
3909,MYL6,Smooth Muscle Contraction,0.00026469887259475004,1,0,1,0.0002889860409118867
3910,ACTB,Gap junction trafficking,0.03149331722105381,0,0,1,0.03438295361698866
3911,ACTB,Gap junction trafficking,0.028176434258020338,1,0,1,0.030761733525422087
3912,ACTB,VEGFA-VEGFR2 Pathway,0.03149331722105381,0,0,1,0.03438295361698866
3913,ACTB,VEGFA-VEGFR2 Pathway,0.028176434258020338,1,0,1,0.030761733525422087
3914,ACTB,RHO GTPase Effectors,0.03149331722105381,0,0,1,0.03438295361698866
3915,ACTB,RHO GTPase Effectors,0.028176434258020338,1,0,1,0.030761733525422087
3916,ACTB,RHO GTPase cycle,0.03149331722105381,0,0,1,0.03438295361698866
3917,ACTB,RHO GTPase cycle,0.028176434258020338,1,0,1,0.030761733525422087
3918,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.03149331722105381,0,0,1,0.03438295361698866
3919,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.028176434258020338,1,0,1,0.030761733525422087
3920,ACTB,EPH-Ephrin signaling,0.03149331722105381,0,0,1,0.03438295361698866
3921,ACTB,EPH-Ephrin signaling,0.028176434258020338,1,0,1,0.030761733525422087
3922,ACTB,L1CAM interactions,0.03149331722105381,0,0,1,0.03438295361698866
3923,ACTB,L1CAM interactions,0.028176434258020338,1,0,1,0.030761733525422087
3924,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.03149331722105381,0,0,1,0.03438295361698866
3925,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.028176434258020338,1,0,1,0.030761733525422087
3926,ACTB,Adherens junctions interactions,0.03149331722105381,0,0,1,0.03438295361698866
3927,ACTB,Adherens junctions interactions,0.028176434258020338,1,0,1,0.030761733525422087
3928,ACTB,B-WICH complex positively regulates rRNA expression,0.03149331722105381,0,0,1,0.03438295361698866
3929,ACTB,B-WICH complex positively regulates rRNA expression,0.028176434258020338,1,0,1,0.030761733525422087
3930,ACTB,RAF/MAP kinase cascade,0.03149331722105381,0,0,1,0.03438295361698866
3931,ACTB,RAF/MAP kinase cascade,0.028176434258020338,1,0,1,0.030761733525422087
3932,ACTB,UCH proteinases,0.03149331722105381,0,0,1,0.03438295361698866
3933,ACTB,UCH proteinases,0.028176434258020338,1,0,1,0.030761733525422087
3934,ACTB,DNA Damage Recognition in GG-NER,0.03149331722105381,0,0,1,0.03438295361698866
3935,ACTB,DNA Damage Recognition in GG-NER,0.028176434258020338,1,0,1,0.030761733525422087
3936,ACTB,Signaling by RAS mutants,0.03149331722105381,0,0,1,0.03438295361698866
3937,ACTB,Signaling by RAS mutants,0.028176434258020338,1,0,1,0.030761733525422087
3938,ACTB,Signaling by moderate kinase activity BRAF mutants,0.03149331722105381,0,0,1,0.03438295361698866
3939,ACTB,Signaling by moderate kinase activity BRAF mutants,0.028176434258020338,1,0,1,0.030761733525422087
3940,ACTB,Signaling by high-kinase activity BRAF mutants,0.03149331722105381,0,0,1,0.03438295361698866
3941,ACTB,Signaling by high-kinase activity BRAF mutants,0.028176434258020338,1,0,1,0.030761733525422087
3942,ACTB,Signaling by BRAF and RAF1 fusions,0.03149331722105381,0,0,1,0.03438295361698866
3943,ACTB,Signaling by BRAF and RAF1 fusions,0.028176434258020338,1,0,1,0.030761733525422087
3944,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.03149331722105381,0,0,1,0.03438295361698866
3945,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.028176434258020338,1,0,1,0.030761733525422087
3946,ACTB,Signaling by RAF1 mutants,0.03149331722105381,0,0,1,0.03438295361698866
3947,ACTB,Signaling by RAF1 mutants,0.028176434258020338,1,0,1,0.030761733525422087
3948,ACTB,Parasite infection,0.03149331722105381,0,0,1,0.03438295361698866
3949,ACTB,Parasite infection,0.028176434258020338,1,0,1,0.030761733525422087
3950,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.03149331722105381,0,0,1,0.03438295361698866
3951,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.028176434258020338,1,0,1,0.030761733525422087
3952,ACTB,HATs acetylate histones,0.03149331722105381,0,0,1,0.03438295361698866
3953,ACTB,HATs acetylate histones,0.028176434258020338,1,0,1,0.030761733525422087
3954,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.03149331722105381,0,0,1,0.03438295361698866
3955,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.028176434258020338,1,0,1,0.030761733525422087
3956,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.03149331722105381,0,0,1,0.03438295361698866
3957,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.028176434258020338,1,0,1,0.030761733525422087
3958,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.004057140080411895,0,0,1,0.004429398726824881
3959,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.0012639979110009119,1,0,1,0.0013799747178382719
3960,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.004057140080411895,0,0,1,0.004429398726824881
3961,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0012639979110009119,1,0,1,0.0013799747178382719
3962,PSA6,Antigen processing-Cross presentation,0.004057140080411895,0,0,1,0.004429398726824881
3963,PSA6,Antigen processing-Cross presentation,0.0012639979110009119,1,0,1,0.0013799747178382719
3964,PSA6,PTEN Regulation,0.004057140080411895,0,0,1,0.004429398726824881
3965,PSA6,PTEN Regulation,0.0012639979110009119,1,0,1,0.0013799747178382719
3966,PSA6,Host Interactions of HIV factors,0.004057140080411895,0,0,1,0.004429398726824881
3967,PSA6,Host Interactions of HIV factors,0.0012639979110009119,1,0,1,0.0013799747178382719
3968,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.004057140080411895,0,0,1,0.004429398726824881
3969,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0012639979110009119,1,0,1,0.0013799747178382719
3970,PSA6,APC/C-mediated degradation of cell cycle proteins,0.004057140080411895,0,0,1,0.004429398726824881
3971,PSA6,APC/C-mediated degradation of cell cycle proteins,0.0012639979110009119,1,0,1,0.0013799747178382719
3972,PSA6,Degradation of AXIN,0.004057140080411895,0,0,1,0.004429398726824881
3973,PSA6,Degradation of AXIN,0.0012639979110009119,1,0,1,0.0013799747178382719
3974,PSA6,Degradation of DVL,0.004057140080411895,0,0,1,0.004429398726824881
3975,PSA6,Degradation of DVL,0.0012639979110009119,1,0,1,0.0013799747178382719
3976,PSA6,Downstream TCR signaling,0.004057140080411895,0,0,1,0.004429398726824881
3977,PSA6,Downstream TCR signaling,0.0012639979110009119,1,0,1,0.0013799747178382719
3978,PSA6,Transcriptional regulation by RUNX3,0.004057140080411895,0,0,1,0.004429398726824881
3979,PSA6,Transcriptional regulation by RUNX3,0.0012639979110009119,1,0,1,0.0013799747178382719
3980,PSA6,Transcriptional regulation by RUNX2,0.004057140080411895,0,0,1,0.004429398726824881
3981,PSA6,Transcriptional regulation by RUNX2,0.0012639979110009119,1,0,1,0.0013799747178382719
3982,PSA6,Transcriptional regulation by RUNX1,0.004057140080411895,0,0,1,0.004429398726824881
3983,PSA6,Transcriptional regulation by RUNX1,0.0012639979110009119,1,0,1,0.0013799747178382719
3984,PSA6,FCERI mediated NF-kB activation,0.004057140080411895,0,0,1,0.004429398726824881
3985,PSA6,FCERI mediated NF-kB activation,0.0012639979110009119,1,0,1,0.0013799747178382719
3986,PSA6,Mitotic Metaphase and Anaphase,0.004057140080411895,0,0,1,0.004429398726824881
3987,PSA6,Mitotic Metaphase and Anaphase,0.0012639979110009119,1,0,1,0.0013799747178382719
3988,PSA6,Regulation of ornithine decarboxylase (ODC),0.004057140080411895,0,0,1,0.004429398726824881
3989,PSA6,Regulation of ornithine decarboxylase (ODC),0.0012639979110009119,1,0,1,0.0013799747178382719
3990,PSA6,Signaling by ROBO receptors,0.004057140080411895,0,0,1,0.004429398726824881
3991,PSA6,Signaling by ROBO receptors,0.0012639979110009119,1,0,1,0.0013799747178382719
3992,PSA6,PCP/CE pathway,0.004057140080411895,0,0,1,0.004429398726824881
3993,PSA6,PCP/CE pathway,0.0012639979110009119,1,0,1,0.0013799747178382719
3994,PSA6,Interleukin-1 family signaling,0.004057140080411895,0,0,1,0.004429398726824881
3995,PSA6,Interleukin-1 family signaling,0.0012639979110009119,1,0,1,0.0013799747178382719
3996,PSA6,G2/M Transition,0.004057140080411895,0,0,1,0.004429398726824881
3997,PSA6,G2/M Transition,0.0012639979110009119,1,0,1,0.0013799747178382719
3998,PSA6,G1/S Transition,0.004057140080411895,0,0,1,0.004429398726824881
3999,PSA6,G1/S Transition,0.0012639979110009119,1,0,1,0.0013799747178382719
4000,PSA6,Hh mutants are degraded by ERAD,0.004057140080411895,0,0,1,0.004429398726824881
4001,PSA6,Hh mutants are degraded by ERAD,0.0012639979110009119,1,0,1,0.0013799747178382719
4002,PSA6,CLEC7A (Dectin-1) signaling,0.004057140080411895,0,0,1,0.004429398726824881
4003,PSA6,CLEC7A (Dectin-1) signaling,0.0012639979110009119,1,0,1,0.0013799747178382719
4004,PSA6,Degradation of GLI1 by the proteasome,0.004057140080411895,0,0,1,0.004429398726824881
4005,PSA6,Degradation of GLI1 by the proteasome,0.0012639979110009119,1,0,1,0.0013799747178382719
4006,PSA6,Degradation of GLI2 by the proteasome,0.004057140080411895,0,0,1,0.004429398726824881
4007,PSA6,Degradation of GLI2 by the proteasome,0.0012639979110009119,1,0,1,0.0013799747178382719
4008,PSA6,GLI3 is processed to GLI3R by the proteasome,0.004057140080411895,0,0,1,0.004429398726824881
4009,PSA6,GLI3 is processed to GLI3R by the proteasome,0.0012639979110009119,1,0,1,0.0013799747178382719
4010,PSA6,Defective CFTR causes cystic fibrosis,0.004057140080411895,0,0,1,0.004429398726824881
4011,PSA6,Defective CFTR causes cystic fibrosis,0.0012639979110009119,1,0,1,0.0013799747178382719
4012,PSA6,NIK-->noncanonical NF-kB signaling,0.004057140080411895,0,0,1,0.004429398726824881
4013,PSA6,NIK-->noncanonical NF-kB signaling,0.0012639979110009119,1,0,1,0.0013799747178382719
4014,PSA6,RAF/MAP kinase cascade,0.004057140080411895,0,0,1,0.004429398726824881
4015,PSA6,RAF/MAP kinase cascade,0.0012639979110009119,1,0,1,0.0013799747178382719
4016,PSA6,UCH proteinases,0.004057140080411895,0,0,1,0.004429398726824881
4017,PSA6,UCH proteinases,0.0012639979110009119,1,0,1,0.0013799747178382719
4018,PSA6,Ub-specific processing proteases,0.004057140080411895,0,0,1,0.004429398726824881
4019,PSA6,Ub-specific processing proteases,0.0012639979110009119,1,0,1,0.0013799747178382719
4020,PSA6,Orc1 removal from chromatin,0.004057140080411895,0,0,1,0.004429398726824881
4021,PSA6,Orc1 removal from chromatin,0.0012639979110009119,1,0,1,0.0013799747178382719
4022,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.004057140080411895,0,0,1,0.004429398726824881
4023,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.0012639979110009119,1,0,1,0.0013799747178382719
4024,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.004057140080411895,0,0,1,0.004429398726824881
4025,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.0012639979110009119,1,0,1,0.0013799747178382719
4026,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.004057140080411895,0,0,1,0.004429398726824881
4027,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.0012639979110009119,1,0,1,0.0013799747178382719
4028,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.004057140080411895,0,0,1,0.004429398726824881
4029,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.0012639979110009119,1,0,1,0.0013799747178382719
4030,PSA6,p53-Independent G1/S DNA damage checkpoint,0.004057140080411895,0,0,1,0.004429398726824881
4031,PSA6,p53-Independent G1/S DNA damage checkpoint,0.0012639979110009119,1,0,1,0.0013799747178382719
4032,PSA6,Negative regulation of NOTCH4 signaling,0.004057140080411895,0,0,1,0.004429398726824881
4033,PSA6,Negative regulation of NOTCH4 signaling,0.0012639979110009119,1,0,1,0.0013799747178382719
4034,PSA6,KEAP1-NFE2L2 pathway,0.004057140080411895,0,0,1,0.004429398726824881
4035,PSA6,KEAP1-NFE2L2 pathway,0.0012639979110009119,1,0,1,0.0013799747178382719
4036,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.004057140080411895,0,0,1,0.004429398726824881
4037,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.0012639979110009119,1,0,1,0.0013799747178382719
4038,PSA6,Degradation of beta-catenin by the destruction complex,0.004057140080411895,0,0,1,0.004429398726824881
4039,PSA6,Degradation of beta-catenin by the destruction complex,0.0012639979110009119,1,0,1,0.0013799747178382719
4040,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.004057140080411895,0,0,1,0.004429398726824881
4041,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0012639979110009119,1,0,1,0.0013799747178382719
4042,PSA6,Hedgehog ligand biogenesis,0.004057140080411895,0,0,1,0.004429398726824881
4043,PSA6,Hedgehog ligand biogenesis,0.0012639979110009119,1,0,1,0.0013799747178382719
4044,PSA6,Hedgehog 'on' state,0.004057140080411895,0,0,1,0.004429398726824881
4045,PSA6,Hedgehog 'on' state,0.0012639979110009119,1,0,1,0.0013799747178382719
4046,PSA6,MAPK6/MAPK4 signaling,0.004057140080411895,0,0,1,0.004429398726824881
4047,PSA6,MAPK6/MAPK4 signaling,0.0012639979110009119,1,0,1,0.0013799747178382719
4048,PSA6,Neddylation,0.004057140080411895,0,0,1,0.004429398726824881
4049,PSA6,Neddylation,0.0012639979110009119,1,0,1,0.0013799747178382719
4050,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.00039298378666396,0,0,1,0.0004290416031520028
4051,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.0007857070509805273,1,0,1,0.0008577987800009991
4052,RAB10,Neutrophil degranulation,0.00039298378666396,0,0,1,0.0004290416031520028
4053,RAB10,Neutrophil degranulation,0.0007857070509805273,1,0,1,0.0008577987800009991
4054,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00039298378666396,0,0,1,0.0004290416031520028
4055,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0007857070509805273,1,0,1,0.0008577987800009991
4056,RAB10,RAB geranylgeranylation,0.00039298378666396,0,0,1,0.0004290416031520028
4057,RAB10,RAB geranylgeranylation,0.0007857070509805273,1,0,1,0.0008577987800009991
4058,LYSC,Neutrophil degranulation,0.0038326355069200754,0,0,1,0.004184294970907715
4059,LYSC,Neutrophil degranulation,0.003473707763221101,1,0,1,0.0037924341873379844
4060,LYSC,Amyloid fiber formation,0.0038326355069200754,0,0,1,0.004184294970907715
4061,LYSC,Amyloid fiber formation,0.003473707763221101,1,0,1,0.0037924341873379844
4062,B2MG,Antigen processing-Cross presentation,0.010212446291186979,0,0,1,0.011149478623710391
4063,B2MG,Antigen processing-Cross presentation,0.010754366155635792,1,0,1,0.01174112177875447
4064,B2MG,Host Interactions of HIV factors,0.010212446291186979,0,0,1,0.011149478623710391
4065,B2MG,Host Interactions of HIV factors,0.010754366155635792,1,0,1,0.01174112177875447
4066,B2MG,DAP12 signaling,0.010212446291186979,0,0,1,0.011149478623710391
4067,B2MG,DAP12 signaling,0.010754366155635792,1,0,1,0.01174112177875447
4068,B2MG,Interferon gamma signaling,0.010212446291186979,0,0,1,0.011149478623710391
4069,B2MG,Interferon gamma signaling,0.010754366155635792,1,0,1,0.01174112177875447
4070,B2MG,Modulation by Mtb of host immune system,0.010212446291186979,0,0,1,0.011149478623710391
4071,B2MG,Modulation by Mtb of host immune system,0.010754366155635792,1,0,1,0.01174112177875447
4072,B2MG,SARS-CoV-2 Infection,0.010212446291186979,0,0,1,0.011149478623710391
4073,B2MG,SARS-CoV-2 Infection,0.010754366155635792,1,0,1,0.01174112177875447
4074,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.010212446291186979,0,0,1,0.011149478623710391
4075,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.010754366155635792,1,0,1,0.01174112177875447
4076,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010212446291186979,0,0,1,0.011149478623710391
4077,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010754366155635792,1,0,1,0.01174112177875447
4078,B2MG,Neutrophil degranulation,0.010212446291186979,0,0,1,0.011149478623710391
4079,B2MG,Neutrophil degranulation,0.010754366155635792,1,0,1,0.01174112177875447
4080,B2MG,Amyloid fiber formation,0.010212446291186979,0,0,1,0.011149478623710391
4081,B2MG,Amyloid fiber formation,0.010754366155635792,1,0,1,0.01174112177875447
4082,NPC2,LDL clearance,0.00024400876982192562,0,0,1,0.000266397539390263
4083,NPC2,LDL clearance,0.00013211248218890733,1,0,1,0.00014423432487098436
4084,NPC2,Neutrophil degranulation,0.00024400876982192562,0,0,1,0.000266397539390263
4085,NPC2,Neutrophil degranulation,0.00013211248218890733,1,0,1,0.00014423432487098436
4086,1433G,Activation of BH3-only proteins,0.0029251750412061434,0,0,1,0.0031935714188953994
4087,1433G,Activation of BH3-only proteins,0.003921382876141423,1,0,1,0.004281185262208227
4088,1433G,RHO GTPase Effectors,0.0029251750412061434,0,0,1,0.0031935714188953994
4089,1433G,RHO GTPase Effectors,0.003921382876141423,1,0,1,0.004281185262208227
4090,1433G,Transcriptional Regulation by TP53,0.0029251750412061434,0,0,1,0.0031935714188953994
4091,1433G,Transcriptional Regulation by TP53,0.003921382876141423,1,0,1,0.004281185262208227
4092,1433G,FOXO-mediated transcription,0.0029251750412061434,0,0,1,0.0031935714188953994
4093,1433G,FOXO-mediated transcription,0.003921382876141423,1,0,1,0.004281185262208227
4094,1433G,G2/M Transition,0.0029251750412061434,0,0,1,0.0031935714188953994
4095,1433G,G2/M Transition,0.003921382876141423,1,0,1,0.004281185262208227
4096,1433G,Mitotic Prometaphase,0.0029251750412061434,0,0,1,0.0031935714188953994
4097,1433G,Mitotic Prometaphase,0.003921382876141423,1,0,1,0.004281185262208227
4098,1433G,G2/M DNA damage checkpoint,0.0029251750412061434,0,0,1,0.0031935714188953994
4099,1433G,G2/M DNA damage checkpoint,0.003921382876141423,1,0,1,0.004281185262208227
4100,1433G,SARS-CoV-2 Infection,0.0029251750412061434,0,0,1,0.0031935714188953994
4101,1433G,SARS-CoV-2 Infection,0.003921382876141423,1,0,1,0.004281185262208227
4102,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0029251750412061434,0,0,1,0.0031935714188953994
4103,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.003921382876141423,1,0,1,0.004281185262208227
4104,1433G,Anchoring of the basal body to the plasma membrane,0.0029251750412061434,0,0,1,0.0031935714188953994
4105,1433G,Anchoring of the basal body to the plasma membrane,0.003921382876141423,1,0,1,0.004281185262208227
4106,1433E,Activation of BH3-only proteins,0.0024700467811594835,0,0,1,0.002696683341176369
4107,1433E,Activation of BH3-only proteins,0.003391265645174092,1,0,1,0.003702427678941288
4108,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.0024700467811594835,0,0,1,0.002696683341176369
4109,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.003391265645174092,1,0,1,0.003702427678941288
4110,1433E,RHO GTPase Effectors,0.0024700467811594835,0,0,1,0.002696683341176369
4111,1433E,RHO GTPase Effectors,0.003391265645174092,1,0,1,0.003702427678941288
4112,1433E,Transcriptional Regulation by TP53,0.0024700467811594835,0,0,1,0.002696683341176369
4113,1433E,Transcriptional Regulation by TP53,0.003391265645174092,1,0,1,0.003702427678941288
4114,1433E,Regulation of HSF1-mediated heat shock response,0.0024700467811594835,0,0,1,0.002696683341176369
4115,1433E,Regulation of HSF1-mediated heat shock response,0.003391265645174092,1,0,1,0.003702427678941288
4116,1433E,HSF1 activation,0.0024700467811594835,0,0,1,0.002696683341176369
4117,1433E,HSF1 activation,0.003391265645174092,1,0,1,0.003702427678941288
4118,1433E,G2/M Transition,0.0024700467811594835,0,0,1,0.002696683341176369
4119,1433E,G2/M Transition,0.003391265645174092,1,0,1,0.003702427678941288
4120,1433E,Mitotic Prometaphase,0.0024700467811594835,0,0,1,0.002696683341176369
4121,1433E,Mitotic Prometaphase,0.003391265645174092,1,0,1,0.003702427678941288
4122,1433E,G2/M DNA damage checkpoint,0.0024700467811594835,0,0,1,0.002696683341176369
4123,1433E,G2/M DNA damage checkpoint,0.003391265645174092,1,0,1,0.003702427678941288
4124,1433E,Neurodegenerative Diseases,0.0024700467811594835,0,0,1,0.002696683341176369
4125,1433E,Neurodegenerative Diseases,0.003391265645174092,1,0,1,0.003702427678941288
4126,1433E,RAB GEFs exchange GTP for GDP on RABs,0.0024700467811594835,0,0,1,0.002696683341176369
4127,1433E,RAB GEFs exchange GTP for GDP on RABs,0.003391265645174092,1,0,1,0.003702427678941288
4128,1433E,SARS-CoV-2 Infection,0.0024700467811594835,0,0,1,0.002696683341176369
4129,1433E,SARS-CoV-2 Infection,0.003391265645174092,1,0,1,0.003702427678941288
4130,1433E,Signaling by Hippo,0.0024700467811594835,0,0,1,0.002696683341176369
4131,1433E,Signaling by Hippo,0.003391265645174092,1,0,1,0.003702427678941288
4132,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0024700467811594835,0,0,1,0.002696683341176369
4133,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.003391265645174092,1,0,1,0.003702427678941288
4134,1433E,Anchoring of the basal body to the plasma membrane,0.0024700467811594835,0,0,1,0.002696683341176369
4135,1433E,Anchoring of the basal body to the plasma membrane,0.003391265645174092,1,0,1,0.003702427678941288
4136,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.0013869805971195798,0,0,1,0.0015142415517456257
4137,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.0010930041010346178,1,0,1,0.0011932915496093985
4138,ACTA,Smooth Muscle Contraction,0.0013869805971195798,0,0,1,0.0015142415517456257
4139,ACTA,Smooth Muscle Contraction,0.0010930041010346178,1,0,1,0.0011932915496093985
4140,H4,Packaging Of Telomere Ends,0.020112257743925614,0,0,1,0.021957636926224572
4141,H4,Packaging Of Telomere Ends,0.017017579746200953,1,0,1,0.01857900998424752
4142,H4,Inhibition of DNA recombination at telomere,0.020112257743925614,0,0,1,0.021957636926224572
4143,H4,Inhibition of DNA recombination at telomere,0.017017579746200953,1,0,1,0.01857900998424752
4144,H4,Pre-NOTCH Transcription and Translation,0.020112257743925614,0,0,1,0.021957636926224572
4145,H4,Pre-NOTCH Transcription and Translation,0.017017579746200953,1,0,1,0.01857900998424752
4146,H4,RHO GTPase Effectors,0.020112257743925614,0,0,1,0.021957636926224572
4147,H4,RHO GTPase Effectors,0.017017579746200953,1,0,1,0.01857900998424752
4148,H4,Formation of the beta-catenin:TCF transactivating complex,0.020112257743925614,0,0,1,0.021957636926224572
4149,H4,Formation of the beta-catenin:TCF transactivating complex,0.017017579746200953,1,0,1,0.01857900998424752
4150,H4,Transcriptional regulation by RUNX1,0.020112257743925614,0,0,1,0.021957636926224572
4151,H4,Transcriptional regulation by RUNX1,0.017017579746200953,1,0,1,0.01857900998424752
4152,H4,Oxidative Stress Induced Senescence,0.020112257743925614,0,0,1,0.021957636926224572
4153,H4,Oxidative Stress Induced Senescence,0.017017579746200953,1,0,1,0.01857900998424752
4154,H4,Senescence-Associated Secretory Phenotype (SASP),0.020112257743925614,0,0,1,0.021957636926224572
4155,H4,Senescence-Associated Secretory Phenotype (SASP),0.017017579746200953,1,0,1,0.01857900998424752
4156,H4,DNA Damage/Telomere Stress Induced Senescence,0.020112257743925614,0,0,1,0.021957636926224572
4157,H4,DNA Damage/Telomere Stress Induced Senescence,0.017017579746200953,1,0,1,0.01857900998424752
4158,H4,SUMO E3 ligases SUMOylate target proteins,0.020112257743925614,0,0,1,0.021957636926224572
4159,H4,SUMO E3 ligases SUMOylate target proteins,0.017017579746200953,1,0,1,0.01857900998424752
4160,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.020112257743925614,0,0,1,0.021957636926224572
4161,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.017017579746200953,1,0,1,0.01857900998424752
4162,H4,B-WICH complex positively regulates rRNA expression,0.020112257743925614,0,0,1,0.021957636926224572
4163,H4,B-WICH complex positively regulates rRNA expression,0.017017579746200953,1,0,1,0.01857900998424752
4164,H4,SIRT1 negatively regulates rRNA expression,0.020112257743925614,0,0,1,0.021957636926224572
4165,H4,SIRT1 negatively regulates rRNA expression,0.017017579746200953,1,0,1,0.01857900998424752
4166,H4,NoRC negatively regulates rRNA expression,0.020112257743925614,0,0,1,0.021957636926224572
4167,H4,NoRC negatively regulates rRNA expression,0.017017579746200953,1,0,1,0.01857900998424752
4168,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.020112257743925614,0,0,1,0.021957636926224572
4169,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.017017579746200953,1,0,1,0.01857900998424752
4170,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.020112257743925614,0,0,1,0.021957636926224572
4171,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.017017579746200953,1,0,1,0.01857900998424752
4172,H4,Assembly of the ORC complex at the origin of replication,0.020112257743925614,0,0,1,0.021957636926224572
4173,H4,Assembly of the ORC complex at the origin of replication,0.017017579746200953,1,0,1,0.01857900998424752
4174,H4,Mitotic Prophase,0.020112257743925614,0,0,1,0.021957636926224572
4175,H4,Mitotic Prophase,0.017017579746200953,1,0,1,0.01857900998424752
4176,H4,G2/M DNA damage checkpoint,0.020112257743925614,0,0,1,0.021957636926224572
4177,H4,G2/M DNA damage checkpoint,0.017017579746200953,1,0,1,0.01857900998424752
4178,H4,RNA Polymerase I Promoter Opening,0.020112257743925614,0,0,1,0.021957636926224572
4179,H4,RNA Polymerase I Promoter Opening,0.017017579746200953,1,0,1,0.01857900998424752
4180,H4,RNA Polymerase I Promoter Escape,0.020112257743925614,0,0,1,0.021957636926224572
4181,H4,RNA Polymerase I Promoter Escape,0.017017579746200953,1,0,1,0.01857900998424752
4182,H4,Depurination,0.020112257743925614,0,0,1,0.021957636926224572
4183,H4,Depurination,0.017017579746200953,1,0,1,0.01857900998424752
4184,H4,Depyrimidination,0.020112257743925614,0,0,1,0.021957636926224572
4185,H4,Depyrimidination,0.017017579746200953,1,0,1,0.01857900998424752
4186,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.020112257743925614,0,0,1,0.021957636926224572
4187,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.017017579746200953,1,0,1,0.01857900998424752
4188,H4,Estrogen-dependent gene expression,0.020112257743925614,0,0,1,0.021957636926224572
4189,H4,Estrogen-dependent gene expression,0.017017579746200953,1,0,1,0.01857900998424752
4190,H4,HCMV Early Events,0.020112257743925614,0,0,1,0.021957636926224572
4191,H4,HCMV Early Events,0.017017579746200953,1,0,1,0.01857900998424752
4192,H4,HCMV Late Events,0.020112257743925614,0,0,1,0.021957636926224572
4193,H4,HCMV Late Events,0.017017579746200953,1,0,1,0.01857900998424752
4194,H4,Transcriptional regulation of granulopoiesis,0.020112257743925614,0,0,1,0.021957636926224572
4195,H4,Transcriptional regulation of granulopoiesis,0.017017579746200953,1,0,1,0.01857900998424752
4196,H4,Meiotic synapsis,0.020112257743925614,0,0,1,0.021957636926224572
4197,H4,Meiotic synapsis,0.017017579746200953,1,0,1,0.01857900998424752
4198,H4,Meiotic recombination,0.020112257743925614,0,0,1,0.021957636926224572
4199,H4,Meiotic recombination,0.017017579746200953,1,0,1,0.01857900998424752
4200,H4,Transcriptional regulation by small RNAs,0.020112257743925614,0,0,1,0.021957636926224572
4201,H4,Transcriptional regulation by small RNAs,0.017017579746200953,1,0,1,0.01857900998424752
4202,H4,PRC2 methylates histones and DNA,0.020112257743925614,0,0,1,0.021957636926224572
4203,H4,PRC2 methylates histones and DNA,0.017017579746200953,1,0,1,0.01857900998424752
4204,H4,DNA methylation,0.020112257743925614,0,0,1,0.021957636926224572
4205,H4,DNA methylation,0.017017579746200953,1,0,1,0.01857900998424752
4206,H4,HDACs deacetylate histones,0.020112257743925614,0,0,1,0.021957636926224572
4207,H4,HDACs deacetylate histones,0.017017579746200953,1,0,1,0.01857900998424752
4208,H4,PKMTs methylate histone lysines,0.020112257743925614,0,0,1,0.021957636926224572
4209,H4,PKMTs methylate histone lysines,0.017017579746200953,1,0,1,0.01857900998424752
4210,H4,HDMs demethylate histones,0.020112257743925614,0,0,1,0.021957636926224572
4211,H4,HDMs demethylate histones,0.017017579746200953,1,0,1,0.01857900998424752
4212,H4,HATs acetylate histones,0.020112257743925614,0,0,1,0.021957636926224572
4213,H4,HATs acetylate histones,0.017017579746200953,1,0,1,0.01857900998424752
4214,H4,RMTs methylate histone arginines,0.020112257743925614,0,0,1,0.021957636926224572
4215,H4,RMTs methylate histone arginines,0.017017579746200953,1,0,1,0.01857900998424752
4216,H4,Amyloid fiber formation,0.020112257743925614,0,0,1,0.021957636926224572
4217,H4,Amyloid fiber formation,0.017017579746200953,1,0,1,0.01857900998424752
4218,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.020112257743925614,0,0,1,0.021957636926224572
4219,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.017017579746200953,1,0,1,0.01857900998424752
4220,H4,Nonhomologous End-Joining (NHEJ),0.020112257743925614,0,0,1,0.021957636926224572
4221,H4,Nonhomologous End-Joining (NHEJ),0.017017579746200953,1,0,1,0.01857900998424752
4222,H4,Defective pyroptosis,0.020112257743925614,0,0,1,0.021957636926224572
4223,H4,Defective pyroptosis,0.017017579746200953,1,0,1,0.01857900998424752
4224,RAP1A,Signaling by NTRK1 (TRKA),0.0038410458716133674,0,0,1,0.0041934770198205585
4225,RAP1A,Signaling by NTRK1 (TRKA),0.003453992344415392,1,0,1,0.0037709098008918644
4226,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.0038410458716133674,0,0,1,0.0041934770198205585
4227,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.003453992344415392,1,0,1,0.0037709098008918644
4228,RAP1A,RAF/MAP kinase cascade,0.0038410458716133674,0,0,1,0.0041934770198205585
4229,RAP1A,RAF/MAP kinase cascade,0.003453992344415392,1,0,1,0.0037709098008918644
4230,RAP1A,Signaling by RAS mutants,0.0038410458716133674,0,0,1,0.0041934770198205585
4231,RAP1A,Signaling by RAS mutants,0.003453992344415392,1,0,1,0.0037709098008918644
4232,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.0038410458716133674,0,0,1,0.0041934770198205585
4233,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.003453992344415392,1,0,1,0.0037709098008918644
4234,RAP1A,Signaling by high-kinase activity BRAF mutants,0.0038410458716133674,0,0,1,0.0041934770198205585
4235,RAP1A,Signaling by high-kinase activity BRAF mutants,0.003453992344415392,1,0,1,0.0037709098008918644
4236,RAP1A,Signaling by BRAF and RAF1 fusions,0.0038410458716133674,0,0,1,0.0041934770198205585
4237,RAP1A,Signaling by BRAF and RAF1 fusions,0.003453992344415392,1,0,1,0.0037709098008918644
4238,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0038410458716133674,0,0,1,0.0041934770198205585
4239,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.003453992344415392,1,0,1,0.0037709098008918644
4240,RAP1A,Signaling by RAF1 mutants,0.0038410458716133674,0,0,1,0.0041934770198205585
4241,RAP1A,Signaling by RAF1 mutants,0.003453992344415392,1,0,1,0.0037709098008918644
4242,RAP1A,MET promotes cell motility,0.0038410458716133674,0,0,1,0.0041934770198205585
4243,RAP1A,MET promotes cell motility,0.003453992344415392,1,0,1,0.0037709098008918644
4244,RAP1A,Rap1 signalling,0.0038410458716133674,0,0,1,0.0041934770198205585
4245,RAP1A,Rap1 signalling,0.003453992344415392,1,0,1,0.0037709098008918644
4246,RAP1A,Neutrophil degranulation,0.0038410458716133674,0,0,1,0.0041934770198205585
4247,RAP1A,Neutrophil degranulation,0.003453992344415392,1,0,1,0.0037709098008918644
4248,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0038410458716133674,0,0,1,0.0041934770198205585
4249,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.003453992344415392,1,0,1,0.0037709098008918644
4250,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.0038410458716133674,0,0,1,0.0041934770198205585
4251,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.003453992344415392,1,0,1,0.0037709098008918644
4252,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.0006412091383682138,0,0,1,0.0007000426124868484
4253,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.00038253114763591177,1,0,1,0.0004176298931579775
4254,PPIA,HIV Life Cycle,0.0006412091383682138,0,0,1,0.0007000426124868484
4255,PPIA,HIV Life Cycle,0.00038253114763591177,1,0,1,0.0004176298931579775
4256,PPIA,Host Interactions of HIV factors,0.0006412091383682138,0,0,1,0.0007000426124868484
4257,PPIA,Host Interactions of HIV factors,0.00038253114763591177,1,0,1,0.0004176298931579775
4258,PPIA,Interleukin-12 family signaling,0.0006412091383682138,0,0,1,0.0007000426124868484
4259,PPIA,Interleukin-12 family signaling,0.00038253114763591177,1,0,1,0.0004176298931579775
4260,PPIA,Platelet degranulation ,0.0006412091383682138,0,0,1,0.0007000426124868484
4261,PPIA,Platelet degranulation ,0.00038253114763591177,1,0,1,0.0004176298931579775
4262,PPIA,Neutrophil degranulation,0.0006412091383682138,0,0,1,0.0007000426124868484
4263,PPIA,Neutrophil degranulation,0.00038253114763591177,1,0,1,0.0004176298931579775
4264,PPIA,Basigin interactions,0.0006412091383682138,0,0,1,0.0007000426124868484
4265,PPIA,Basigin interactions,0.00038253114763591177,1,0,1,0.0004176298931579775
4266,1433Z,Activation of BH3-only proteins,0.00042255328857287435,0,0,1,0.0004613242237942001
4267,1433Z,Activation of BH3-only proteins,0.0035242552829530434,1,0,1,0.0038476196418964306
4268,1433Z,RHO GTPase Effectors,0.00042255328857287435,0,0,1,0.0004613242237942001
4269,1433Z,RHO GTPase Effectors,0.0035242552829530434,1,0,1,0.0038476196418964306
4270,1433Z,Deactivation of the beta-catenin transactivating complex,0.00042255328857287435,0,0,1,0.0004613242237942001
4271,1433Z,Deactivation of the beta-catenin transactivating complex,0.0035242552829530434,1,0,1,0.0038476196418964306
4272,1433Z,Transcriptional Regulation by TP53,0.00042255328857287435,0,0,1,0.0004613242237942001
4273,1433Z,Transcriptional Regulation by TP53,0.0035242552829530434,1,0,1,0.0038476196418964306
4274,1433Z,FOXO-mediated transcription,0.00042255328857287435,0,0,1,0.0004613242237942001
4275,1433Z,FOXO-mediated transcription,0.0035242552829530434,1,0,1,0.0038476196418964306
4276,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.00042255328857287435,0,0,1,0.0004613242237942001
4277,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.0035242552829530434,1,0,1,0.0038476196418964306
4278,1433Z,G2/M DNA damage checkpoint,0.00042255328857287435,0,0,1,0.0004613242237942001
4279,1433Z,G2/M DNA damage checkpoint,0.0035242552829530434,1,0,1,0.0038476196418964306
4280,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.00042255328857287435,0,0,1,0.0004613242237942001
4281,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0035242552829530434,1,0,1,0.0038476196418964306
4282,1433Z,Negative regulation of NOTCH4 signaling,0.00042255328857287435,0,0,1,0.0004613242237942001
4283,1433Z,Negative regulation of NOTCH4 signaling,0.0035242552829530434,1,0,1,0.0038476196418964306
4284,1433Z,SARS-CoV-2 Infection,0.00042255328857287435,0,0,1,0.0004613242237942001
4285,1433Z,SARS-CoV-2 Infection,0.0035242552829530434,1,0,1,0.0038476196418964306
4286,1433Z,Rap1 signalling,0.00042255328857287435,0,0,1,0.0004613242237942001
4287,1433Z,Rap1 signalling,0.0035242552829530434,1,0,1,0.0038476196418964306
4288,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00042255328857287435,0,0,1,0.0004613242237942001
4289,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0035242552829530434,1,0,1,0.0038476196418964306
4290,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.00042255328857287435,0,0,1,0.0004613242237942001
4291,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.0035242552829530434,1,0,1,0.0038476196418964306
4292,1433Z,GP1b-IX-V activation signalling,0.00042255328857287435,0,0,1,0.0004613242237942001
4293,1433Z,GP1b-IX-V activation signalling,0.0035242552829530434,1,0,1,0.0038476196418964306
4294,TPM4,RHO GTPase cycle,0.001618958032674624,0,0,1,0.001767503834371888
4295,TPM4,RHO GTPase cycle,0.0025894523032132517,1,0,1,0.002827044792069907
4296,TPM4,Signaling by ALK fusions and activated point mutants,0.001618958032674624,0,0,1,0.001767503834371888
4297,TPM4,Signaling by ALK fusions and activated point mutants,0.0025894523032132517,1,0,1,0.002827044792069907
4298,TPM4,Striated Muscle Contraction,0.001618958032674624,0,0,1,0.001767503834371888
4299,TPM4,Striated Muscle Contraction,0.0025894523032132517,1,0,1,0.002827044792069907
4300,TPM4,Smooth Muscle Contraction,0.001618958032674624,0,0,1,0.001767503834371888
4301,TPM4,Smooth Muscle Contraction,0.0025894523032132517,1,0,1,0.002827044792069907
4302,TBA1B,Activation of NMDA receptors and postsynaptic events,0.0018660258742576456,0,0,1,0.0020372411274544827
4303,TBA1B,Activation of NMDA receptors and postsynaptic events,0.004197020591874867,1,0,1,0.00458211382837464
4304,TBA1B,Gap junction trafficking,0.0018660258742576456,0,0,1,0.0020372411274544827
4305,TBA1B,Gap junction trafficking,0.004197020591874867,1,0,1,0.00458211382837464
4306,TBA1B,RHO GTPase Effectors,0.0018660258742576456,0,0,1,0.0020372411274544827
4307,TBA1B,RHO GTPase Effectors,0.004197020591874867,1,0,1,0.00458211382837464
4308,TBA1B,RHO GTPase cycle,0.0018660258742576456,0,0,1,0.0020372411274544827
4309,TBA1B,RHO GTPase cycle,0.004197020591874867,1,0,1,0.00458211382837464
4310,TBA1B,COPI-mediated anterograde transport,0.0018660258742576456,0,0,1,0.0020372411274544827
4311,TBA1B,COPI-mediated anterograde transport,0.004197020591874867,1,0,1,0.00458211382837464
4312,TBA1B,Mitotic Metaphase and Anaphase,0.0018660258742576456,0,0,1,0.0020372411274544827
4313,TBA1B,Mitotic Metaphase and Anaphase,0.004197020591874867,1,0,1,0.00458211382837464
4314,TBA1B,L1CAM interactions,0.0018660258742576456,0,0,1,0.0020372411274544827
4315,TBA1B,L1CAM interactions,0.004197020591874867,1,0,1,0.00458211382837464
4316,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0018660258742576456,0,0,1,0.0020372411274544827
4317,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.004197020591874867,1,0,1,0.00458211382837464
4318,TBA1B,G2/M Transition,0.0018660258742576456,0,0,1,0.0020372411274544827
4319,TBA1B,G2/M Transition,0.004197020591874867,1,0,1,0.00458211382837464
4320,TBA1B,Golgi-to-ER retrograde transport,0.0018660258742576456,0,0,1,0.0020372411274544827
4321,TBA1B,Golgi-to-ER retrograde transport,0.004197020591874867,1,0,1,0.00458211382837464
4322,TBA1B,Mitotic Prometaphase,0.0018660258742576456,0,0,1,0.0020372411274544827
4323,TBA1B,Mitotic Prometaphase,0.004197020591874867,1,0,1,0.00458211382837464
4324,TBA1B,HCMV Early Events,0.0018660258742576456,0,0,1,0.0020372411274544827
4325,TBA1B,HCMV Early Events,0.004197020591874867,1,0,1,0.00458211382837464
4326,TBA1B,Aggrephagy,0.0018660258742576456,0,0,1,0.0020372411274544827
4327,TBA1B,Aggrephagy,0.004197020591874867,1,0,1,0.00458211382837464
4328,TBA1B,MHC class II antigen presentation,0.0018660258742576456,0,0,1,0.0020372411274544827
4329,TBA1B,MHC class II antigen presentation,0.004197020591874867,1,0,1,0.00458211382837464
4330,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0018660258742576456,0,0,1,0.0020372411274544827
4331,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.004197020591874867,1,0,1,0.00458211382837464
4332,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0018660258742576456,0,0,1,0.0020372411274544827
4333,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.004197020591874867,1,0,1,0.00458211382837464
4334,TBA1B,Post-chaperonin tubulin folding pathway,0.0018660258742576456,0,0,1,0.0020372411274544827
4335,TBA1B,Post-chaperonin tubulin folding pathway,0.004197020591874867,1,0,1,0.00458211382837464
4336,TBA1B,Intraflagellar transport,0.0018660258742576456,0,0,1,0.0020372411274544827
4337,TBA1B,Intraflagellar transport,0.004197020591874867,1,0,1,0.00458211382837464
4338,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.0018660258742576456,0,0,1,0.0020372411274544827
4339,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.004197020591874867,1,0,1,0.00458211382837464
4340,TBA1B,Kinesins,0.0018660258742576456,0,0,1,0.0020372411274544827
4341,TBA1B,Kinesins,0.004197020591874867,1,0,1,0.00458211382837464
4342,TBA4A,Activation of NMDA receptors and postsynaptic events,0.0015166461276474338,0,0,1,0.0016558044074641393
4343,TBA4A,Activation of NMDA receptors and postsynaptic events,0.0003520268182105472,1,0,1,0.0003843266708779031
4344,TBA4A,Gap junction trafficking,0.0015166461276474338,0,0,1,0.0016558044074641393
4345,TBA4A,Gap junction trafficking,0.0003520268182105472,1,0,1,0.0003843266708779031
4346,TBA4A,RHO GTPase Effectors,0.0015166461276474338,0,0,1,0.0016558044074641393
4347,TBA4A,RHO GTPase Effectors,0.0003520268182105472,1,0,1,0.0003843266708779031
4348,TBA4A,COPI-mediated anterograde transport,0.0015166461276474338,0,0,1,0.0016558044074641393
4349,TBA4A,COPI-mediated anterograde transport,0.0003520268182105472,1,0,1,0.0003843266708779031
4350,TBA4A,Mitotic Metaphase and Anaphase,0.0015166461276474338,0,0,1,0.0016558044074641393
4351,TBA4A,Mitotic Metaphase and Anaphase,0.0003520268182105472,1,0,1,0.0003843266708779031
4352,TBA4A,L1CAM interactions,0.0015166461276474338,0,0,1,0.0016558044074641393
4353,TBA4A,L1CAM interactions,0.0003520268182105472,1,0,1,0.0003843266708779031
4354,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0015166461276474338,0,0,1,0.0016558044074641393
4355,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0003520268182105472,1,0,1,0.0003843266708779031
4356,TBA4A,G2/M Transition,0.0015166461276474338,0,0,1,0.0016558044074641393
4357,TBA4A,G2/M Transition,0.0003520268182105472,1,0,1,0.0003843266708779031
4358,TBA4A,Golgi-to-ER retrograde transport,0.0015166461276474338,0,0,1,0.0016558044074641393
4359,TBA4A,Golgi-to-ER retrograde transport,0.0003520268182105472,1,0,1,0.0003843266708779031
4360,TBA4A,Mitotic Prometaphase,0.0015166461276474338,0,0,1,0.0016558044074641393
4361,TBA4A,Mitotic Prometaphase,0.0003520268182105472,1,0,1,0.0003843266708779031
4362,TBA4A,Platelet degranulation ,0.0015166461276474338,0,0,1,0.0016558044074641393
4363,TBA4A,Platelet degranulation ,0.0003520268182105472,1,0,1,0.0003843266708779031
4364,TBA4A,HCMV Early Events,0.0015166461276474338,0,0,1,0.0016558044074641393
4365,TBA4A,HCMV Early Events,0.0003520268182105472,1,0,1,0.0003843266708779031
4366,TBA4A,Aggrephagy,0.0015166461276474338,0,0,1,0.0016558044074641393
4367,TBA4A,Aggrephagy,0.0003520268182105472,1,0,1,0.0003843266708779031
4368,TBA4A,MHC class II antigen presentation,0.0015166461276474338,0,0,1,0.0016558044074641393
4369,TBA4A,MHC class II antigen presentation,0.0003520268182105472,1,0,1,0.0003843266708779031
4370,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0015166461276474338,0,0,1,0.0016558044074641393
4371,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0003520268182105472,1,0,1,0.0003843266708779031
4372,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0015166461276474338,0,0,1,0.0016558044074641393
4373,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0003520268182105472,1,0,1,0.0003843266708779031
4374,TBA4A,Post-chaperonin tubulin folding pathway,0.0015166461276474338,0,0,1,0.0016558044074641393
4375,TBA4A,Post-chaperonin tubulin folding pathway,0.0003520268182105472,1,0,1,0.0003843266708779031
4376,TBA4A,Anchoring of the basal body to the plasma membrane,0.0015166461276474338,0,0,1,0.0016558044074641393
4377,TBA4A,Anchoring of the basal body to the plasma membrane,0.0003520268182105472,1,0,1,0.0003843266708779031
4378,TBA4A,Intraflagellar transport,0.0015166461276474338,0,0,1,0.0016558044074641393
4379,TBA4A,Intraflagellar transport,0.0003520268182105472,1,0,1,0.0003843266708779031
4380,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.0015166461276474338,0,0,1,0.0016558044074641393
4381,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.0003520268182105472,1,0,1,0.0003843266708779031
4382,TBA4A,Kinesins,0.0015166461276474338,0,0,1,0.0016558044074641393
4383,TBA4A,Kinesins,0.0003520268182105472,1,0,1,0.0003843266708779031
4384,HBB,Cytoprotection by HMOX1,0.0165732948795442,0,0,1,0.01809396022414232
4385,HBB,Cytoprotection by HMOX1,0.011866665630509603,1,0,1,0.01295547912905672
4386,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.0165732948795442,0,0,1,0.01809396022414232
4387,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.011866665630509603,1,0,1,0.01295547912905672
4388,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.0165732948795442,0,0,1,0.01809396022414232
4389,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.011866665630509603,1,0,1,0.01295547912905672
4390,HBB,Neutrophil degranulation,0.0165732948795442,0,0,1,0.01809396022414232
4391,HBB,Neutrophil degranulation,0.011866665630509603,1,0,1,0.01295547912905672
4392,HBB,Scavenging of heme from plasma,0.0165732948795442,0,0,1,0.01809396022414232
4393,HBB,Scavenging of heme from plasma,0.011866665630509603,1,0,1,0.01295547912905672
4394,HBB,Heme signaling,0.0165732948795442,0,0,1,0.01809396022414232
4395,HBB,Heme signaling,0.011866665630509603,1,0,1,0.01295547912905672
4396,HBB,Chaperone Mediated Autophagy,0.0165732948795442,0,0,1,0.01809396022414232
4397,HBB,Chaperone Mediated Autophagy,0.011866665630509603,1,0,1,0.01295547912905672
4398,HBB,Late endosomal microautophagy,0.0165732948795442,0,0,1,0.01809396022414232
4399,HBB,Late endosomal microautophagy,0.011866665630509603,1,0,1,0.01295547912905672
4400,HBA,Cytoprotection by HMOX1,0.00144483393595863,0,0,1,0.001577403163205253
4401,HBA,Cytoprotection by HMOX1,0.0012148139445473255,1,0,1,0.0013262779279636673
4402,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.00144483393595863,0,0,1,0.001577403163205253
4403,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.0012148139445473255,1,0,1,0.0013262779279636673
4404,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.00144483393595863,0,0,1,0.001577403163205253
4405,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.0012148139445473255,1,0,1,0.0013262779279636673
4406,HBA,Scavenging of heme from plasma,0.00144483393595863,0,0,1,0.001577403163205253
4407,HBA,Scavenging of heme from plasma,0.0012148139445473255,1,0,1,0.0013262779279636673
4408,HBA,Heme signaling,0.00144483393595863,0,0,1,0.001577403163205253
4409,HBA,Heme signaling,0.0012148139445473255,1,0,1,0.0013262779279636673
4410,GSTO1,Methylation,0.001263886642273572,0,0,1,0.0013798532397651844
4411,GSTO1,Methylation,0.0019134309321292085,1,0,1,0.0020889957868499365
4412,GSTO1,Glutathione conjugation,0.001263886642273572,0,0,1,0.0013798532397651844
4413,GSTO1,Glutathione conjugation,0.0019134309321292085,1,0,1,0.0020889957868499365
4414,GSTO1,Vitamin C (ascorbate) metabolism,0.001263886642273572,0,0,1,0.0013798532397651844
4415,GSTO1,Vitamin C (ascorbate) metabolism,0.0019134309321292085,1,0,1,0.0020889957868499365
4416,GSTO1,Interleukin-12 family signaling,0.001263886642273572,0,0,1,0.0013798532397651844
4417,GSTO1,Interleukin-12 family signaling,0.0019134309321292085,1,0,1,0.0020889957868499365
4418,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0010272130495600138,0,0,1,0.0011214639089900745
4419,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.00045853722147900405,1,0,1,0.0005006098248435929
4420,NGAL,Interleukin-4 and Interleukin-13 signaling,0.004028067902837268,0,0,1,0.00439765906199132
4421,NGAL,Interleukin-4 and Interleukin-13 signaling,0.004345799532110237,1,0,1,0.004744543824725665
4422,NGAL,Metal sequestration by antimicrobial proteins,0.004028067902837268,0,0,1,0.00439765906199132
4423,NGAL,Metal sequestration by antimicrobial proteins,0.004345799532110237,1,0,1,0.004744543824725665
4424,NGAL,Neutrophil degranulation,0.004028067902837268,0,0,1,0.00439765906199132
4425,NGAL,Neutrophil degranulation,0.004345799532110237,1,0,1,0.004744543824725665
4426,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.00033417696862343064,0,0,1,0.0003648390270036095
4427,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.0011453135605360178,1,0,1,0.0012504006088787732
4428,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.00033417696862343064,0,0,1,0.0003648390270036095
4429,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.0011453135605360178,1,0,1,0.0012504006088787732
4430,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.00033417696862343064,0,0,1,0.0003648390270036095
4431,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.0011453135605360178,1,0,1,0.0012504006088787732
4432,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.00033417696862343064,0,0,1,0.0003648390270036095
4433,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.0011453135605360178,1,0,1,0.0012504006088787732
4434,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.00033417696862343064,0,0,1,0.0003648390270036095
4435,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.0011453135605360178,1,0,1,0.0012504006088787732
4436,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.00033417696862343064,0,0,1,0.0003648390270036095
4437,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0011453135605360178,1,0,1,0.0012504006088787732
4438,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.00033417696862343064,0,0,1,0.0003648390270036095
4439,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.0011453135605360178,1,0,1,0.0012504006088787732
4440,S10AC,TRAF6 mediated NF-kB activation,0.00033417696862343064,0,0,1,0.0003648390270036095
4441,S10AC,TRAF6 mediated NF-kB activation,0.0011453135605360178,1,0,1,0.0012504006088787732
4442,S10AC,Interleukin-1 family signaling,0.00033417696862343064,0,0,1,0.0003648390270036095
4443,S10AC,Interleukin-1 family signaling,0.0011453135605360178,1,0,1,0.0012504006088787732
4444,S10AC,Neutrophil degranulation,0.00033417696862343064,0,0,1,0.0003648390270036095
4445,S10AC,Neutrophil degranulation,0.0011453135605360178,1,0,1,0.0012504006088787732
4446,S10AC,Advanced glycosylation endproduct receptor signaling,0.00033417696862343064,0,0,1,0.0003648390270036095
4447,S10AC,Advanced glycosylation endproduct receptor signaling,0.0011453135605360178,1,0,1,0.0012504006088787732
4448,BASP1,RHO GTPase cycle,0.0033159556693449464,0,0,1,0.003620207715015131
4449,BASP1,RHO GTPase cycle,0.003813673711977521,1,0,1,0.004163593356294413
4450,LV321,Initial triggering of complement,0.0024445938164495916,0,0,1,0.002668894966300127
4451,LV321,Initial triggering of complement,0.002688173483912223,1,0,1,0.002934824031492737
4452,LV321,Regulation of Complement cascade,0.0024445938164495916,0,0,1,0.002668894966300127
4453,LV321,Regulation of Complement cascade,0.002688173483912223,1,0,1,0.002934824031492737
4454,LV321,FCGR activation,0.0024445938164495916,0,0,1,0.002668894966300127
4455,LV321,FCGR activation,0.002688173483912223,1,0,1,0.002934824031492737
4456,LV321,Regulation of actin dynamics for phagocytic cup formation,0.0024445938164495916,0,0,1,0.002668894966300127
4457,LV321,Regulation of actin dynamics for phagocytic cup formation,0.002688173483912223,1,0,1,0.002934824031492737
4458,LV321,Role of phospholipids in phagocytosis,0.0024445938164495916,0,0,1,0.002668894966300127
4459,LV321,Role of phospholipids in phagocytosis,0.002688173483912223,1,0,1,0.002934824031492737
4460,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.0024445938164495916,0,0,1,0.002668894966300127
4461,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.002688173483912223,1,0,1,0.002934824031492737
4462,LV321,FCERI mediated MAPK activation,0.0024445938164495916,0,0,1,0.002668894966300127
4463,LV321,FCERI mediated MAPK activation,0.002688173483912223,1,0,1,0.002934824031492737
4464,LV321,FCERI mediated Ca+2 mobilization,0.0024445938164495916,0,0,1,0.002668894966300127
4465,LV321,FCERI mediated Ca+2 mobilization,0.002688173483912223,1,0,1,0.002934824031492737
4466,LV321,FCERI mediated NF-kB activation,0.0024445938164495916,0,0,1,0.002668894966300127
4467,LV321,FCERI mediated NF-kB activation,0.002688173483912223,1,0,1,0.002934824031492737
4468,LV321,Parasite infection,0.0024445938164495916,0,0,1,0.002668894966300127
4469,LV321,Parasite infection,0.002688173483912223,1,0,1,0.002934824031492737
4470,LV321,Leishmania parasite growth and survival,0.0024445938164495916,0,0,1,0.002668894966300127
4471,LV321,Leishmania parasite growth and survival,0.002688173483912223,1,0,1,0.002934824031492737
4472,LV321,Potential therapeutics for SARS,0.0024445938164495916,0,0,1,0.002668894966300127
4473,LV321,Potential therapeutics for SARS,0.002688173483912223,1,0,1,0.002934824031492737
4474,LV321,CD22 mediated BCR regulation,0.0024445938164495916,0,0,1,0.002668894966300127
4475,LV321,CD22 mediated BCR regulation,0.002688173483912223,1,0,1,0.002934824031492737
4476,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0024445938164495916,0,0,1,0.002668894966300127
4477,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002688173483912223,1,0,1,0.002934824031492737
4478,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0024445938164495916,0,0,1,0.002668894966300127
4479,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002688173483912223,1,0,1,0.002934824031492737
4480,LV321,Scavenging of heme from plasma,0.0024445938164495916,0,0,1,0.002668894966300127
4481,LV321,Scavenging of heme from plasma,0.002688173483912223,1,0,1,0.002934824031492737
4482,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.003127176792663404,0,0,1,0.003414107629868511
4483,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.0032607176784912907,1,0,1,0.0035599014200609997
4484,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.003127176792663404,0,0,1,0.003414107629868511
4485,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.0032607176784912907,1,0,1,0.0035599014200609997
4486,PGBM,Diseases associated with glycosaminoglycan metabolism,0.003127176792663404,0,0,1,0.003414107629868511
4487,PGBM,Diseases associated with glycosaminoglycan metabolism,0.0032607176784912907,1,0,1,0.0035599014200609997
4488,PGBM,SARS-CoV-2 Infection,0.003127176792663404,0,0,1,0.003414107629868511
4489,PGBM,SARS-CoV-2 Infection,0.0032607176784912907,1,0,1,0.0035599014200609997
4490,PGBM,Integrin cell surface interactions,0.003127176792663404,0,0,1,0.003414107629868511
4491,PGBM,Integrin cell surface interactions,0.0032607176784912907,1,0,1,0.0035599014200609997
4492,PGBM,Laminin interactions,0.003127176792663404,0,0,1,0.003414107629868511
4493,PGBM,Laminin interactions,0.0032607176784912907,1,0,1,0.0035599014200609997
4494,PGBM,ECM proteoglycans,0.003127176792663404,0,0,1,0.003414107629868511
4495,PGBM,ECM proteoglycans,0.0032607176784912907,1,0,1,0.0035599014200609997
4496,PGBM,Retinoid metabolism and transport,0.003127176792663404,0,0,1,0.003414107629868511
4497,PGBM,Retinoid metabolism and transport,0.0032607176784912907,1,0,1,0.0035599014200609997
4498,PGBM,Amyloid fiber formation,0.003127176792663404,0,0,1,0.003414107629868511
4499,PGBM,Amyloid fiber formation,0.0032607176784912907,1,0,1,0.0035599014200609997
4500,DHSO,Fructose biosynthesis,0.0007148240748314225,0,0,1,0.0007804120104821789
4501,DHSO,Fructose biosynthesis,0.0004905861188411751,1,0,1,0.0005355993352766981
4502,DHSO,Formation of xylulose-5-phosphate,0.0007148240748314225,0,0,1,0.0007804120104821789
4503,DHSO,Formation of xylulose-5-phosphate,0.0004905861188411751,1,0,1,0.0005355993352766981
4504,CAP1,Signaling by ROBO receptors,2.2252427252452357e-05,0,0,1,2.4294175450498397e-05
4505,CAP1,Signaling by ROBO receptors,2.4877023079811184e-05,1,0,1,2.715958832402995e-05
4506,CAP1,Platelet degranulation ,2.2252427252452357e-05,0,0,1,2.4294175450498397e-05
4507,CAP1,Platelet degranulation ,2.4877023079811184e-05,1,0,1,2.715958832402995e-05
4508,CAP1,Neutrophil degranulation,2.2252427252452357e-05,0,0,1,2.4294175450498397e-05
4509,CAP1,Neutrophil degranulation,2.4877023079811184e-05,1,0,1,2.715958832402995e-05
4510,DSC2,Formation of the cornified envelope,0.0005317235516458407,0,0,1,0.0005805112902199277
4511,DSC2,Formation of the cornified envelope,0.0006500815870083732,1,0,1,0.000709729143376004
4512,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002504740589945979,0,0,1,0.002734560444116331
4513,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0018795926463943883,1,0,1,0.0020520527045848223
4514,NUCB1,Post-translational protein phosphorylation,0.002504740589945979,0,0,1,0.002734560444116331
4515,NUCB1,Post-translational protein phosphorylation,0.0018795926463943883,1,0,1,0.0020520527045848223
4516,FHR3,Regulation of Complement cascade,0.001034496226383901,0,0,1,0.00112941534608901
4517,FHR3,Regulation of Complement cascade,0.0012108443252561167,1,0,1,0.0013219440804045576
4518,ACY1,Defective ACY1 causes encephalopathy,0.0017997224532720175,0,0,1,0.001964854105395324
4519,ACY1,Defective ACY1 causes encephalopathy,0.003033196398761445,1,0,1,0.0033115041631788483
4520,ACY1,Aflatoxin activation and detoxification,0.0017997224532720175,0,0,1,0.001964854105395324
4521,ACY1,Aflatoxin activation and detoxification,0.003033196398761445,1,0,1,0.0033115041631788483
4522,ACY1,Paracetamol ADME,0.0017997224532720175,0,0,1,0.001964854105395324
4523,ACY1,Paracetamol ADME,0.003033196398761445,1,0,1,0.0033115041631788483
4524,FHR1,Regulation of Complement cascade,0.0001678159692161857,0,0,1,0.00018321374802311277
4525,FHR1,Regulation of Complement cascade,0.0001979078048364541,1,0,1,0.00021606662856025913
4526,HGFA,MET Receptor Activation,0.005710052279628052,0,0,1,0.006233972156790864
4527,HGFA,MET Receptor Activation,0.004838310461674169,1,0,1,0.005282244579720633
4528,AK1C1,Bile acid and bile salt metabolism,0.001304695251673167,0,0,1,0.0014244062004555897
4529,AK1C1,Bile acid and bile salt metabolism,0.0008308032304781305,1,0,1,0.0009070327123011801
4530,AK1C1,Retinoid metabolism and transport,0.001304695251673167,0,0,1,0.0014244062004555897
4531,AK1C1,Retinoid metabolism and transport,0.0008308032304781305,1,0,1,0.0009070327123011801
4532,1433F,Activation of BH3-only proteins,0.0006602472291569707,0,0,1,0.0007208275233919545
4533,1433F,Activation of BH3-only proteins,0.0021300446714846615,1,0,1,0.0023254846933942756
4534,1433F,RHO GTPase Effectors,0.0006602472291569707,0,0,1,0.0007208275233919545
4535,1433F,RHO GTPase Effectors,0.0021300446714846615,1,0,1,0.0023254846933942756
4536,1433F,Transcriptional Regulation by TP53,0.0006602472291569707,0,0,1,0.0007208275233919545
4537,1433F,Transcriptional Regulation by TP53,0.0021300446714846615,1,0,1,0.0023254846933942756
4538,1433F,G2/M DNA damage checkpoint,0.0006602472291569707,0,0,1,0.0007208275233919545
4539,1433F,G2/M DNA damage checkpoint,0.0021300446714846615,1,0,1,0.0023254846933942756
4540,1433F,SARS-CoV-2 Infection,0.0006602472291569707,0,0,1,0.0007208275233919545
4541,1433F,SARS-CoV-2 Infection,0.0021300446714846615,1,0,1,0.0023254846933942756
4542,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0006602472291569707,0,0,1,0.0007208275233919545
4543,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0021300446714846615,1,0,1,0.0023254846933942756
4544,EF1A2,Eukaryotic Translation Elongation,0.0018436916028905831,0,0,1,0.0020128575983682047
4545,EF1A2,Eukaryotic Translation Elongation,0.0011803008675655624,1,0,1,0.0012885981396862287
4546,ITIH3,Platelet degranulation ,0.0006708717613863545,0,0,1,0.0007324268984682927
4547,ITIH3,Platelet degranulation ,0.0007185686762877687,1,0,1,0.0007845001939302404
4548,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.0017171337855459773,0,0,1,0.0018746876008070112
4549,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.00250701102600102,1,0,1,0.0027370392016579036
4550,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0017171337855459773,0,0,1,0.0018746876008070112
4551,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00250701102600102,1,0,1,0.0027370392016579036
4552,PSME1,Antigen processing-Cross presentation,0.0017171337855459773,0,0,1,0.0018746876008070112
4553,PSME1,Antigen processing-Cross presentation,0.00250701102600102,1,0,1,0.0027370392016579036
4554,PSME1,PTEN Regulation,0.0017171337855459773,0,0,1,0.0018746876008070112
4555,PSME1,PTEN Regulation,0.00250701102600102,1,0,1,0.0027370392016579036
4556,PSME1,Host Interactions of HIV factors,0.0017171337855459773,0,0,1,0.0018746876008070112
4557,PSME1,Host Interactions of HIV factors,0.00250701102600102,1,0,1,0.0027370392016579036
4558,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0017171337855459773,0,0,1,0.0018746876008070112
4559,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00250701102600102,1,0,1,0.0027370392016579036
4560,PSME1,APC/C-mediated degradation of cell cycle proteins,0.0017171337855459773,0,0,1,0.0018746876008070112
4561,PSME1,APC/C-mediated degradation of cell cycle proteins,0.00250701102600102,1,0,1,0.0027370392016579036
4562,PSME1,Degradation of AXIN,0.0017171337855459773,0,0,1,0.0018746876008070112
4563,PSME1,Degradation of AXIN,0.00250701102600102,1,0,1,0.0027370392016579036
4564,PSME1,Degradation of DVL,0.0017171337855459773,0,0,1,0.0018746876008070112
4565,PSME1,Degradation of DVL,0.00250701102600102,1,0,1,0.0027370392016579036
4566,PSME1,Downstream TCR signaling,0.0017171337855459773,0,0,1,0.0018746876008070112
4567,PSME1,Downstream TCR signaling,0.00250701102600102,1,0,1,0.0027370392016579036
4568,PSME1,Transcriptional regulation by RUNX3,0.0017171337855459773,0,0,1,0.0018746876008070112
4569,PSME1,Transcriptional regulation by RUNX3,0.00250701102600102,1,0,1,0.0027370392016579036
4570,PSME1,Transcriptional regulation by RUNX2,0.0017171337855459773,0,0,1,0.0018746876008070112
4571,PSME1,Transcriptional regulation by RUNX2,0.00250701102600102,1,0,1,0.0027370392016579036
4572,PSME1,Transcriptional regulation by RUNX1,0.0017171337855459773,0,0,1,0.0018746876008070112
4573,PSME1,Transcriptional regulation by RUNX1,0.00250701102600102,1,0,1,0.0027370392016579036
4574,PSME1,FCERI mediated NF-kB activation,0.0017171337855459773,0,0,1,0.0018746876008070112
4575,PSME1,FCERI mediated NF-kB activation,0.00250701102600102,1,0,1,0.0027370392016579036
4576,PSME1,Mitotic Metaphase and Anaphase,0.0017171337855459773,0,0,1,0.0018746876008070112
4577,PSME1,Mitotic Metaphase and Anaphase,0.00250701102600102,1,0,1,0.0027370392016579036
4578,PSME1,Regulation of ornithine decarboxylase (ODC),0.0017171337855459773,0,0,1,0.0018746876008070112
4579,PSME1,Regulation of ornithine decarboxylase (ODC),0.00250701102600102,1,0,1,0.0027370392016579036
4580,PSME1,Signaling by ROBO receptors,0.0017171337855459773,0,0,1,0.0018746876008070112
4581,PSME1,Signaling by ROBO receptors,0.00250701102600102,1,0,1,0.0027370392016579036
4582,PSME1,PCP/CE pathway,0.0017171337855459773,0,0,1,0.0018746876008070112
4583,PSME1,PCP/CE pathway,0.00250701102600102,1,0,1,0.0027370392016579036
4584,PSME1,Interleukin-1 family signaling,0.0017171337855459773,0,0,1,0.0018746876008070112
4585,PSME1,Interleukin-1 family signaling,0.00250701102600102,1,0,1,0.0027370392016579036
4586,PSME1,G2/M Transition,0.0017171337855459773,0,0,1,0.0018746876008070112
4587,PSME1,G2/M Transition,0.00250701102600102,1,0,1,0.0027370392016579036
4588,PSME1,G1/S Transition,0.0017171337855459773,0,0,1,0.0018746876008070112
4589,PSME1,G1/S Transition,0.00250701102600102,1,0,1,0.0027370392016579036
4590,PSME1,Hh mutants are degraded by ERAD,0.0017171337855459773,0,0,1,0.0018746876008070112
4591,PSME1,Hh mutants are degraded by ERAD,0.00250701102600102,1,0,1,0.0027370392016579036
4592,PSME1,CLEC7A (Dectin-1) signaling,0.0017171337855459773,0,0,1,0.0018746876008070112
4593,PSME1,CLEC7A (Dectin-1) signaling,0.00250701102600102,1,0,1,0.0027370392016579036
4594,PSME1,Degradation of GLI1 by the proteasome,0.0017171337855459773,0,0,1,0.0018746876008070112
4595,PSME1,Degradation of GLI1 by the proteasome,0.00250701102600102,1,0,1,0.0027370392016579036
4596,PSME1,Degradation of GLI2 by the proteasome,0.0017171337855459773,0,0,1,0.0018746876008070112
4597,PSME1,Degradation of GLI2 by the proteasome,0.00250701102600102,1,0,1,0.0027370392016579036
4598,PSME1,GLI3 is processed to GLI3R by the proteasome,0.0017171337855459773,0,0,1,0.0018746876008070112
4599,PSME1,GLI3 is processed to GLI3R by the proteasome,0.00250701102600102,1,0,1,0.0027370392016579036
4600,PSME1,Defective CFTR causes cystic fibrosis,0.0017171337855459773,0,0,1,0.0018746876008070112
4601,PSME1,Defective CFTR causes cystic fibrosis,0.00250701102600102,1,0,1,0.0027370392016579036
4602,PSME1,NIK-->noncanonical NF-kB signaling,0.0017171337855459773,0,0,1,0.0018746876008070112
4603,PSME1,NIK-->noncanonical NF-kB signaling,0.00250701102600102,1,0,1,0.0027370392016579036
4604,PSME1,RAF/MAP kinase cascade,0.0017171337855459773,0,0,1,0.0018746876008070112
4605,PSME1,RAF/MAP kinase cascade,0.00250701102600102,1,0,1,0.0027370392016579036
4606,PSME1,UCH proteinases,0.0017171337855459773,0,0,1,0.0018746876008070112
4607,PSME1,UCH proteinases,0.00250701102600102,1,0,1,0.0027370392016579036
4608,PSME1,Ub-specific processing proteases,0.0017171337855459773,0,0,1,0.0018746876008070112
4609,PSME1,Ub-specific processing proteases,0.00250701102600102,1,0,1,0.0027370392016579036
4610,PSME1,Orc1 removal from chromatin,0.0017171337855459773,0,0,1,0.0018746876008070112
4611,PSME1,Orc1 removal from chromatin,0.00250701102600102,1,0,1,0.0027370392016579036
4612,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.0017171337855459773,0,0,1,0.0018746876008070112
4613,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.00250701102600102,1,0,1,0.0027370392016579036
4614,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.0017171337855459773,0,0,1,0.0018746876008070112
4615,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.00250701102600102,1,0,1,0.0027370392016579036
4616,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.0017171337855459773,0,0,1,0.0018746876008070112
4617,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.00250701102600102,1,0,1,0.0027370392016579036
4618,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.0017171337855459773,0,0,1,0.0018746876008070112
4619,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.00250701102600102,1,0,1,0.0027370392016579036
4620,PSME1,p53-Independent G1/S DNA damage checkpoint,0.0017171337855459773,0,0,1,0.0018746876008070112
4621,PSME1,p53-Independent G1/S DNA damage checkpoint,0.00250701102600102,1,0,1,0.0027370392016579036
4622,PSME1,Negative regulation of NOTCH4 signaling,0.0017171337855459773,0,0,1,0.0018746876008070112
4623,PSME1,Negative regulation of NOTCH4 signaling,0.00250701102600102,1,0,1,0.0027370392016579036
4624,PSME1,KEAP1-NFE2L2 pathway,0.0017171337855459773,0,0,1,0.0018746876008070112
4625,PSME1,KEAP1-NFE2L2 pathway,0.00250701102600102,1,0,1,0.0027370392016579036
4626,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.0017171337855459773,0,0,1,0.0018746876008070112
4627,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.00250701102600102,1,0,1,0.0027370392016579036
4628,PSME1,Degradation of beta-catenin by the destruction complex,0.0017171337855459773,0,0,1,0.0018746876008070112
4629,PSME1,Degradation of beta-catenin by the destruction complex,0.00250701102600102,1,0,1,0.0027370392016579036
4630,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0017171337855459773,0,0,1,0.0018746876008070112
4631,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00250701102600102,1,0,1,0.0027370392016579036
4632,PSME1,Hedgehog ligand biogenesis,0.0017171337855459773,0,0,1,0.0018746876008070112
4633,PSME1,Hedgehog ligand biogenesis,0.00250701102600102,1,0,1,0.0027370392016579036
4634,PSME1,Hedgehog 'on' state,0.0017171337855459773,0,0,1,0.0018746876008070112
4635,PSME1,Hedgehog 'on' state,0.00250701102600102,1,0,1,0.0027370392016579036
4636,PSME1,MAPK6/MAPK4 signaling,0.0017171337855459773,0,0,1,0.0018746876008070112
4637,PSME1,MAPK6/MAPK4 signaling,0.00250701102600102,1,0,1,0.0027370392016579036
4638,PSME1,Neddylation,0.0017171337855459773,0,0,1,0.0018746876008070112
4639,PSME1,Neddylation,0.00250701102600102,1,0,1,0.0027370392016579036
4640,LRP1,Scavenging of heme from plasma,0.0002349693918508104,0,0,1,0.0002565287627439113
4641,LRP1,Scavenging of heme from plasma,0.0007726040988706105,1,0,1,0.000843493580219132
4642,LRP1,Retinoid metabolism and transport,0.0002349693918508104,0,0,1,0.0002565287627439113
4643,LRP1,Retinoid metabolism and transport,0.0007726040988706105,1,0,1,0.000843493580219132
4644,LG3BP,Platelet degranulation ,0.0008010470726016563,0,0,1,0.0008745463092682649
4645,LG3BP,Platelet degranulation ,0.0008525827757084652,1,0,1,0.0009308106169340109
4646,BST1,Nicotinate metabolism,0.0012171017964840937,0,0,1,0.0013287756993629867
4647,BST1,Nicotinate metabolism,0.0006162282261911184,1,0,1,0.000672769602830027
4648,BST1,Neutrophil degranulation,0.0012171017964840937,0,0,1,0.0013287756993629867
4649,BST1,Neutrophil degranulation,0.0006162282261911184,1,0,1,0.000672769602830027
4650,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.0012171017964840937,0,0,1,0.0013287756993629867
4651,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.0006162282261911184,1,0,1,0.000672769602830027
4652,FBLN3,Molecules associated with elastic fibres,0.004486567908832993,0,0,1,0.004898228256683874
4653,FBLN3,Molecules associated with elastic fibres,0.0016527979697194186,1,0,1,0.0018044487194611967
4654,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0035288027950992743,0,0,1,0.003852584406265299
4655,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00358405798262335,1,0,1,0.0039129094757523655
4656,FSTL1,Post-translational protein phosphorylation,0.0035288027950992743,0,0,1,0.003852584406265299
4657,FSTL1,Post-translational protein phosphorylation,0.00358405798262335,1,0,1,0.0039129094757523655
4658,FSTL1,Signaling by BMP,0.0035288027950992743,0,0,1,0.003852584406265299
4659,FSTL1,Signaling by BMP,0.00358405798262335,1,0,1,0.0039129094757523655
4660,LMAN2,COPII-mediated vesicle transport,0.0016621094764928868,0,0,1,0.0018146145938036558
4661,LMAN2,COPII-mediated vesicle transport,0.0015606245067062775,1,0,1,0.0017038179767149423
4662,LMAN2,Cargo concentration in the ER,0.0016621094764928868,0,0,1,0.0018146145938036558
4663,LMAN2,Cargo concentration in the ER,0.0015606245067062775,1,0,1,0.0017038179767149423
4664,TRAP1,Respiratory electron transport,0.0010903742433842367,0,0,1,0.0011904203921197743
4665,TRAP1,Respiratory electron transport,0.0006021286239333422,1,0,1,0.000657376306307963
4666,SPP24,Platelet degranulation ,0.0002642862337908929,0,0,1,0.00028853554086598793
4667,SPP24,Platelet degranulation ,0.00018457735129421163,1,0,1,0.00020151305318999178
4668,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002642862337908929,0,0,1,0.00028853554086598793
4669,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00018457735129421163,1,0,1,0.00020151305318999178
4670,SPP24,Post-translational protein phosphorylation,0.0002642862337908929,0,0,1,0.00028853554086598793
4671,SPP24,Post-translational protein phosphorylation,0.00018457735129421163,1,0,1,0.00020151305318999178
4672,MMRN1,Platelet degranulation ,3.2730515843336735e-05,0,0,1,3.573367010539079e-05
4673,MMRN1,Platelet degranulation ,3.474426697315084e-05,1,0,1,3.7932190864781284e-05
4674,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.00037708007337568033,0,0,1,0.0004116786612779963
4675,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0001562626832845883,1,0,1,0.00017060040241960925
4676,APOF,LDL remodeling,0.0006614804871953985,0,0,1,0.0007221739377323497
4677,APOF,LDL remodeling,0.0006895411961730521,1,0,1,0.0007528093277252936
4678,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,0.00035307801476039164,0,0,1,0.00038547431886817185
4679,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,0.0003967571911342362,1,0,1,0.0004331612324044243
4680,TBB2A,Activation of NMDA receptors and postsynaptic events,0.0020932630995680874,0,0,1,0.0022853282668009517
4681,TBB2A,Activation of NMDA receptors and postsynaptic events,0.001507540809341912,1,0,1,0.0016458636401969371
4682,TBB2A,Gap junction trafficking,0.0020932630995680874,0,0,1,0.0022853282668009517
4683,TBB2A,Gap junction trafficking,0.001507540809341912,1,0,1,0.0016458636401969371
4684,TBB2A,RHO GTPase Effectors,0.0020932630995680874,0,0,1,0.0022853282668009517
4685,TBB2A,RHO GTPase Effectors,0.001507540809341912,1,0,1,0.0016458636401969371
4686,TBB2A,COPI-mediated anterograde transport,0.0020932630995680874,0,0,1,0.0022853282668009517
4687,TBB2A,COPI-mediated anterograde transport,0.001507540809341912,1,0,1,0.0016458636401969371
4688,TBB2A,Mitotic Metaphase and Anaphase,0.0020932630995680874,0,0,1,0.0022853282668009517
4689,TBB2A,Mitotic Metaphase and Anaphase,0.001507540809341912,1,0,1,0.0016458636401969371
4690,TBB2A,L1CAM interactions,0.0020932630995680874,0,0,1,0.0022853282668009517
4691,TBB2A,L1CAM interactions,0.001507540809341912,1,0,1,0.0016458636401969371
4692,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0020932630995680874,0,0,1,0.0022853282668009517
4693,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.001507540809341912,1,0,1,0.0016458636401969371
4694,TBB2A,G2/M Transition,0.0020932630995680874,0,0,1,0.0022853282668009517
4695,TBB2A,G2/M Transition,0.001507540809341912,1,0,1,0.0016458636401969371
4696,TBB2A,Golgi-to-ER retrograde transport,0.0020932630995680874,0,0,1,0.0022853282668009517
4697,TBB2A,Golgi-to-ER retrograde transport,0.001507540809341912,1,0,1,0.0016458636401969371
4698,TBB2A,Mitotic Prometaphase,0.0020932630995680874,0,0,1,0.0022853282668009517
4699,TBB2A,Mitotic Prometaphase,0.001507540809341912,1,0,1,0.0016458636401969371
4700,TBB2A,HCMV Early Events,0.0020932630995680874,0,0,1,0.0022853282668009517
4701,TBB2A,HCMV Early Events,0.001507540809341912,1,0,1,0.0016458636401969371
4702,TBB2A,Aggrephagy,0.0020932630995680874,0,0,1,0.0022853282668009517
4703,TBB2A,Aggrephagy,0.001507540809341912,1,0,1,0.0016458636401969371
4704,TBB2A,MHC class II antigen presentation,0.0020932630995680874,0,0,1,0.0022853282668009517
4705,TBB2A,MHC class II antigen presentation,0.001507540809341912,1,0,1,0.0016458636401969371
4706,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0020932630995680874,0,0,1,0.0022853282668009517
4707,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.001507540809341912,1,0,1,0.0016458636401969371
4708,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0020932630995680874,0,0,1,0.0022853282668009517
4709,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001507540809341912,1,0,1,0.0016458636401969371
4710,TBB2A,Post-chaperonin tubulin folding pathway,0.0020932630995680874,0,0,1,0.0022853282668009517
4711,TBB2A,Post-chaperonin tubulin folding pathway,0.001507540809341912,1,0,1,0.0016458636401969371
4712,TBB2A,Intraflagellar transport,0.0020932630995680874,0,0,1,0.0022853282668009517
4713,TBB2A,Intraflagellar transport,0.001507540809341912,1,0,1,0.0016458636401969371
4714,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.0020932630995680874,0,0,1,0.0022853282668009517
4715,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.001507540809341912,1,0,1,0.0016458636401969371
4716,TBB2A,Kinesins,0.0020932630995680874,0,0,1,0.0022853282668009517
4717,TBB2A,Kinesins,0.001507540809341912,1,0,1,0.0016458636401969371
4718,DAG1,Signaling by ROBO receptors,0.00199997077310732,0,0,1,0.0021834760004611855
4719,DAG1,Signaling by ROBO receptors,0.0016427486366710536,1,0,1,0.0017934773203653717
4720,DAG1,Diseases associated with O-glycosylation of proteins,0.00199997077310732,0,0,1,0.0021834760004611855
4721,DAG1,Diseases associated with O-glycosylation of proteins,0.0016427486366710536,1,0,1,0.0017934773203653717
4722,DAG1,ECM proteoglycans,0.00199997077310732,0,0,1,0.0021834760004611855
4723,DAG1,ECM proteoglycans,0.0016427486366710536,1,0,1,0.0017934773203653717
4724,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.00199997077310732,0,0,1,0.0021834760004611855
4725,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0016427486366710536,1,0,1,0.0017934773203653717
4726,KRT81,Formation of the cornified envelope,9.944989810742646e-05,0,0,1,0.00010857481953523711
4727,KRT81,Formation of the cornified envelope,0.00012522588929013767,1,0,1,0.00013671585984059408
4728,ITIH4,Platelet degranulation ,8.553672241794694e-05,0,0,1,9.338505495633827e-05
4729,ITIH4,Platelet degranulation ,9.109474479326426e-05,1,0,1,9.945304786389282e-05
4730,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.0045580624213896045,0,0,1,0.0049762826734939215
4731,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.0030792910906457848,1,0,1,0.0033618282253258846
4732,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.0045580624213896045,0,0,1,0.0049762826734939215
4733,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.0030792910906457848,1,0,1,0.0033618282253258846
4734,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.002122509756851185,0,0,1,0.0023172584205462185
4735,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0017448730204197658,1,0,1,0.0019049720201757853
4736,GANAB,SARS-CoV-1 Infection,0.002122509756851185,0,0,1,0.0023172584205462185
4737,GANAB,SARS-CoV-1 Infection,0.0017448730204197658,1,0,1,0.0019049720201757853
4738,GANAB,SARS-CoV-2 Infection,0.002122509756851185,0,0,1,0.0023172584205462185
4739,GANAB,SARS-CoV-2 Infection,0.0017448730204197658,1,0,1,0.0019049720201757853
4740,PCOC1,Crosslinking of collagen fibrils,0.0010570423990171308,0,0,1,0.0011540302192205938
4741,PCOC1,Crosslinking of collagen fibrils,0.0007425295098904558,1,0,1,0.000810659528769532
4742,PON3,Arachidonic acid metabolism,0.0014244491428379554,0,0,1,0.0015551479847037166
4743,PON3,Arachidonic acid metabolism,0.002530002737300497,1,0,1,0.0027621404933902537
4744,PON3,Atorvastatin ADME,0.0014244491428379554,0,0,1,0.0015551479847037166
4745,PON3,Atorvastatin ADME,0.002530002737300497,1,0,1,0.0027621404933902537
4746,FCN2,Initial triggering of complement,7.836960625363784e-05,0,0,1,8.556032754146087e-05
4747,FCN2,Initial triggering of complement,7.586975056634623e-05,1,0,1,8.28311002091349e-05
4748,BGH3,Amyloid fiber formation,0.0008284637856307979,0,0,1,0.000904478614137727
4749,BGH3,Amyloid fiber formation,0.0007328962492857929,1,0,1,0.0008001423784094846
4750,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0019269282909528077,0,0,1,0.0021037315817211554
4751,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0008127932467982531,1,0,1,0.0008873702413978617
4752,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0019269282909528077,0,0,1,0.0021037315817211554
4753,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0008127932467982531,1,0,1,0.0008873702413978617
4754,ECM1,Platelet degranulation ,9.617762341643906e-05,0,0,1,0.00010500230070108107
4755,ECM1,Platelet degranulation ,0.00010226932704084225,1,0,1,0.00011165294222277746
4756,UGPA,Glucuronidation,0.0023243081124220515,0,0,1,0.002537572573256027
4757,UGPA,Glucuronidation,0.002735326493272397,1,0,1,0.002986303515929151
4758,UGPA,Glycogen synthesis,0.0023243081124220515,0,0,1,0.002537572573256027
4759,UGPA,Glycogen synthesis,0.002735326493272397,1,0,1,0.002986303515929151
4760,TKFC,Fructose catabolism,0.0004062631163704162,0,0,1,0.0004435393638723803
4761,TKFC,Fructose catabolism,0.00028730597084643424,1,0,1,0.00031366742982834946
4762,TKFC,SARS-CoV-2 Infection,0.0004062631163704162,0,0,1,0.0004435393638723803
4763,TKFC,SARS-CoV-2 Infection,0.00028730597084643424,1,0,1,0.00031366742982834946
4764,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.000968263331483955,0,0,1,0.001057105321162791
4765,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0005306287716733183,1,0,1,0.0005793160598555989
4766,CTRB2,Activation of Matrix Metalloproteinases,0.000968263331483955,0,0,1,0.001057105321162791
4767,CTRB2,Activation of Matrix Metalloproteinases,0.0005306287716733183,1,0,1,0.0005793160598555989
4768,OLFM4,Neutrophil degranulation,3.06050416912711e-05,0,0,1,3.341317529464644e-05
4769,OLFM4,Neutrophil degranulation,3.144330701634594e-05,1,0,1,3.432835477823257e-05
4770,LDH6A,Pyruvate metabolism,0.0011855110276347812,0,0,1,0.0012942863525454724
4771,LDH6A,Pyruvate metabolism,0.0005477214052025651,1,0,1,0.0005979770101042883
4772,TBA1A,Activation of NMDA receptors and postsynaptic events,0.0010975235621620686,0,0,1,0.0011982256891675852
4773,TBA1A,Activation of NMDA receptors and postsynaptic events,0.0031132375872292115,1,0,1,0.003398889447212887
4774,TBA1A,Gap junction trafficking,0.0010975235621620686,0,0,1,0.0011982256891675852
4775,TBA1A,Gap junction trafficking,0.0031132375872292115,1,0,1,0.003398889447212887
4776,TBA1A,RHO GTPase Effectors,0.0010975235621620686,0,0,1,0.0011982256891675852
4777,TBA1A,RHO GTPase Effectors,0.0031132375872292115,1,0,1,0.003398889447212887
4778,TBA1A,COPI-mediated anterograde transport,0.0010975235621620686,0,0,1,0.0011982256891675852
4779,TBA1A,COPI-mediated anterograde transport,0.0031132375872292115,1,0,1,0.003398889447212887
4780,TBA1A,Mitotic Metaphase and Anaphase,0.0010975235621620686,0,0,1,0.0011982256891675852
4781,TBA1A,Mitotic Metaphase and Anaphase,0.0031132375872292115,1,0,1,0.003398889447212887
4782,TBA1A,L1CAM interactions,0.0010975235621620686,0,0,1,0.0011982256891675852
4783,TBA1A,L1CAM interactions,0.0031132375872292115,1,0,1,0.003398889447212887
4784,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0010975235621620686,0,0,1,0.0011982256891675852
4785,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0031132375872292115,1,0,1,0.003398889447212887
4786,TBA1A,G2/M Transition,0.0010975235621620686,0,0,1,0.0011982256891675852
4787,TBA1A,G2/M Transition,0.0031132375872292115,1,0,1,0.003398889447212887
4788,TBA1A,Golgi-to-ER retrograde transport,0.0010975235621620686,0,0,1,0.0011982256891675852
4789,TBA1A,Golgi-to-ER retrograde transport,0.0031132375872292115,1,0,1,0.003398889447212887
4790,TBA1A,Mitotic Prometaphase,0.0010975235621620686,0,0,1,0.0011982256891675852
4791,TBA1A,Mitotic Prometaphase,0.0031132375872292115,1,0,1,0.003398889447212887
4792,TBA1A,HCMV Early Events,0.0010975235621620686,0,0,1,0.0011982256891675852
4793,TBA1A,HCMV Early Events,0.0031132375872292115,1,0,1,0.003398889447212887
4794,TBA1A,Aggrephagy,0.0010975235621620686,0,0,1,0.0011982256891675852
4795,TBA1A,Aggrephagy,0.0031132375872292115,1,0,1,0.003398889447212887
4796,TBA1A,MHC class II antigen presentation,0.0010975235621620686,0,0,1,0.0011982256891675852
4797,TBA1A,MHC class II antigen presentation,0.0031132375872292115,1,0,1,0.003398889447212887
4798,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0010975235621620686,0,0,1,0.0011982256891675852
4799,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0031132375872292115,1,0,1,0.003398889447212887
4800,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0010975235621620686,0,0,1,0.0011982256891675852
4801,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0031132375872292115,1,0,1,0.003398889447212887
4802,TBA1A,Post-chaperonin tubulin folding pathway,0.0010975235621620686,0,0,1,0.0011982256891675852
4803,TBA1A,Post-chaperonin tubulin folding pathway,0.0031132375872292115,1,0,1,0.003398889447212887
4804,TBA1A,Anchoring of the basal body to the plasma membrane,0.0010975235621620686,0,0,1,0.0011982256891675852
4805,TBA1A,Anchoring of the basal body to the plasma membrane,0.0031132375872292115,1,0,1,0.003398889447212887
4806,TBA1A,Intraflagellar transport,0.0010975235621620686,0,0,1,0.0011982256891675852
4807,TBA1A,Intraflagellar transport,0.0031132375872292115,1,0,1,0.003398889447212887
4808,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.0010975235621620686,0,0,1,0.0011982256891675852
4809,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.0031132375872292115,1,0,1,0.003398889447212887
4810,TBA1A,Kinesins,0.0010975235621620686,0,0,1,0.0011982256891675852
4811,TBA1A,Kinesins,0.0031132375872292115,1,0,1,0.003398889447212887
4812,DCXR,Essential pentosuria,0.0005752263661754095,0,0,1,0.000628005660015266
4813,DCXR,Essential pentosuria,0.000511886348397126,1,0,1,0.0005588539451265576
4814,DCXR,Formation of xylulose-5-phosphate,0.0005752263661754095,0,0,1,0.000628005660015266
4815,DCXR,Formation of xylulose-5-phosphate,0.000511886348397126,1,0,1,0.0005588539451265576
4816,K2C1B,Formation of the cornified envelope,0.00022693073667608306,0,0,1,0.0002477525291678927
4817,K2C1B,Formation of the cornified envelope,0.0002917378344856732,1,0,1,0.000318505934482375
4818,URP2,Platelet degranulation ,0.00023509019365750472,0,0,1,0.00025666064859408276
4819,URP2,Platelet degranulation ,0.0002513056808800749,1,0,1,0.0002743639708937667
4820,C163A,Leishmania parasite growth and survival,0.0018732417195166406,0,0,1,0.0020451190550511834
4821,C163A,Leishmania parasite growth and survival,0.0030009859165793986,1,0,1,0.003276338241879654
4822,C163A,Scavenging of heme from plasma,0.0018732417195166406,0,0,1,0.0020451190550511834
4823,C163A,Scavenging of heme from plasma,0.0030009859165793986,1,0,1,0.003276338241879654
4824,K2C78,Formation of the cornified envelope,0.0010726071504443449,0,0,1,0.001171023098142351
4825,K2C78,Formation of the cornified envelope,0.0013814641933635274,1,0,1,0.0015082189961302351
4826,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003088870020476903,0,0,1,0.0033722860598490623
4827,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002973169793799132,1,0,1,0.0032459698798349276
4828,LIRA3,Neutrophil degranulation,0.003088870020476903,0,0,1,0.0033722860598490623
4829,LIRA3,Neutrophil degranulation,0.002973169793799132,1,0,1,0.0032459698798349276
4830,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025548368598143027,0,0,1,0.002789253244851696
4831,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0020495794898461608,1,0,1,0.002237636513139399
4832,GOLM1,Post-translational protein phosphorylation,0.0025548368598143027,0,0,1,0.002789253244851696
4833,GOLM1,Post-translational protein phosphorylation,0.0020495794898461608,1,0,1,0.002237636513139399
4834,TXND5,Lysosome Vesicle Biogenesis,0.0026561205345087776,0,0,1,0.0028998300972275467
4835,TXND5,Lysosome Vesicle Biogenesis,0.0030501199213121334,1,0,1,0.0033299804858479445
4836,TXND5,Golgi Associated Vesicle Biogenesis,0.0026561205345087776,0,0,1,0.0028998300972275467
4837,TXND5,Golgi Associated Vesicle Biogenesis,0.0030501199213121334,1,0,1,0.0033299804858479445
4838,TXND5,Neutrophil degranulation,0.0026561205345087776,0,0,1,0.0028998300972275467
4839,TXND5,Neutrophil degranulation,0.0030501199213121334,1,0,1,0.0033299804858479445
4840,BHMT1,Choline catabolism,0.0013091187308977362,0,0,1,0.0014292355513917433
4841,BHMT1,Choline catabolism,0.0012959232113588846,1,0,1,0.001414829290753277
4842,H2B1A,Packaging Of Telomere Ends,0.04226927943338597,0,0,1,0.0461476529760434
4843,H2B1A,Packaging Of Telomere Ends,0.031047547907393596,1,0,1,0.03389628320599716
4844,H2B1A,Inhibition of DNA recombination at telomere,0.04226927943338597,0,0,1,0.0461476529760434
4845,H2B1A,Inhibition of DNA recombination at telomere,0.031047547907393596,1,0,1,0.03389628320599716
4846,H2B1A,Pre-NOTCH Transcription and Translation,0.04226927943338597,0,0,1,0.0461476529760434
4847,H2B1A,Pre-NOTCH Transcription and Translation,0.031047547907393596,1,0,1,0.03389628320599716
4848,H2B1A,RHO GTPase Effectors,0.04226927943338597,0,0,1,0.0461476529760434
4849,H2B1A,RHO GTPase Effectors,0.031047547907393596,1,0,1,0.03389628320599716
4850,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.04226927943338597,0,0,1,0.0461476529760434
4851,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.031047547907393596,1,0,1,0.03389628320599716
4852,H2B1A,Transcriptional regulation by RUNX1,0.04226927943338597,0,0,1,0.0461476529760434
4853,H2B1A,Transcriptional regulation by RUNX1,0.031047547907393596,1,0,1,0.03389628320599716
4854,H2B1A,Oxidative Stress Induced Senescence,0.04226927943338597,0,0,1,0.0461476529760434
4855,H2B1A,Oxidative Stress Induced Senescence,0.031047547907393596,1,0,1,0.03389628320599716
4856,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.04226927943338597,0,0,1,0.0461476529760434
4857,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.031047547907393596,1,0,1,0.03389628320599716
4858,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.04226927943338597,0,0,1,0.0461476529760434
4859,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.031047547907393596,1,0,1,0.03389628320599716
4860,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.04226927943338597,0,0,1,0.0461476529760434
4861,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.031047547907393596,1,0,1,0.03389628320599716
4862,H2B1A,B-WICH complex positively regulates rRNA expression,0.04226927943338597,0,0,1,0.0461476529760434
4863,H2B1A,B-WICH complex positively regulates rRNA expression,0.031047547907393596,1,0,1,0.03389628320599716
4864,H2B1A,SIRT1 negatively regulates rRNA expression,0.04226927943338597,0,0,1,0.0461476529760434
4865,H2B1A,SIRT1 negatively regulates rRNA expression,0.031047547907393596,1,0,1,0.03389628320599716
4866,H2B1A,NoRC negatively regulates rRNA expression,0.04226927943338597,0,0,1,0.0461476529760434
4867,H2B1A,NoRC negatively regulates rRNA expression,0.031047547907393596,1,0,1,0.03389628320599716
4868,H2B1A,Ub-specific processing proteases,0.04226927943338597,0,0,1,0.0461476529760434
4869,H2B1A,Ub-specific processing proteases,0.031047547907393596,1,0,1,0.03389628320599716
4870,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.04226927943338597,0,0,1,0.0461476529760434
4871,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.031047547907393596,1,0,1,0.03389628320599716
4872,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.04226927943338597,0,0,1,0.0461476529760434
4873,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.031047547907393596,1,0,1,0.03389628320599716
4874,H2B1A,Assembly of the ORC complex at the origin of replication,0.04226927943338597,0,0,1,0.0461476529760434
4875,H2B1A,Assembly of the ORC complex at the origin of replication,0.031047547907393596,1,0,1,0.03389628320599716
4876,H2B1A,Mitotic Prophase,0.04226927943338597,0,0,1,0.0461476529760434
4877,H2B1A,Mitotic Prophase,0.031047547907393596,1,0,1,0.03389628320599716
4878,H2B1A,G2/M DNA damage checkpoint,0.04226927943338597,0,0,1,0.0461476529760434
4879,H2B1A,G2/M DNA damage checkpoint,0.031047547907393596,1,0,1,0.03389628320599716
4880,H2B1A,RNA Polymerase I Promoter Opening,0.04226927943338597,0,0,1,0.0461476529760434
4881,H2B1A,RNA Polymerase I Promoter Opening,0.031047547907393596,1,0,1,0.03389628320599716
4882,H2B1A,RNA Polymerase I Promoter Escape,0.04226927943338597,0,0,1,0.0461476529760434
4883,H2B1A,RNA Polymerase I Promoter Escape,0.031047547907393596,1,0,1,0.03389628320599716
4884,H2B1A,Depurination,0.04226927943338597,0,0,1,0.0461476529760434
4885,H2B1A,Depurination,0.031047547907393596,1,0,1,0.03389628320599716
4886,H2B1A,Depyrimidination,0.04226927943338597,0,0,1,0.0461476529760434
4887,H2B1A,Depyrimidination,0.031047547907393596,1,0,1,0.03389628320599716
4888,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.04226927943338597,0,0,1,0.0461476529760434
4889,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.031047547907393596,1,0,1,0.03389628320599716
4890,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.04226927943338597,0,0,1,0.0461476529760434
4891,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.031047547907393596,1,0,1,0.03389628320599716
4892,H2B1A,Estrogen-dependent gene expression,0.04226927943338597,0,0,1,0.0461476529760434
4893,H2B1A,Estrogen-dependent gene expression,0.031047547907393596,1,0,1,0.03389628320599716
4894,H2B1A,HCMV Early Events,0.04226927943338597,0,0,1,0.0461476529760434
4895,H2B1A,HCMV Early Events,0.031047547907393596,1,0,1,0.03389628320599716
4896,H2B1A,HCMV Late Events,0.04226927943338597,0,0,1,0.0461476529760434
4897,H2B1A,HCMV Late Events,0.031047547907393596,1,0,1,0.03389628320599716
4898,H2B1A,Transcriptional regulation of granulopoiesis,0.04226927943338597,0,0,1,0.0461476529760434
4899,H2B1A,Transcriptional regulation of granulopoiesis,0.031047547907393596,1,0,1,0.03389628320599716
4900,H2B1A,Meiotic synapsis,0.04226927943338597,0,0,1,0.0461476529760434
4901,H2B1A,Meiotic synapsis,0.031047547907393596,1,0,1,0.03389628320599716
4902,H2B1A,Meiotic recombination,0.04226927943338597,0,0,1,0.0461476529760434
4903,H2B1A,Meiotic recombination,0.031047547907393596,1,0,1,0.03389628320599716
4904,H2B1A,Transcriptional regulation by small RNAs,0.04226927943338597,0,0,1,0.0461476529760434
4905,H2B1A,Transcriptional regulation by small RNAs,0.031047547907393596,1,0,1,0.03389628320599716
4906,H2B1A,PRC2 methylates histones and DNA,0.04226927943338597,0,0,1,0.0461476529760434
4907,H2B1A,PRC2 methylates histones and DNA,0.031047547907393596,1,0,1,0.03389628320599716
4908,H2B1A,DNA methylation,0.04226927943338597,0,0,1,0.0461476529760434
4909,H2B1A,DNA methylation,0.031047547907393596,1,0,1,0.03389628320599716
4910,H2B1A,HDACs deacetylate histones,0.04226927943338597,0,0,1,0.0461476529760434
4911,H2B1A,HDACs deacetylate histones,0.031047547907393596,1,0,1,0.03389628320599716
4912,H2B1A,HATs acetylate histones,0.04226927943338597,0,0,1,0.0461476529760434
4913,H2B1A,HATs acetylate histones,0.031047547907393596,1,0,1,0.03389628320599716
4914,H2B1A,Amyloid fiber formation,0.04226927943338597,0,0,1,0.0461476529760434
4915,H2B1A,Amyloid fiber formation,0.031047547907393596,1,0,1,0.03389628320599716
4916,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.04226927943338597,0,0,1,0.0461476529760434
4917,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.031047547907393596,1,0,1,0.03389628320599716
4918,H2B1A,Nonhomologous End-Joining (NHEJ),0.04226927943338597,0,0,1,0.0461476529760434
4919,H2B1A,Nonhomologous End-Joining (NHEJ),0.031047547907393596,1,0,1,0.03389628320599716
4920,H2B1A,Defective pyroptosis,0.04226927943338597,0,0,1,0.0461476529760434
4921,H2B1A,Defective pyroptosis,0.031047547907393596,1,0,1,0.03389628320599716
4922,CBPB2,Regulation of Complement cascade,0.0034036180850590347,0,0,1,0.0037159135040336247
4923,CBPB2,Regulation of Complement cascade,0.003103861906043297,1,0,1,0.003388653510201861
4924,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.0034036180850590347,0,0,1,0.0037159135040336247
4925,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.003103861906043297,1,0,1,0.003388653510201861
4926,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.0016373165545992194,0,0,1,0.001787546823282178
4927,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.000989062709131158,1,0,1,0.001079813123960647
4928,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0016373165545992194,0,0,1,0.001787546823282178
4929,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.000989062709131158,1,0,1,0.001079813123960647
4930,PSB7,Antigen processing-Cross presentation,0.0016373165545992194,0,0,1,0.001787546823282178
4931,PSB7,Antigen processing-Cross presentation,0.000989062709131158,1,0,1,0.001079813123960647
4932,PSB7,PTEN Regulation,0.0016373165545992194,0,0,1,0.001787546823282178
4933,PSB7,PTEN Regulation,0.000989062709131158,1,0,1,0.001079813123960647
4934,PSB7,Host Interactions of HIV factors,0.0016373165545992194,0,0,1,0.001787546823282178
4935,PSB7,Host Interactions of HIV factors,0.000989062709131158,1,0,1,0.001079813123960647
4936,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0016373165545992194,0,0,1,0.001787546823282178
4937,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.000989062709131158,1,0,1,0.001079813123960647
4938,PSB7,APC/C-mediated degradation of cell cycle proteins,0.0016373165545992194,0,0,1,0.001787546823282178
4939,PSB7,APC/C-mediated degradation of cell cycle proteins,0.000989062709131158,1,0,1,0.001079813123960647
4940,PSB7,Degradation of AXIN,0.0016373165545992194,0,0,1,0.001787546823282178
4941,PSB7,Degradation of AXIN,0.000989062709131158,1,0,1,0.001079813123960647
4942,PSB7,Degradation of DVL,0.0016373165545992194,0,0,1,0.001787546823282178
4943,PSB7,Degradation of DVL,0.000989062709131158,1,0,1,0.001079813123960647
4944,PSB7,Downstream TCR signaling,0.0016373165545992194,0,0,1,0.001787546823282178
4945,PSB7,Downstream TCR signaling,0.000989062709131158,1,0,1,0.001079813123960647
4946,PSB7,Transcriptional regulation by RUNX3,0.0016373165545992194,0,0,1,0.001787546823282178
4947,PSB7,Transcriptional regulation by RUNX3,0.000989062709131158,1,0,1,0.001079813123960647
4948,PSB7,Transcriptional regulation by RUNX2,0.0016373165545992194,0,0,1,0.001787546823282178
4949,PSB7,Transcriptional regulation by RUNX2,0.000989062709131158,1,0,1,0.001079813123960647
4950,PSB7,Transcriptional regulation by RUNX1,0.0016373165545992194,0,0,1,0.001787546823282178
4951,PSB7,Transcriptional regulation by RUNX1,0.000989062709131158,1,0,1,0.001079813123960647
4952,PSB7,FCERI mediated NF-kB activation,0.0016373165545992194,0,0,1,0.001787546823282178
4953,PSB7,FCERI mediated NF-kB activation,0.000989062709131158,1,0,1,0.001079813123960647
4954,PSB7,Mitotic Metaphase and Anaphase,0.0016373165545992194,0,0,1,0.001787546823282178
4955,PSB7,Mitotic Metaphase and Anaphase,0.000989062709131158,1,0,1,0.001079813123960647
4956,PSB7,Regulation of ornithine decarboxylase (ODC),0.0016373165545992194,0,0,1,0.001787546823282178
4957,PSB7,Regulation of ornithine decarboxylase (ODC),0.000989062709131158,1,0,1,0.001079813123960647
4958,PSB7,Signaling by ROBO receptors,0.0016373165545992194,0,0,1,0.001787546823282178
4959,PSB7,Signaling by ROBO receptors,0.000989062709131158,1,0,1,0.001079813123960647
4960,PSB7,PCP/CE pathway,0.0016373165545992194,0,0,1,0.001787546823282178
4961,PSB7,PCP/CE pathway,0.000989062709131158,1,0,1,0.001079813123960647
4962,PSB7,Interleukin-1 family signaling,0.0016373165545992194,0,0,1,0.001787546823282178
4963,PSB7,Interleukin-1 family signaling,0.000989062709131158,1,0,1,0.001079813123960647
4964,PSB7,G2/M Transition,0.0016373165545992194,0,0,1,0.001787546823282178
4965,PSB7,G2/M Transition,0.000989062709131158,1,0,1,0.001079813123960647
4966,PSB7,G1/S Transition,0.0016373165545992194,0,0,1,0.001787546823282178
4967,PSB7,G1/S Transition,0.000989062709131158,1,0,1,0.001079813123960647
4968,PSB7,Hh mutants are degraded by ERAD,0.0016373165545992194,0,0,1,0.001787546823282178
4969,PSB7,Hh mutants are degraded by ERAD,0.000989062709131158,1,0,1,0.001079813123960647
4970,PSB7,CLEC7A (Dectin-1) signaling,0.0016373165545992194,0,0,1,0.001787546823282178
4971,PSB7,CLEC7A (Dectin-1) signaling,0.000989062709131158,1,0,1,0.001079813123960647
4972,PSB7,Degradation of GLI1 by the proteasome,0.0016373165545992194,0,0,1,0.001787546823282178
4973,PSB7,Degradation of GLI1 by the proteasome,0.000989062709131158,1,0,1,0.001079813123960647
4974,PSB7,Degradation of GLI2 by the proteasome,0.0016373165545992194,0,0,1,0.001787546823282178
4975,PSB7,Degradation of GLI2 by the proteasome,0.000989062709131158,1,0,1,0.001079813123960647
4976,PSB7,GLI3 is processed to GLI3R by the proteasome,0.0016373165545992194,0,0,1,0.001787546823282178
4977,PSB7,GLI3 is processed to GLI3R by the proteasome,0.000989062709131158,1,0,1,0.001079813123960647
4978,PSB7,Defective CFTR causes cystic fibrosis,0.0016373165545992194,0,0,1,0.001787546823282178
4979,PSB7,Defective CFTR causes cystic fibrosis,0.000989062709131158,1,0,1,0.001079813123960647
4980,PSB7,NIK-->noncanonical NF-kB signaling,0.0016373165545992194,0,0,1,0.001787546823282178
4981,PSB7,NIK-->noncanonical NF-kB signaling,0.000989062709131158,1,0,1,0.001079813123960647
4982,PSB7,RAF/MAP kinase cascade,0.0016373165545992194,0,0,1,0.001787546823282178
4983,PSB7,RAF/MAP kinase cascade,0.000989062709131158,1,0,1,0.001079813123960647
4984,PSB7,UCH proteinases,0.0016373165545992194,0,0,1,0.001787546823282178
4985,PSB7,UCH proteinases,0.000989062709131158,1,0,1,0.001079813123960647
4986,PSB7,Ub-specific processing proteases,0.0016373165545992194,0,0,1,0.001787546823282178
4987,PSB7,Ub-specific processing proteases,0.000989062709131158,1,0,1,0.001079813123960647
4988,PSB7,Orc1 removal from chromatin,0.0016373165545992194,0,0,1,0.001787546823282178
4989,PSB7,Orc1 removal from chromatin,0.000989062709131158,1,0,1,0.001079813123960647
4990,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.0016373165545992194,0,0,1,0.001787546823282178
4991,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.000989062709131158,1,0,1,0.001079813123960647
4992,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.0016373165545992194,0,0,1,0.001787546823282178
4993,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.000989062709131158,1,0,1,0.001079813123960647
4994,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.0016373165545992194,0,0,1,0.001787546823282178
4995,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.000989062709131158,1,0,1,0.001079813123960647
4996,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.0016373165545992194,0,0,1,0.001787546823282178
4997,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.000989062709131158,1,0,1,0.001079813123960647
4998,PSB7,p53-Independent G1/S DNA damage checkpoint,0.0016373165545992194,0,0,1,0.001787546823282178
4999,PSB7,p53-Independent G1/S DNA damage checkpoint,0.000989062709131158,1,0,1,0.001079813123960647
5000,PSB7,Negative regulation of NOTCH4 signaling,0.0016373165545992194,0,0,1,0.001787546823282178
5001,PSB7,Negative regulation of NOTCH4 signaling,0.000989062709131158,1,0,1,0.001079813123960647
5002,PSB7,KEAP1-NFE2L2 pathway,0.0016373165545992194,0,0,1,0.001787546823282178
5003,PSB7,KEAP1-NFE2L2 pathway,0.000989062709131158,1,0,1,0.001079813123960647
5004,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.0016373165545992194,0,0,1,0.001787546823282178
5005,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.000989062709131158,1,0,1,0.001079813123960647
5006,PSB7,Neutrophil degranulation,0.0016373165545992194,0,0,1,0.001787546823282178
5007,PSB7,Neutrophil degranulation,0.000989062709131158,1,0,1,0.001079813123960647
5008,PSB7,Degradation of beta-catenin by the destruction complex,0.0016373165545992194,0,0,1,0.001787546823282178
5009,PSB7,Degradation of beta-catenin by the destruction complex,0.000989062709131158,1,0,1,0.001079813123960647
5010,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0016373165545992194,0,0,1,0.001787546823282178
5011,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.000989062709131158,1,0,1,0.001079813123960647
5012,PSB7,Hedgehog ligand biogenesis,0.0016373165545992194,0,0,1,0.001787546823282178
5013,PSB7,Hedgehog ligand biogenesis,0.000989062709131158,1,0,1,0.001079813123960647
5014,PSB7,Hedgehog 'on' state,0.0016373165545992194,0,0,1,0.001787546823282178
5015,PSB7,Hedgehog 'on' state,0.000989062709131158,1,0,1,0.001079813123960647
5016,PSB7,MAPK6/MAPK4 signaling,0.0016373165545992194,0,0,1,0.001787546823282178
5017,PSB7,MAPK6/MAPK4 signaling,0.000989062709131158,1,0,1,0.001079813123960647
5018,PSB7,Neddylation,0.0016373165545992194,0,0,1,0.001787546823282178
5019,PSB7,Neddylation,0.000989062709131158,1,0,1,0.001079813123960647
5020,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0013330445953524852,0,0,1,0.0014553567085254875
5021,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0005963050870317611,1,0,1,0.0006510184368663779
5022,PARK7,Aggrephagy,0.0013330445953524852,0,0,1,0.0014553567085254875
5023,PARK7,Aggrephagy,0.0005963050870317611,1,0,1,0.0006510184368663779
5024,PARK7,Chaperone Mediated Autophagy,0.0013330445953524852,0,0,1,0.0014553567085254875
5025,PARK7,Chaperone Mediated Autophagy,0.0005963050870317611,1,0,1,0.0006510184368663779
5026,PARK7,Late endosomal microautophagy,0.0013330445953524852,0,0,1,0.0014553567085254875
5027,PARK7,Late endosomal microautophagy,0.0005963050870317611,1,0,1,0.0006510184368663779
5028,RARR2,Platelet degranulation ,8.523078948311947e-05,0,0,1,9.305105146492294e-05
5029,RARR2,Platelet degranulation ,9.083838959128199e-05,1,0,1,9.917317105836731e-05
5030,FUCO2,Neutrophil degranulation,0.0009172624241511058,0,0,1,0.0010014248788981252
5031,FUCO2,Neutrophil degranulation,0.0006580774424577529,1,0,1,0.000718458650182622
5032,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0009172624241511058,0,0,1,0.0010014248788981252
5033,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006580774424577529,1,0,1,0.000718458650182622
5034,FUCO2,Post-translational protein phosphorylation,0.0009172624241511058,0,0,1,0.0010014248788981252
5035,FUCO2,Post-translational protein phosphorylation,0.0006580774424577529,1,0,1,0.000718458650182622
5036,COL11,Initial triggering of complement,0.0008291823514025105,0,0,1,0.0009052631111605759
5037,COL11,Initial triggering of complement,0.0018242946266005203,1,0,1,0.001991680872797829
5038,COL11,Scavenging by Class A Receptors,0.0008291823514025105,0,0,1,0.0009052631111605759
5039,COL11,Scavenging by Class A Receptors,0.0018242946266005203,1,0,1,0.001991680872797829
5040,FHR5,Regulation of Complement cascade,0.0002550630086372464,0,0,1,0.00027846604833108057
5041,FHR5,Regulation of Complement cascade,0.00030021443168558743,1,0,1,0.00032776029299624117
5042,CHM4A,HIV Life Cycle,0.00414136556263181,0,0,1,0.0045213522301096945
5043,CHM4A,HIV Life Cycle,0.0031868705725732263,1,0,1,0.003479278550145212
5044,CHM4A,Mitotic Metaphase and Anaphase,0.00414136556263181,0,0,1,0.0045213522301096945
5045,CHM4A,Mitotic Metaphase and Anaphase,0.0031868705725732263,1,0,1,0.003479278550145212
5046,CHM4A,HCMV Late Events,0.00414136556263181,0,0,1,0.0045213522301096945
5047,CHM4A,HCMV Late Events,0.0031868705725732263,1,0,1,0.003479278550145212
5048,CHM4A,SARS-CoV-1 Infection,0.00414136556263181,0,0,1,0.0045213522301096945
5049,CHM4A,SARS-CoV-1 Infection,0.0031868705725732263,1,0,1,0.003479278550145212
5050,CHM4A,SARS-CoV-2 Infection,0.00414136556263181,0,0,1,0.0045213522301096945
5051,CHM4A,SARS-CoV-2 Infection,0.0031868705725732263,1,0,1,0.003479278550145212
5052,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.00414136556263181,0,0,1,0.0045213522301096945
5053,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.0031868705725732263,1,0,1,0.003479278550145212
5054,CHM4A,Pyroptosis,0.00414136556263181,0,0,1,0.0045213522301096945
5055,CHM4A,Pyroptosis,0.0031868705725732263,1,0,1,0.003479278550145212
5056,CHM4A,Late endosomal microautophagy,0.00414136556263181,0,0,1,0.0045213522301096945
5057,CHM4A,Late endosomal microautophagy,0.0031868705725732263,1,0,1,0.003479278550145212
5058,TBB1,Activation of NMDA receptors and postsynaptic events,0.011355416430869533,0,0,1,0.012397320793605294
5059,TBB1,Activation of NMDA receptors and postsynaptic events,0.0063384465759780805,1,0,1,0.00692002411482783
5060,TBB1,Gap junction trafficking,0.011355416430869533,0,0,1,0.012397320793605294
5061,TBB1,Gap junction trafficking,0.0063384465759780805,1,0,1,0.00692002411482783
5062,TBB1,RHO GTPase Effectors,0.011355416430869533,0,0,1,0.012397320793605294
5063,TBB1,RHO GTPase Effectors,0.0063384465759780805,1,0,1,0.00692002411482783
5064,TBB1,COPI-mediated anterograde transport,0.011355416430869533,0,0,1,0.012397320793605294
5065,TBB1,COPI-mediated anterograde transport,0.0063384465759780805,1,0,1,0.00692002411482783
5066,TBB1,Mitotic Metaphase and Anaphase,0.011355416430869533,0,0,1,0.012397320793605294
5067,TBB1,Mitotic Metaphase and Anaphase,0.0063384465759780805,1,0,1,0.00692002411482783
5068,TBB1,L1CAM interactions,0.011355416430869533,0,0,1,0.012397320793605294
5069,TBB1,L1CAM interactions,0.0063384465759780805,1,0,1,0.00692002411482783
5070,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.011355416430869533,0,0,1,0.012397320793605294
5071,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0063384465759780805,1,0,1,0.00692002411482783
5072,TBB1,G2/M Transition,0.011355416430869533,0,0,1,0.012397320793605294
5073,TBB1,G2/M Transition,0.0063384465759780805,1,0,1,0.00692002411482783
5074,TBB1,Golgi-to-ER retrograde transport,0.011355416430869533,0,0,1,0.012397320793605294
5075,TBB1,Golgi-to-ER retrograde transport,0.0063384465759780805,1,0,1,0.00692002411482783
5076,TBB1,Mitotic Prometaphase,0.011355416430869533,0,0,1,0.012397320793605294
5077,TBB1,Mitotic Prometaphase,0.0063384465759780805,1,0,1,0.00692002411482783
5078,TBB1,HCMV Early Events,0.011355416430869533,0,0,1,0.012397320793605294
5079,TBB1,HCMV Early Events,0.0063384465759780805,1,0,1,0.00692002411482783
5080,TBB1,Aggrephagy,0.011355416430869533,0,0,1,0.012397320793605294
5081,TBB1,Aggrephagy,0.0063384465759780805,1,0,1,0.00692002411482783
5082,TBB1,MHC class II antigen presentation,0.011355416430869533,0,0,1,0.012397320793605294
5083,TBB1,MHC class II antigen presentation,0.0063384465759780805,1,0,1,0.00692002411482783
5084,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.011355416430869533,0,0,1,0.012397320793605294
5085,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0063384465759780805,1,0,1,0.00692002411482783
5086,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.011355416430869533,0,0,1,0.012397320793605294
5087,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0063384465759780805,1,0,1,0.00692002411482783
5088,TBB1,Post-chaperonin tubulin folding pathway,0.011355416430869533,0,0,1,0.012397320793605294
5089,TBB1,Post-chaperonin tubulin folding pathway,0.0063384465759780805,1,0,1,0.00692002411482783
5090,TBB1,Intraflagellar transport,0.011355416430869533,0,0,1,0.012397320793605294
5091,TBB1,Intraflagellar transport,0.0063384465759780805,1,0,1,0.00692002411482783
5092,TBB1,Carboxyterminal post-translational modifications of tubulin,0.011355416430869533,0,0,1,0.012397320793605294
5093,TBB1,Carboxyterminal post-translational modifications of tubulin,0.0063384465759780805,1,0,1,0.00692002411482783
5094,TBB1,Kinesins,0.011355416430869533,0,0,1,0.012397320793605294
5095,TBB1,Kinesins,0.0063384465759780805,1,0,1,0.00692002411482783
5096,RETN,FOXO-mediated transcription,0.010107935967661326,0,0,1,0.01103537906471326
5097,RETN,FOXO-mediated transcription,0.007498566508009501,1,0,1,0.008186589638338777
5098,RETN,Neutrophil degranulation,0.010107935967661326,0,0,1,0.01103537906471326
5099,RETN,Neutrophil degranulation,0.007498566508009501,1,0,1,0.008186589638338777
5100,SAE1,Processing and activation of SUMO,8.232988110081018e-05,0,0,1,8.988397326684114e-05
5101,SAE1,Processing and activation of SUMO,0.0002138204250273739,1,0,1,0.00023343929458044554
5102,GRHPR,Glyoxylate metabolism and glycine degradation,0.0004660908254229837,0,0,1,0.0005088565018202987
5103,GRHPR,Glyoxylate metabolism and glycine degradation,0.0005295224500929956,1,0,1,0.0005781082288953125
5104,CATZ,COPII-mediated vesicle transport,0.016099533205615538,0,0,1,0.017576729043131435
5105,CATZ,COPII-mediated vesicle transport,0.015639271265661656,1,0,1,0.017074236250072462
5106,CATZ,Cargo concentration in the ER,0.016099533205615538,0,0,1,0.017576729043131435
5107,CATZ,Cargo concentration in the ER,0.015639271265661656,1,0,1,0.017074236250072462
5108,CATZ,Lysosome Vesicle Biogenesis,0.016099533205615538,0,0,1,0.017576729043131435
5109,CATZ,Lysosome Vesicle Biogenesis,0.015639271265661656,1,0,1,0.017074236250072462
5110,CATZ,Neutrophil degranulation,0.016099533205615538,0,0,1,0.017576729043131435
5111,CATZ,Neutrophil degranulation,0.015639271265661656,1,0,1,0.017074236250072462
5112,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.016099533205615538,0,0,1,0.017576729043131435
5113,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.015639271265661656,1,0,1,0.017074236250072462
5114,FBLN5,Molecules associated with elastic fibres,0.0005005517511613869,0,0,1,0.000546479353771566
5115,FBLN5,Molecules associated with elastic fibres,0.00018783792955410407,1,0,1,0.00020507280239924616
5116,DMBT1,Surfactant metabolism,0.0003905957572837006,0,0,1,0.0004264344626325984
5117,DMBT1,Surfactant metabolism,0.00045865193307949325,1,0,1,0.000500735061687056
5118,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006782930201055065,0,0,1,0.0007405290870224313
5119,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005898097828515527,1,0,1,0.0006439271628418354
5120,ZPI,Post-translational protein phosphorylation,0.0006782930201055065,0,0,1,0.0007405290870224313
5121,ZPI,Post-translational protein phosphorylation,0.0005898097828515527,1,0,1,0.0006439271628418354
5122,MINP1,Synthesis of IPs in the ER lumen,0.0016279618337343867,0,0,1,0.0017773337697845808
5123,MINP1,Synthesis of IPs in the ER lumen,0.00078763579875869,1,0,1,0.000859904498015077
5124,TLN1,Semaphorin interactions,0.00551765934247429,0,0,1,0.00602392640683183
5125,TLN1,Semaphorin interactions,0.004725566364323654,1,0,1,0.005159155765589599
5126,TLN1,IRE1alpha activates chaperones,0.00551765934247429,0,0,1,0.00602392640683183
5127,TLN1,IRE1alpha activates chaperones,0.004725566364323654,1,0,1,0.005159155765589599
5128,TLN1,RAF/MAP kinase cascade,0.00551765934247429,0,0,1,0.00602392640683183
5129,TLN1,RAF/MAP kinase cascade,0.004725566364323654,1,0,1,0.005159155765589599
5130,TLN1,Signaling by RAS mutants,0.00551765934247429,0,0,1,0.00602392640683183
5131,TLN1,Signaling by RAS mutants,0.004725566364323654,1,0,1,0.005159155765589599
5132,TLN1,Signaling by moderate kinase activity BRAF mutants,0.00551765934247429,0,0,1,0.00602392640683183
5133,TLN1,Signaling by moderate kinase activity BRAF mutants,0.004725566364323654,1,0,1,0.005159155765589599
5134,TLN1,Signaling by high-kinase activity BRAF mutants,0.00551765934247429,0,0,1,0.00602392640683183
5135,TLN1,Signaling by high-kinase activity BRAF mutants,0.004725566364323654,1,0,1,0.005159155765589599
5136,TLN1,Signaling by BRAF and RAF1 fusions,0.00551765934247429,0,0,1,0.00602392640683183
5137,TLN1,Signaling by BRAF and RAF1 fusions,0.004725566364323654,1,0,1,0.005159155765589599
5138,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00551765934247429,0,0,1,0.00602392640683183
5139,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.004725566364323654,1,0,1,0.005159155765589599
5140,TLN1,Signaling by RAF1 mutants,0.00551765934247429,0,0,1,0.00602392640683183
5141,TLN1,Signaling by RAF1 mutants,0.004725566364323654,1,0,1,0.005159155765589599
5142,TLN1,Platelet degranulation ,0.00551765934247429,0,0,1,0.00602392640683183
5143,TLN1,Platelet degranulation ,0.004725566364323654,1,0,1,0.005159155765589599
5144,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00551765934247429,0,0,1,0.00602392640683183
5145,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.004725566364323654,1,0,1,0.005159155765589599
5146,TLN1,p130Cas linkage to MAPK signaling for integrins,0.00551765934247429,0,0,1,0.00602392640683183
5147,TLN1,p130Cas linkage to MAPK signaling for integrins,0.004725566364323654,1,0,1,0.005159155765589599
5148,TLN1,Smooth Muscle Contraction,0.00551765934247429,0,0,1,0.00602392640683183
5149,TLN1,Smooth Muscle Contraction,0.004725566364323654,1,0,1,0.005159155765589599
5150,HYOU1,IRE1alpha activates chaperones,0.004251742150473792,0,0,1,0.004641856306372427
5151,HYOU1,IRE1alpha activates chaperones,0.0033801896961495694,1,0,1,0.0036903354677937207
5152,HYOU1,Scavenging by Class F Receptors,0.004251742150473792,0,0,1,0.004641856306372427
5153,HYOU1,Scavenging by Class F Receptors,0.0033801896961495694,1,0,1,0.0036903354677937207
5154,COL10,Initial triggering of complement,0.00012173208737581008,0,0,1,0.0001329014877843229
5155,COL10,Initial triggering of complement,0.0001168047083272282,1,0,1,0.00012752200222262243
5156,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.000482867825034708,0,1,2,0.01246813855023025
5157,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.0012685719820307946,1,1,2,0.032755819321287884
5158,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.0008058039518126756,0,1,2,0.020806677924339524
5159,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.0008074771761996477,1,1,2,0.02084988228048169
5160,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,2.021863256859107e-05,0,1,2,0.0005220656649534918
5161,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,2.8139294285173845e-05,1,1,2,0.0007265852095820041
5162,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,0.00015920426956996049,0,1,2,0.004110816227284961
5163,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,8.809071125628997e-05,1,1,2,0.002274591795079335
5164,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.005813537252965644,0,1,2,0.15011144702319013
5165,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.0004031602348783483,1,1,2,0.010410007471600133
5166,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),2.5990267929870324e-05,0,1,2,0.0006710951624990478
5167,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),4.018076237956718e-05,1,1,2,0.001037508167719216
5168,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,0.0008362079403547154,0,1,2,0.021591739843912477
5169,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,0.0008481493755390992,1,1,2,0.021900079850531867
5170,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0009154281508045148,0,1,2,0.023637286282620632
5171,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.001095804647923102,1,1,2,0.028294790967506395
5172,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.0016488700336599392,0,1,2,0.04257550195960401
5173,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.0014987914086683526,1,1,2,0.03870031916048367
5174,Downregulation of ERBB2 signaling,Signaling by ERBB2,0.0005211320431367612,0,1,2,0.01345615959466065
5175,Downregulation of ERBB2 signaling,Signaling by ERBB2,0.00010869042992726002,1,1,2,0.0028064974909433288
5176,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,0.0001632817640831472,0,1,2,0.004216101284380163
5177,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,3.4050988637466104e-05,1,1,2,0.000879231172782587
5178,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,5.895845598263753e-05,0,1,2,0.0015223673224579375
5179,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,8.532222735656834e-05,1,1,2,0.002203106723914509
5180,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,4.414719219058327e-05,0,1,2,0.0011399254211983797
5181,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,6.388848974006924e-05,1,1,2,0.0016496658102802574
5182,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,5.651775373841475e-05,0,1,2,0.0014593459071490168
5183,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,8.179177883750969e-05,1,1,2,0.0021119469509954607
5184,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,7.611943047191134e-05,0,1,2,0.0019654811447008115
5185,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,0.0001101586667619596,1,1,2,0.0028444088599153036
5186,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,2.410179338185486e-05,0,1,2,0.0006223328281862411
5187,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,3.487902686082159e-05,1,1,2,0.0009006119622210644
5188,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,1.2207758424023647e-05,0,1,2,0.00031521674364517197
5189,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,1.7666738181867517e-05,1,1,2,0.00045617315538954
5190,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.0012768057040098422,0,1,2,0.032968422400425454
5191,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.0012813092461730433,1,1,2,0.03308470844133853
5192,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0019395531601033784,0,1,2,0.05008123604832775
5193,Nuclear signaling by ERBB4,Signaling by ERBB4,0.001768004472710876,1,1,2,0.045651674392679815
5194,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.004106919807842123,0,1,2,0.10604484814282247
5195,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.004493549137570077,1,1,2,0.11602801082359188
5196,PTEN Regulation,PIP3 activates AKT signaling,0.0027281900439092292,0,1,2,0.07044464280960121
5197,PTEN Regulation,PIP3 activates AKT signaling,0.0013899109975599121,1,1,2,0.03588891616214042
5198,Defensins,Antimicrobial peptides,0.0012326480331845454,0,1,2,0.03182822641021698
5199,Defensins,Antimicrobial peptides,0.0010324582911606496,1,1,2,0.026659123582317083
5200,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.0013547326523224413,0,1,2,0.034980575494884134
5201,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.0013245230414762829,1,1,2,0.03420053260519404
5202,Antagonism of Activin by Follistatin,Signaling by Activin,9.41919373726545e-06,0,1,2,0.00024321316612728388
5203,Antagonism of Activin by Follistatin,Signaling by Activin,4.030919732021946e-05,1,1,2,0.0010408244885667028
5204,Methylation,Phase II - Conjugation of compounds,0.0010495925960981945,0,1,2,0.027101548769598607
5205,Methylation,Phase II - Conjugation of compounds,0.0015071619914839905,1,1,2,0.03891645612567502
5206,Glucuronidation,Phase II - Conjugation of compounds,0.0007246465783868799,0,1,2,0.018711111966568654
5207,Glucuronidation,Phase II - Conjugation of compounds,0.0011347237663275,1,1,2,0.02929972220409059
5208,Glutathione conjugation,Phase II - Conjugation of compounds,0.00011397491627188724,0,1,2,0.0029429483052150728
5209,Glutathione conjugation,Phase II - Conjugation of compounds,0.0001675927206047463,1,1,2,0.0043274145680752465
5210,Packaging Of Telomere Ends,Telomere Maintenance,0.0006118239108786262,0,1,2,0.015797915896819427
5211,Packaging Of Telomere Ends,Telomere Maintenance,0.0021346922902399815,1,1,2,0.05511992693840661
5212,Inhibition of DNA recombination at telomere,Telomere Maintenance,0.0008243783551807808,0,1,2,0.021286287918367917
5213,Inhibition of DNA recombination at telomere,Telomere Maintenance,0.0029041752795958276,1,1,2,0.07498876065629707
5214,Gap junction trafficking,Gap junction trafficking and regulation,0.001377073292451545,0,1,2,0.03555743355414802
5215,Gap junction trafficking,Gap junction trafficking and regulation,0.0018371564156202717,1,1,2,0.04743724791924474
5216,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.007264756460369477,0,1,2,0.18758340354331185
5217,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.005901540700910843,1,1,2,0.1523837855907885
5218,Methionine salvage pathway,Sulfur amino acid metabolism,6.360913931036387e-05,0,1,2,0.0016424526979520904
5219,Methionine salvage pathway,Sulfur amino acid metabolism,7.119366266013615e-05,1,1,2,0.0018382928079358524
5220,Cysteine formation from homocysteine,Sulfur amino acid metabolism,2.4333678938170393e-05,0,1,2,0.000628320349188974
5221,Cysteine formation from homocysteine,Sulfur amino acid metabolism,2.7634123359214567e-05,1,1,2,0.0007135411822729663
5222,HIV Life Cycle,HIV Infection,0.000346373522232835,0,1,2,0.008943716771809813
5223,HIV Life Cycle,HIV Infection,0.0002117624664541776,1,1,2,0.005467922347692955
5224,Host Interactions of HIV factors,HIV Infection,0.0006500712810633891,0,1,2,0.016785501910882992
5225,Host Interactions of HIV factors,HIV Infection,0.00039489179224049247,1,1,2,0.010196507869724595
5226,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0012286628039506874,0,1,2,0.031725323736512025
5227,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0008556310695384494,1,1,2,0.022093264802061034
5228,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.001796754902030157,0,1,2,0.04639403973065948
5229,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.0012587325286704026,1,1,2,0.032501754624086165
5230,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,0.001132833147374204,0,1,2,0.029250904499051555
5231,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,0.0007926123885249927,1,1,2,0.02046605833811396
5232,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.0026596373060188104,0,1,2,0.06867454136630476
5233,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.0018524469508284817,1,1,2,0.047832065096118
5234,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.00042431117048744715,0,1,2,0.01095614614965823
5235,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.00026237561412806846,1,1,2,0.0067748053184437515
5236,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,0.00023941324413180834,0,1,2,0.006181893561412845
5237,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,4.0036199322046946e-05,1,1,2,0.0010337754024841797
5238,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,0.00017144933303709964,0,1,2,0.00442699622510047
5239,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,2.867522955500417e-05,1,1,2,0.0007404236035518636
5240,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.001742800975666496,0,1,2,0.045000894454966925
5241,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.0032822544293372945,1,1,2,0.08475114899018747
5242,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.001218574563506132,0,1,2,0.03146483510366159
5243,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.001541952656608664,1,1,2,0.03981478649796254
5244,Signaling by NTRK1 (TRKA),Signaling by NTRKs,3.969165036165389e-06,0,1,2,0.0001024878797755526
5245,Signaling by NTRK1 (TRKA),Signaling by NTRKs,8.151347323312477e-06,1,1,2,0.0002104760817120156
5246,Initial triggering of complement,Complement cascade,0.0007444247098231378,0,1,2,0.019221803444084685
5247,Initial triggering of complement,Complement cascade,0.0010031358506747325,1,1,2,0.025901988334005567
5248,Terminal pathway of complement,Complement cascade,0.0005693617781882383,0,1,2,0.014701500426428617
5249,Terminal pathway of complement,Complement cascade,0.0007684337471638233,1,1,2,0.019841741216910617
5250,Activation of C3 and C5,Complement cascade,0.00013028596409440484,0,1,2,0.0033641161561398323
5251,Activation of C3 and C5,Complement cascade,0.00017646427017469534,1,1,2,0.004556487004586024
5252,Regulation of Complement cascade,Complement cascade,0.0022757334774105215,0,1,2,0.058761753897585034
5253,Regulation of Complement cascade,Complement cascade,0.00305960612268297,1,1,2,0.07900214317241376
5254,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.002057330381583985,0,1,2,0.053122363742797364
5255,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.002602789637712519,1,1,2,0.06720667672933203
5256,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.00011506714313869858,0,1,2,0.002971150714233957
5257,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.00014441162125198215,1,1,2,0.003728854996506896
5258,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.00015723971754882514,0,1,2,0.004060089495208974
5259,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.0001984894472207319,1,1,2,0.0051251994860680855
5260,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0008473176611658595,0,1,2,0.021878604139162972
5261,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0010621436628192214,1,1,2,0.02742563008278136
5262,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.0006524170396448708,0,1,2,0.01684607178421676
5263,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.0008254276634538551,1,1,2,0.021313382125627747
5264,Virus Assembly and Release,Influenza Infection,0.003424797790966512,0,1,2,0.08843176362231979
5265,Virus Assembly and Release,Influenza Infection,0.0032174628633334476,1,1,2,0.08307816483191541
5266,Influenza Viral RNA Transcription and Replication,Influenza Infection,0.0007999543669966858,0,1,2,0.020655635692561417
5267,Influenza Viral RNA Transcription and Replication,Influenza Infection,0.0007537299134682268,1,1,2,0.01946207327004946
5268,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.00034489354510498495,0,1,2,0.008905502256523192
5269,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.0006660960362349556,1,1,2,0.017199277394263454
5270,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,7.960868316126026e-06,0,1,2,0.00020555771993808653
5271,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,9.981910732233419e-06,1,1,2,0.0002577430914900383
5272,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.00023926959684427248,0,1,2,0.0061781844422905815
5273,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.00030251500889163173,1,1,2,0.007811245332227069
5274,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0012785703022502027,0,1,2,0.03301398612243308
5275,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0016191218151764906,1,1,2,0.04180737269017609
5276,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0013396753194896067,0,1,2,0.03459177984062156
5277,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.000925109176184983,1,1,2,0.023887260208183585
5278,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.00096844687982296,0,1,2,0.025006283811316133
5279,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.0013088783845776719,1,1,2,0.033796571645963266
5280,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.0005185633009449735,0,1,2,0.013389832057627653
5281,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,1.2742646340894954e-05,1,1,2,0.00032902809389597014
5282,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0010776866541251772,0,1,2,0.027826965932967178
5283,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0009195899032706366,1,1,2,0.02374474696579131
5284,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0010776866541251772,0,1,2,0.027826965932967178
5285,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0009195899032706366,1,1,2,0.02374474696579131
5286,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.0010386477497838873,0,1,2,0.026818941701612767
5287,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.0018000214410773515,1,1,2,0.04647838509249268
5288,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.0012358814804563016,0,1,2,0.03191171730873817
5289,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.001552040836317902,1,1,2,0.04007527356256528
5290,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.001592821839690929,0,1,2,0.041128280563468185
5291,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.0020080498647592803,1,1,2,0.05184989065649635
5292,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,6.500820625848696e-05,0,1,2,0.0016785780300737588
5293,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,0.00010254902409994849,1,1,2,0.0026479201437311643
5294,Bile acid and bile salt metabolism,Metabolism of steroids,8.660579427346697e-05,0,1,2,0.0022362497277111145
5295,Bile acid and bile salt metabolism,Metabolism of steroids,7.936453410621159e-05,1,1,2,0.002049273022362991
5296,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,0.00014646413846005347,0,1,2,0.003781853079212294
5297,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,9.838852775594556e-05,1,1,2,0.0025404918949116736
5298,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.0037412167379868157,0,1,2,0.09660202278399314
5299,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.00252914687717485,1,1,2,0.06530514572229282
5300,RHO GTPase Effectors,Signaling by Rho GTPases,0.0005047363358271884,0,1,2,0.013032805749640882
5301,RHO GTPase Effectors,Signaling by Rho GTPases,0.0006361637910840774,1,1,2,0.01642639636903925
5302,RHO GTPase cycle,Signaling by Rho GTPases,0.003801273569183765,0,1,2,0.09815275127205826
5303,RHO GTPase cycle,Signaling by Rho GTPases,0.004809351921629493,1,1,2,0.12418236003068228
5304,Metabolism of steroid hormones,Metabolism of steroids,0.0011270372255110367,0,1,2,0.029101247899316243
5305,Metabolism of steroid hormones,Metabolism of steroids,0.0010250389489274636,1,1,2,0.026467548616831878
5306,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,0.00018068625290375558,0,1,2,0.004665502894428795
5307,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,0.0002448343706405259,1,1,2,0.006321872563749889
5308,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,7.00779448638299e-05,0,1,2,0.0018094838392158847
5309,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,9.639390003857105e-05,1,1,2,0.002488988577757404
5310,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,7.868991643237959e-05,0,1,2,0.0020318537076153853
5311,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,0.0001042447097772892,1,1,2,0.0026917044732445365
5312,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,1.5760135510145997e-05,0,1,2,0.0004069427344776592
5313,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,2.105507627938405e-05,1,1,2,0.0005436634926300117
5314,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.00016224500832137851,0,1,2,0.004189331195734162
5315,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.000214964522567086,1,1,2,0.005550602694552852
5316,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,3.3460351051654856e-05,0,1,2,0.0008639803093556464
5317,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,4.500752779884739e-05,1,1,2,0.0011621401619771067
5318,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.0010434320243009009,0,1,2,0.026942476537540536
5319,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.001259859192237753,1,1,2,0.03253084622375158
5320,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.0021654050677743218,0,1,2,0.05591296210394706
5321,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.002627991021811421,1,1,2,0.0678574021086428
5322,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.00010669822960421166,0,1,2,0.0027550568515803827
5323,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.0001258142643742818,1,1,2,0.0032486523195060448
5324,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0016557652930428303,0,1,2,0.04275354457265134
5325,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0020739174537924426,1,1,2,0.053550658824216085
5326,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0006053350486332318,0,1,2,0.01563036687136278
5327,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0007552692669530655,1,1,2,0.019501820943287715
5328,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,9.34871047163516e-05,0,1,2,0.0024139321649347266
5329,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,2.5918167479355665e-05,1,1,2,0.0006692334555060707
5330,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,4.7577048309770174e-05,0,1,2,0.0012284877960020925
5331,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,1.412354468928111e-05,1,1,2,0.00036468429428626365
5332,Degradation of AXIN,TCF dependent signaling in response to WNT,9.323398570921217e-06,0,1,2,0.00024073963746271322
5333,Degradation of AXIN,TCF dependent signaling in response to WNT,3.726008613638008e-06,1,1,2,9.620933353936095e-05
5334,Degradation of DVL,TCF dependent signaling in response to WNT,0.00011638364724737774,0,1,2,0.0030051441898352334
5335,Degradation of DVL,TCF dependent signaling in response to WNT,3.8010460254524336e-05,1,1,2,0.000981468758613943
5336,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,0.0006067634136241691,0,1,2,0.015667248708760052
5337,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,0.00017287533857602354,1,1,2,0.004463817139046064
5338,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0002838084936454056,0,1,2,0.007328224075084544
5339,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,7.991016940668188e-05,1,1,2,0.0020633618809935516
5340,Downstream TCR signaling,TCR signaling,0.000186294989228183,0,1,2,0.0048103261730965
5341,Downstream TCR signaling,TCR signaling,0.0004422551676443941,1,1,2,0.011419478413889484
5342,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0008887279424191451,0,1,2,0.022947859735211136
5343,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0006536385745389707,1,1,2,0.016877613058068428
5344,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0002537917427676216,0,1,2,0.006553161026008837
5345,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.00018726452849027807,1,1,2,0.004835360663329558
5346,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0004598809687564509,0,1,2,0.011874594532483905
5347,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.00033861600367423575,1,1,2,0.00874340974951516
5348,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,0.0004896559926260471,0,1,2,0.012643415944256067
5349,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,0.0002840056862586963,1,1,2,0.007333315788999037
5350,Catecholamine biosynthesis,Metabolism of amine-derived hormones,2.417846169102486e-05,0,1,2,0.0006243124819373991
5351,Catecholamine biosynthesis,Metabolism of amine-derived hormones,0.00033435735907243197,1,1,2,0.008633447212815467
5352,Ethanol oxidation,Phase I - Functionalization of compounds,0.0013993648530887014,0,1,2,0.03613302433099248
5353,Ethanol oxidation,Phase I - Functionalization of compounds,0.0009707713294756565,1,1,2,0.02506630346642728
5354,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,0.00056031229388711,0,1,2,0.014467833534113954
5355,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,0.00037901158380170875,1,1,2,0.009786464730057835
5356,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.001349509714365119,0,1,2,0.034845713922596784
5357,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.0009092946618388828,1,1,2,0.023478913356832273
5358,Transcriptional Regulation by TP53,Generic Transcription Pathway,8.516194772968688e-05,0,1,2,0.0021989681408672874
5359,Transcriptional Regulation by TP53,Generic Transcription Pathway,5.7646888408496546e-05,1,1,2,0.0014885013132012559
5360,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0035035799388646095,0,1,2,0.09046599884022358
5361,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.002392918755522537,1,1,2,0.06178759701198772
5362,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0046445333039254215,0,1,2,0.11992657562209369
5363,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0031663339300047745,1,1,2,0.0817579637507571
5364,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.0006108994016196753,0,1,2,0.015774044127084632
5365,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.0004129572488669085,1,1,2,0.01066297634103999
5366,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.003199122802687797,0,1,2,0.08260460580541956
5367,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0021550344713293923,1,1,2,0.05564518275187569
5368,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.00242781979848467,0,1,2,0.06268877745234558
5369,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.0016526849965949682,1,1,2,0.04267400818423083
5370,FOXO-mediated transcription,Generic Transcription Pathway,0.007695919400917811,0,1,2,0.1987164693674738
5371,FOXO-mediated transcription,Generic Transcription Pathway,0.005209813165114389,1,1,2,0.13452267679833663
5372,Arachidonic acid metabolism,Fatty acid metabolism,0.00235593273285345,0,1,2,0.06083258027417343
5373,Arachidonic acid metabolism,Fatty acid metabolism,0.0013755503196033931,1,1,2,0.03551810884561597
5374,DAP12 signaling,DAP12 interactions,0.0019541703172001176,0,1,2,0.0504586659172148
5375,DAP12 signaling,DAP12 interactions,0.0010664066104522515,1,1,2,0.027535703728125558
5376,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.00032032085621763767,0,1,2,0.008271010427258887
5377,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.0007316818832967024,1,1,2,0.018892770697614723
5378,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,0.0004322263321689765,0,1,2,0.011160523677785491
5379,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,0.00018472057457485585,1,1,2,0.004769673184813869
5380,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0010851309847853118,0,1,2,0.028019186125061386
5381,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0011013595681452636,1,1,2,0.028438224659656848
5382,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.00014779058988916417,0,1,2,0.0038161034047483025
5383,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.00014799922778771133,1,1,2,0.003821490647573454
5384,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0007547808017919904,0,1,2,0.019489208275825752
5385,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0007584806104573961,1,1,2,0.019584741100043858
5386,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0012718117508008762,0,1,2,0.03283947344732782
5387,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0012864718454125646,1,1,2,0.033218012006538886
5388,Retinoid cycle disease events,Diseases associated with visual transduction,0.0024365641131992234,0,1,2,0.06291456455543125
5389,Retinoid cycle disease events,Diseases associated with visual transduction,0.0015340580806518175,1,1,2,0.039610940514192124
5390,Retinoid metabolism disease events,Diseases associated with visual transduction,0.002222031415871627,0,1,2,0.0573751120279351
5391,Retinoid metabolism disease events,Diseases associated with visual transduction,0.0013966815550623965,1,1,2,0.03606373884575411
5392,Mitotic Metaphase and Anaphase,M Phase,0.000584077221691619,0,1,2,0.015081468150339498
5393,Mitotic Metaphase and Anaphase,M Phase,0.0009777922676897702,1,1,2,0.025247591234772344
5394,Oxidative Stress Induced Senescence,Cellular Senescence,0.00107289107349024,0,1,2,0.027703139161570887
5395,Oxidative Stress Induced Senescence,Cellular Senescence,0.00040535081749276474,1,1,2,0.010466570543576003
5396,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.0003691277734284723,0,1,2,0.009531254689652146
5397,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.00013542756220828655,1,1,2,0.003496877450907965
5398,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,0.0004284452318869381,0,1,2,0.011062891821313422
5399,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,0.0001633235822804853,1,1,2,0.004217181072784568
5400,EPH-Ephrin signaling,Axon guidance,0.00040775630636721524,0,1,2,0.010528682713848542
5401,EPH-Ephrin signaling,Axon guidance,0.0009960594142513644,1,1,2,0.025719267545429296
5402,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.00042300901850698036,0,1,2,0.010922523260610382
5403,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.00018493126984181512,1,1,2,0.004775113550984751
5404,Processing and activation of SUMO,SUMOylation,0.00013836172517128455,0,1,2,0.0035726405240615417
5405,Processing and activation of SUMO,SUMOylation,5.808891000924632e-05,1,1,2,0.0014999147606802768
5406,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.0014047919696149342,0,1,2,0.03627315800167649
5407,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.0022855079609476418,1,1,2,0.05901414100784446
5408,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.0006199410195106881,0,1,2,0.016007507900686207
5409,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.0005583910955682385,1,1,2,0.014418226238741897
5410,HSF1 activation,Cellular response to heat stress,0.001232730717351542,0,1,2,0.03183036139953823
5411,HSF1 activation,Cellular response to heat stress,0.0011147784947022929,1,1,2,0.02878471499683427
5412,HSF1-dependent transactivation,Cellular response to heat stress,0.0014411137931785772,0,1,2,0.037211024442779635
5413,HSF1-dependent transactivation,Cellular response to heat stress,0.0012795488174251566,1,1,2,0.033039252379868954
5414,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,0.0006042912476923587,0,1,2,0.015603414869023982
5415,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,0.00015240982482162528,1,1,2,0.003935376750678628
5416,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0022756810583371306,0,1,2,0.05876040038377478
5417,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.003009563717338272,1,1,2,0.07770999734932102
5418,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.003314685944917932,0,1,2,0.08558856372086304
5419,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.004543212520046591,1,1,2,0.11731036989058034
5420,Semaphorin interactions,Axon guidance,0.0009776092068895551,0,1,2,0.025242864418650285
5421,Semaphorin interactions,Axon guidance,0.0023242258295268874,1,1,2,0.06001387576917576
5422,L1CAM interactions,Axon guidance,0.00040579772615754263,0,1,2,0.010478110180020714
5423,L1CAM interactions,Axon guidance,0.0009617418601935939,1,1,2,0.024833153382269754
5424,NCAM signaling for neurite out-growth,Axon guidance,0.00021683060422588907,0,1,2,0.005598786821681902
5425,NCAM signaling for neurite out-growth,Axon guidance,0.0005174287685010225,1,1,2,0.01336053727556199
5426,Signaling by ROBO receptors,Axon guidance,4.156780302018711e-05,0,1,2,0.0010733229683446385
5427,Signaling by ROBO receptors,Axon guidance,0.00010098726634357995,1,1,2,0.00260759396940613
5428,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.0013631564756421545,0,1,2,0.035198087184061796
5429,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.001797885142924098,1,1,2,0.04642322370053732
5430,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.0019171620226216379,0,1,2,0.04950307409603878
5431,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.002518322927793689,1,1,2,0.0650256603361309
5432,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,0.0002925456488616694,0,1,2,0.007553826312639745
5433,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,0.00038193272183921663,1,1,2,0.00986189148638267
5434,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.006157177930779348,0,1,2,0.1589845989714864
5435,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.0034663164119477273,1,1,2,0.08950381666037649
5436,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.002251355510355462,0,1,2,0.05813228998415576
5437,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.0012538658382423163,1,1,2,0.03237609172547805
5438,PERK regulates gene expression,Unfolded Protein Response (UPR),0.001332319541416389,0,1,2,0.03440184616642193
5439,PERK regulates gene expression,Unfolded Protein Response (UPR),0.0007475586662714271,1,1,2,0.019302725388314144
5440,PCP/CE pathway,Beta-catenin independent WNT signaling,0.00020692088598022986,0,1,2,0.005342907813649543
5441,PCP/CE pathway,Beta-catenin independent WNT signaling,0.00012849959993216055,1,1,2,0.0033179904158828033
5442,G alpha (q) signalling events,GPCR downstream signalling,0.0019137585691838504,0,1,2,0.04941519346533298
5443,G alpha (q) signalling events,GPCR downstream signalling,0.001835365024808059,1,1,2,0.04739099238577102
5444,G alpha (s) signalling events,GPCR downstream signalling,0.0003223326904952497,0,1,2,0.008322958035305802
5445,G alpha (s) signalling events,GPCR downstream signalling,0.0003039052734260308,1,1,2,0.007847143377070114
5446,G alpha (i) signalling events,GPCR downstream signalling,6.084429329646563e-05,0,1,2,0.0015710615607006963
5447,G alpha (i) signalling events,GPCR downstream signalling,5.778922660637903e-05,1,1,2,0.0014921766302966977
5448,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.000678533842206141,0,1,2,0.017520434199644875
5449,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.0015662677394912784,1,1,2,0.040442626678075966
5450,Peroxisomal lipid metabolism,Fatty acid metabolism,0.0004769932859970805,0,1,2,0.01231645197505906
5451,Peroxisomal lipid metabolism,Fatty acid metabolism,0.0002766596128632844,1,1,2,0.007143632699454662
5452,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.00401917384481421,0,1,2,0.10377915809777388
5453,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.0024389054739317705,1,1,2,0.06297502087183081
5454,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,7.018316200674927e-05,0,1,2,0.001812200652902288
5455,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,1.8426860564718227e-05,1,1,2,0.000475800288723248
5456,Adherens junctions interactions,Cell-cell junction organization,0.0032102287797786786,0,1,2,0.08289137343400374
5457,Adherens junctions interactions,Cell-cell junction organization,0.0025964146830188967,1,1,2,0.06704206891276067
5458,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,0.00029885465804272365,0,1,2,0.007716731348978427
5459,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,5.10094913746807e-05,1,1,2,0.0013171169683765518
5460,Netrin-1 signaling,Axon guidance,5.14368615927312e-06,0,1,2,0.00013281521022468043
5461,Netrin-1 signaling,Axon guidance,1.2300927180153918e-05,1,1,2,0.00031762245572570114
5462,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0036356814892171897,0,1,2,0.09387699528087026
5463,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.004597362842668453,1,1,2,0.11870858631748869
5464,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,0.00021846926824879942,0,1,2,0.0056410987940595505
5465,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,0.00027142032239436015,1,1,2,0.00700834888867942
5466,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,0.0009402694646860023,0,1,2,0.024278714282553904
5467,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,0.0011722780227824232,1,1,2,0.030269411316421083
5468,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",0.0012812343391691093,0,1,2,0.03308277426628066
5469,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",0.0006461637989522743,1,1,2,0.016684606746993322
5470,Glycosphingolipid metabolism,Sphingolipid metabolism,0.00017753030738853812,0,1,2,0.00458401317011784
5471,Glycosphingolipid metabolism,Sphingolipid metabolism,0.0003696533137099784,1,1,2,0.009544824674446794
5472,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.008258529526885588,0,1,2,0.21324363526390627
5473,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.005894026768104882,1,1,2,0.15218976820047034
5474,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,0.00017799341897208358,0,1,2,0.004595971182411258
5475,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,8.422618801550417e-05,1,1,2,0.002174805872931304
5476,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,0.0006141957672824611,0,1,2,0.01585915964248034
5477,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,0.0003318930556524904,1,1,2,0.00856981639113579
5478,Interleukin-1 family signaling,Signaling by Interleukins,0.0018463971558262393,0,1,2,0.04767585323362121
5479,Interleukin-1 family signaling,Signaling by Interleukins,0.0017933559908305129,1,1,2,0.04630627638516417
5480,Interleukin-12 family signaling,Signaling by Interleukins,0.002091304567758999,0,1,2,0.053999611797854556
5481,Interleukin-12 family signaling,Signaling by Interleukins,0.0020400233449960198,1,1,2,0.05267547844855117
5482,Other interleukin signaling,Signaling by Interleukins,0.001996824965363668,0,1,2,0.0515600523330031
5483,Other interleukin signaling,Signaling by Interleukins,0.0019222630327589618,1,1,2,0.049634787367954784
5484,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00021687843879964174,0,1,2,0.005600021959046866
5485,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00020892579955608627,1,1,2,0.005394676722135459
5486,Interleukin-10 signaling,Signaling by Interleukins,0.0011467186723679989,0,1,2,0.029609442882620338
5487,Interleukin-10 signaling,Signaling by Interleukins,0.0011108163058050537,1,1,2,0.028682407248063868
5488,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.0030901496092788357,0,1,2,0.07979080707367284
5489,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.003015552587902246,1,1,2,0.07786463608083238
5490,G2/M Transition,Mitotic G2-G2/M phases,0.0006221008665962301,0,1,2,0.016063277350033787
5491,G2/M Transition,Mitotic G2-G2/M phases,0.0006458112812711979,1,1,2,0.01667550438178862
5492,G1/S Transition,Mitotic G1 phase and G1/S transition,0.00032735117434564814,0,1,2,0.008452540394524626
5493,G1/S Transition,Mitotic G1 phase and G1/S transition,0.0009949223887039708,1,1,2,0.025689908388896066
5494,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.001417943407762272,0,1,2,0.03661274151595186
5495,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0015415940429216225,1,1,2,0.039805526727681256
5496,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,0.0009014442355341283,0,1,2,0.023276207362000215
5497,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,0.0006963229802588408,1,1,2,0.017979767844238593
5498,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.0017498843682666018,0,1,2,0.04518379485910432
5499,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.0018940863247195094,1,1,2,0.0489072360971696
5500,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.002023917515571572,0,1,2,0.052259609545469966
5501,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.0022611074607735405,1,1,2,0.058384095266354546
5502,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.002973298784487214,0,1,2,0.07677359988430192
5503,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.002438467425420682,1,1,2,0.06296371001356937
5504,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.0032614003357039896,0,1,2,0.08421267507397481
5505,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.0026566880828403127,1,1,2,0.06859838942306351
5506,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,0.0006235630994131978,0,1,2,0.01610103368915896
5507,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,0.0003067637096557454,1,1,2,0.007920951108919959
5508,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.008027072785193807,0,1,2,0.20726718669106844
5509,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.010063243529426648,1,1,2,0.25984318706797427
5510,RA biosynthesis pathway,Signaling by Retinoic Acid,0.0009838177548924716,0,1,2,0.025403175445152318
5511,RA biosynthesis pathway,Signaling by Retinoic Acid,0.00018293564499536531,1,1,2,0.004723584486943199
5512,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0007611991293068862,0,1,2,0.019654936022773323
5513,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0002845839820660386,1,1,2,0.00734824797514841
5514,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,0.0005140004035139806,0,1,2,0.013272013403307458
5515,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,0.0006639463589899005,1,1,2,0.017143770540544848
5516,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,3.4709547832956326e-06,0,1,2,8.962358412802448e-05
5517,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,4.494765024564405e-06,1,1,2,0.00011605940626292481
5518,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,0.00030158356393198126,0,1,2,0.007787194475643281
5519,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,0.00039337771413741434,1,1,2,0.01015741283256056
5520,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.004489198396056843,0,1,2,0.1159156702509324
5521,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0052480357755235576,1,1,2,0.1355096234898018
5522,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.005007883153952863,0,1,2,0.12930863845061594
5523,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.005871767398007781,1,1,2,0.15161500861612331
5524,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),9.224577637594728e-05,0,1,2,0.0023818798041600653
5525,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.00010852055627045157,1,1,2,0.0028021111802816693
5526,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,0.0003196778931486719,0,1,2,0.00825440846661682
5527,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,0.0005139678933419371,1,1,2,0.013271173957586882
5528,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,0.00010740335737529658,0,1,2,0.00277326396808244
5529,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,0.0001752922096398963,1,1,2,0.004526223209030624
5530,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,0.00014209880916916454,0,1,2,0.003669135835291001
5531,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,0.00022825304906549959,1,1,2,0.005893725969537507
5532,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.0006186664189317064,0,1,2,0.015974596416857677
5533,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.00040694341689767344,1,1,2,0.010507693080647073
5534,Defective ABCA1 causes TGD,ABC transporter disorders,0.0036958379870678623,0,1,2,0.0954302972633432
5535,Defective ABCA1 causes TGD,ABC transporter disorders,0.00239019838510717,1,1,2,0.061717354279943404
5536,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.00011123899462360115,0,1,2,0.002872304024513717
5537,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,5.6418443333073846e-05,1,1,2,0.0014567816114368708
5538,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,0.0001582353159457003,0,1,2,0.004085796858816674
5539,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,8.045951406455771e-05,1,1,2,0.0020775465190065157
5540,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.0013480494081580168,0,1,2,0.034808007330498617
5541,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.0006836897146474123,1,1,2,0.017653564072070034
5542,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,0.0006901782858014097,0,1,2,0.01782110558125063
5543,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,0.00033566395246582153,1,1,2,0.008667184783664024
5544,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.00163871674180305,0,1,2,0.04231333363309868
5545,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.001894640317895842,1,1,2,0.048921540764658884
5546,Fructose biosynthesis,Fructose metabolism,6.467748640984079e-06,0,1,2,0.00016700385070812397
5547,Fructose biosynthesis,Fructose metabolism,3.043256180525841e-06,1,1,2,7.857997103019517e-05
5548,Fructose catabolism,Fructose metabolism,0.00215225549454587,0,1,2,0.05557342674377484
5549,Fructose catabolism,Fructose metabolism,0.0010142040490454239,1,1,2,0.026187780477595363
5550,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.0013312677451260593,0,1,2,0.03437468771602507
5551,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.0017574649590882435,1,1,2,0.04537953342721049
5552,Essential pentosuria,Diseases of carbohydrate metabolism,3.3761735140075046e-05,0,1,2,0.0008717623531706132
5553,Essential pentosuria,Diseases of carbohydrate metabolism,4.490184091345636e-05,1,1,2,0.001159411219062132
5554,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,0.0008674272482914538,0,1,2,0.02239785413982685
5555,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,0.0011482095408789947,1,1,2,0.029647938624501536
5556,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.00042900602576604436,0,1,2,0.011077372089867896
5557,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.000714488268113662,1,1,2,0.01844881405944758
5558,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0003918742322316275,0,1,2,0.010118591399991996
5559,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0004186499466478441,1,1,2,0.010809967589943749
5560,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.0006485874729164814,0,1,2,0.01674718847478632
5561,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.0019086998949999813,1,1,2,0.049284573350811114
5562,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,0.00022784682904632508,0,1,2,0.005883236955322114
5563,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,0.0006705281705250444,1,1,2,0.017313719611236768
5564,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,6.62097609073023e-05,0,1,2,0.0017096033936626997
5565,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,0.00019489548176906407,1,1,2,0.005032399641321929
5566,UCH proteinases,Deubiquitination,0.0010758383515635534,0,1,2,0.027779240880217156
5567,UCH proteinases,Deubiquitination,0.0009300722264883293,1,1,2,0.024015411216815056
5568,Ub-specific processing proteases,Deubiquitination,0.0009342431023127907,0,1,2,0.02412310747438089
5569,Ub-specific processing proteases,Deubiquitination,0.000819879512538289,1,1,2,0.021170123223861217
5570,Metalloprotease DUBs,Deubiquitination,0.0030947610963996367,0,1,2,0.07990988036322286
5571,Metalloprotease DUBs,Deubiquitination,0.0026569003954312297,1,1,2,0.06860387155018458
5572,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.0031251150300385913,0,1,2,0.08069364981426834
5573,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.0013563182319604277,1,1,2,0.0350215167744308
5574,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,0.003126653159648265,0,1,2,0.08073336588580458
5575,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,0.001192504191947841,1,1,2,0.030791671583972967
5576,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.005953089532155858,0,1,2,0.15371482886338406
5577,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.004336592729676451,1,1,2,0.11197523667194177
5578,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0012611285533124007,0,1,2,0.032563622418247125
5579,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0005213059875833618,1,1,2,0.013460651017256683
5580,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00043207949992235566,0,1,2,0.011156732319779027
5581,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00017767877675696535,1,1,2,0.004587846800275084
5582,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0004323074972486963,0,1,2,0.011162619442727615
5583,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00017815071138121833,1,1,2,0.004600032632456829
5584,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,3.785948646031809e-06,0,1,2,9.775704616348846e-05
5585,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,1.5582045251804163e-06,1,1,2,4.02344262804189e-05
5586,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0009582616712468226,0,1,2,0.024743291362645223
5587,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0003966499589832985,1,1,2,0.010241905523921447
5588,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.00041025594036171075,0,1,2,0.010593225806911319
5589,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.00016920812468673238,1,1,2,0.004369125945111732
5590,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.00023041887079255636,0,1,2,0.00594964969020807
5591,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,9.952255070483109e-05,1,1,2,0.0025697735212963455
5592,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.0018388286401754214,0,1,2,0.04748042645871195
5593,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.0015239614569259982,1,1,2,0.039350235416489646
5594,MET Receptor Activation,Signaling by MET,0.004822448011034028,0,1,2,0.1245205143841023
5595,MET Receptor Activation,Signaling by MET,0.004206831335119057,1,1,2,0.10862466543498599
5596,MET promotes cell motility,Signaling by MET,0.00027499437894294915,0,1,2,0.0071006346652911926
5597,MET promotes cell motility,Signaling by MET,0.00024112787002708003,1,1,2,0.006226166946624467
5598,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.00012066436554261523,0,1,2,0.0031156766917589023
5599,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0015658445571795068,1,1,2,0.040431699680206934
5600,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,1.1111803370496381e-05,0,1,2,0.00028691806905193154
5601,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0001292068611354378,1,1,2,0.003336252619774788
5602,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.00017958816454268756,0,1,2,0.004637149135664257
5603,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.0009598156910712491,1,1,2,0.02478341773569433
5604,Mitotic Prophase,M Phase,0.0010631038576274694,0,1,2,0.027450423289708304
5605,Mitotic Prophase,M Phase,0.001911501395740655,1,1,2,0.04935691095040327
5606,Mitotic Prometaphase,M Phase,0.0002639682651658455,0,1,2,0.006815929188728016
5607,Mitotic Prometaphase,M Phase,0.00044180960074226077,1,1,2,0.011407973423121468
5608,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.00018044285470208298,0,1,2,0.0046592181052090694
5609,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.0020448446782596746,1,1,2,0.05279997017902371
5610,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.00014192344018955353,0,1,2,0.003664607629803204
5611,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.001377609236706098,1,1,2,0.035571272180112565
5612,Cyclin A:Cdk2-associated events at S phase entry,S Phase,0.00027534430954326267,0,1,2,0.007109670229438297
5613,Cyclin A:Cdk2-associated events at S phase entry,S Phase,0.000518399537601359,1,1,2,0.013385603521469775
5614,Ubiquitin-dependent degradation of Cyclin D,S Phase,0.00030852188037759073,0,1,2,0.007966348865859656
5615,Ubiquitin-dependent degradation of Cyclin D,S Phase,0.0005816598390508265,1,1,2,0.015019048870918353
5616,G2/M DNA damage checkpoint,G2/M Checkpoints,0.00023418263884791325,0,1,2,0.006046834010952048
5617,G2/M DNA damage checkpoint,G2/M Checkpoints,0.00028397531723800833,1,1,2,0.007332531629985035
5618,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,5.904191950349247e-05,0,1,2,0.0015245224354887852
5619,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,7.22159796614367e-05,1,1,2,0.0018646900730954334
5620,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0012159456970491612,0,1,2,0.031396955096926395
5621,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0014915095244358214,1,1,2,0.038512293500435994
5622,Glycolysis,Glucose metabolism,0.0016025008337265223,0,1,2,0.04137820203763962
5623,Glycolysis,Glucose metabolism,0.0014149303859334497,1,1,2,0.03653494222664547
5624,Gluconeogenesis,Glucose metabolism,0.00013393776412617118,0,1,2,0.0034584093485895994
5625,Gluconeogenesis,Glucose metabolism,0.00011970713667139493,1,1,2,0.0030909600683437944
5626,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0024290242470826878,0,1,2,0.06271987754064745
5627,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0005906914751132688,1,1,2,0.015252254903549938
5628,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,0.00028764146019209433,0,1,2,0.007427195171282717
5629,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,6.849205390165199e-05,1,1,2,0.0017685345209618242
5630,mRNA Splicing - Major Pathway,mRNA Splicing,0.0009586877358881142,0,1,2,0.024754292785195163
5631,mRNA Splicing - Major Pathway,mRNA Splicing,0.001462455500900594,1,1,2,0.03776208905089988
5632,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.0018676603815712149,0,1,2,0.048224891357240486
5633,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.0022501363420473685,1,1,2,0.058100809817962736
5634,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.003115271375902224,0,1,2,0.08043947664875674
5635,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.0037291662739164333,1,1,2,0.09629086754060268
5636,Depurination,"Base-Excision Repair, AP Site Formation",0.0003843292486700253,0,1,2,0.009923772247569686
5637,Depurination,"Base-Excision Repair, AP Site Formation",0.00017807238192996602,1,1,2,0.004598010086326928
5638,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.000568164874466259,0,1,2,0.014670595154502801
5639,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.0003409521451998776,1,1,2,0.008803731300681994
5640,Utilization of Ketone Bodies,Ketone body metabolism,2.8385685235140406e-05,0,1,2,0.0007329472746077387
5641,Utilization of Ketone Bodies,Ketone body metabolism,6.614571557836134e-06,1,1,2,0.0001707949678104672
5642,Synthesis of Ketone Bodies,Ketone body metabolism,3.431740075366687e-05,0,1,2,0.0008861102046916035
5643,Synthesis of Ketone Bodies,Ketone body metabolism,7.99810312757448e-06,1,1,2,0.00020651916065532146
5644,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.0024384838071653827,0,1,2,0.06296413300688562
5645,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.0024742633173113534,1,1,2,0.063887996363752
5646,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.0011032488312912622,0,1,2,0.028487007356371958
5647,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.001539653867393316,1,1,2,0.03975542942145268
5648,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,0.003981211161841331,0,1,2,0.1027989229971844
5649,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,0.002716849285631729,1,1,2,0.07015181289189365
5650,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0011029782621783293,0,1,2,0.028480020986577665
5651,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0006589514375545736,1,1,2,0.01701479658685743
5652,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0003358200657447956,0,1,2,0.008671215787369105
5653,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.00012578706290521137,1,1,2,0.003247949949897725
5654,Extra-nuclear estrogen signaling,ESR-mediated signaling,0.00010782129596881888,0,1,2,0.002784055567810895
5655,Extra-nuclear estrogen signaling,ESR-mediated signaling,0.0001356953975220381,1,1,2,0.003503793231225816
5656,Estrogen-dependent gene expression,ESR-mediated signaling,0.0008155533427741617,0,1,2,0.0210584171187649
5657,Estrogen-dependent gene expression,ESR-mediated signaling,0.0009957526281833835,1,1,2,0.025711346017005674
5658,Pyrimidine catabolism,Nucleotide catabolism,5.2947928198420576e-05,0,1,2,0.0013671693794841252
5659,Pyrimidine catabolism,Nucleotide catabolism,4.3912904397915427e-05,1,1,2,0.0011338758720088053
5660,Pyrimidine salvage,Nucleotide salvage,0.00012079006644733472,0,1,2,0.003118922417016781
5661,Pyrimidine salvage,Nucleotide salvage,2.0659913415951027e-05,1,1,2,0.0005334599854262868
5662,Vitamin D (calciferol) metabolism,Metabolism of steroids,0.00032154983558458397,0,1,2,0.00830274392497404
5663,Vitamin D (calciferol) metabolism,Metabolism of steroids,0.00029387175142252036,1,1,2,0.007588067630042321
5664,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.0006685200141227451,0,1,2,0.01726186696967259
5665,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.00041160075230196565,1,1,2,0.010627950219526502
5666,VLDL assembly,Plasma lipoprotein assembly,0.002585025390161427,0,1,2,0.06674798578281539
5667,VLDL assembly,Plasma lipoprotein assembly,0.0037150402072279923,1,1,2,0.09592611812573204
5668,Chylomicron assembly,Plasma lipoprotein assembly,0.00516077488023926,0,1,2,0.13325645838743955
5669,Chylomicron assembly,Plasma lipoprotein assembly,0.007431493780672016,1,1,2,0.19188873080523233
5670,HDL assembly,Plasma lipoprotein assembly,0.0024280598600451755,0,1,2,0.06269497608609541
5671,HDL assembly,Plasma lipoprotein assembly,0.003475068008372333,1,1,2,0.08972979178462472
5672,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0015369411782320257,0,1,2,0.03968538502720412
5673,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.002010726289454812,1,1,2,0.0519189986653407
5674,Chylomicron remodeling,Plasma lipoprotein remodeling,0.007427491798078308,0,1,2,0.19178539554272983
5675,Chylomicron remodeling,Plasma lipoprotein remodeling,0.009905577196044077,1,1,2,0.2557720819178654
5676,LDL remodeling,Plasma lipoprotein remodeling,0.0010860443215712765,0,1,2,0.028042769410175927
5677,LDL remodeling,Plasma lipoprotein remodeling,0.001447994254053141,1,1,2,0.03738868494328478
5678,HDL remodeling,Plasma lipoprotein remodeling,0.0011045095421574733,0,1,2,0.028519560193684262
5679,HDL remodeling,Plasma lipoprotein remodeling,0.0014600817454395048,1,1,2,0.03770079626964841
5680,HDL clearance,Plasma lipoprotein clearance,1.1127680244141842e-05,0,1,2,0.0002873280260838416
5681,HDL clearance,Plasma lipoprotein clearance,1.9138985240417776e-05,1,1,2,0.0004941880724216578
5682,Chylomicron clearance,Plasma lipoprotein clearance,3.411054061832878e-05,0,1,2,0.0008807688655213465
5683,Chylomicron clearance,Plasma lipoprotein clearance,5.8288198038168175e-05,1,1,2,0.001505060580358408
5684,LDL clearance,Plasma lipoprotein clearance,0.0002045555635083871,0,1,2,0.005281832780760803
5685,LDL clearance,Plasma lipoprotein clearance,0.0003396699770675077,1,1,2,0.008770624414925154
5686,VLDL clearance,Plasma lipoprotein clearance,6.671161410565963e-05,0,1,2,0.001722561753869337
5687,VLDL clearance,Plasma lipoprotein clearance,0.00011508046729671013,1,1,2,0.0029714947575508652
5688,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,0.0008126768774174504,0,1,2,0.020984143856511744
5689,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,0.0004771238598153515,1,1,2,0.012319823523902925
5690,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,1.651337599704569e-05,0,1,2,0.0004263921702557279
5691,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,1.2072240202440594e-05,1,1,2,0.0003117175252769635
5692,NADPH regeneration,Metabolism of cofactors,0.00011145004797524472,0,1,2,0.0028777536367954903
5693,NADPH regeneration,Metabolism of cofactors,8.284161499824652e-05,1,1,2,0.0021390547888518506
5694,Triglyceride catabolism,Triglyceride metabolism,0.0015970509730369269,0,1,2,0.041237481089515894
5695,Triglyceride catabolism,Triglyceride metabolism,0.0009733509223732085,1,1,2,0.025132911179723477
5696,Glycogen synthesis,Glycogen metabolism,5.7620421809269595e-05,0,1,2,0.001487817918680009
5697,Glycogen synthesis,Glycogen metabolism,2.4282114643650864e-06,1,1,2,6.26988906638897e-05
5698,Glycogen breakdown (glycogenolysis),Glycogen metabolism,0.00017403642676367664,0,1,2,0.004493797617434025
5699,Glycogen breakdown (glycogenolysis),Glycogen metabolism,5.123411300265416e-06,1,1,2,0.00013229169273585984
5700,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,0.0004866080360692751,0,1,2,0.012564714604728662
5701,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,0.0005904038359593071,1,1,2,0.015244827767927871
5702,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,0.0005471260158531915,0,1,2,0.014127350418518217
5703,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,0.0007903066583415511,1,1,2,0.020406522038745635
5704,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,0.00020210663121227108,0,1,2,0.005218598857138096
5705,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,0.0002878263253420799,1,1,2,0.007431968577551738
5706,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.00022393897776230818,0,1,2,0.005782332259012486
5707,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.0003263764982769543,1,1,2,0.008427373266718595
5708,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.0013633276546269957,0,1,2,0.035202507199621404
5709,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.0005020294068109357,1,1,2,0.01296291008819802
5710,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.0003377237316719753,0,1,2,0.00872037037854884
5711,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00012435937786890256,1,1,2,0.0032110856696207996
5712,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,5.5404686862196575e-05,0,1,2,0.0014306053878829783
5713,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,7.502030659312774e-05,1,1,2,0.0019371006478152394
5714,Interferon gamma signaling,Interferon Signaling,0.0037292614194350602,0,1,2,0.09629332429470219
5715,Interferon gamma signaling,Interferon Signaling,0.0037980003999755953,1,1,2,0.09806823471272264
5716,Interferon alpha/beta signaling,Interferon Signaling,0.0003553198607709982,0,1,2,0.009174720335576078
5717,Interferon alpha/beta signaling,Interferon Signaling,0.00036247566314727344,1,1,2,0.009359490433809592
5718,HCMV Early Events,HCMV Infection,0.0008916542554168719,0,1,2,0.023023420114274235
5719,HCMV Early Events,HCMV Infection,0.0008910726671532996,1,1,2,0.023008402913555003
5720,HCMV Late Events,HCMV Infection,0.0004276510660393949,0,1,2,0.011042385651082846
5721,HCMV Late Events,HCMV Infection,0.00042746201296985727,1,1,2,0.01103750410846987
5722,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.0025296176768117525,0,1,2,0.06531730224794635
5723,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.0029763087179605747,1,1,2,0.07685131942912796
5724,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0004710351081646572,0,1,2,0.012162605761105533
5725,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.000566294325484899,1,1,2,0.014622295676559927
5726,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002582622919934517,0,1,2,0.06668595155709375
5727,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00245535202232296,1,1,2,0.06339968748530765
5728,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001299939923226213,0,1,2,0.033565771479172585
5729,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001235624546745897,1,1,2,0.031905083018910894
5730,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00031629786714022095,0,1,2,0.008167132755973397
5731,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00029920131594754186,1,1,2,0.0077256824087979445
5732,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0021736585471684483,0,1,2,0.05612607533964472
5733,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0020571556708211557,1,1,2,0.05311785253313659
5734,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002767372104009261,0,1,2,0.07145636346830431
5735,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002616593070038084,1,1,2,0.06756309539667955
5736,Parasite infection,Leishmania infection,0.0033852928676895103,0,1,2,0.08741170630788085
5737,Parasite infection,Leishmania infection,0.002822474024656534,1,1,2,0.07287915112445971
5738,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0004534364971391369,0,1,2,0.011708191718210824
5739,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0003804521098982034,1,1,2,0.009823660579574267
5740,Leishmania parasite growth and survival,Leishmania infection,0.002698435883134808,0,1,2,0.06967636010417422
5741,Leishmania parasite growth and survival,Leishmania infection,0.0022526427753296117,1,1,2,0.058165528475553285
5742,Lipophagy,Selective autophagy,1.095324502004707e-05,0,1,2,0.0002828239311135508
5743,Lipophagy,Selective autophagy,1.885771050141843e-05,1,1,2,0.0004869252724695764
5744,Aggrephagy,Selective autophagy,0.0001101141817510089,0,1,2,0.0028432602116699956
5745,Aggrephagy,Selective autophagy,0.00019577266689777603,1,1,2,0.005055049453862651
5746,SARS-CoV-1 Infection,SARS-CoV Infections,0.000311002217254815,0,1,2,0.008030393687720077
5747,SARS-CoV-1 Infection,SARS-CoV Infections,0.0003305038751708532,1,1,2,0.008533946337638059
5748,Potential therapeutics for SARS,SARS-CoV Infections,0.005393954892645012,0,1,2,0.13927740356350374
5749,Potential therapeutics for SARS,SARS-CoV Infections,0.005723881660100611,1,1,2,0.147796448392739
5750,SARS-CoV-2 Infection,SARS-CoV Infections,0.0014368327502493484,0,1,2,0.037100483558476005
5751,SARS-CoV-2 Infection,SARS-CoV Infections,0.0015296460417931683,1,1,2,0.039497017181705264
5752,ALK mutants bind TKIs,Signaling by ALK in cancer,6.968995516907746e-05,0,1,2,0.0017994655505260402
5753,ALK mutants bind TKIs,Signaling by ALK in cancer,1.2672026878481766e-05,1,1,2,0.0003272046275226472
5754,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.001204831164993155,0,1,2,0.031109966570438217
5755,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.00022207853480762802,1,1,2,0.005734293728961153
5756,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0028385765803951996,0,1,2,0.07329493549764311
5757,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.002261914517023377,1,1,2,0.058404934279888056
5758,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0018219732531405254,0,1,2,0.0470452032154699
5759,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0014515573307684933,1,1,2,0.03748068720943064
5760,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.000750250182344122,0,1,2,0.019372223071872
5761,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.0005970103333043502,1,1,2,0.01541541425134868
5762,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.0006956150137199157,0,1,2,0.017961487427862518
5763,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.0007751479780626173,1,1,2,0.020015109490305896
5764,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.0020058295488658774,0,1,2,0.051792559841004074
5765,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.002182953559291759,1,1,2,0.05636608201014752
5766,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0013163669329865832,0,1,2,0.03398993358532152
5767,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0020294471277001722,1,1,2,0.052402389756894215
5768,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0024303272384251966,0,1,2,0.06275352210287725
5769,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0037515605425345122,1,1,2,0.09686911034201777
5770,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0026540577287812598,0,1,2,0.06853047100492896
5771,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.004953884542867988,1,1,2,0.12791433936995586
5772,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.002185569822485917,0,1,2,0.056433636587813335
5773,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.004273782221892634,1,1,2,0.11035340545259584
5774,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.0036873085956741596,0,1,2,0.09521005969908183
5775,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.0024350891850111753,1,1,2,0.0628764804089075
5776,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0003714261993197309,0,1,2,0.009590602384764342
5777,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0003485948510661512,1,1,2,0.009001073742441303
5778,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0030406080901405307,0,1,2,0.07851159464207032
5779,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.004225935659319314,1,1,2,0.1091179585240838
5780,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.003067958361886118,0,1,2,0.07921780648686638
5781,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.005098884237520509,1,1,2,0.13165837902001698
5782,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0035641219287130955,0,1,2,0.09202925461831005
5783,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003578383711352808,1,1,2,0.09239750835713066
5784,MHC class II antigen presentation,MHC class II antigen presentation,0.0010372980056584814,0,1,2,0.02678408993495859
5785,MHC class II antigen presentation,MHC class II antigen presentation,0.0006337620278121312,1,1,2,0.016364380397614096
5786,Rap1 signalling,Rap1 signalling,0.0007439955272256789,0,1,2,0.01921072151273405
5787,Rap1 signalling,Rap1 signalling,0.0001485545032104027,1,1,2,0.0038358284239683833
5788,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.00230879505833109,0,1,2,0.05961543755641583
5789,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.0049547621128491525,1,1,2,0.1279369991197785
5790,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.0031888246720406786,0,1,2,0.0823386975939801
5791,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.004894165976886863,1,1,2,0.1263723452339411
5792,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.004022739020924954,0,1,2,0.10387121457244484
5793,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.006014987355663068,1,1,2,0.15531309364607096
5794,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.003708714089205082,0,1,2,0.09576277132168873
5795,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.002170539160435168,1,1,2,0.056045529600281176
5796,Collagen degradation,Collagen degradation,0.0030318287124384996,0,1,2,0.0782849021769721
5797,Collagen degradation,Collagen degradation,0.0031090620128443195,1,1,2,0.08027914457670561
5798,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.004833549598723426,0,1,2,0.12480716867387404
5799,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.003937893354729572,1,1,2,0.10168041314260311
5800,Fibronectin matrix formation,Fibronectin matrix formation,0.0004921435179104786,0,1,2,0.012707646378104636
5801,Fibronectin matrix formation,Fibronectin matrix formation,0.0012809411937857666,1,1,2,0.033075204954213504
5802,Integrin cell surface interactions,Integrin cell surface interactions,0.00791009600453172,0,1,2,0.20424672719296472
5803,Integrin cell surface interactions,Integrin cell surface interactions,0.007167893702913014,1,1,2,0.1850823085899719
5804,Laminin interactions,Laminin interactions,0.0003808154013551231,0,1,2,0.009833041134633333
5805,Laminin interactions,Laminin interactions,2.3078499964971968e-05,1,1,2,0.0005959103509828421
5806,ECM proteoglycans,ECM proteoglycans,0.005125245826157939,0,1,2,0.13233906206099622
5807,ECM proteoglycans,ECM proteoglycans,0.0027176284325685232,1,1,2,0.07017193125856726
5808,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0019701125366843146,0,1,2,0.05087031024516906
5809,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.002099273808919995,1,1,2,0.05420538571316637
5810,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0019865616106776564,0,1,2,0.05129504207226322
5811,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.004070912325351592,1,1,2,0.1051150983080625
5812,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.0012646862152056193,0,1,2,0.032655484868176016
5813,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.0007738742846191913,1,1,2,0.019982221429640405
5814,Meiotic synapsis,Meiotic synapsis,0.0010207996876977696,0,1,2,0.026358086578522233
5815,Meiotic synapsis,Meiotic synapsis,0.0005542079818416066,1,1,2,0.014310213986090215
5816,Meiotic recombination,Meiotic recombination,0.004167728011591211,0,1,2,0.10761497783468953
5817,Meiotic recombination,Meiotic recombination,0.0021795980805580043,1,1,2,0.05627944013511309
5818,Nephrin family interactions,Nephrin family interactions,0.00016722765125044405,0,1,2,0.00431798810589679
5819,Nephrin family interactions,Nephrin family interactions,0.00026655433194825264,1,1,2,0.006882704064318211
5820,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.006092521903252963,0,1,2,0.15731511455460992
5821,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.00230078332195927,1,1,2,0.059408566371522545
5822,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,0.0015170977351629188,0,1,2,0.03917300713687472
5823,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,0.003749442660854893,1,1,2,0.09681442448215002
5824,Cristae formation,Cristae formation,3.131243968578319e-05,0,1,2,0.0008085190524342989
5825,Cristae formation,Cristae formation,0.0001673929862640225,1,1,2,0.004322257224172277
5826,Signaling by Hippo,Signaling by Hippo,0.00010190088024157219,0,1,2,0.002631184409835174
5827,Signaling by Hippo,Signaling by Hippo,0.0004962535023536808,1,1,2,0.012813770358250657
5828,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.0007780666151374306,0,1,2,0.02009047166922928
5829,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.0008354115633189538,1,1,2,0.021571176578552266
5830,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0016833234467274192,0,1,2,0.043465124140627934
5831,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0008705165915292815,1,1,2,0.02247762412556919
5832,mTORC1-mediated signalling,mTORC1-mediated signalling,0.0002882963476045445,0,1,2,0.007444105030606319
5833,mTORC1-mediated signalling,mTORC1-mediated signalling,0.00014510027850625875,1,1,2,0.0037466368275065583
5834,Neutrophil degranulation,Neutrophil degranulation,0.008051707688742868,0,1,2,0.20790328496620034
5835,Neutrophil degranulation,Neutrophil degranulation,0.008606100577177353,1,1,2,0.22221827342865724
5836,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0001048945407546853,0,1,2,0.002708483770270226
5837,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0001822667567591503,1,1,2,0.004706313112104446
5838,Heme biosynthesis,Heme biosynthesis,4.2695414588335556e-05,0,1,2,0.001102439046355234
5839,Heme biosynthesis,Heme biosynthesis,4.992543922226151e-05,1,1,2,0.0012891256388008728
5840,Heme degradation,Heme degradation,0.0026252520230332383,0,1,2,0.0677866783733166
5841,Heme degradation,Heme degradation,0.001308128145819172,1,1,2,0.033777199717866684
5842,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,0.0004301879841903678,0,1,2,0.011107891459001712
5843,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,0.0009157459628625885,1,1,2,0.02364549251332716
5844,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0010938154923840252,0,1,2,0.028243428947563598
5845,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0021182184405941296,1,1,2,0.05469455537875594
5846,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.00015261222264607705,0,1,2,0.003940602868441493
5847,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.0005534429163042678,1,1,2,0.01429045921547807
5848,eNOS activation,eNOS activation,0.0008967162936046568,0,1,2,0.023154127090800006
5849,eNOS activation,eNOS activation,0.0004542007296125116,1,1,2,0.01172792497826379
5850,PECAM1 interactions,PECAM1 interactions,0.001969092475902762,0,1,2,0.05084397123789903
5851,PECAM1 interactions,PECAM1 interactions,0.001652475809004763,1,1,2,0.04266860674780777
5852,Basigin interactions,Basigin interactions,0.0003588723712717986,0,1,2,0.0092664497713113
5853,Basigin interactions,Basigin interactions,0.0002568688795794564,1,1,2,0.006632615829412257
5854,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,0.004386659886517803,0,1,2,0.11326802160386223
5855,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,0.0002158272110270346,1,1,2,0.005572878188356049
5856,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,0.00014136085918452118,0,1,2,0.003650081215838954
5857,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,0.00020599000836320122,1,1,2,0.005318871606429509
5858,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0007490572409500748,0,1,2,0.019341420111284976
5859,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",3.341761007138376e-05,1,1,2,0.0008628766937570002
5860,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.000715368000529281,0,1,2,0.018471529645528055
5861,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.0004179180208029259,1,1,2,0.01079106851990884
5862,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.0014980707594704978,0,1,2,0.038681711264949695
5863,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.0015039332906804138,1,1,2,0.038833087785791656
5864,DNA methylation,DNA methylation,0.00019199584017898935,0,1,2,0.004957527945142001
5865,DNA methylation,DNA methylation,0.00013453620589745402,1,1,2,0.00347386172402601
5866,Abacavir metabolism,Abacavir metabolism,0.0034248774084097086,0,1,2,0.0884338194257122
5867,Abacavir metabolism,Abacavir metabolism,0.005345766352215394,1,1,2,0.13803312641878682
5868,Scavenging of heme from plasma,Scavenging of heme from plasma,0.0031877609170122678,0,1,2,0.08231123035679822
5869,Scavenging of heme from plasma,Scavenging of heme from plasma,0.0065395237194800565,1,1,2,0.1688571562645196
5870,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0027501172935721634,0,1,2,0.07101082670641252
5871,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.006334396212809095,1,1,2,0.163560555329361
5872,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.0028606893469314775,0,1,2,0.07386590962888366
5873,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.007860907884125556,1,1,2,0.2029766398762018
5874,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0066187602179308145,0,1,2,0.1709031232759852
5875,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.010649068347719996,1,1,2,0.27496977994071314
5876,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.00111941238280225,0,1,2,0.02890436670245863
5877,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0003170648132563748,1,1,2,0.008186936085043997
5878,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.00239512793096917,0,1,2,0.06184464016980925
5879,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.001862890771028872,1,1,2,0.048101735160059
5880,Retinoid metabolism and transport,Retinoid metabolism and transport,0.0190806996217943,0,1,2,0.49268307844441117
5881,Retinoid metabolism and transport,Retinoid metabolism and transport,0.017966797108215936,1,1,2,0.4639209821714891
5882,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.0190806996217943,0,1,2,0.49268307844441117
5883,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.017966797108215936,1,1,2,0.4639209821714891
5884,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001928700323776238,0,1,2,0.04980100477182878
5885,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0004890517355001953,1,1,2,0.012627813410447684
5886,Heme signaling,Heme signaling,2.202733866931852e-05,0,1,2,0.0005687682967946082
5887,Heme signaling,Heme signaling,0.0001912740449612554,1,1,2,0.00493889045820869
5888,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.008045829974010299,0,1,2,0.20775151639135453
5889,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.0073012731207449276,1,1,2,0.18852630086913824
5890,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",0.0009867127096116618,0,1,2,0.025477926121557217
5891,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",0.0005644805640369512,1,1,2,0.01457546251050987
5892,Syndecan interactions,Syndecan interactions,0.0027679460504190373,0,1,2,0.0714711833485831
5893,Syndecan interactions,Syndecan interactions,0.0014036936880560701,1,1,2,0.03624479925434828
5894,HDACs deacetylate histones,HDACs deacetylate histones,0.002811925906479964,0,1,2,0.07260678798065276
5895,HDACs deacetylate histones,HDACs deacetylate histones,0.0005032095729009466,1,1,2,0.012993383177436221
5896,PKMTs methylate histone lysines,PKMTs methylate histone lysines,0.0037721492229549564,0,1,2,0.09740073101902201
5897,PKMTs methylate histone lysines,PKMTs methylate histone lysines,0.0003612050632415824,1,1,2,0.009326682251436028
5898,HDMs demethylate histones,HDMs demethylate histones,0.0001143725946547092,0,1,2,0.0029532167656889084
5899,HDMs demethylate histones,HDMs demethylate histones,0.0006939870789044343,1,1,2,0.017919452494537424
5900,HATs acetylate histones,HATs acetylate histones,0.002668691783730357,0,1,2,0.0689083371935571
5901,HATs acetylate histones,HATs acetylate histones,0.0004460034428776282,1,1,2,0.01151626269420263
5902,RMTs methylate histone arginines,RMTs methylate histone arginines,0.0034055410686946535,0,1,2,0.08793453545995139
5903,RMTs methylate histone arginines,RMTs methylate histone arginines,0.0004401973133578076,1,1,2,0.011366342522386459
5904,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0011342193215522673,0,1,2,0.029286696926732157
5905,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00016155695720925246,1,1,2,0.0041715650159415635
5906,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.0012826965595572777,0,1,2,0.03312053028448159
5907,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.0013610670741150796,1,1,2,0.035144136710710705
5908,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0018188473545452154,0,1,2,0.04696448933320306
5909,Miscellaneous transport and binding events,Miscellaneous transport and binding events,7.946858307690984e-05,1,1,2,0.0020519596726540548
5910,Intracellular oxygen transport,Intracellular oxygen transport,0.0014366811982871313,0,1,2,0.03709657033261063
5911,Intracellular oxygen transport,Intracellular oxygen transport,0.0008967118742544828,1,1,2,0.023154012978681915
5912,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.0016846925225458993,0,1,2,0.04350047507126688
5913,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.0008206983730921594,1,1,2,0.021191267036535504
5914,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.001162266376756869,0,1,2,0.030010900429402472
5915,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.0017108101123556269,1,1,2,0.044174857814251164
5916,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005124986138038791,0,1,2,0.13233235664953263
5917,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00262785182650045,1,1,2,0.06785380794408526
5918,Surfactant metabolism,Surfactant metabolism,0.00225754754959374,0,1,2,0.0582921747375575
5919,Surfactant metabolism,Surfactant metabolism,0.0020443296552219705,1,1,2,0.052786671760165105
5920,Amyloid fiber formation,Amyloid fiber formation,0.009309803580966905,0,1,2,0.24038860098947715
5921,Amyloid fiber formation,Amyloid fiber formation,0.008081380224355016,1,1,2,0.20866946002688555
5922,Striated Muscle Contraction,Striated Muscle Contraction,0.0015077685778026899,0,1,2,0.03893211880161263
5923,Striated Muscle Contraction,Striated Muscle Contraction,0.00019996106657068076,1,1,2,0.005163198195025435
5924,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0007909062957606245,0,1,2,0.020422005287024547
5925,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0013360522041389207,1,1,2,0.034498227315823346
5926,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0044270204581074455,0,1,2,0.11431017262833766
5927,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.000544046227088042,1,1,2,0.014047827138981905
5928,Platelet sensitization by LDL,Platelet sensitization by LDL,0.004176378894986131,0,1,2,0.10783835244603787
5929,Platelet sensitization by LDL,Platelet sensitization by LDL,0.006582571517780711,1,1,2,0.16996869421686991
5930,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.003967381570739955,0,1,2,0.10244182888362942
5931,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.0037385027644077913,1,1,2,0.09653194522477183
5932,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.00022105109316638438,0,1,2,0.005707764140384028
5933,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0004737974785467454,1,1,2,0.012233932975024687
5934,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.001515186105090723,0,1,2,0.039123646903367316
5935,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0031604831253809543,1,1,2,0.08160689002229968
5936,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",5.5432313227473215e-05,0,1,2,0.0014313187287436655
5937,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.00042885454087329054,1,1,2,0.011073460595804307
5938,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,0.0018479469367037216,0,1,2,0.04771587015274717
5939,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,0.0034243131292361036,1,1,2,0.08841924916330755
5940,Pyroptosis,Pyroptosis,0.0007958528850247206,0,1,2,0.020549731254873818
5941,Pyroptosis,Pyroptosis,0.0009381948051216148,1,1,2,0.024225144461679043
5942,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.0005493177225843038,0,1,2,0.01418394251633094
5943,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.00038576196070861616,1,1,2,0.009960766330160404
5944,Hedgehog 'on' state,Hedgehog 'on' state,0.0002418089835756582,0,1,2,0.0062437539914674345
5945,Hedgehog 'on' state,Hedgehog 'on' state,0.00010630366290660263,1,1,2,0.0027448687379848197
5946,Physiological factors,Physiological factors,0.0007535898499545371,0,1,2,0.01945845668761432
5947,Physiological factors,Physiological factors,0.000647882134475607,1,1,2,0.016728975918575945
5948,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.00045918484929320284,0,1,2,0.011856620019655957
5949,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,5.314376621615989e-05,1,1,2,0.0013722261163632095
5950,Intraflagellar transport,Intraflagellar transport,0.0006446687500267891,0,1,2,0.016646003062556525
5951,Intraflagellar transport,Intraflagellar transport,0.0014224612219956453,1,1,2,0.03672939607623832
5952,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0017218332813435464,0,1,2,0.04445948725336135
5953,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.00204116901448306,1,1,2,0.0527050608004011
5954,Metallothioneins bind metals,Metallothioneins bind metals,0.006192990378382129,0,1,2,0.15990931280700077
5955,Metallothioneins bind metals,Metallothioneins bind metals,0.0042097181469428965,1,1,2,0.1086992058535477
5956,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,9.892881712057068e-05,0,1,2,0.0025544427160393347
5957,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,7.107041208397036e-05,1,1,2,0.0018351103526543888
5958,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.00028220814049187344,0,1,2,0.007286901328334742
5959,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.000183012303653778,1,1,2,0.004725563891501984
5960,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.0071486363206342395,0,1,2,0.18458506338555342
5961,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.002162108081983885,1,1,2,0.055827830576224424
5962,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0003939994777124296,0,1,2,0.010173467400698787
5963,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0005811048894392471,1,1,2,0.015004719507297842
5964,RAB geranylgeranylation,RAB geranylgeranylation,8.88339138309398e-05,0,1,2,0.002293782041749748
5965,RAB geranylgeranylation,RAB geranylgeranylation,0.00011792193360407754,1,1,2,0.003044864308739167
5966,Protein methylation,Protein methylation,0.0017732163683776057,0,1,2,0.04578625084178877
5967,Protein methylation,Protein methylation,0.0014920382681279088,1,1,2,0.038525946200551255
5968,Neddylation,Neddylation,0.00174471467335717,0,1,2,0.04505030807648719
5969,Neddylation,Neddylation,0.0016027222832674154,1,1,2,0.04138392009010572
5970,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.001510414686595256,0,1,2,0.039000444022996614
5971,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.0020801847406935127,1,1,2,0.05371248654883404
5972,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.009754636377074164,0,1,2,0.2518746363929604
5973,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.008542441042885597,1,1,2,0.22057451948100976
5974,Formation of the cornified envelope,Formation of the cornified envelope,0.0060543781764678855,0,1,2,0.15633020471858122
5975,Formation of the cornified envelope,Formation of the cornified envelope,0.007885033050968392,1,1,2,0.20359957623093258
5976,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,0.00014348114659304455,0,1,2,0.0037048291940747747
5977,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,0.00019756199968275543,1,1,2,0.005101251846979212
5978,Choline catabolism,Choline catabolism,0.000754169968186126,0,1,2,0.019473435930612015
5979,Choline catabolism,Choline catabolism,0.000540086444568357,1,1,2,0.01394558152532839
5980,Urea cycle,Urea cycle,0.000979223847330127,0,1,2,0.025284556077688466
5981,Urea cycle,Urea cycle,2.7177965693674546e-05,1,1,2,0.0007017627272179131
5982,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.00026609492177961556,0,1,2,0.006870841626323838
5983,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.00010642554803171105,1,1,2,0.002748015935930665
5984,Tryptophan catabolism,Tryptophan catabolism,0.0001105350779583985,0,1,2,0.0028541281799978144
5985,Tryptophan catabolism,Tryptophan catabolism,0.00020521614894236623,1,1,2,0.0052988897687979005
5986,Threonine catabolism,Threonine catabolism,0.00014830373764170457,0,1,2,0.003829353401835917
5987,Threonine catabolism,Threonine catabolism,4.730870360216046e-05,1,1,2,0.0012215588626165257
5988,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,0.0007904818960965427,0,1,2,0.02041104685588024
5989,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,0.0004410587793300614,1,1,2,0.01138858645031352
5990,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,9.783999145289217e-05,0,1,2,0.0025263281294427083
5991,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,0.00038179051031141077,1,1,2,0.00985821944003749
5992,Alanine metabolism,Alanine metabolism,3.047886984582357e-05,0,1,2,0.0007869954310267993
5993,Alanine metabolism,Alanine metabolism,1.8809352404971875e-05,1,1,2,0.0004856766172159825
5994,Lactose synthesis,Lactose synthesis,0.001256170443809013,0,1,2,0.03243559898609774
5995,Lactose synthesis,Lactose synthesis,0.0010611938250019244,1,1,2,0.02740110430389879
5996,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,0.00010845059001107546,0,1,2,0.002800304580275384
5997,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,0.0002797193693797527,1,1,2,0.007222638725947635
5998,Galactose catabolism,Galactose catabolism,7.981170151444142e-05,0,1,2,0.002060819339826898
5999,Galactose catabolism,Galactose catabolism,4.7686989951609094e-05,1,1,2,0.0012313266010576765
6000,Pentose phosphate pathway,Pentose phosphate pathway,0.00015831268240336027,0,1,2,0.004087794539472194
6001,Pentose phosphate pathway,Pentose phosphate pathway,0.00021608697387435932,1,1,2,0.0055795855293771955
6002,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,0.0015898453698701552,0,1,2,0.0410514250842005
6003,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,0.001110346552320203,1,1,2,0.028670277735120746
6004,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.0016040631032634514,0,1,2,0.041418541426659454
6005,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.0017579238143439237,1,1,2,0.0453913815367877
6006,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.00025177926611905224,0,1,2,0.006501196831290203
6007,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.0012582328296171716,1,1,2,0.032488851886098485
6008,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.001250533015663308,0,1,2,0.03229003485541132
6009,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0017094274110276814,1,1,2,0.04413915505909416
6010,Signaling by SCF-KIT,Signaling by SCF-KIT,0.00035869170015448524,0,1,2,0.009261784659233215
6011,Signaling by SCF-KIT,Signaling by SCF-KIT,0.0007341884661331148,1,1,2,0.018957493216846096
6012,Signaling by PDGF,Signaling by PDGF,0.004539012599061007,0,1,2,0.11720192365740147
6013,Signaling by PDGF,Signaling by PDGF,0.0032017947630224005,1,1,2,0.08267359853992234
6014,Signaling by MST1,Signaling by MST1,0.0004891391138728973,0,1,2,0.012630069608936503
6015,Signaling by MST1,Signaling by MST1,0.00013416920788576907,1,1,2,0.0034643854619515638
6016,Signaling by BMP,Signaling by BMP,0.0024266308232631325,0,1,2,0.06265807690236824
6017,Signaling by BMP,Signaling by BMP,0.0016368246465321007,1,1,2,0.04226447780803571
6018,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,4.6214506034034616e-05,0,1,2,0.0011933055680845544
6019,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,0.000167643743035913,1,1,2,0.00432873201916222
6020,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0015854019432569155,0,1,2,0.040936691287953735
6021,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0015004214498227793,1,1,2,0.03874240848162348
6022,Mitochondrial protein import,Mitochondrial protein import,0.0009079307553851516,0,1,2,0.023443695904450862
6023,Mitochondrial protein import,Mitochondrial protein import,0.00041931865606909067,1,1,2,0.010827234347598077
6024,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.011885118383241225,0,1,2,0.30688584951272896
6025,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.005000258626160079,1,1,2,0.12911176538520996
6026,Late endosomal microautophagy,Late endosomal microautophagy,0.010514921316895326,0,1,2,0.27150596711304387
6027,Late endosomal microautophagy,Late endosomal microautophagy,0.004390373990308436,1,1,2,0.11336392354275869
6028,Defective pyroptosis,Defective pyroptosis,0.0005860194587674109,0,1,2,0.015131618687821731
6029,Defective pyroptosis,Defective pyroptosis,0.00018369520131933213,1,1,2,0.004743197004060572
6030,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.001012081248495287,0,1,2,0.026132967607486016
6031,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.0011400202117703127,1,1,2,0.029436481814445616
6032,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.0053509014520792975,0,1,2,0.1381657199221287
6033,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.0028585629922145478,1,1,2,0.07381100498657144
6034,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.001801213625697939,0,1,2,0.046509168512418965
6035,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.002460996908736108,1,1,2,0.06354544419604807
6036,Aspirin ADME,Aspirin ADME,0.0004900613921424989,0,1,2,0.012653883772256316
6037,Aspirin ADME,Aspirin ADME,0.004362547924211881,1,1,2,0.1126454262037099
6038,Paracetamol ADME,Paracetamol ADME,0.00027539576172971994,0,1,2,0.007110998777244139
6039,Paracetamol ADME,Paracetamol ADME,0.0017962037017781685,1,1,2,0.0463798071793185
6040,Atorvastatin ADME,Atorvastatin ADME,0.004619433475953177,0,1,2,0.11927847252530444
6041,Atorvastatin ADME,Atorvastatin ADME,0.011631097665545886,1,1,2,0.3003267761211093
6042,Kinesins,Kinesins,0.00033662407481342644,0,1,2,0.008691976119583434
6043,Kinesins,Kinesins,6.87887612483169e-05,1,1,2,0.0017761958065461835
6044,Stimuli-sensing channels,Stimuli-sensing channels,3.2667094386823834e-05,0,1,2,0.0008434976151477732
6045,Stimuli-sensing channels,Stimuli-sensing channels,0.00010922659011005169,1,1,2,0.002820341692394694
6046,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.00012725875651026653,0,2,3,0.00497196329407949
6047,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.0006536687928328412,1,2,3,0.025538653162841044
6048,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.00268693976837026,0,2,3,0.10497796983158185
6049,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.004028892102013082,1,2,3,0.15740766448083102
6050,Physiological factors,Cardiac conduction,0.0006455149458571181,0,2,3,0.02522008468880786
6051,Physiological factors,Cardiac conduction,0.00022793123720251217,1,2,3,0.008905208380325406
6052,Regulation of insulin secretion,Integration of energy metabolism,7.727584541378765e-05,0,2,3,0.003019145223891269
6053,Regulation of insulin secretion,Integration of energy metabolism,9.929795622359371e-05,1,2,3,0.0038795428075787505
6054,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0010623811462357876,0,2,3,0.04150692815374397
6055,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0010619876823391697,1,2,3,0.04149155563160738
6056,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0017294124236240567,0,2,3,0.0675676497741841
6057,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0001391551726859467,1,2,3,0.005436752878533771
6058,MHC class II antigen presentation,Adaptive Immune System,0.0005695440980861381,0,2,3,0.022251925350342688
6059,MHC class II antigen presentation,Adaptive Immune System,0.0008783775672985348,1,2,3,0.03431796084380902
6060,Chaperonin-mediated protein folding,Protein folding,0.0002966507505117462,0,2,3,0.011590060151079228
6061,Chaperonin-mediated protein folding,Protein folding,0.0008894745381504496,1,2,3,0.03475151632764512
6062,Heme degradation,Metabolism of porphyrins,0.0018600016181610534,0,2,3,0.07266973233137906
6063,Heme degradation,Metabolism of porphyrins,0.0011530292759411639,1,2,3,0.045048524708129034
6064,Triglyceride metabolism,Metabolism of lipids,0.001181774295223546,0,2,3,0.046171584406956755
6065,Triglyceride metabolism,Metabolism of lipids,0.0006459205382418474,1,2,3,0.025235931067513196
6066,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0026076799865042658,0,2,3,0.10188131277676708
6067,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004938676169391319,1,2,3,0.19295266831856703
6068,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0008420659222960825,0,2,3,0.03289927523779908
6069,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0014450897730325248,1,2,3,0.05645924496824495
6070,Switching of origins to a post-replicative state,Synthesis of DNA,0.0002717959405443133,0,2,3,0.010618989819825224
6071,Switching of origins to a post-replicative state,Synthesis of DNA,0.002393195454351602,1,2,3,0.09350146332471916
6072,HDACs deacetylate histones,Chromatin modifying enzymes,0.0032826474091265027,0,2,3,0.12825209732632745
6073,HDACs deacetylate histones,Chromatin modifying enzymes,0.0006922802082220091,1,2,3,0.027047190141448966
6074,Glucose metabolism,Metabolism of carbohydrates,0.0009041824106794491,0,2,3,0.03532614870936485
6075,Glucose metabolism,Metabolism of carbohydrates,0.00047762413341762266,1,2,3,0.018660638566960736
6076,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,0.000913065729064744,0,2,3,0.03567321742316094
6077,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,0.0006624468803750871,1,2,3,0.025881610537634676
6078,GPCR ligand binding,Signaling by GPCR,0.002175525069447426,0,2,3,0.08499714351499034
6079,GPCR ligand binding,Signaling by GPCR,0.0034746281673903056,1,2,3,0.13575273075566768
6080,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,0.0003896395226796914,0,2,3,0.015223104938399977
6081,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,8.907531136067744e-05,1,2,3,0.0034801469905786876
6082,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,0.00030553819847158465,0,2,3,0.011937290206174053
6083,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,0.00031610409500045455,1,2,3,0.012350096767790463
6084,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.0012761920981279333,0,2,3,0.049860461017269805
6085,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.0025698403357457236,1,2,3,0.10040292842199712
6086,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,0.0010850303692608448,0,2,3,0.042391826832688086
6087,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,0.0013214056229403214,1,2,3,0.05162694052663866
6088,Telomere Maintenance,Chromosome Maintenance,0.0006484640448457304,0,2,3,0.025335305144547616
6089,Telomere Maintenance,Chromosome Maintenance,0.002623257959971552,1,2,3,0.10248993975379748
6090,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,0.0015994495637466667,0,2,3,0.06249003793336865
6091,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,0.000866648036074177,1,2,3,0.03385969140676983
6092,Cellular response to heat stress,Cellular responses to stress,0.0012213585523060486,0,2,3,0.04771813003285034
6093,Cellular response to heat stress,Cellular responses to stress,0.0007276486612089526,1,2,3,0.028429025504623152
6094,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.0007057881455065985,0,2,3,0.027574941395660604
6095,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.0010016238465958374,1,2,3,0.03913315779843761
6096,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,4.2607171488658784e-05,0,2,3,0.0016646500289280407
6097,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,3.3000325442640016e-05,1,2,3,0.001289313295940047
6098,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.002289876393527076,0,2,3,0.08946481710810407
6099,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.002092231796767213,1,2,3,0.08174289912532146
6100,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.00012773205653594707,0,2,3,0.00499045499099137
6101,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.000198816326429103,1,2,3,0.007767697126519375
6102,Aflatoxin activation and detoxification,Biological oxidations,2.088674227476252e-05,0,2,3,0.0008160390590854132
6103,Aflatoxin activation and detoxification,Biological oxidations,1.5369862841150747e-05,1,2,3,0.0006004961542671745
6104,Tryptophan catabolism,Metabolism of amino acids and derivatives,9.43422034056473e-05,0,2,3,0.003685922959475231
6105,Tryptophan catabolism,Metabolism of amino acids and derivatives,8.040798991548635e-05,1,2,3,0.0031415172155816206
6106,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.003052065856859672,0,2,3,0.11924334189290416
6107,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.004930857582423165,1,2,3,0.19264719835733812
6108,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.002100450916711872,0,2,3,0.08206401779562045
6109,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.001405029829682342,1,2,3,0.05489411441564565
6110,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0023378672259208966,0,2,3,0.09133980523196765
6111,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004359333949295557,1,2,3,0.17031793313793314
6112,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.005030084937583164,0,2,3,0.19652398280151348
6113,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.004887090707750315,1,2,3,0.19093723905601154
6114,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,0.0005076693329276981,0,2,3,0.019834495936181046
6115,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,0.00045038446875467545,1,2,3,0.017596392643449123
6116,Type I hemidesmosome assembly,Cell junction organization,0.0038473029392842337,0,2,3,0.15031302772302468
6117,Type I hemidesmosome assembly,Cell junction organization,0.0027691072450187247,1,2,3,0.10818822969162017
6118,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.0022314062824467687,0,2,3,0.08718040655700313
6119,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.0017849055609773584,1,2,3,0.06973575081147239
6120,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00468927063934297,0,2,3,0.1832084654460457
6121,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0030377790371581277,1,2,3,0.11868515992497429
6122,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
6123,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
6124,Anchoring of the basal body to the plasma membrane,Cilium Assembly,3.706663836812811e-05,0,2,3,0.001448182981313224
6125,Anchoring of the basal body to the plasma membrane,Cilium Assembly,8.082061173398164e-05,1,2,3,0.0031576382322578236
6126,Uptake and actions of bacterial toxins,Infectious disease,0.00046564882422022065,0,2,3,0.018192766654665786
6127,Uptake and actions of bacterial toxins,Infectious disease,0.00038871608539643997,1,2,3,0.015187026507315038
6128,Heme biosynthesis,Metabolism of porphyrins,1.3777392925117356e-05,0,2,3,0.0005382788091778006
6129,Heme biosynthesis,Metabolism of porphyrins,8.531387062550936e-06,1,2,3,0.00033331885746632975
6130,Laminin interactions,Laminin interactions,9.537821711149674e-05,0,2,3,0.0037263997192589957
6131,Laminin interactions,Laminin interactions,8.94247911449252e-05,1,2,3,0.0034938010659991284
6132,ESR-mediated signaling,Signaling by Nuclear Receptors,0.00012783510618679005,0,2,3,0.004994481111436902
6133,ESR-mediated signaling,Signaling by Nuclear Receptors,0.00015526277058994808,1,2,3,0.006066072131138802
6134,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0028305935239000364,0,2,3,0.11059048105781795
6135,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0015159206244475011,1,2,3,0.059226586116162334
6136,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.007386298070469372,0,2,3,0.28858055738224314
6137,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.006159714610891436,1,2,3,0.2406582917135971
6138,Metabolism of steroids,Metabolism of lipids,0.0007283583123020906,0,2,3,0.02845675137028019
6139,Metabolism of steroids,Metabolism of lipids,0.00039413094371326305,1,2,3,0.015398583476219677
6140,Regulation of Apoptosis,Apoptosis,0.0009557306196529219,0,2,3,0.03734012252083274
6141,Regulation of Apoptosis,Apoptosis,0.0012557621574317262,1,2,3,0.04906226906547616
6142,PKMTs methylate histone lysines,Chromatin modifying enzymes,0.0029063473909450364,0,2,3,0.1135501630212507
6143,PKMTs methylate histone lysines,Chromatin modifying enzymes,0.0005613297379190976,1,2,3,0.021930992643196687
6144,SUMOylation,Post-translational protein modification,6.953961174151561e-05,0,2,3,0.0027168927824268163
6145,SUMOylation,Post-translational protein modification,5.390618132702143e-05,1,2,3,0.0021060991182977763
6146,Retinoid metabolism and transport,Visual phototransduction,0.009799164629650366,0,2,3,0.3828505651580299
6147,Retinoid metabolism and transport,Visual phototransduction,0.008248791913982057,1,2,3,0.3222779456713441
6148,C-type lectin receptors (CLRs),Innate Immune System,0.0005704292646806621,0,2,3,0.022286508556542437
6149,C-type lectin receptors (CLRs),Innate Immune System,0.0005653459751011737,1,2,3,0.0220879058835676
6150,Interferon Signaling,Cytokine Signaling in Immune system,0.002249849795603248,0,2,3,0.08790098935179487
6151,Interferon Signaling,Cytokine Signaling in Immune system,0.002339007805659754,1,2,3,0.09138436735681532
6152,Platelet sensitization by LDL,Platelet homeostasis,0.0036411533406484303,0,2,3,0.14225882174448565
6153,Platelet sensitization by LDL,Platelet homeostasis,0.005117105362339044,1,2,3,0.19992384595895787
6154,Protein ubiquitination,Post-translational protein modification,0.003986225239483422,0,2,3,0.15574068233996835
6155,Protein ubiquitination,Post-translational protein modification,0.003093879206016244,1,2,3,0.12087697750989398
6156,Gap junction trafficking and regulation,Membrane Trafficking,0.0008063026960886409,0,2,3,0.03150201619757802
6157,Gap junction trafficking and regulation,Membrane Trafficking,0.0013771051469356173,1,2,3,0.05380310503112186
6158,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0021837927823736177,0,2,3,0.0853201606992082
6159,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0033769879959491766,1,2,3,0.13193795712636733
6160,Metallothioneins bind metals,Response to metal ions,0.004480957550582887,0,2,3,0.17506973252586433
6161,Metallothioneins bind metals,Response to metal ions,0.0029682621376371475,1,2,3,0.11596915450252117
6162,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.00046198863234273404,0,2,3,0.0180497640027211
6163,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0004585760058452607,1,2,3,0.01791643365951229
6164,S Phase,"Cell Cycle, Mitotic",4.7251561358889425e-05,0,2,3,0.001846105015534942
6165,S Phase,"Cell Cycle, Mitotic",0.00023993071217801243,1,2,3,0.009374024442673146
6166,Generic Transcription Pathway,RNA Polymerase II Transcription,0.009473030916639712,0,2,3,0.3701086140772804
6167,Generic Transcription Pathway,RNA Polymerase II Transcription,0.006752785082500139,1,2,3,0.26382938576246123
6168,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0026964899127771675,0,2,3,0.1053510912477138
6169,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0038829162734741497,1,2,3,0.1517044305249039
6170,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.0007919767573810366,0,2,3,0.030942305861246897
6171,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.0012628125014643172,1,2,3,0.049337723994488034
6172,DNA methylation,Epigenetic regulation of gene expression,5.125378784722103e-05,0,2,3,0.0020024708621002594
6173,DNA methylation,Epigenetic regulation of gene expression,4.764278951901139e-05,1,2,3,0.0018613901880847755
6174,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00016490940124282678,0,2,3,0.006442963237361309
6175,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,3.6982384892549994e-05,1,2,3,0.0014448912220703996
6176,Meiotic recombination,Meiosis,0.003982555318926934,0,2,3,0.15559729959131188
6177,Meiotic recombination,Meiosis,0.0020085418570031347,1,2,3,0.07847315706590449
6178,Syndecan interactions,Non-integrin membrane-ECM interactions,0.0029615795412730205,0,2,3,0.11570806736995197
6179,Syndecan interactions,Non-integrin membrane-ECM interactions,0.0006098907234828693,1,2,3,0.023828256488674527
6180,Phospholipid metabolism,Metabolism of lipids,0.0007040848059350445,0,2,3,0.027508392404774963
6181,Phospholipid metabolism,Metabolism of lipids,0.00038109461482623735,1,2,3,0.014889257827492227
6182,Deubiquitination,Post-translational protein modification,0.003972313922748598,0,2,3,0.15519717116577045
6183,Deubiquitination,Post-translational protein modification,0.003076946100503071,1,2,3,0.12021540591061876
6184,Paracetamol ADME,Paracetamol ADME,0.00030080198930914167,0,2,3,0.011752247866027897
6185,Paracetamol ADME,Paracetamol ADME,0.0018901425061586695,1,2,3,0.07384732822249576
6186,M Phase,"Cell Cycle, Mitotic",0.00029718688083991263,0,2,3,0.011611006609975919
6187,M Phase,"Cell Cycle, Mitotic",0.0014909349642325397,1,2,3,0.058250403503085274
6188,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,0.0008617216329780442,0,2,3,0.03366721824392044
6189,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,0.0007280830496678816,1,2,3,0.028445996937728365
6190,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.0006995806746039454,0,2,3,0.027332417279258697
6191,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.0008475062962406348,1,2,3,0.03311182909499631
6192,Lactose synthesis,Metabolism of carbohydrates,0.0008255856010347841,0,2,3,0.03225539379000886
6193,Lactose synthesis,Metabolism of carbohydrates,0.0004380364492684804,1,2,3,0.01711395904655171
6194,Defective pyroptosis,Diseases of programmed cell death,6.553302249222046e-05,0,2,3,0.0025603564840358927
6195,Defective pyroptosis,Diseases of programmed cell death,0.0006877965541964374,1,2,3,0.02687201505841493
6196,Beta-catenin independent WNT signaling,Signaling by WNT,1.3232130181319553e-05,0,2,3,0.0005169755494090079
6197,Beta-catenin independent WNT signaling,Signaling by WNT,0.00013143811785277585,1,2,3,0.00513524974883889
6198,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,0.0017164305618718784,0,2,3,0.06706045214086888
6199,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,0.001326871276061293,1,2,3,0.0518404820340433
6200,Cristae formation,Mitochondrial biogenesis,8.073244368673388e-05,0,2,3,0.0031541935318171815
6201,Cristae formation,Mitochondrial biogenesis,0.000290134897718394,1,2,3,0.01133548764222748
6202,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.0003796699894997699,0,2,3,0.014833598122610224
6203,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.000577126720600063,1,2,3,0.022548176247694916
6204,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0022116011207471815,0,2,3,0.08640662454228014
6205,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0005461651681004608,1,2,3,0.02133851722872345
6206,Pyroptosis,Regulated Necrosis,0.0011158871239892278,0,2,3,0.04359739143264987
6207,Pyroptosis,Regulated Necrosis,0.0009815857127823111,1,2,3,0.03835027362971899
6208,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,8.058279012046138e-06,0,2,3,0.0003148346609697721
6209,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,6.928522946174473e-06,1,2,3,0.00027069541393631225
6210,Homology Directed Repair,DNA Double-Strand Break Repair,0.0024897969554788266,0,2,3,0.09727565640131731
6211,Homology Directed Repair,DNA Double-Strand Break Repair,0.0007250113291594999,1,2,3,0.02832598569421042
6212,Abacavir metabolism,Abacavir ADME,0.0026601166558938884,0,2,3,0.10392999848310551
6213,Abacavir metabolism,Abacavir ADME,0.005198040228989448,1,2,3,0.2030859480981892
6214,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,2.3131465157920902e-05,0,2,3,0.0009037397414313338
6215,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,1.822493240887049e-05,1,2,3,0.000712042907370964
6216,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,8.363707607589225e-07,0,2,3,3.2676766902081306e-05
6217,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,7.353094951603392e-07,1,2,3,2.8728332100513542e-05
6218,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,0.0009867207031652124,0,2,3,0.038550896238326485
6219,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,0.0031862878766582173,1,2,3,0.12448735789617023
6220,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,1.4253765365431945e-05,0,2,3,0.0005568905444524898
6221,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,1.1286677077149933e-05,1,2,3,0.0004409672519092283
6222,Aspirin ADME,Aspirin ADME,0.0001406654722078228,0,2,3,0.00549575984977687
6223,Aspirin ADME,Aspirin ADME,0.003371235356290217,1,2,3,0.13171320313683652
6224,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.007527721495022477,0,2,3,0.29410593021381193
6225,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.0024451496449492986,1,2,3,0.09553129872236836
6226,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.00022195423200033882,0,2,3,0.008671688493060669
6227,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.0002192532677087327,1,2,3,0.008566162589109206
6228,RAB geranylgeranylation,Post-translational protein modification,0.00011951686683644808,0,2,3,0.004669489874248981
6229,RAB geranylgeranylation,Post-translational protein modification,9.251526015238046e-05,1,2,3,0.003614544808024599
6230,Signaling by NOTCH4,Signaling by NOTCH,0.00048579595532288375,0,2,3,0.01897990931636048
6231,Signaling by NOTCH4,Signaling by NOTCH,0.0007669262629117603,1,2,3,0.029963590192359037
6232,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,1.119928284859658e-06,0,2,3,4.375527843441094e-05
6233,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,1.429974902386737e-07,1,2,3,5.586871128626956e-06
6234,Diseases associated with surfactant metabolism,Diseases of metabolism,0.00044367454559270407,0,2,3,0.017334237860687877
6235,Diseases associated with surfactant metabolism,Diseases of metabolism,0.0006782525881763246,1,2,3,0.02649913503009158
6236,Fibronectin matrix formation,Fibronectin matrix formation,5.910729651868032e-05,0,2,3,0.0023093052043097907
6237,Fibronectin matrix formation,Fibronectin matrix formation,0.0013122123953688033,1,2,3,0.051267763749392535
6238,Mitochondrial protein import,Mitochondrial protein import,0.0008306085797387819,0,2,3,0.03245164013429249
6239,Mitochondrial protein import,Mitochondrial protein import,0.0004103189892121378,1,2,3,0.016031045793394687
6240,Fructose metabolism,Metabolism of carbohydrates,0.0011278030635025393,0,2,3,0.04406294378833296
6241,Fructose metabolism,Metabolism of carbohydrates,0.0005959723960408673,1,2,3,0.023284471408148214
6242,Late endosomal microautophagy,Late endosomal microautophagy,0.009419330613025818,0,2,3,0.36801055854247194
6243,Late endosomal microautophagy,Late endosomal microautophagy,0.0031071014425759842,1,2,3,0.12139356651833177
6244,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.001527683528333425,0,2,3,0.059686159413563526
6245,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.0012129527817751988,1,2,3,0.047389718977423535
6246,HATs acetylate histones,Chromatin modifying enzymes,0.0022133058543294267,0,2,3,0.0864732279967656
6247,HATs acetylate histones,Chromatin modifying enzymes,0.0004892632719251021,1,2,3,0.019115376386351784
6248,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,3.496919812627205e-05,0,2,3,0.0013662365897248998
6249,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0003104520715515455,1,2,3,0.012129273824867982
6250,Formation of the cornified envelope,Keratinization,0.005399068663851712,0,2,3,0.21094007166980203
6251,Formation of the cornified envelope,Keratinization,0.006919900640107509,1,2,3,0.270358542899294
6252,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.001963684645631802,0,2,3,0.07672059862097706
6253,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.003033747097821835,1,2,3,0.11852763320591991
6254,DNA Double Strand Break Response,DNA Double-Strand Break Repair,0.0024499488985024126,0,2,3,0.0957188041888636
6255,DNA Double Strand Break Response,DNA Double-Strand Break Repair,0.0007977438795877867,1,2,3,0.03116762567978621
6256,HIV Infection,Infectious disease,0.0006060043740593949,0,2,3,0.02367641792595902
6257,HIV Infection,Infectious disease,0.0004962902414752599,1,2,3,0.019389918081006638
6258,Hedgehog 'off' state,Signaling by Hedgehog,8.733704471382719e-05,0,2,3,0.003412233408830269
6259,Hedgehog 'off' state,Signaling by Hedgehog,0.0003524389496887665,1,2,3,0.013769689169602315
6260,Transferrin endocytosis and recycling,Iron uptake and transport,0.0008280544622731596,0,2,3,0.03235185149391852
6261,Transferrin endocytosis and recycling,Iron uptake and transport,0.0010484492505025596,1,2,3,0.04096261296395219
6262,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,0.00017828448579415736,0,2,3,0.006965523973203957
6263,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,0.0005535891931533558,1,2,3,0.02162857176854086
6264,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.001144191325125243,0,2,3,0.04470322849231937
6265,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.0019605157190960712,1,2,3,0.07659678956571557
6266,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.0008637639001037849,0,2,3,0.033747009037609896
6267,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.0010930253284378213,1,2,3,0.04270418760577471
6268,MAPK1/MAPK3 signaling,MAPK family signaling cascades,2.124499283998486e-05,0,2,3,0.0008300358064151342
6269,MAPK1/MAPK3 signaling,MAPK family signaling cascades,2.5509299776038156e-05,1,2,3,0.0009966410612687374
6270,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.0032030367194589224,0,2,3,0.12514173040386242
6271,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.002751856710296272,1,2,3,0.1075142562237405
6272,Heme signaling,Cellular responses to stress,9.245719321211139e-05,0,2,3,0.0036122761492420187
6273,Heme signaling,Cellular responses to stress,5.526781198140441e-05,1,2,3,0.002159297639321667
6274,Cellular Senescence,Cellular responses to stress,0.0009781583108866784,0,2,3,0.03821636601592135
6275,Cellular Senescence,Cellular responses to stress,0.0005833978131322464,1,2,3,0.022793186043003393
6276,Sphingolipid metabolism,Metabolism of lipids,0.0009995709808051662,0,2,3,0.03905295291793443
6277,Sphingolipid metabolism,Metabolism of lipids,0.0005404647214569832,1,2,3,0.02111580240541035
6278,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,2.6212234127522578e-05,0,2,3,0.0010241045057464945
6279,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,2.1129072059653102e-05,1,2,3,0.0008255068146142122
6280,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,0.0018449697131172843,0,2,3,0.07208244009179413
6281,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,0.0015501009267406198,1,2,3,0.06056200077085619
6282,Choline catabolism,Metabolism of amino acids and derivatives,2.905640824880217e-05,0,2,3,0.0011352255768676954
6283,Choline catabolism,Metabolism of amino acids and derivatives,2.5200527465694257e-05,1,2,3,0.0009845774152348068
6284,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.01050168375293993,0,2,3,0.4102977867887303
6285,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0037596914692765468,1,2,3,0.14689007259629105
6286,TCF dependent signaling in response to WNT,Signaling by WNT,3.089100452069167e-05,0,2,3,0.0012069027295715548
6287,TCF dependent signaling in response to WNT,Signaling by WNT,0.00029357670056785035,1,2,3,0.011469957897180619
6288,Intrinsic Pathway for Apoptosis,Apoptosis,0.000755779654733709,0,2,3,0.029528095392358483
6289,Intrinsic Pathway for Apoptosis,Apoptosis,0.0010077991342020746,1,2,3,0.03937442452263445
6290,SLC transporter disorders,Disorders of transmembrane transporters,0.0011351090490584307,0,2,3,0.04434838655869381
6291,SLC transporter disorders,Disorders of transmembrane transporters,0.0005960044510927593,1,2,3,0.02328572378987634
6292,Antimicrobial peptides,Innate Immune System,0.0010631755757398431,0,2,3,0.04153796628771772
6293,Antimicrobial peptides,Innate Immune System,0.0010633860240005066,1,2,3,0.04154618844119474
6294,Fatty acid metabolism,Metabolism of lipids,0.0018853420209085053,0,2,3,0.07365977463394832
6295,Fatty acid metabolism,Metabolism of lipids,0.0010109689144901773,1,2,3,0.03949826693375743
6296,ROS and RNS production in phagocytes,Innate Immune System,0.0009520317293818199,0,2,3,0.037195607933694974
6297,ROS and RNS production in phagocytes,Innate Immune System,0.0009542128974146346,1,2,3,0.037280825546178085
6298,HCMV Infection,Infectious disease,0.0007839541575566759,0,2,3,0.03062886517595628
6299,HCMV Infection,Infectious disease,0.0006437299666530344,1,2,3,0.025150346060781245
6300,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.00722160195747271,0,2,3,0.28214592725578175
6301,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.00935277028847988,1,2,3,0.36541006566041456
6302,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.0034035708531565214,0,2,3,0.13297654177005752
6303,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.0019674458709615754,1,2,3,0.07686754862106517
6304,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,0.00012787580301380612,0,2,3,0.004996071124852545
6305,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,0.0001508029993135378,1,2,3,0.005891830140297778
6306,Degradation of beta-catenin by the destruction complex,Signaling by WNT,4.2952225395405605e-05,0,2,3,0.0016781311865777739
6307,Degradation of beta-catenin by the destruction complex,Signaling by WNT,0.00042239519151167435,1,2,3,0.016502859570392662
6308,Intracellular oxygen transport,Intracellular oxygen transport,0.0010882935654856548,0,2,3,0.042519318977795005
6309,Intracellular oxygen transport,Intracellular oxygen transport,0.0010300800913405903,1,2,3,0.04024493515850351
6310,HDMs demethylate histones,Chromatin modifying enzymes,0.00040994319604735745,0,2,3,0.016016363661707327
6311,HDMs demethylate histones,Chromatin modifying enzymes,7.913763301202054e-05,1,2,3,0.003091884733954292
6312,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0010672655082278762,0,2,3,0.04169775878265792
6313,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0016084993073726657,1,2,3,0.06284360883381719
6314,Infection with Mycobacterium tuberculosis,Infectious disease,0.002421886178985153,0,2,3,0.09462240174711409
6315,Infection with Mycobacterium tuberculosis,Infectious disease,0.0019825375473254115,1,2,3,0.07745717610906491
6316,Influenza Infection,Infectious disease,0.0014157334201068614,0,2,3,0.05531230063846386
6317,Influenza Infection,Infectious disease,0.00115596157194591,1,2,3,0.04516308867608512
6318,Toll-like Receptor Cascades,Innate Immune System,0.00252776154796584,0,2,3,0.09875892219375725
6319,Toll-like Receptor Cascades,Innate Immune System,0.0025441411024002066,1,2,3,0.09939886671038055
6320,Alanine metabolism,Metabolism of amino acids and derivatives,5.462342818793729e-06,0,2,3,0.0002134121748433878
6321,Alanine metabolism,Metabolism of amino acids and derivatives,4.82093992681728e-06,1,2,3,0.00018835274692601643
6322,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,2.2094081911750507e-05,0,2,3,0.0008632094740981299
6323,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,1.958445388624896e-05,1,2,3,0.0007651590234512996
6324,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0035058946780408945,0,2,3,0.13697430440255565
6325,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.001304575873965511,1,2,3,0.050969407037816786
6326,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,0.00025721144596401954,0,2,3,0.010049177779346328
6327,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,0.00039405350051929604,1,2,3,0.015395557792735576
6328,Molecules associated with elastic fibres,Elastic fibre formation,0.004776514791799319,0,2,3,0.18661706958089003
6329,Molecules associated with elastic fibres,Elastic fibre formation,0.0018268590465964818,1,2,3,0.0713748615200557
6330,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,0.00018514092221382183,0,2,3,0.00723340298712479
6331,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,0.0001492525542776578,1,2,3,0.005831254695281064
6332,Diseases of carbohydrate metabolism,Diseases of metabolism,0.0007672432869642342,0,2,3,0.029975976231602735
6333,Diseases of carbohydrate metabolism,Diseases of metabolism,0.0011696975457267528,1,2,3,0.04569974925111815
6334,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.004170974249700982,0,2,3,0.1629587734372605
6335,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.00041200190118181895,1,2,3,0.016096796683705696
6336,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0010783274582568567,0,2,3,0.0421299460129378
6337,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.002849200082370222,1,2,3,0.11131743398647903
6338,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.002420798928040608,0,2,3,0.09457992316303886
6339,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.005738308284857764,1,2,3,0.22419406683518348
6340,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,0.0005578348018804584,0,2,3,0.02179444648970769
6341,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,2.9222027767226685e-05,1,2,3,0.0011416962841806603
6342,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.0004546104528621589,0,2,3,0.017761500636328777
6343,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.002278481551311508,1,2,3,0.08901962387510984
6344,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,4.75966744627189e-05,0,2,3,0.0018595884859977983
6345,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,4.189579626862202e-05,1,2,3,0.0016368568021251748
6346,Neutrophil degranulation,Innate Immune System,0.005998006872336385,0,2,3,0.23434041652361395
6347,Neutrophil degranulation,Innate Immune System,0.006070743804969259,1,2,3,0.2371822277206722
6348,Leishmania infection,Infectious disease,0.0031025818827244995,0,2,3,0.12121698860492772
6349,Leishmania infection,Infectious disease,0.002551259888951527,1,2,3,0.09967699566906402
6350,Nephrin family interactions,Nephrin family interactions,0.00032647723359156865,0,2,3,0.012755372331796605
6351,Nephrin family interactions,Nephrin family interactions,0.0007555807737082829,1,2,3,0.02952032516746062
6352,Complement cascade,Innate Immune System,0.002284968106302729,0,2,3,0.08927305172719463
6353,Complement cascade,Innate Immune System,0.002294774007944208,1,2,3,0.0896561655054819
6354,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.0003662166775963351,0,2,3,0.014307981066448873
6355,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,4.655653424090579e-05,1,2,3,0.001818950504413142
6356,ECM proteoglycans,ECM proteoglycans,0.0038244076212447047,0,2,3,0.14941851418210675
6357,ECM proteoglycans,ECM proteoglycans,0.0020527448746710214,1,2,3,0.08020015634956126
6358,O-linked glycosylation,Post-translational protein modification,0.0010473144439160724,0,2,3,0.040918276394519816
6359,O-linked glycosylation,Post-translational protein modification,0.0008103395287245692,1,2,3,0.03165973409645249
6360,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,0.00040380337982403637,0,2,3,0.015776482794316614
6361,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,0.00041964630941153613,1,2,3,0.016395461531338768
6362,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.0019493817818343113,0,2,3,0.07616178981479794
6363,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.004644916596714261,1,2,3,0.18147556566027587
6364,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0012158286068845738,0,2,3,0.047502076643615644
6365,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.003268569719467695,1,2,3,0.1277020860094764
6366,Meiotic synapsis,Meiosis,0.001260510466973354,0,2,3,0.049247784163983316
6367,Meiotic synapsis,Meiosis,0.0006444543527689851,1,2,3,0.025178647619573835
6368,Striated Muscle Contraction,Striated Muscle Contraction,0.0011603838406907404,0,2,3,0.045335865453721466
6369,Striated Muscle Contraction,Striated Muscle Contraction,0.000635012733126012,1,2,3,0.024809766234993157
6370,RMTs methylate histone arginines,Chromatin modifying enzymes,0.0029049202318771313,0,2,3,0.11349440432381393
6371,RMTs methylate histone arginines,Chromatin modifying enzymes,0.0005578851284506499,1,2,3,0.021796412734440627
6372,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.0001376193107864707,0,2,3,0.005376747192493975
6373,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.00023568563952481818,1,2,3,0.00920817066576091
6374,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0002064905271210388,0,2,3,0.008067525957147827
6375,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0002071656227192601,1,2,3,0.008093901749481458
6376,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.001397810219882812,0,2,3,0.05461204632143208
6377,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0005202138409881143,1,2,3,0.020324606285590616
6378,Threonine catabolism,Metabolism of amino acids and derivatives,5.848456927141421e-06,0,2,3,0.00022849754285007642
6379,Threonine catabolism,Metabolism of amino acids and derivatives,5.2710980742003485e-06,1,2,3,0.00020594029725807457
6380,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.00221203449661613,0,2,3,0.08642355641378384
6381,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0039000654841849962,1,2,3,0.1523744452925705
6382,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.00834325570223125,0,2,3,0.3259686189159534
6383,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.008300536309651378,1,2,3,0.3242995844410223
6384,Atorvastatin ADME,Atorvastatin ADME,0.003110119321431993,0,2,3,0.12151147418385924
6385,Atorvastatin ADME,Atorvastatin ADME,0.010832728607240865,1,2,3,0.42323161475793064
6386,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.006809760561404362,0,2,3,0.2660554014610473
6387,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.005260487016841331,1,2,3,0.20552572627571428
6388,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.0014870873898599265,0,2,3,0.058100079870539556
6389,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.00032814845855260073,1,2,3,0.012820666614015453
6390,Surfactant metabolism,Surfactant metabolism,0.0019184942330649774,0,2,3,0.07495502210044558
6391,Surfactant metabolism,Surfactant metabolism,0.0016554072481546986,1,2,3,0.06467628869149211
6392,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0004624810044979913,0,2,3,0.018069000842291884
6393,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00011125746095785871,1,2,3,0.004346797244009915
6394,Phase I - Functionalization of compounds,Biological oxidations,0.0006575915789570562,0,2,3,0.02569191529705456
6395,Phase I - Functionalization of compounds,Biological oxidations,0.0005031309444860609,1,2,3,0.01965718239513388
6396,GPCR downstream signalling,Signaling by GPCR,0.0006614460494232023,0,2,3,0.025842508358006288
6397,GPCR downstream signalling,Signaling by GPCR,0.0011106093982141893,1,2,3,0.043391192193011754
6398,Nucleosome assembly,Chromosome Maintenance,7.413201949140766e-05,0,2,3,0.0028963168424290635
6399,Nucleosome assembly,Chromosome Maintenance,0.00029542678325947583,1,2,3,0.01154224009988336
6400,Nucleotide catabolism,Metabolism of nucleotides,7.180302326228945e-07,0,2,3,2.8053236245101763e-05
6401,Nucleotide catabolism,Metabolism of nucleotides,2.0177432970786652e-06,1,2,3,7.883265470333834e-05
6402,Transcriptional regulation by small RNAs,Gene Silencing by RNA,0.0032036657915521546,0,2,3,0.12516630807099238
6403,Transcriptional regulation by small RNAs,Gene Silencing by RNA,0.0005551755235076594,1,2,3,0.02169054924270583
6404,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0027537372389183083,0,2,3,0.10758772794025438
6405,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0035802860219782216,1,2,3,0.1398807529770692
6406,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00216991032069244,0,2,3,0.08477777688372033
6407,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.005167042510271444,1,2,3,0.20187487607538748
6408,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0039830464837937625,0,2,3,0.15561648926246835
6409,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.009329684250435536,1,2,3,0.3645081007433447
6410,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0032943396602784533,0,2,3,0.12870891024157832
6411,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0017416669690235925,1,2,3,0.06804643136519553
6412,Asparagine N-linked glycosylation,Post-translational protein modification,0.0064291431963237515,0,2,3,0.2511847896448979
6413,Asparagine N-linked glycosylation,Post-translational protein modification,0.00495942743941784,1,2,3,0.19376341451558077
6414,Hedgehog 'on' state,Signaling by Hedgehog,5.3100024422234624e-05,0,2,3,0.0020746027981247486
6415,Hedgehog 'on' state,Signaling by Hedgehog,0.0001882190012074162,1,2,3,0.007353662654845129
6416,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.00017400587407533796,0,2,3,0.0067983598345706196
6417,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0004115215040259001,1,2,3,0.0160780277039411
6418,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,0.002819524841174941,0,2,3,0.11015803078302253
6419,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,0.002236573812680326,1,2,3,0.08738230048828809
6420,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0003849267378649215,0,2,3,0.015038977780831525
6421,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.000919578258622165,1,2,3,0.035927660094133396
6422,Cellular response to hypoxia,Cellular responses to stress,0.0009719689210376295,0,2,3,0.037974548321122986
6423,Cellular response to hypoxia,Cellular responses to stress,0.0005824228342192738,1,2,3,0.022755093895156498
6424,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.002283573223320474,0,2,3,0.08921855404721182
6425,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.0013501293118688548,1,2,3,0.05274916685462973
6426,Clathrin-mediated endocytosis,Membrane Trafficking,0.0006191404080946801,0,2,3,0.02418963902637067
6427,Clathrin-mediated endocytosis,Membrane Trafficking,0.0010570238951015827,1,2,3,0.04129762188102172
6428,Glycogen metabolism,Metabolism of carbohydrates,6.948672018303012e-05,0,2,3,0.0027148263243333384
6429,Glycogen metabolism,Metabolism of carbohydrates,3.708802958310005e-05,1,2,3,0.0014490187299765994
6430,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0007046018945771804,0,2,3,0.027528594910433406
6431,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0009183512390756668,1,2,3,0.03587972079067324
6432,Signaling by Interleukins,Cytokine Signaling in Immune system,0.004182797093465889,0,2,3,0.16342068856862524
6433,Signaling by Interleukins,Cytokine Signaling in Immune system,0.004371944876359794,1,2,3,0.17081063845886435
6434,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,0.00034319060614160923,0,2,3,0.013408359026919416
6435,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,0.0003363178856171053,1,2,3,0.01313984379767039
6436,Metabolism of polyamines,Metabolism of amino acids and derivatives,0.0002063239166054146,0,2,3,0.008061016531857125
6437,Metabolism of polyamines,Metabolism of amino acids and derivatives,0.00017989863226368821,1,2,3,0.007028588215051456
6438,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,4.568967543366802e-05,0,2,3,0.0017850825782371699
6439,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,2.9558338637059766e-05,1,2,3,0.0011548358538736514
6440,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.005775987340532111,0,2,3,0.22566617678585174
6441,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.003433391865403118,1,2,3,0.1341416402068823
6442,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0005763225065517554,0,2,3,0.022516755834369993
6443,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0013609466669656058,1,2,3,0.0531717978307208
6444,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.0013398972836429156,0,2,3,0.0523494044323146
6445,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.0008694375131286913,1,2,3,0.0339686754791044
6446,DAP12 interactions,Innate Immune System,0.0005734172444812115,0,2,3,0.02240324807450704
6447,DAP12 interactions,Innate Immune System,0.0005739035144833352,1,2,3,0.022422246504696604
6448,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.004230283245363764,0,2,3,0.16527595896956046
6449,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.0027376992813312106,1,2,3,0.10696112951495372
6450,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.001579964987161424,0,2,3,0.061728781087560226
6451,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.0014437898467748787,1,2,3,0.05640845722038961
6452,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.00209211473643359,0,2,3,0.0817383256114987
6453,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.001957705486190581,1,2,3,0.07648699456820761
6454,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.00038988162723883755,0,2,3,0.015232563894423224
6455,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.00014335818407364503,1,2,3,0.005600963333808401
6456,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,8.714923348962117e-05,0,2,3,0.0034048956779064786
6457,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,7.633924829620847e-05,1,2,3,0.0029825526418352853
6458,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,5.024959676602431e-05,0,2,3,0.001963237403178717
6459,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0006613874342982748,1,2,3,0.02584021828180557
6460,G2/M Checkpoints,Cell Cycle Checkpoints,0.00029186262152617774,0,2,3,0.011402989318262757
6461,G2/M Checkpoints,Cell Cycle Checkpoints,0.00041333406323265355,1,2,3,0.016148843874800017
6462,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.00031976368168423893,0,2,3,0.01249307577498994
6463,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.0011027543894180716,1,2,3,0.04308429924135999
6464,Signaling by BMP,Signaling by TGFB family members,0.002061599380984373,0,2,3,0.08054609938393019
6465,Signaling by BMP,Signaling by TGFB family members,0.0013476737351204046,1,2,3,0.05265322817194973
6466,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.0008019216953046448,0,2,3,0.031330851747392585
6467,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.001241515392486256,1,2,3,0.048505652025433485
6468,Phase II - Conjugation of compounds,Biological oxidations,0.0012042114331335784,0,2,3,0.04704819698099116
6469,Phase II - Conjugation of compounds,Biological oxidations,0.0009067130459434939,1,2,3,0.03542501990682558
6470,p75 NTR receptor-mediated signalling,Death Receptor Signalling,0.0002874351556954768,0,2,3,0.011230009491964827
6471,p75 NTR receptor-mediated signalling,Death Receptor Signalling,0.0005964764173297439,1,2,3,0.023304163376044563
6472,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.001603934522934069,0,2,3,0.06266526400870288
6473,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.0004254651180511345,1,2,3,0.016622800724056887
6474,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.006854659071305015,0,2,3,0.26780957342772765
6475,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.00980124228056591,1,2,3,0.38293173838628763
6476,Galactose catabolism,Metabolism of carbohydrates,0.00014198659741181436,0,2,3,0.005547375834415219
6477,Galactose catabolism,Metabolism of carbohydrates,7.712822189851668e-05,1,2,3,0.003013377615285011
6478,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0011400581036452634,0,2,3,0.04454174470881955
6479,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.00430266344110212,1,2,3,0.16810383255797134
6480,Hedgehog ligand biogenesis,Signaling by Hedgehog,2.90948453423722e-06,0,2,3,0.00011367273031425852
6481,Hedgehog ligand biogenesis,Signaling by Hedgehog,1.3272597975524865e-05,1,2,3,0.0005185566145781065
6482,Rap1 signalling,Adaptive Immune System,0.0004037307368432686,0,2,3,0.01577364465379211
6483,Rap1 signalling,Adaptive Immune System,0.0006200716504563065,1,2,3,0.024226022399639953
6484,mTORC1-mediated signalling,MTOR signalling,0.00020412432939818172,0,2,3,0.007975079287486784
6485,mTORC1-mediated signalling,MTOR signalling,0.00018077721392843982,1,2,3,0.007062914149924502
6486,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.006625500879613009,0,2,3,0.2588564282857007
6487,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.009513964775038486,1,2,3,0.37170788824139134
6488,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.0008603182045428489,0,2,3,0.03361238669553032
6489,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.0014690901597472484,1,2,3,0.05739693322688899
6490,ER to Golgi Anterograde Transport,Membrane Trafficking,0.001592253459702665,0,2,3,0.06220888820231445
6491,ER to Golgi Anterograde Transport,Membrane Trafficking,0.0027289957774536823,1,2,3,0.1066210861026526
6492,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.00011869921552359181,0,2,3,0.004637544470833466
6493,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.00026629062532775526,1,2,3,0.010403898725666563
6494,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0001608550959361432,0,2,3,0.006284562686227554
6495,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0004531356184732542,1,2,3,0.01770387927770825
6496,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,0.0006452164757343217,0,2,3,0.02520842354630091
6497,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,0.00016878049219083891,1,2,3,0.00659420565579565
6498,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0009984936200274478,0,2,3,0.03901086073985422
6499,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0020998530493541575,1,2,3,0.0820406592886006
6500,Diseases associated with visual transduction,Diseases of the neuronal system,0.0019142930566512252,0,2,3,0.07479088333707927
6501,Diseases associated with visual transduction,Diseases of the neuronal system,0.0014273367350313326,1,2,3,0.05576563884069172
6502,Neddylation,Post-translational protein modification,0.001817381962526842,0,2,3,0.07100459455044758
6503,Neddylation,Post-translational protein modification,0.0014094907922294554,1,2,3,0.055068402949093036
6504,Integrin cell surface interactions,Integrin cell surface interactions,0.006932459198692459,0,2,3,0.27084920219868674
6505,Integrin cell surface interactions,Integrin cell surface interactions,0.005168856140952983,1,2,3,0.20194573410846045
6506,Eukaryotic Translation Elongation,Translation,0.0014144392364403128,0,2,3,0.05526173725200364
6507,Eukaryotic Translation Elongation,Translation,0.0015050065452540246,1,2,3,0.05880017615721963
6508,Metabolism of cofactors,Metabolism of vitamins and cofactors,6.415437340563987e-05,0,2,3,0.00250649305772352
6509,Metabolism of cofactors,Metabolism of vitamins and cofactors,6.256821038236298e-05,1,2,3,0.002444522121134
6510,ABC transporter disorders,Disorders of transmembrane transporters,0.0033823894496004306,0,2,3,0.1321489903788142
6511,ABC transporter disorders,Disorders of transmembrane transporters,0.001827124053777667,1,2,3,0.07138521527498504
6512,Neurotransmitter release cycle,Transmission across Chemical Synapses,7.03424748142166e-05,0,2,3,0.0027482604135203917
6513,Neurotransmitter release cycle,Transmission across Chemical Synapses,4.101343066554587e-06,1,2,3,0.0001602383029861818
6514,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.0002017174793916195,0,2,3,0.00788104434470454
6515,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.00023721270820387504,1,2,3,0.00926783280318873
6516,Post-translational protein phosphorylation,Post-translational protein modification,0.009454837050430003,0,2,3,0.3693977849174437
6517,Post-translational protein phosphorylation,Post-translational protein modification,0.007287720024749267,1,2,3,0.28472914127255555
6518,Intraflagellar transport,Cilium Assembly,0.0007203887243015969,0,2,3,0.028145381841817176
6519,Intraflagellar transport,Cilium Assembly,0.0015235006051944086,1,2,3,0.05952273380043122
6520,Selective autophagy,Macroautophagy,5.562958007624909e-05,0,2,3,0.0021734318155297435
6521,Selective autophagy,Macroautophagy,3.844766469768646e-05,1,2,3,0.001502139285830214
6522,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.0014092474517697316,0,2,3,0.055058895706786966
6523,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.0008413592592941899,1,2,3,0.03287166611601413
6524,Neurotransmitter clearance,Transmission across Chemical Synapses,0.00028182529760282344,0,2,3,0.011010833937476228
6525,Neurotransmitter clearance,Transmission across Chemical Synapses,2.3203158010284054e-05,1,2,3,0.0009065407607102603
6526,PECAM1 interactions,Cell surface interactions at the vascular wall,0.0013702744816023345,0,2,3,0.05353623288619025
6527,PECAM1 interactions,Cell surface interactions at the vascular wall,0.0005715392194753324,1,2,3,0.02232987417356183
6528,SARS-CoV Infections,Infectious disease,0.005137233490607143,0,2,3,0.20071024618533007
6529,SARS-CoV Infections,Infectious disease,0.004231930177900786,1,2,3,0.16534030415370687
6530,Apoptotic execution phase,Apoptosis,0.0005084166376239728,0,2,3,0.019863692917365373
6531,Apoptotic execution phase,Apoptosis,0.000668824127844835,1,2,3,0.026130767776054574
6532,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00039389953281680773,0,2,3,0.015389542318545524
6533,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,9.476010780944016e-05,1,2,3,0.003702250365251231
6534,Amyloid fiber formation,Amyloid fiber formation,0.00857746135170139,0,2,3,0.33511896679270353
6535,Amyloid fiber formation,Amyloid fiber formation,0.007993944763261493,1,2,3,0.31232114023233165
6536,TCR signaling,Adaptive Immune System,1.1201808887606807e-05,0,2,3,0.0004376514759672454
6537,TCR signaling,Adaptive Immune System,1.7339757979188185e-05,1,2,3,0.0006774593950538127
6538,Kinesins,Factors involved in megakaryocyte development and platelet production,0.00017056802708484517,0,2,3,0.006664044133898085
6539,Kinesins,Factors involved in megakaryocyte development and platelet production,0.0002527554126277325,1,2,3,0.009875081828759019
6540,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.00022310703165951358,0,2,3,0.008716728046707273
6541,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.0005301551472382067,1,2,3,0.0207130102832886
6542,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.00023036956668297397,0,2,3,0.009000473217167893
6543,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.00027840521351815256,1,2,3,0.010877212228464187
6544,Post-chaperonin tubulin folding pathway,Protein folding,0.0006636426323755328,0,2,3,0.025928328226995083
6545,Post-chaperonin tubulin folding pathway,Protein folding,0.0018694802319753896,1,2,3,0.07304005906767586
6546,Cellular response to chemical stress,Cellular responses to stress,0.0024570833893033657,0,2,3,0.09599754670809782
6547,Cellular response to chemical stress,Cellular responses to stress,0.0014697941051146266,1,2,3,0.057424436171469154
6548,Axon guidance,Nervous system development,0.0009998433325023226,0,2,3,0.03906359362100646
6549,Axon guidance,Nervous system development,0.0020701716824858404,1,2,3,0.080881016756847
6550,Signaling by Hippo,Signaling by Hippo,8.63553171142817e-05,0,2,3,0.0033738775917252104
6551,Signaling by Hippo,Signaling by Hippo,0.0006110278172578029,1,2,3,0.023872682417906674
6552,Protein methylation,Post-translational protein modification,0.0019141072309859627,0,2,3,0.07478362318137667
6553,Protein methylation,Post-translational protein modification,0.0014816417209898608,1,2,3,0.05788731914211381
6554,Signaling by MET,Signaling by Receptor Tyrosine Kinases,0.002883899074341054,0,2,3,0.11267311369883436
6555,Signaling by MET,Signaling by Receptor Tyrosine Kinases,0.002282910149737807,1,2,3,0.08919264795159451
6556,Signaling by Activin,Signaling by TGFB family members,2.2804599262451633e-05,0,2,3,0.0008909691841909092
6557,Signaling by Activin,Signaling by TGFB family members,1.5586039923531237e-05,1,2,3,0.0006089421311735282
6558,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.00031790204440893216,0,2,3,0.012420342138000735
6559,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.00044983326252864565,1,2,3,0.017574857173525943
6560,Diseases of glycosylation,Diseases of metabolism,0.002709157460434062,0,2,3,0.10584600871903926
6561,Diseases of glycosylation,Diseases of metabolism,0.004142413305458914,1,2,3,0.16184290549771832
6562,Cell-extracellular matrix interactions,Cell junction organization,0.0005694787857284637,0,2,3,0.0222493736151701
6563,Cell-extracellular matrix interactions,Cell junction organization,0.00040572903423066617,1,2,3,0.015851717562354546
6564,Nucleotide salvage,Metabolism of nucleotides,8.637851877829419e-05,0,2,3,0.0033747840741158537
6565,Nucleotide salvage,Metabolism of nucleotides,0.0002427340107248992,1,2,3,0.009483548516769712
6566,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,0.0001684853985648145,0,2,3,0.006582676432053849
6567,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,9.124772522536751e-05,1,2,3,0.0035650225802118228
6568,Unfolded Protein Response (UPR),Cellular responses to stress,0.006132817374873873,0,2,3,0.23960742437952312
6569,Unfolded Protein Response (UPR),Cellular responses to stress,0.003684007085588478,1,2,3,0.1439331053277813
6570,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.0002915381287009045,0,2,3,0.011390311476197557
6571,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.0006945299626722356,1,2,3,0.027135087405684107
6572,Collagen degradation,Degradation of the extracellular matrix,0.002679232933366025,0,2,3,0.1046768659876865
6573,Collagen degradation,Degradation of the extracellular matrix,0.0023359307036481384,1,2,3,0.09126414585950204
6574,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.0020051228668104748,0,2,3,0.07833957809494109
6575,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.003024815351641406,1,2,3,0.11817867243199041
6576,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.001570977822731098,0,2,3,0.06137765513842498
6577,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.0024161607483444737,1,2,3,0.09439871080616137
6578,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.004577391771457825,0,2,3,0.17883739001075152
6579,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.0036933844555837106,1,2,3,0.1442994764969632
6580,Cell-cell junction organization,Cell junction organization,0.0027796527581924082,0,2,3,0.10860023988136737
6581,Cell-cell junction organization,Cell junction organization,0.001972276819546336,1,2,3,0.07705629240340031
6582,Ketone body metabolism,Metabolism of lipids,0.00012099449372842086,0,2,3,0.004727220335167329
6583,Ketone body metabolism,Metabolism of lipids,6.399200072632878e-05,1,2,3,0.0025001492034879887
6584,Urea cycle,Metabolism of amino acids and derivatives,9.233278528489361e-05,0,2,3,0.0036074155670346997
6585,Urea cycle,Metabolism of amino acids and derivatives,8.06155782308179e-05,1,2,3,0.003149627631810817
6586,Stimuli-sensing channels,Ion channel transport,0.0002513131300571876,0,2,3,0.009818732260390721
6587,Stimuli-sensing channels,Ion channel transport,2.968276370444387e-05,1,2,3,0.0011596971057423761
6588,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,0.0007361607704470185,0,2,3,0.028761591182989217
6589,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,0.0009459583751994232,1,2,3,0.03695832371927328
6590,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,0.0001954967718935167,0,2,3,0.007638003078296464
6591,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,0.00015477578234554662,1,2,3,0.0060470456394284494
6592,Rab regulation of trafficking,Membrane Trafficking,0.0003044423861810252,0,2,3,0.011894477132753652
6593,Rab regulation of trafficking,Membrane Trafficking,0.0005272401364249541,1,2,3,0.02059912164283055
6594,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.001570905772454639,0,2,3,0.06137484015468865
6595,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0029549295116889024,1,2,3,0.11544825261218235
6596,RIPK1-mediated regulated necrosis,Regulated Necrosis,0.0004597825314648695,0,2,3,0.017963572271098342
6597,RIPK1-mediated regulated necrosis,Regulated Necrosis,0.0004113367730252289,1,2,3,0.016070810316471645
6598,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.0002451048760472792,0,2,3,0.00957617754821187
6599,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.00021495343630219399,1,2,3,0.008398169403333296
6600,Pentose phosphate pathway,Metabolism of carbohydrates,4.064151674674807e-05,0,2,3,0.0015878524592077604
6601,Pentose phosphate pathway,Metabolism of carbohydrates,2.1642401709402576e-05,1,2,3,0.0008455624575130264
6602,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,0.005089948527180462,0,2,3,0.19886283616054024
6603,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,0.0003673393318409617,1,2,3,0.014351842847353323
6604,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0031677147133191952,0,2,3,0.12376170970575191
6605,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.002507443117054042,1,2,3,0.0979650868974128
6606,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.00013157824681343878,0,2,3,0.005140724547335741
6607,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.0006600176131246486,1,2,3,0.025786699759532624
6608,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,4.896151883863217e-05,0,2,3,0.0019129125662046024
6609,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,6.278224031453175e-05,1,2,3,0.0024528842094944316
6610,Basigin interactions,Cell surface interactions at the vascular wall,0.00023704161707064573,0,2,3,0.009261148321447074
6611,Basigin interactions,Cell surface interactions at the vascular wall,9.640189508422534e-05,1,2,3,0.0037663945254706507
6612,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.00012506706035462695,0,2,3,0.004886334350842597
6613,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0003883431002342256,1,2,3,0.015172454083486452
6614,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,1.4105444652067014e-05,0,2,3,0.0005510956965156987
6615,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,1.255909487808083e-05,1,2,3,0.000490680252212287
6616,Meiosis,Reproduction,0.003090572538133016,0,3,4,0.21667368717543714
6617,Meiosis,Reproduction,0.0016025813648494814,1,3,4,0.11235368496813995
6618,Meiosis,Cell Cycle,0.003090572538133016,0,3,4,0.21667368717543714
6619,Meiosis,Cell Cycle,0.0016025813648494814,1,3,4,0.11235368496813995
6620,Aspirin ADME,Drug ADME,0.0006222577151001027,0,3,4,0.043625209193617405
6621,Aspirin ADME,Drug ADME,0.0024113810558156006,1,3,4,0.16905696860433223
6622,RNA Polymerase I Transcription,Gene expression (Transcription),0.0016458389776384194,0,3,4,0.11538638727353498
6623,RNA Polymerase I Transcription,Gene expression (Transcription),0.001071407058575252,1,3,4,0.07511414632174473
6624,Inositol phosphate metabolism,Metabolism,0.00020738964793118672,0,3,4,0.014539661873269381
6625,Inositol phosphate metabolism,Metabolism,8.97197243303999e-05,1,3,4,0.006290065430651556
6626,Base Excision Repair,DNA Repair,0.000903777216607232,0,3,4,0.06336196270796428
6627,Base Excision Repair,DNA Repair,0.0005024018573195338,1,3,4,0.03522236139940946
6628,Metabolism of lipids,Metabolism,0.0034859734587279014,0,3,4,0.24439443286924642
6629,Metabolism of lipids,Metabolism,0.0014860732138599654,1,3,4,0.10418553801497354
6630,ABC-family proteins mediated transport,Transport of small molecules,0.0005129547853288257,0,3,4,0.03596220548786159
6631,ABC-family proteins mediated transport,Transport of small molecules,0.0008455059272782265,1,3,4,0.05927668240484947
6632,Mitochondrial protein import,Protein localization,0.000779615057521378,0,3,4,0.05465720898196151
6633,Mitochondrial protein import,Protein localization,0.000451582936884872,1,3,4,0.03165955135920084
6634,Signaling by NOTCH,Signal Transduction,0.0005897254135801594,0,3,4,0.0413444364126338
6635,Signaling by NOTCH,Signal Transduction,0.00041430829099822243,1,3,4,0.029046302563785736
6636,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0011170077660472319,0,3,4,0.07831111817852926
6637,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0010707315463644724,1,3,4,0.07506678754933746
6638,Epigenetic regulation of gene expression,Gene expression (Transcription),0.004537480564183082,0,3,4,0.3181134343872556
6639,Epigenetic regulation of gene expression,Gene expression (Transcription),0.0029373420676861812,1,3,4,0.20593101389736582
6640,Integrin cell surface interactions,Extracellular matrix organization,0.002060034925888971,0,3,4,0.14442481371823115
6641,Integrin cell surface interactions,Extracellular matrix organization,0.0005671075440922632,1,3,4,0.039758744079731706
6642,Gene Silencing by RNA,Gene expression (Transcription),0.0016683033306440008,0,3,4,0.1169613168814549
6643,Gene Silencing by RNA,Gene expression (Transcription),0.001079478809612373,1,3,4,0.07568004019338048
6644,Degradation of the extracellular matrix,Extracellular matrix organization,0.0011815874184017024,0,3,4,0.08283866484488381
6645,Degradation of the extracellular matrix,Extracellular matrix organization,0.0003228343293219259,1,3,4,0.02263325115910301
6646,Fibronectin matrix formation,Extracellular matrix organization,0.0005112833111016112,0,3,4,0.03584502186594018
6647,Fibronectin matrix formation,Extracellular matrix organization,0.00013948088639806556,1,3,4,0.009778718206246617
6648,Keratinization,Developmental Biology,0.003801445580111572,0,3,4,0.2665115347647254
6649,Keratinization,Developmental Biology,0.005909790548121883,1,3,4,0.4143232662222679
6650,Paracetamol ADME,Drug ADME,0.0004605493170852172,0,3,4,0.03228816584232805
6651,Paracetamol ADME,Drug ADME,0.0018531200044604047,1,3,4,0.1299184339441371
6652,Response to metal ions,Cellular responses to stimuli,0.0034033126755603376,0,3,4,0.23859925529203774
6653,Response to metal ions,Cellular responses to stimuli,0.00213377992356631,1,3,4,0.14959492390342863
6654,Signaling by WNT,Signal Transduction,0.00011033665017469405,0,3,4,0.007735475718159105
6655,Signaling by WNT,Signal Transduction,7.766324142000351e-05,1,3,4,0.0054448101990298755
6656,Cardiac conduction,Muscle contraction,0.0003973520139284281,0,3,4,0.027857532836445806
6657,Cardiac conduction,Muscle contraction,0.0015807043968435132,1,3,4,0.11081993571502076
6658,Regulated Necrosis,Programmed Cell Death,0.00018971495464846592,0,3,4,0.013300525462131948
6659,Regulated Necrosis,Programmed Cell Death,0.00032860358882557154,1,3,4,0.023037722082695042
6660,Ion channel transport,Transport of small molecules,3.580232665340445e-05,0,3,4,0.0025100275207061637
6661,Ion channel transport,Transport of small molecules,5.9031718874070675e-05,1,3,4,0.004138592455259251
6662,MTOR signalling,Signal Transduction,0.00012044712432351692,0,3,4,0.008444300276032369
6663,MTOR signalling,Signal Transduction,8.486567435861178e-05,1,3,4,0.005949757965887598
6664,SLC-mediated transmembrane transport,Transport of small molecules,0.001425058109142704,0,3,4,0.09990789445561198
6665,SLC-mediated transmembrane transport,Transport of small molecules,0.0023491170047287447,1,3,4,0.16469176398253146
6666,Chaperone Mediated Autophagy,Autophagy,0.008013936349570155,0,3,4,0.5618406027446214
6667,Chaperone Mediated Autophagy,Autophagy,0.0005501697957102058,1,3,4,0.03857127336059849
6668,Integration of energy metabolism,Metabolism,0.0006469397020861885,0,3,4,0.04535561256098894
6669,Integration of energy metabolism,Metabolism,0.0002821233191831465,1,3,4,0.01977908593030867
6670,Cell junction organization,Cell-Cell communication,0.0032117039380204107,0,3,4,0.22516596060454713
6671,Cell junction organization,Cell-Cell communication,0.002508201987378934,1,3,4,0.17584488507571236
6672,Disorders of transmembrane transporters,Disease,0.001503135555504755,0,3,4,0.10538174371162316
6673,Disorders of transmembrane transporters,Disease,0.0014426189606942922,1,3,4,0.10113904965701088
6674,Elastic fibre formation,Extracellular matrix organization,0.0025356277521385137,0,3,4,0.17776764906223702
6675,Elastic fibre formation,Extracellular matrix organization,0.0006963840439547206,1,3,4,0.0488220537237288
6676,Cell Cycle Checkpoints,Cell Cycle,6.762773403832324e-05,0,3,4,0.004741241407087353
6677,Cell Cycle Checkpoints,Cell Cycle,0.0002526741058927701,1,3,4,0.01771446212701287
6678,DNA Double-Strand Break Repair,DNA Repair,0.0072846282888109305,0,3,4,0.5107103138865808
6679,DNA Double-Strand Break Repair,DNA Repair,0.004065784512248438,1,3,4,0.2850437938796374
6680,Integrin signaling,Signal Transduction,0.0004542979602389225,0,3,4,0.03184989606511896
6681,Integrin signaling,Signal Transduction,0.00031837669740262446,1,3,4,0.022320735749058816
6682,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.001513191531853293,0,3,4,0.10608674754075281
6683,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.0044353166087077005,1,3,4,0.31095092949337255
6684,Metabolism of vitamins and cofactors,Metabolism,0.00403330453319462,0,3,4,0.28276668931919147
6685,Metabolism of vitamins and cofactors,Metabolism,0.0017051424579706685,1,3,4,0.11954403236595099
6686,Death Receptor Signalling,Signal Transduction,0.0007624666683427838,0,3,4,0.05345497066960987
6687,Death Receptor Signalling,Signal Transduction,0.0005390281766253585,1,3,4,0.037790157351046294
6688,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0014274924732337684,0,3,4,0.10007856271757001
6689,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.002344810132401597,1,3,4,0.16438981801756775
6690,Nephrin family interactions,Cell-Cell communication,0.00023810287526374927,0,3,4,0.016692903102554297
6691,Nephrin family interactions,Cell-Cell communication,0.00018721938353069695,1,3,4,0.013125566101358566
6692,Biological oxidations,Metabolism,0.001491809099750495,0,3,4,0.10458766918315811
6693,Biological oxidations,Metabolism,0.0006460652202758173,1,3,4,0.045294304438987874
6694,Diseases of metabolism,Disease,0.0021255071171050665,0,3,4,0.1490149344493292
6695,Diseases of metabolism,Disease,0.0020345434790085956,1,3,4,0.14263766078172563
6696,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.00022728065877008195,0,3,4,0.015934179752054894
6697,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.0004730651496825645,1,3,4,0.033165625136189494
6698,Diseases of Immune System,Disease,0.004628901168118854,0,3,4,0.32452274499044076
6699,Diseases of Immune System,Disease,0.004464818725490507,1,3,4,0.31301926225176574
6700,MAPK family signaling cascades,Signal Transduction,0.00010380011130753811,0,3,4,0.0072772124157330104
6701,MAPK family signaling cascades,Signal Transduction,7.331490850929602e-05,1,3,4,0.005139957517785755
6702,Miscellaneous transport and binding events,Transport of small molecules,0.00017907813362675888,0,3,4,0.012554799807043224
6703,Miscellaneous transport and binding events,Transport of small molecules,0.00029542969986124924,1,3,4,0.02071196892493535
6704,Apoptosis,Programmed Cell Death,0.004198705086642333,0,3,4,0.29436258209769367
6705,Apoptosis,Programmed Cell Death,0.0067056667300819175,1,3,4,0.47012050920966675
6706,Abacavir ADME,Drug ADME,0.0009725512338383832,0,3,4,0.06818356767321852
6707,Abacavir ADME,Drug ADME,0.0038983650218345567,1,3,4,0.27330635758088545
6708,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.006627751182483924,0,3,4,0.4646580103431788
6709,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.014163107395841064,1,3,4,0.9929463435834454
6710,Innate Immune System,Immune System,0.005988232703890703,0,3,4,0.41982268450503296
6711,Innate Immune System,Immune System,0.009928733953257059,1,3,4,0.6960831263762335
6712,Synthesis of DNA,DNA Replication,0.0005814691578299583,0,3,4,0.0407656072948613
6713,Synthesis of DNA,DNA Replication,0.0017540862126369816,1,3,4,0.12297537838903004
6714,"Platelet activation, signaling and aggregation",Hemostasis,0.000364027642556116,0,3,4,0.025521229666417553
6715,"Platelet activation, signaling and aggregation",Hemostasis,0.0007622124193298837,1,3,4,0.053437145793990205
6716,Dissolution of Fibrin Clot,Hemostasis,0.0011129333289562997,0,3,4,0.07802546777014573
6717,Dissolution of Fibrin Clot,Hemostasis,0.0023623907302119497,1,3,4,0.16562235758857508
6718,Transmission across Chemical Synapses,Neuronal System,0.005285928241165738,0,3,4,0.37058556239227797
6719,Transmission across Chemical Synapses,Neuronal System,0.00031127689298447535,1,3,4,0.021822983056790958
6720,Diseases of the neuronal system,Disease,0.000637596061923095,0,3,4,0.0447005491574291
6721,Diseases of the neuronal system,Disease,0.0006150556312063438,1,3,4,0.043120285897576514
6722,Fertilization,Reproduction,0.002875143127880042,0,3,4,0.20157037409360298
6723,Fertilization,Reproduction,0.001577721908743946,1,3,4,0.11061083960563758
6724,Nucleotide Excision Repair,DNA Repair,0.004720024222506669,0,3,4,0.33091119500650895
6725,Nucleotide Excision Repair,DNA Repair,0.002616495406742652,1,3,4,0.18343711408210456
6726,Transcriptional regulation of testis differentiation,Developmental Biology,0.002855877200196802,0,3,4,0.20021967950983993
6727,Transcriptional regulation of testis differentiation,Developmental Biology,0.004383865721576724,1,3,4,0.3073438135672567
6728,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,0.0005957512487095975,0,3,4,0.04176689532589242
6729,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,0.001757443806884555,1,3,4,0.123210772419322
6730,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0022730121166246757,0,3,4,0.1593562067308825
6731,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0015988109303052994,1,3,4,0.11208934755335302
6732,Platelet Adhesion to exposed collagen,Hemostasis,0.0012830788757109707,0,3,4,0.08995402227483493
6733,Platelet Adhesion to exposed collagen,Hemostasis,0.002696125435425432,1,3,4,0.1890198116928866
6734,Intracellular oxygen transport,Transport of small molecules,0.0006391014394097427,0,3,4,0.04480608807832429
6735,Intracellular oxygen transport,Transport of small molecules,0.0010617084623619365,1,3,4,0.07443419767920802
6736,DNA Replication Pre-Initiation,DNA Replication,0.00043921513342358253,0,3,4,0.030792470083756147
6737,DNA Replication Pre-Initiation,DNA Replication,0.0012565975741501442,1,3,4,0.08809747266158588
6738,Translation,Metabolism of proteins,0.00023884605645878136,0,3,4,0.016745006008336383
6739,Translation,Metabolism of proteins,0.00017050727748319148,1,3,4,0.011953914702434471
6740,Smooth Muscle Contraction,Muscle contraction,0.00019307710495867545,0,3,4,0.013536238908609154
6741,Smooth Muscle Contraction,Muscle contraction,0.0006631426235337481,1,3,4,0.04649156607437178
6742,Laminin interactions,Extracellular matrix organization,0.00015851935285963965,0,3,4,0.011113465951364131
6743,Laminin interactions,Extracellular matrix organization,4.2549080809301174e-05,1,3,4,0.002983028584873851
6744,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0019401965278097687,0,3,4,0.13602318998779309
6745,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0013688736508086592,1,3,4,0.09596891758353175
6746,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.0008738809520870519,0,3,4,0.06126599706197664
6747,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.0003815997777652635,1,3,4,0.026753175941851465
6748,Chromatin modifying enzymes,Chromatin organization,0.00146153251777433,0,3,4,0.1024650402621725
6749,Chromatin modifying enzymes,Chromatin organization,0.0017903121628718472,1,3,4,0.12551510528816434
6750,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.008851292258907678,0,3,4,0.6205459041461229
6751,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.014813137359339224,1,3,4,1.0385186080191942
6752,Transcriptional regulation of granulopoiesis,Developmental Biology,0.0019594887265614066,0,3,4,0.13737572638215445
6753,Transcriptional regulation of granulopoiesis,Developmental Biology,0.00300864112057586,1,3,4,0.21092964392177402
6754,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.003604878587553722,0,3,4,0.2527306270109068
6755,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.00012474120739156908,1,3,4,0.00874534961233254
6756,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.001422981386424211,0,3,4,0.09976229969506036
6757,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0003876682873896691,1,3,4,0.027178626676223776
6758,Iron uptake and transport,Transport of small molecules,0.0008069418332157918,0,3,4,0.05657303304862508
6759,Iron uptake and transport,Transport of small molecules,0.0013272101743477555,1,3,4,0.09304797689893472
6760,Post-translational protein modification,Metabolism of proteins,0.014129935510964475,0,3,4,0.9906207309281567
6761,Post-translational protein modification,Metabolism of proteins,0.009905997157300147,1,3,4,0.694489096353073
6762,Metabolism of amino acids and derivatives,Metabolism,0.00015215449393000767,0,3,4,0.010667238776425223
6763,Metabolism of amino acids and derivatives,Metabolism,6.601873635344652e-05,1,3,4,0.004628437887112512
6764,Chromosome Maintenance,Cell Cycle,0.0005331289845242577,0,3,4,0.037376577120156816
6765,Chromosome Maintenance,Cell Cycle,0.0020166896944556817,1,3,4,0.1413859686498035
6766,"Cell Cycle, Mitotic",Cell Cycle,0.000853503388101173,0,3,4,0.059837367942292226
6767,"Cell Cycle, Mitotic",Cell Cycle,0.003208919750000758,1,3,4,0.22497076690610954
6768,Peptide hormone metabolism,Metabolism of proteins,0.006118401329289841,0,3,4,0.4289485392364114
6769,Peptide hormone metabolism,Metabolism of proteins,0.004335200788090088,1,3,4,0.30393201512389556
6770,Signaling by GPCR,Signal Transduction,0.0018521518708956616,0,3,4,0.1298505600901625
6771,Signaling by GPCR,Signal Transduction,0.0013026992541855008,1,3,4,0.09132956667490978
6772,Nervous system development,Developmental Biology,0.002129691159019517,0,3,4,0.1493082690265685
6773,Nervous system development,Developmental Biology,0.0032448595387914022,1,3,4,0.22749043161466853
6774,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.00046267778905502877,0,3,4,0.03243738863650561
6775,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.0007117123999010838,1,3,4,0.04989669324771887
6776,Adaptive Immune System,Immune System,0.0029986585998577646,0,3,4,0.21022978991588762
6777,Adaptive Immune System,Immune System,0.004972261020544826,1,3,4,0.34859499837883456
6778,Diseases of hemostasis,Disease,0.0013677382180595963,0,3,4,0.09588931472767132
6779,Diseases of hemostasis,Disease,0.001313138713610696,1,3,4,0.09206145571419498
6780,Peroxisomal protein import,Protein localization,0.00016991358554640165,0,3,4,0.011912292181233824
6781,Peroxisomal protein import,Protein localization,9.478126865794509e-05,1,3,4,0.006644919898139203
6782,Protein folding,Metabolism of proteins,0.0016089770601242636,0,3,4,0.11280207401584524
6783,Protein folding,Metabolism of proteins,0.001145174405784702,1,3,4,0.08028582338669324
6784,RNA Polymerase II Transcription,Gene expression (Transcription),0.008454405663352989,0,3,4,0.5927210008350718
6785,RNA Polymerase II Transcription,Gene expression (Transcription),0.005388478157014854,1,3,4,0.3777751261745218
6786,Striated Muscle Contraction,Muscle contraction,0.0002546728797168896,0,3,4,0.017854592050824118
6787,Striated Muscle Contraction,Muscle contraction,0.0008387748117447561,1,3,4,0.058804777732350856
6788,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0036693662820149893,0,3,4,0.2572517266984121
6789,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0025996672591433252,1,3,4,0.18225732724853574
6790,Sensory processing of sound,Sensory Perception,0.0025032240657753674,0,3,4,0.17549589322549466
6791,Sensory processing of sound,Sensory Perception,0.002473449628054331,1,3,4,0.17340846860594844
6792,Signaling by Nuclear Receptors,Signal Transduction,0.00018356738816734214,0,3,4,0.012869532214056992
6793,Signaling by Nuclear Receptors,Signal Transduction,0.00012895277931765045,1,3,4,0.009040614262092178
6794,ECM proteoglycans,Extracellular matrix organization,0.0013315657884996298,0,3,4,0.09335334005302857
6795,ECM proteoglycans,Extracellular matrix organization,0.0003650674039393375,1,3,4,0.025594125199496134
6796,Signaling by Hippo,Signal Transduction,0.0008614794685042033,0,3,4,0.06039655454244765
6797,Signaling by Hippo,Signal Transduction,0.0006085503612985353,1,3,4,0.04266421479760882
6798,Activation of HOX genes during differentiation,Developmental Biology,0.0016195001271718432,0,3,4,0.11353982461365868
6799,Activation of HOX genes during differentiation,Developmental Biology,0.002473726469370515,1,3,4,0.17342787738150697
6800,Signaling by Hedgehog,Signal Transduction,0.0006152978896865035,0,3,4,0.0431372701415954
6801,Signaling by Hedgehog,Signal Transduction,0.0004325967780750759,1,3,4,0.030328470796017543
6802,Intracellular signaling by second messengers,Signal Transduction,0.001385328464202942,0,3,4,0.09712253072347016
6803,Intracellular signaling by second messengers,Signal Transduction,0.0009723208205116118,1,3,4,0.0681674138685529
6804,Cilium Assembly,Organelle biogenesis and maintenance,0.000685932516314482,0,3,4,0.04808931860669625
6805,Cilium Assembly,Organelle biogenesis and maintenance,0.0017981996228221124,1,3,4,0.12606807889055874
6806,Macroautophagy,Autophagy,0.00013022150665280519,0,3,4,0.009129562127361929
6807,Macroautophagy,Autophagy,7.573324704431281e-06,1,3,4,0.0005309502260953981
6808,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.003139497907560432,0,3,4,0.2201037442472127
6809,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.006694938048488711,1,3,4,0.46936834339875344
6810,Surfactant metabolism,Metabolism of proteins,0.000927400462793867,0,3,4,0.0650181399344025
6811,Surfactant metabolism,Metabolism of proteins,0.000657061577318378,1,3,4,0.04606523642537916
6812,Cell surface interactions at the vascular wall,Hemostasis,0.0004046025255613436,0,3,4,0.028365851301723193
6813,Cell surface interactions at the vascular wall,Hemostasis,0.0008423744984796072,1,3,4,0.059057144369241976
6814,Collagen formation,Extracellular matrix organization,0.0012678299055163373,0,3,4,0.08888494832270064
6815,Collagen formation,Extracellular matrix organization,0.0003481918326910838,1,3,4,0.024411013591392684
6816,Infectious disease,Disease,0.004969986420416767,0,3,4,0.3484355308398866
6817,Infectious disease,Disease,0.0047507431445225805,1,3,4,0.3330648354783366
6818,Membrane Trafficking,Vesicle-mediated transport,0.0025049069134248443,0,3,4,0.17561387421466987
6819,Membrane Trafficking,Vesicle-mediated transport,0.005447798105969323,1,3,4,0.3819339258481862
6820,Late endosomal microautophagy,Autophagy,0.008479016839362257,0,3,4,0.594446439790429
6821,Late endosomal microautophagy,Autophagy,0.0005715845853307475,1,3,4,0.04007262023724293
6822,Platelet homeostasis,Hemostasis,0.0020022680694956082,0,3,4,0.1403748981712416
6823,Platelet homeostasis,Hemostasis,0.004255589836635769,1,3,4,0.29835065497838276
6824,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,1.2468667422082741e-05,0,3,4,0.0008741526403838911
6825,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,5.353757702729763e-06,1,3,4,0.00037534094650148905
6826,Amyloid fiber formation,Metabolism of proteins,0.008108556622873901,0,3,4,0.5684742355894454
6827,Amyloid fiber formation,Metabolism of proteins,0.005730335436004827,1,3,4,0.40174203722824703
6828,Atorvastatin ADME,Drug ADME,0.0027419515936529066,0,3,4,0.1922325894386664
6829,Atorvastatin ADME,Drug ADME,0.009814229083683597,1,3,4,0.6880554253648824
6830,Mitochondrial biogenesis,Organelle biogenesis and maintenance,0.0011894867018569582,0,3,4,0.08339246736890679
6831,Mitochondrial biogenesis,Organelle biogenesis and maintenance,0.003140121989122351,1,3,4,0.2201474973225574
6832,Metabolism of porphyrins,Metabolism,0.0011941218467354747,0,3,4,0.08371742784759764
6833,Metabolism of porphyrins,Metabolism,0.0005153038705960858,1,3,4,0.03612689502679545
6834,Metabolism of carbohydrates,Metabolism,0.0025043550271576227,0,3,4,0.17557518260302024
6835,Metabolism of carbohydrates,Metabolism,0.0010632909862096807,1,3,4,0.07454514517288534
6836,Cellular responses to stress,Cellular responses to stimuli,0.006595634857841488,0,3,4,0.46240640084592893
6837,Cellular responses to stress,Cellular responses to stimuli,0.004160629591996472,1,3,4,0.29169318744212247
6838,Reversible hydration of carbon dioxide,Metabolism,0.0015826545786325286,0,3,4,0.11095665895114439
6839,Reversible hydration of carbon dioxide,Metabolism,0.0006777314175742319,1,3,4,0.04751435643350187
6840,Metabolism of nucleotides,Metabolism,2.2183058334740237e-05,0,3,4,0.0015552086168213767
6841,Metabolism of nucleotides,Metabolism,9.369999753718804e-06,1,3,4,0.0006569114202696029
6842,Signaling by TGFB family members,Signal Transduction,0.001439262704502999,0,3,4,0.10090374943509402
6843,Signaling by TGFB family members,Signal Transduction,0.0010083072994916042,1,3,4,0.07069035193030332
6844,Diseases of programmed cell death,Disease,0.0007013399451495716,0,3,4,0.0491695017683601
6845,Diseases of programmed cell death,Disease,0.0006743143491115602,1,3,4,0.047274792788254034
6846,Cytokine Signaling in Immune system,Immune System,0.001907975509524024,0,3,4,0.13376424063443576
6847,Cytokine Signaling in Immune system,Immune System,0.0031648491952593555,1,3,4,0.2218810709116402
6848,Visual phototransduction,Sensory Perception,0.006820043639503277,0,3,4,0.47813923919780926
6849,Visual phototransduction,Sensory Perception,0.007186168583420514,1,3,4,0.5038075063511083
6850,Autophagy,root,0.007269655751834822,0,4,5,1.3325194909581222
6851,Autophagy,root,0.0021504955668741636,1,4,5,0.3941833500651805
6852,Neuronal System,root,0.002654348482806407,0,4,5,0.4865390067806092
6853,Neuronal System,root,0.002645760914739245,1,4,5,0.4849649154865978
6854,DNA Repair,root,0.004108054173511523,0,4,5,0.7530015784769918
6855,DNA Repair,root,0.0022078603067274376,1,4,5,0.404698240530102
6856,Cell Cycle,root,0.0005185213575400505,0,4,5,0.09504436509607667
6857,Cell Cycle,root,0.0028474852860462616,1,4,5,0.5219407594252917
6858,Extracellular matrix organization,root,0.005497616359248864,0,4,5,1.0077067199035357
6859,Extracellular matrix organization,root,0.001712301091225379,1,4,5,0.31386280951072504
6860,Metabolism of proteins,root,0.0114239867331063,0,4,5,2.0940035547720433
6861,Metabolism of proteins,root,0.006480982678860833,1,4,5,1.1879566288904884
6862,Signal Transduction,root,0.0038636880241342784,0,4,5,0.7082095459390856
6863,Signal Transduction,root,0.0030499909640768355,1,4,5,0.5590598159827254
6864,Circadian Clock,root,0.0030808901617558775,0,4,5,0.5647236031781369
6865,Circadian Clock,root,0.0004464018948702378,1,4,5,0.08182495100474271
6866,Metabolism,root,0.003351717629188643,0,4,5,0.6143659647094792
6867,Metabolism,root,0.0005044669316869423,1,4,5,0.09246820509307163
6868,Immune System,root,0.004318834785717719,0,4,5,0.7916374208977215
6869,Immune System,root,0.007237468570025241,1,4,5,1.326619617761313
6870,Gene expression (Transcription),root,0.0037862347992716787,0,4,5,0.6940124594070407
6871,Gene expression (Transcription),root,0.0005965519430255281,1,4,5,0.10934728116249831
6872,Developmental Biology,root,0.002117188162107046,0,4,5,0.3880781412959463
6873,Developmental Biology,root,0.0054977305391481325,1,4,5,1.007727648947007
6874,Cell-Cell communication,root,0.00151497586353466,0,4,5,0.2776933235086859
6875,Cell-Cell communication,root,0.00019406181476032945,1,4,5,0.03557130618648298
6876,Transport of small molecules,root,0.0034368348122943136,0,4,5,0.6299678459230608
6877,Transport of small molecules,root,0.00887497401409806,1,4,5,1.6267724716603909
6878,Metabolism of RNA,root,0.0024164360392515028,0,4,5,0.44292993105534273
6879,Metabolism of RNA,root,0.001923684798998808,1,4,5,0.35260919865136586
6880,Drug ADME,root,0.004166996151010617,0,4,5,0.7638055747781006
6881,Drug ADME,root,0.00575616066657281,1,4,5,1.0550975923940895
6882,Muscle contraction,root,0.0007515987886316385,0,4,5,0.1377671886291719
6883,Muscle contraction,root,0.000772487867889971,1,4,5,0.14159613269614116
6884,Disease,root,0.006750378796717312,0,4,5,1.2373366257000493
6885,Disease,root,0.005739611872090121,1,4,5,1.0520642175063615
6886,Cellular responses to stimuli,root,0.004353584284873079,0,4,5,0.7980069639003408
6887,Cellular responses to stimuli,root,0.003117014847364928,1,4,5,0.5713452162671261
6888,Organelle biogenesis and maintenance,root,0.002549407699648858,0,4,5,0.4673034826062286
6889,Organelle biogenesis and maintenance,root,0.001607717238224778,1,4,5,0.2946927102212743
6890,Reproduction,root,0.002182721685550795,0,4,5,0.4000903603446841
6891,Reproduction,root,0.00010260747997385413,1,4,5,0.01880783239959427
6892,Vesicle-mediated transport,root,0.008743104801202937,0,4,5,1.6026009974615323
6893,Vesicle-mediated transport,root,0.011159331338340652,1,4,5,2.0454925270217355
6894,Sensory Perception,root,0.0005082070064034888,0,4,5,0.0931537564627056
6895,Sensory Perception,root,0.008761136911231504,1,4,5,1.6059062623731621
6896,Chromatin organization,root,0.002359227461580956,0,4,5,0.4324436649378921
6897,Chromatin organization,root,0.0014291515046149152,1,4,5,0.2619618177863302
6898,Protein localization,root,0.00025265301436649165,0,4,5,0.0463110053055401
6899,Protein localization,root,0.00042013006485247555,1,4,5,0.07700935494945893
6900,Programmed Cell Death,root,0.004750118663290833,0,4,5,0.8706912568179604
6901,Programmed Cell Death,root,0.0006560080518085421,1,4,5,0.12024551713328636
6902,Hemostasis,root,0.0006848231337590469,0,4,5,0.12552728832622245
6903,Hemostasis,root,0.005933684857962657,1,4,5,1.0876375713447912
6904,DNA Replication,root,0.001265725098757943,0,4,5,0.23200594661778356
6905,DNA Replication,root,0.001839634744082737,1,4,5,0.3372029208006578
